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RESUMEN 
 
Objetivos 
Evaluar la eficacia en el alivio del dolor de las alternativas terapéuticas existentes 
para el tratamiento de la neuropatía diabética dolorosa 
 
Metodología 
Se realizó una búsqueda en las principales bases de datos para Ciencias de la Salud 
como son PUBMED y Web of Science (WOS) para obtener ensayos clínicos 
aleatorizados con grupo control sobre tratamientos utilizados para la neuropatía 
diabética dolorosa. Los estudios analizados debían de cumplir con los criterios de 
inclusión y exclusión seleccionados, considerando especialmente los resultados 
relacionados con la intensidad del dolor, además de cumplir los criterios de calidad 
mediante escala JADAD. Tras la selección de los estudios se realizó una evaluación 
del nivel de riesgo de los estudios incluidos y se procedió a la extracción de datos 
de los estudios incluidos para posteriormente realizar el meta-análisis de los 
mismos.  
 
Resultados  
Se obtuvieron 12 ensayos clínicos aleatorizados sobre tratamientos farmacológicos 
orales, físicos y tópicos para la neuropatía diabética dolorosa, con un total de 2872 
pacientes incluidos. A través del meta-análisis realizado se obtuvo el estadístico g 
de Hedges para los estudios de Richter 2005 (Pregabalina 150 mg/día (g: 0,407; 
0,070 a 0,744; p<0,05), Pregabalina 600 mg/día( g: 0,607; 0,235 a 0,980; p<0,05)), 
Raskin 2005 (Duloxetina 60 mg/día (g: 4,984; 4,961 a 5,007; p<0,05), Duloxetina 
120 mg/día (g: 3,710; 3,687 a 3,733; p<0,05)), Goldstein 2004 (Duloxetina 20 
mg/día (g: 1,622; 1,594 a 1,650; p<0,05), Duloxetina 60 mg/día (g: 3,534; 3,505 a 
3,562; p<0,05), Duloxetina 120 mg/día (g: 5,448; 5,419 a 5,477; p<0,05)), 
Wernicke 2006 (Duloxetina 60 mg/día (g: 5,007; 4,977 a 5,036; p<0,05), 
Duloxetina 120 mg/día (g: 4,983; 4,952 a 5,013; p<0,05)), Niesters 2013 
(Tapentadol 500 mg/día (g: 1,333; 1,072 a 1,594; p<0,05)) y Eisenberg 2001 
(Lamotrigina 400 mg/día (g: 10,837; 10,811 a 10,864; p<0,05)). Para el resto de 
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estudios no se obtuvo efecto positivo por valor de p>0,05. Los resultados 
obtenidos también se muestran mediante gráfica tipo Forest Plot. 
 
Conclusiones 
Según los resultados obtenidos las terapias más efectivas para el tratamiento de la 
neuropatía diabética dolorosa son la duloxetina, pregabalina, tapentadol y 
lamotrigina. Sin embargo, en cuanto a términos de eficacia y aplicabilidad clínica, 
las terapias farmacológicas orales sobre duloxetina, pregabalina y gabapentina 
estarían consideradas como primera línea de recomendación, siendo el tapentadol 
u otros opioides la segunda línea de recomendación , y la capsaicina tópica la 
terapia adyuvante en caso de no ser posible la ingesta oral de fármacos. 
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SUMMARY 
 
Objectives 
 To assess the efficacy in pain relief of existing therapeutic alternatives for the 
treatment of painful diabetic neuropathy. 
 
Methodology  
A search was made in the main databases for Health Sciences such as PUBMED and 
Web of Science (WOS) to obtain randomized clinical trials with a control group on 
treatments used for painful diabetic neuropathy. The studies analyzed must meet 
the inclusion and exclusion criteria selected, especially considering the results 
related to the intensity of pain, in addition to meeting the quality criteria using the 
JADAD scale. After the selection of the studies, an assessment of the risk level of the 
included studies was carried out and the data were extracted from the included 
studies to later perform the meta-analysis of the same.   
 
Results  
We obtained 12 randomized clinical trials on oral, physical and topical 
pharmacological treatments for painful diabetic neuropathy, with a total of 2872 
patients included. Through the meta-analysis performed, the Hedges g statistic 
was obtained for the following studies: Richter 2005 (Pregabalin 150 mg / day (g: 
0.407, 0.070 to 0.744, p <0.05), Pregabalin 600 mg / day (g: 0.607, 0.235 to 0.980, 
p <0.05), Raskin 2005 (Duloxetine 60 mg / day (g: 4.984, 4.961 to 5.007, p <0.05), 
Duloxetine 120 mg / day (g: 3.710, 3.687 a 3,733, p <0.05), Goldstein 2004 
(Duloxetine 20 mg / day (g: 1.622, 1.594 to 1.650, p <0.05), Duloxetine 60 mg / day 
(g: 3.534, 3.505 to 3.562, p < 0.05), Duloxetine 120 mg / day (g: 5.448, 5.419 to 
5.477, p <0.05)), Wernicke 2006 (Duloxetine 60 mg / day (g: 5.007, 4.977 to 5.036, 
p <0.05) , Duloxetine 120 mg / day (g: 4.983, 4.952 to 5.013, p <0.05)), Niesters 
2013 (Tapentadol 500 mg / day (g: 1.333, 1.072 to 1.594, p <0.05)) and Eisenberg 
2001 (Lamotrigine 400 mg / day (g: 10.837, 10.811 to 10.864, p <0.05)). For the 
rest of the studies, no positive effect was obtained for p value> 0.05. The results 
obtained are also shown by Forest Plot graph. 
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Conclusions 
According to the results obtained, the most effective therapies for the treatment of 
painful diabetic neuropathy are duloxetine, pregabalin, tapentadol and 
lamotrigine. However, regarding terms of efficacy and clinical applicability, oral 
pharmacological therapies on duloxetine, pregabalin and gabapentin would be 
considered as the first line of recommendation, being tapentadol or other opioids 
the second line of recommendation, and topical capsaicin adjuvant therapy if oral 
intake of drugs is not possible. 
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INTRODUCCIÓN 
 
Problema de investigación  
 
La Diabetes Mellitus (en adelante DM) es una enfermedad que afecta a 425 
millones de personas en el mundo, estimándose para el año 2045 una prevalencia 
de 629 millones de personas afectadas por esta enfermedad, siendo la neuropatía 
diabética una de sus complicaciones más importantes  junto con las enfermedades 
cardiovasculares. Las cifras son mas preocupantes al saber que en 2017 se estima 
que las muertes relacionadas con la DM se sitúan en torno a los 4 millones de 
personas. (1,2).  
 
La neuropatía diabética se define como la presencia de síntomas o signos de 
disfunción del sistema nervioso periférico en el paciente diabético (3). Ésta 
complicación de la DM se caracteriza por una presentación mas común 
denominada polineuropatía simétrica distal, cuyas manifestaciones principales son 
la presencia de una distribución muy característica denominada en guante y 
calcetín, donde hay una afectación de fibras nerviosas que alteran la sensación 
térmica y dolorosa y la sensibilidad vibratoria y propioceptiva. A su vez, las 
manifestaciones clínicas de esta patología de caracterizan por la aparición 
predominantemente nocturna de parestesias o entumecimiento, dolor quemante, 
alodinia, disestesias o escozor, apareciendo a su vez edemas, atrofia y debilidad 
muscular, disminución de reflejos osteotendinosos y pérdida de sensibilidad 
cuando la enfermedad continua su progresión (4–7). 
 
Como ya se ha comentado anteriormente, una de las características de la 
neuropatía diabética es la presencia de dolor, en cuyo caso se denomina 
neuropatía diabética dolorosa (en adelante NDD), que es definida por la Asociación 
Internacional para el estudio del Dolor como el dolor que surge como consecuencia 
directa de anomalías en el sistema somatosensorial en personas con DM (8). Éste 
proceso doloroso puede conllevar alteraciones en el plano psicológico y afectivo, 
además de incapacidades y deterioro en la calidad de vida de los pacientes (9–11). 
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Ante las importantes consecuencias de la neuropatía diabética dolorosa, existen 
diferentes tratamientos cuya función principal es intentar reducir el nivel de dolor 
que sufren estos pacientes (12–16). El arsenal terapéutico existente para el 
tratamiento de la NDD puede dividirse en 3 grupos claramente diferenciados: 
 
 Terapias farmacológicas orales, entre las que se encuentran los 
grupos farmacológicos denominados antidepresivos, antiepilépticos y 
opioides fundamentalmente. Un ejemplo de estos fármacos serían la 
gabapentina, pregabalina, duloxetina, tapentadol, o topiramato entre otros. 
 Terapias tópicas, cuyos principales agentes terapéuticos consisten en 
la aplicación de capsaicina tópica, clonidina, ketamina, entre otros. 
 Terapias físicas, las cuales se basan en terapias eléctricas o 
electromagnéticas, como son las terapias mediante TENS, FREMS, PENS  
magnetoterapia o neuroestimulación entre otros.  
 
Todas estas terapias componen un grupo de tratamientos en manos de los 
profesionales de la salud con el que conseguir que los pacientes alivien el dolor 
producido por la NDD y mejoren su calidad de vida.  
 
Justificación y pertinencia 
 
En la literatura científica existen diversas revisiones de importancia realizadas 
sobre los tratamientos para la NDD, cuyos resultados en gran mayoría coinciden, y 
son de gran utilidad a la hora de abordar dicha patología. Sin embargo, muchos de 
los artículos relacionados con el tratamiento de la NDD no cumplen criterios de 
calidad metodológica, y algunos de ellos son incluidos en las revisiones 
mencionadas anteriormente. A ello se une que gran parte de dichas revisiones 
tienen cierta antigüedad, y existen ensayos clínicos realizados posteriormente a las 
mismas, por lo que se hace más necesario aún la realización de revisiones más 
actualizadas con cierta calidad metodología en los estudios que se incluyan. 
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Los avances continuos en la investigación del manejo del dolor neuropático y la 
aparición de mayor cantidad de terapias diferentes y estudios más actualizados 
hacen necesario que los profesionales de Podología y resto de disciplinas 
relacionadas con la salud actualicen constantemente los conocimientos acerca de 
esta patología y sus tratamientos.  
 
En el caso del profesional de la Podología es mas importante si cabe debido a sus 
competencias en el abordaje de pacientes con DM y problemas en los pies, lo que 
conlleva a su vez estar capacitados para actuar ante las complicaciones del mismo, 
como es el caso de la neuropatía diabética y la aparición de dolor. A esto se le une 
que la presencia de pacientes con pie diabético es cada vez más frecuente en las 
consultas de Podología, siendo mas necesario si cabe la continua actualización de 
conocimientos en torno a la NDD. 
 
Debido a todo ello es por lo que se hace necesario la realización de este estudio, a 
través del cual se pretende obtener unos resultados actualizados sobre los 
tratamientos para la NDD que nos ayuden en la toma de decisiones para el correcto 
abordaje clínico de estos pacientes con el fin de aliviar el dolor que padecen. 
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MARCO TEÓRICO 
 
Diabetes Mellitus 
 
La Diabetes Mellitus es un desorden metabólico caracterizado por la presencia de 
hiperglucemia debida a una deficiente secreción de insulina, deficiente acción de la 
misma, o ambos (2). Esta hiperglucemia mantenida puede provocar daños 
orgánicos de relevante importancia por la presencia de enfermedades renales, 
oculares, cardiovasculares y neuropatías entre otros. La DM se clasifica en DM Tipo 
1, DM Tipo 2 y DM gestacional (1). La DM Tipo I se produce por la insuficiente o 
nula producción de insulina a través del páncreas, siendo la DM Tipo II generada 
por una inadecuada producción de esta hormona y la incapacidad del organismo a 
reaccionar a ella (1).  Se habla de DM gestacional cuando existe una primera cifra 
elevada de glucosa en sangre durante el proceso del embarazo (1). 
 
Según la Federación Internacional de Diabetes (en adelante FID) en su octava y 
última edición de 2017 (1), la DM afecta a nivel mundial a 425 millones de 
personas, 327 millones correspondientes a personas de edad comprendida entre 
20 – 64 años, y 98 millones a edades superiores a 65 años. Se estima que para el 
año 2045 estas cifras aumenten a un total de 629 millones de personas, 438 de 
ellas correspondientes a la horquilla de edad 20 – 64 años y 191 a 65 años en 
adelante. Estas cifras son de suma importancia sabiendo además que las muertes 
relacionadas con DM rondan los 4 millones de personas en 2017 (1). 
 
En cuanto a los datos a nivel europeo, los afectados por DM en 2017 se sitúan en 
58 millones de personas, estimándose para 2045 en 67 millones. Otro aspecto 
importante relacionado con la DM es su existencia sin diagnosticar, por lo que se 
cree que existen 22 millones de personas en Europa en esta situación. A nivel 
nacional, los datos sobre DM nos colocan en una prevalencia en torno al 10,4 %, 
con la importante cifra de 11.557,2 muertes relacionadas con esta enfermedad. 
Otro aspecto importante a destacar es la prevalencia de la enfermedad en los 
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pacientes varones hasta los 70 años, siendo más prevalente en mujeres a partir de 
esa edad (1).  
 
Los datos obtenidos por la FID reflejan una situación preocupante en cuanto a la 
prevalencia y mortalidad de la DM y sobre todo a las enfermedades que se 
relacionan con su existencia, las cuales pueden conllevar un serio deterioro de la 
vida del paciente. En este aspecto,  dos de los problemas derivados de la DM que 
más nos preocupan son las enfermedades cardiovasculares y la neuropatía 
diabética (1).  
 
Con respecto al grupo de enfermedades cardiovasculares, la enfermedad arterial 
periférica resulta de gran importancia para el tema que tratamos debido a su 
importante implicación en la aparición del pie diabético, como veremos a 
continuación (17). 
 
 Enfermedad arterial periférica  
 
La enfermedad arterial periférica es definida como un proceso clínico en el que se 
produce una oclusión o estenosis de trayectos arteriales, de miembros inferiores 
predominantemente, debido a un proceso ateroesclerótico (18,19). Esta 
ateroesclerosis es el resultado de un proceso por el que factores de riesgo 
producen fundamentalmente un acúmulo de lipoproteínas de baja densidad (LDL) 
en la capa túnica íntima de las arterias debido a un daño endovascular, siendo 
éstos oxidados por radicales libres generados en macrófagos, células endoteliales y 
células de músculo liso. Este proceso conlleva una respuesta del sistema inmune e 
inflamación que favorece a su vez el depósito de LDL en la pared arterial y un 
engrosamiento de la capa túnica íntima, creándose así un círculo vicioso donde se 
produce una reducción del espacio intravascular y la aparición de una placa de 
ateroma. En el caso de la DM, este proceso de formación ateroesclerótica se ve 
acelerado por la hiperglucemia mantenida fundamentalmente (20,21).  
 
La ateroesclerosis en la principal causa de enfermedad arterial periférica en 
personas mayores de 40 años, aumentando el riesgo de sufrirla aún más en 
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pacientes con DM. Se estima que en esa población el riesgo de padecer esta 
enfermedad es de 9,5 % en personas con DM frente al 4,5 % en personas sin DM 
(19).  
 
 Neuropatía diabética  
 
La otra afección de suma importancia que puede aparecer en los pacientes con DM 
es la neuropatía diabética, definiéndose como la presencia de síntomas o signos de 
disfunción del sistema nervioso periférico en el paciente con DM (3), una vez 
excluidas otras causas, ya que como se demostró en el estudio de Rochester en 
1993 alrededor del 10% de las neuropatías que se diagnosticaban como diabéticas 
no lo eran en realidad, sino que tenían una etiología diferente a la DM. Este mismo 
estudio apuntaba que aproximadamente entre el 60 – 70% de los pacientes con 
DM presentan algún tipo de neuropatía (22). La patogenia de la neuropatía 
diabética no se conoce con exactitud, existiendo varias teorías que relacionan su 
desarrollo a factores metabólicos, factores vasculares o trastornos en mecanismos 
de reparación y mantenimiento de fibras nerviosas periféricas (6). 
 
En la actualidad se considera la neuropatía periférica diabética como una de las 
complicaciones más frecuentes de la DM (7,23). La prevalencia a nivel nacional de 
esta afección se sitúa entre el 13% y 24% en pacientes con DM tipo 1 y DM tipo 2 
respectivamente (7). Dentro de la neuropatía diabética periférica, la forma mas 
común de presentación es la polineuropatía simétrica distal (Figura 1) (24,25). 
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Figura 1: Tipos de neuropatía diabética (7) 
 
La polineuropatía simétrica distal se caracteriza por una distribución denominada 
en guante y calcetín. Afecta en su inicio a las fibras nerviosas más pequeñas sin 
recubrimiento de mielina y que conducen la sensación térmica y dolorosa, seguido 
por la afectación de las fibras nerviosas más largas con recubrimiento de mielina 
que se encargan de la sensibilidad vibratoria y propioceptiva. Su evolución va de 
distal a proximal, siendo la afectación en los pies la mayoritaria, y la afectación en 
manos la minoritaria y tardía. La prevalencia de este tipo de presentación se sitúa 
en torno al 50 % en personas DM tipo 2 mayores de 60 años.  Los síntomas 
iniciales que suelen tener los pacientes van relacionados con la presencia de 
parestesias o entumecimiento, pudiendo aparecer también dolor quemante, 
alodinia, disestesias o escozor, todos ellos de predominio nocturno. Cuando la 
enfermedad va avanzando pueden aparecer edemas, atrofia y debilidad muscular, 
disminución de reflejos osteotendinosos y pérdida de sensibilidad. Todos estos 
síntomas pueden conllevar la aparición de procesos ulcerosos y la artropatía de 
Charcot (4–7).  
 
Neuropatía 
diabética 
Difusa 
Polineuropatía 
distal simétrica 
Autónoma 
Cardiovascular 
Gastrointestinal 
Urogenital 
Disfunción 
sudomotora 
Mononeuropatía Radiculopatía o 
poliradiculopatía 
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La presencia de estas dos patologías analizadas anteriormente puede conllevar 
una de las complicaciones mas determinantes en un paciente diabético, el 
denominado pie diabético. 
 
 Pie diabético 
 
Para la Organización Mundial de la Salud (en adelante OMS) el pie diabético 
consiste en la “presencia de ulceración, infección y/o gangrena del pie asociada a la 
neuropatía diabética y diferentes grados de enfermedad vascular periférica, 
resultados de la interacción compleja de diferentes factores inducidos por una 
hiperglicemia mantenida” (26).  
 
Se estima una prevalencia del pie diabético a nivel mundial que va del 3 % al 13 %, 
con un promedio del 6,4 %, estimándose también que entre el 15 % y 25 % de 
personas diabéticas sufrirán a lo largo de su vida un proceso ulceroso que puede 
conllevar la amputación del miembro (27).  
 
Según el Consenso sobre Úlceras Vasculares y Pie Diabético de la Asociación 
Española de Enfermería Vascular y Heridas (en adelante AEEVH) existen 3 tipos de 
factores que componen el síndrome del pie diabético (28): 
 
 Factores predisponentes: Neuropatía asociada en mayor o 
menor grado a una macro o microangiopatía. 
 Factores desencadenantes: Traumatismos mecánicos, 
térmicos o químicos. 
 Factores agravantes: Nos determinarán el pronóstico de la 
enfermedad, como la infección, la isquemia y la neuropatía. 
 
 Neuropatía diabética dolorosa 
 
Una vez analizado el síndrome del pie diabético y las patologías más importantes 
que lo componen, esta tesis pondrá el foco sobre uno de los síntomas más 
importantes derivados de la DM como es el dolor neuropático o también 
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denominado neuropatía diabética dolorosa, definida por la Asociación 
Internacional para el estudio del Dolor (en adelante IASP) como el dolor que surge 
como consecuencia directa de anomalías en el sistema somatosensorial en 
personas con DM (8). Este tipo de dolor tiene los principales signos y síntomas 
mostrados en la tabla 1 (29). 
 
Signos/síntomas dolor neuropático Signos/síntomas neuropatía 
diabética dolorosa 
Dolor urente espontáneo Dolor urente espontáneo 
Dolor disestésico espontáneo Dolor disestésico espontáneo 
Dolor espontáneo profundo opresivo  
Dolor espontaneo de otras cualidades Dolor espontáneo de otras cualidades 
Alodinia mecánica dinámica  
Alodinia mecánica estática  
Alodinia al calor  
Alodinia al frio  
Hiperalgesia mecánica  
Hiperalgesia al calor Hiperalgesia al calor 
Hiperalgesia al frío Hiperalgesia al frío 
Disestesias provocados por tacto Disestesias provocados por tacto 
Parestesias provocadas por tacto Parestesias provocadas por tacto 
Signo de Tinel que induce a hormigueos  
Signo de Tinel que induce dolor urente  
Dolor referido  
Distorsión de la cualidad de la sensación   
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Localización errónea de las sensaciones  
Patrones anormales de sumación 
temporal 
 
 
Tabla 1: Signos y síntomas relacionados con dolor neuropático y neuropatíaa 
diabética dolorosa (29) 
 
Esta complicación derivada de la DM genera un importante deterioro de la calidad 
de vida y altos grados de invalidez. Se estima que un 20 % de los pacientes con 
polineuropatía simétrica distal sufren dolor (10). A la repercusiónn fisiológica 
derivada de esta enfermedad se le une el aspecto psíquico o afectivo-emocional 
que también se ve afectado en estos pacientes. La combinación de todos estos 
factores genera un estado continuo de malestar y ansiedad en ellos que terminan 
por complicar la resoluciónn del problema (9,11).  
 
La NDD se trata mediante numerosas alternativas terapéuticas. Las formas más 
comunes de tratamiento son los fármacos antidepresivos, anticonvulsionantes, 
opioides y anestésicos locales entre otros, cuyo uso está avalado mediante diversos 
estudios por parte sociedades internacionales, revisiones Cochrane y guías de 
práctica clínica. Además de estos fármacos, la mayoría administrados por vía oral, 
existen otras formas de presentación también utilizadas comúnmente como 
parches o cremas, así como tratamientos no farmacológicos como son las 
denominadas terapias físicas, entre las que se destacan la magnetoterapia, la 
estimulación nerviosa transcutánea o la estimulación medular.  
 
Terapias utilizadas en el tratamiento del dolor neuropático 
 
 El tratamiento del dolor neuropático se basa fundamentalmente en el control de 
los signos y síntomas derivados de éste.  Existen diversas opciones de tratamiento 
para los pacientes que sufren este tipo de dolor, pudiéndose englobar en dos 
grupos bien determinados: los tratamientos farmacológicos (orales y tópicos) y las 
terapias físicas. 
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Tratamientos farmacológicos orales 
 
Componen un grupo de fármacos de diversas características pudiéndose clasificar 
según el tipo de fármaco (Tabla 2). Cabe destacar que el uso de analgesia de primer 
escalón (véase fármacos no opioides tales como paracetamol, nolotil, 
antiinflamatorios, entre otros) no es de elección para esta patología por su 
ineficacia. 
 
TRATAMIENTO FARMACOLÓGICO 
TIPOS 
 
EJEMPLOS 
Antidepresivos Amitriptilina, Duloxetina, Venlafaxina, Paroxetina… 
 
Antiepilépticos Gabapentina, Pregabalina, Oxcarbacepina, Topiramato… 
 
Opioides Tramadol, Oxicodona, Morfina, Fentanilo… 
 
Tratamientos 
tópicos 
Parche de Capsaicina 8%, Parche de Lidocaína 5%... 
 
Tabla 2: Tipos de fármacos usados para el tratamiento del dolor neuropático 
(13,30) 
 
1. Fármacos antidepresivos. 
 
Se trata de un grupo de fármacos de gran importancia por el habitual uso y 
efectividad en el tratamiento del dolor neuropático, aún no siendo su indicación 
primaria. El mecanismo de acción de estos fármacos para el alivio del dolor todavía 
sigue siendo algo relativamente desconocido. El alivio del dolor se consigue 
normalmente de manera rápida (pocos días) y a bajas dosis (31). Dentro de este 
grupo de fármacos nos podemos encontrar varios tipos: 
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 Antidepresivos tricíclicos (TCA): Amitriptilina, Imipramina 
 Inhibidores selectivos de la recaptación de serotonina (ISRS): 
Paroxetina 
 Inhibidores de la recaptación de serotonina y noradrenalina (IRSN): 
Duloxetina, Venlafaxina 
 
La dosis máximas diarias de estos fármacos van desde los 60-120 mg para la 
duloxetina, los 150-225 mg para la venlafaxina y los 25-150 mg para el resto de 
antidepresivos tricíclicos (30–32). 
 
2. Fármacos antiepilépticos 
 
Los fármacos antiepilépticos constituyen el otro grupo de más importancia para el 
tratamiento del dolor neuropático.  El mecanismo de acción de estos fármacos se 
basa fundamentalmente en las modificaciones que pueden realizar en los canales 
de Na+ y Ca++  (14,33).  
 
En la actualidad existen muchos fármacos utilizados para el dolor neuropático 
desde que en 1942 se usara por primera vez la fenitoína para el tratamiento de la 
neuralgia del trigémino (29,34). Los más utilizados a día de hoy son la pregabalina 
y gabapentina, cuyas dosis máximas diarias van desde los 300-600 mg de la 
pregabalina hasta los 1200-3600 mg de la gabapentina (14,16,35). 
 
Según el “Neuropathic Pain Special Interest Group (NeuPSIG)” de la “International 
Association for the Study of Pain (IASP)”, basándose en “Grading of 
Recommendations Assessment, Development, and Evaluation (GRADE)”, tanto los 
fármacos antiepilépticos como antidepresivos estarían incluidos en la primera 
línea de recomendación de tratamiento para el dolor neuropático (30). 
 
3. Opioides 
 
Los opioides son los fármacos analgésicos de amplio espectro más efectivos que 
existen para dolor de intensidad media o moderada, sin embargo, en procesos 
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crónicos su uso puede llegar a ser limitado. El mecanismo de acción de estos 
fármacos se basa en su acción a nivel de los receptores opioides. A día de hoy, la 
utilidad de los opioides en términos de seguridad y efectividad para el dolor 
neuropático no está definida. La limitación del uso de estos fármacos radica en la 
tolerancia y efectos secundarios que pueden provocar en el paciente, por lo que la 
vigilancia de estos signos y síntomas que puedan aparecer es realmente 
importante (36). 
 
Los opioides más utilizados para el tratamiento del dolor neuropático son 
tramadol  y oxicodona (14,37–40). Según neuPSIG, los opioides estarían incluidos 
en la segunda línea de tratamiento para el dolor neuropático (30). 
 
4. Tratamientos tópicos 
 
Con respecto a los tratamientos tópicos para el dolor neuropático nos 
encontraríamos principalmente con dos fármacos de uso más común: parches de 
lidocaína 5% y parche de capsaicina 8%. 
 
 Los parches de lidocaína 5% consisten en unos apósitos 
medicamentosos indicados fundamentalmente para el dolor neuropático 
tras infección por el virus del Herpes Zoster (neuralgia postherpética). Este 
apósito debe  estar colocado a lo largo del área dolorosa durante 12 horas 
en un periodo de 24 horas. La gran ventaja de esta terapia es la seguridad y 
tolerabilidad, con el único efecto adverso posible en forma de reacciones 
cutáneas provocadas por la hipersensibilidad (41). 
 
 El parche de capsaicina 8% es un tratamiento indicado en pacientes 
adultos con dolor neuropático periférico, sólo o en combinación con otros 
medicamentos para el dolor. La capsaicina es una sustancia química 
perteneciente al grupo de los anestésicos locales, cuyo origen se encuentra 
en una variante de las guindillas (42). Esta sustancia actúa como agonista 
de los TRPV1 (transient receptor potential vanilloid 1), activando los 
nociceptores cutáneos que expresan dicha sustancia, lo que provoca la 
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presencia de dolor y eritema. Tras la exposición a esta sustancia, dichos 
nociceptores pierden parte de su sensibilidad, lo que conlleva la aparición 
de alivio de dolor en el paciente. Esta perdida de sensibilidad es transitoria 
y temporal (43). En el caso de la capsaicina, no solo existe la presentación 
en parche al 8%, también se pueden encontrar dos versiones de este 
producto en cremas al 0,025% y 0,075% (44).  
 
Además de los fármacos descritos, también existen otros fármacos menos 
habituales, pero que su uso en algunos casos está en expansión para el tratamiento 
del dolor neuropático como son la clonidina tópica, Toxina Botulínica A y 
perfusiones intravenosas de lidocaína, entre otros (30,45–47).  
 
Con respecto a los tratamientos tópicos, en la mayoría de guías de recomendación 
se encuentran en un segundo nivel o escalón para el tratamiento del dolor 
neuropático, es decir, su utilización estaría indicada ante la ineficacia de fármacos 
orales o la imposibilidad del uso de los mismos (13,16,30,35,48).  
 
Tratamientos no farmacológicos 
 
Los tratamientos no farmacológicos se basan mayoritariamente en terapias 
intervencionistas con aplicación de energía, las cuales asumen el protagonismo del 
tratamiento del dolor neuropático periférico cuando los tratamientos 
farmacológicos no son suficientes para el alivio de dicho dolor.  
 
1. Estimulación nerviosa 
 
a. Estimulación medular 
 
La estimulación medular consiste en una cirugía mediante la que se implantan uno 
o más electrodos en el canal medular del paciente. Estos electrodos, conectados a 
un generador de corriente implantado, y mediante la programación de los 
parámetros asociados al tipo de estimulación como son frecuencia, ancho de pulso 
e intensidad, pretenden generar en el paciente una sensación agradable de 
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parestesia a lo largo de su área dolorosa que “enmascare” dicho dolor. A día de hoy 
comienzan a proliferar dispositivos que no generan dicha sensación de parestesia, 
sino que usan modos de estimulación de alta frecuencia o Burst®, denominados 
comúnmente como estimulaciones de tipo “Free Paresthesia” (49). 
 
Su mecanismo de acción se basó, a priori, en la teoría de la puerta de entrada de 
Wall y Melzack, sin embargo a día de hoy todavía no se conoce fielmente el origen 
del alivio del dolor mediante estímulos eléctricos medulares (50). 
 
Son múltiples los estudios que avalan su uso en dolor neuropático periférico, 
especialmente en casos de neuropatía diabética o neuralgia postherpética, entre 
otros (51,52). 
 
 
Imagen 1: Electrodos implantados en columna dorsal (Imagen propia) 
 
 
Imagen 2: Modelo de sistema de neuroestimulación (Imagen propia) 
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b. Estimulación nerviosa transcutánea (TENS) 
 
La terapia TENS es otra alternativa para el tratamiento del dolor neuropático 
periférico, que consiste en la colocación de electrodos adhesivos en la piel 
conectados a un generador de corriente. Dicho generador puede ser modificado en 
términos de intensidad, duración y frecuencia, pudiendo programarse ésta última 
como baja frecuencia (igual o < 10 Hz) o alta frecuencia (50-100 Hz o superior) 
(53).  
 
Su uso constituye un elemento más para el alivio del dolor, pudiendo ser 
combinado con tratamientos farmacológicos, sin embargo, la calidad de la 
evidencia de los estudios clínicos sobre esta terapia aún es relativamente baja (53). 
 
c. Estimulación nerviosa periférica (PNS) 
 
Este tipo de terapia actúa de forma similar a la estimulación medular. La diferencia 
radica en la colocación del electrodo, ya que éste debe ser colocado en la región 
próxima al nervio periférico afectado. Su mecanismo de acción y los parámetros de 
ajuste son similares a la estimulación medular (54).   
 
Su eficacia ha sido demostrada para patologías tales como cefalea en racimos, 
neuralgia postherpética,  neuralgia del trigémino, neuralgia femorocutánea, entre 
otros (55,56). 
 
2. Radiofrecuencia 
 
a. Radiofrecuencia convencional 
 
La radiofrecuencia es considerada como un procedimiento mínimamente invasivo 
para el tratamiento del dolor cuya técnica consiste en la introducción de una aguja 
a través de la piel que se coloca cercana a la localización de la zona afectada. Esta 
aguja va conectada a un generador de radiofrecuencia mediante el cual se aplica un 
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voltaje determinado que conlleva el aumento de temperatura en la zona de 
aplicación de la aguja. La finalidad de esta terapia es la destrucción tisular, y es 
conocida como radiofrecuencia convencional (57).  
 
Una de sus grandes indicaciones es la neurolisis del ganglio de Gasser para la 
neuralgia del trigémino (58). 
 
b. Radiofrecuencia pulsada 
 
La radiofrecuencia pulsada es prácticamente similar a la convencional, sin 
embargo, su gran diferencia es que no tiene carácter destructivo en los tejidos. El 
generador de corriente realiza una actividad mediante pulsos cíclicos, por lo que la 
temperatura alrededor de la punta de la aguja no aumenta por encima de un nivel 
que pueda lesionar (42º). No existe un criterio único para definir la influencia de la 
radiofrecuencia pulsada en las estructuras nerviosas. Aunque su uso comienza a 
ser habitual para el manejo del dolor neuropático siendo una alternativa eficaz en 
la neuralgia postherpética, no queda del todo claro los beneficios reales en otros 
tipos de patología por dolor neuropático (58,59). 
 
Centrándonos en el tratamiento no farmacológico de la neuropatía diabética,  
existen más terapias utilizadas en la literatura científica como son la terapia 
magnética (60–63), acupuntura (64–66), u otras terapias de estimulación nerviosa 
como PENS (Percutaneous electrical nerve stimulation) (67) o FREMS (Frequency-
modulated electromagnetic neural stimulation) (68). Todas estas terapias tienen 
escasos ensayos clínicos aleatorizados publicados, y las principales revisiones y 
guías de recomendación de tratamiento para la NDD les otorgan un nivel bajo de 
recomendación o incluso ni las mencionan (13,14,16,30,35,48,69).  
 
Escalas y cuestionarios de medición del dolor 
 
A la hora de hablar del dolor es inevitable hablar también sobre su valoración, y 
dicha valoración la hacemos mediante el uso de cuestionarios o escalas. A lo largo 
de la literatura científica existen multitud de estudios sobre el dolor que obtienen 
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sus resultados a través del uso de escalas, sin embargo no existe un criterio único a 
la hora de la elección de una determinada escala o cuestionario, y también hay que 
tener en cuenta su nivel de validez.  
 
De las escalas y cuestionarios más utilizados y revisados en estudios de diferentes 
ámbitos podemos destacar los siguientes: 
 
1. Escalas numéricas 
 
Es uno de los métodos mas comunes a la hora de realizar una valoración del dolor. 
Para el paciente se trata de un elemento de valoración bastante sencillo en el cual 
debe determinar en una escala de 0 a 10 o de 0 a 100 el nivel mínimo y máximo de 
dolor que percibe (70). 
 
2. Escala análoga visual (EVA) 
 
Al igual que con la escala numérica, se trata de un método de valoración sencillo de 
usar y de entender por parte del paciente. La escala EVA se basa en una línea 
dibujada en la que aparece en un extremo el 0 y en el otro extremo aparece el 10, 
siendo 0 la inexistencia de dolor y 10 el peor dolor imaginable (Figura 2). El 
paciente tiene que señalar su nivel de dolor a lo largo de esa línea (70). 
 
 
 
 
Figura 2: Escala EVA 
 
 
 
 
No dolor                                                                       Dolor insoportable 
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3. Escala de imágenes faciales 
 
Esta escala es de gran utilidad en pacientes pediátricos o personas con déficit 
intelectual (Figura 3). Se trata de una escala donde aparecen 6 caras que expresan 
de forma progresiva desde una cara llorosa a una cara de felicidad (71,72).  
 
 
 
Figura 3: Escala de imágenes faciales (73) 
 
 
4. McGill Pain Questionaire (MPQ) 
 
Uno de los más famosos y utilizados sistemas de evaluación multidimensional del 
dolor, creado en 1975 por el Dr. Ronald Melzack. Este instrumento de medida se 
basa en 4 subclases que son sensorial, afectiva, evaluativa y miscelánea del dolor, 
además de respuestas al Pain Rating Index (PRI), que contiene 78 descriptores del 
dolor y 20 subclases a su vez, y una escala de intensidad del dolor de 5 puntos 
(Present Pain Intensity (PPI)). Cuanto más alta sea la puntuación obtenida en MPQ, 
más alto será el nivel de dolor del paciente (74). También existe una versión corta 
de esta escala denominada SF-MPQ (75) (Figura 4).  
Sin dolor                         Muchísimo Dolor 
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Figura 4: SF McGill Pain Questionnaire (75) 
 
 
5. Brief Pain Inventory (BPI) 
 
Esta escala es uno de los instrumentos de medida multidimensional del dolor más 
usados hoy en día, proporcionando una percepción rápida de la intensidad del 
dolor así como interfiere este dolor en la funcionalidad del paciente. 
Originariamente se utilizaba solo en pacientes que presentaban un dolor de tipo 
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oncológico, sin embargo, su uso con el paso de los años ha sido validado para 
dolores crónicos no malignos entre otras patologías (76). Este instrumento 
permite a los pacientes valorar la intensidad del dolor en función de si es peor, si 
es menor, dolor de media e intensidad actual, además de siete dominios de 
funcionamiento como son la actividad general, estado de ánimo, la capacidad para 
caminar, el trabajo habitual, las relaciones con otras personas, el sueño, y el 
disfrute de la vida, todo ello reflejado en una escala de 0 a 10 (77,78). 
 
De esta escala también cabe destacar la existencia de una versión más acotada 
denominada SF-BPI, la cual se usa con más frecuencia en investigaciones y 
aspectos clínicos, y estando validada en pacientes españoles con dolor de etiología 
no oncológica (79). 
 
Además de estos 5 cuestionarios o escalas descritas anteriormente, también se 
encuentran descritas otras que tienen como finalidad la valoración del dolor de 
tipo neuropático. Entre las mas destacadas se encuentran las siguientes:  
 
1. Neuropathic Pain Questionnaire (NPQ) 
 
Esta herramienta creada por Krause y Backonja en 2003 consiste en un 
cuestionario de 12 ítems, donde los diez primeros están relacionados con la 
percepción del dolor y los otros dos con las situaciones que causan un cambio en 
dicho dolor. Estos 12 ítems se valoran en escalas de 0 a 100, y las puntuaciones 
obtenidas son multiplicadas por unos coeficientes predeterminados. 
 
Tras el cálculo de la operación se predice que valores inferiores a 0 tendrán un 
dolor no neuropático, y valores iguales o superiores a 0 tendrán un dolor 
neuropático (80). 
 
2. ID-PAIN 
 
Se trata de un cuestionario breve  autoadministrable creado por Portenoy en 2006 
(81). Se componen de 3 apartados:  
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 Apartado 1: consta de dos preguntas relacionadas con la presencia 
de dolor, y si este está presente en cabeza o en forma de migraña. 
 Apartado 2: muestra una imagen corporal donde el paciente debe 
señalar la localización del dolor. 
 Apartado 3: consta de 6 preguntas relacionadas con las 
características del dolor en la última semana.  
 
Para evaluar los resultados se valora solo el apartado 3, donde una respuesta 
afirmativa en las 5 primeras preguntas otorga 1 punto por cada una y negativa 0 
puntos, y una respuesta positiva en la 6 pregunta otorga -1 punto. Puntuaciones 
totales entre -1 y 5 sugieren la presencia de componente neuropático (Anexo 1). 
 
Este tipo de cuestionario tiene una adaptación y validación al castellano por parte 
de Rafael Gálvez y colaboradores en 2008 (82). 
 
3. Douleur Neuropathique en 4 questions (DN4) 
 
El cuestionario DN4 fue creado por Bouhassira y colaboradores en 2005 (83). Está 
compuesto por un total de 10 ítems divididos en 4 secciones, donde los 7 primeros 
corresponden a preguntas relacionadas con las características del dolor y los 3 
restantes con un examen neurológico de la zona dolorosa. Las respuestas 
afirmativas son puntuadas con 1 punto y las negativas con 0 puntos, por lo que la 
máxima puntuación es 10 y la mínima es 0. Para considerar la presencia de dolor 
neuropático se debe obtener una puntuación igual o superior a 4 puntos (Anexo 2). 
 
 Al igual que en el cuestionario ID-Pain, existe una versión española validada 
realizada por Concepción Pérez y colaboradores en 2007 (84). 
 
4. Leeds assessment of neuropathic symptoms and signs (LANSS) 
 
La escala LANSS fue la primera herramienta desarrollada para la valoración del 
dolor neuropático, en concreto fue creada por Bennett en 2001 (85). Esta escala, 
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realizada por un entrevistador entrenado para ello, consta de ítems agrupados en 
dos secciones (Anexo 3).  
 
En la primera sección se realizan cinco preguntas relacionadas con las 
características propias del dolor neuropático, otorgándose 0 puntos en caso de 
ausencia de manifestación, y de 1 a 5 puntos según cada ítem si existe dicha 
sintomatología.  
 
En la segunda sección se realiza un análisis sensorial mediante dos preguntas para 
las cuales se utilizan instrumentos como una torunda de algodón y una aguja. En 
caso de no obtenerse respuesta a la estimulación mediante estos instrumentos se 
obtendrá una puntuación de 0, y en caso positivo se obtendrán 5 y 3 puntos 
respectivamente. 
 
Una puntuación total igual o superior a 12 indica la presencia de mecanismos 
neuropáticos que contribuyen al dolor del paciente. 
 
Para esta escala también existe una versión validada al español a cargo de 
Concepción Pérez y colaboradores en 2006 (86). 
 
5. painDETECT 
 
PainDETECT es un cuestionario auto-administrado desarrollado para detectar de 
forma rápida la presencia de un componente neuropático del dolor. Este 
cuestionario fue por primera vez desarrollado y validado en alemán por 
Freynhagen y colaboradores en 2005 (87). Esta escala consta de 4 bloques 
diferenciados (Anexo 4): 
 
 Bloque 1: contiene 3 ítems relacionados con la intensidad de dolor 
actual y en las últimas 4 semanas. Se valora la intensidad mediante una 
escala Likert de 11 puntos donde 0 es “no dolor” y 10 es “máximo dolor”. 
 Bloque 2: se representan 4 gráficas que describen el curso del dolor. 
Las puntuaciones van desde -1 a + 1 según el ítem seleccionado.  
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 Bloque 3: el tercer bloque representa un mapa sensorial 
caracterizado por una figura humana en posición frontal y de espaldas. En 
ella se le pide al paciente que dibuje donde localiza el dolor, si existen la 
presencia de irradiación, y en ese caso que dibuje también hacia donde se le 
irradia. En el caso que la respuesta acerca de la irradiación sea positiva se 
sumaran dos puntos. 
 Bloque 4: consta de 7 ítems relacionados con las características del 
dolor y sus factores asociados. Se valora mediante escala Likert de 6 puntos 
donde 0 es “nunca” y 5 es “muy intenso” 
 
La puntuación total de esta escala oscila entre el 0 y los 35 puntos, interpretándose 
el resultado de la siguiente manera: 
 
 Puntuación de 0 a 12: poca probabilidad de componente neuropático 
(<15%). 
 Puntuación de 12 a 18: resultado ambiguo, aunque puede existir 
componente neuropático. 
 Puntuación de 18 a 35: alta probabilidad de presencia de 
componente neuropático (>90%). 
 
Al igual que en escalas anteriores, existe una versión validada al español por José 
de Andrés y colaboradores en 2012 (88). 
 
Además de las escalas existentes y analizadas anteriormente, existe también una 
herramienta  para la detección del dolor neuropático localizado llamada 
“Screening Tool”, facilitada por la Sociedad Española del Dolor (89).  
 
Esta herramienta permite confirmar la existencia del dolor neuropático localizado 
mediante 4 ítems relacionados con el principal motivo de consulta y apartados 
relacionados con la anamnesis, anatomía, pruebas sensoriales y extensión de la 
zona dolorosa. A través de las respuestas de los diferentes apartados se 
comprueba mediante un algoritmo la presencia de dolor neuropático localizado.  
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Antecedentes y estado actual de conocimiento sobre el problema de 
investigación 
 
La neuropatía diabética dolorosa es una enfermedad que viene siendo  investigada 
desde hace varias décadas, siendo una línea común el desconocimiento de la 
etiología y la presencia de los mismos signos y síntomas. 
 
A principios de los años 70 se comenzaron a describir las características del dolor 
asociado a la neuropatía diabética. Lo describían como una sensación de 
quemazón, parestesias y dolores punzantes, que tenían predominio nocturno, y 
podían provocar la presencia de insomnio y depresiones. Su distribución por sexos 
se creía predominantemente masculina, y el inicio de la terapia con insulina a 
veces mejoraba los síntomas y otras los empeoraba inexplicablemente. El 
tratamiento era complejo, con una prolongación de los síntomas importante, 
siendo el uso de antidepresivos y analgésicos no adictivos las preferencias 
farmacológicas para su cura. Se entendía que los síntomas que padecían los 
pacientes por esta enfermedad podían durar desde pocos meses hasta dos años 
(90–93). 
 
Desde finales de los años 70 a finales de los 80, la literatura científica existente 
refleja el uso de diversos tratamientos para la NDD diferentes a los utilizados 
tradicionalmente, de todos ellos caben destacar los siguientes. 
 
 Infusión subcutánea de insulina: los estudios que analizan dicha 
terapia corren a cargo de Boulton y colaboradores en 1982 (94) y 
Bertelsmann y colaboradores en 1987 (95). En el primero se realiza un 
análisis de la efectividad de la aplicación de esta terapia en 9 pacientes a los 
que se le realiza una medición del dolor a las 6 semanas y a los 4 meses; se 
concluye que, además del beneficio obtenido en cuanto a cifras de glucemia, 
el dolor en estos pacientes disminuye significativamente, sin embargo, no 
excluyen el efecto placebo y refieren la dificultad real de medición de los 
síntomas del dolor en este tipo de pacientes. En el segundo estudio se 
analiza la terapia en 15 pacientes a lo largo de 12 meses, en los cuales 
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reportan, al igual que en el estudio de Boulton y colaboradores, una mejoría 
en las cifras de glucemia y en la percepción del dolor, además de una 
mejoría en la función de los nervios periféricos.  
 
 Inhibidor de la aldosa reductasa: este fármaco también llamado 
Sorbinil fué analizado en tres ensayos clínicos con grupo placebo, dos de 
ellos a cargo de Jaspan y colaboradores (96), en los que se medía la 
percepción del dolor y la función nerviosa. En todos ellos se obtiene en la 
mayoría de los pacientes una disminución del dolor (incrementándose éste 
cuando detenían la toma de medicación) y una mejoría en la función 
nerviosa autónoma (96–98). Sin embargo, en un ensayo clínico a cargo de 
Lewin y colaboradores (99), se estudió la administración de Sorbinil 200 
mg diarios en 4 semanas a 13 pacientes en los que se analizó la función 
nerviosa sensitiva, motora y autónoma, la duración del sueño y el nivel del 
dolor; en ninguno de estos aspectos se reportó mejoría, no encontrándose 
beneficio ninguno con el tratamiento mediante Sorbinil. 
 
 Perfusión intravenosa de lidocaína: se describen varios artículos en 
la literatura científica con el uso de infusiones de lidocaína a 5 mg/kg de 
peso corporal. Todos estos artículos han sido llevados a cabo por Kastrup y 
colaboradores donde se analizan los signos y síntomas de neuropatía 
además del nivel del dolor, determinándose como una terapia efectiva en la 
reducción del dolor (100–102).  
 
A finales de los años 80 y principios de los 90 nos encontramos que en la literatura 
científica comienzan a surgir estudios que analizan la efectividad de la terapia 
mediante capsaicina en la NDD. La capsaicina es una sustancia que proviene de los 
pimientos picantes o guindillas, cuyo mecanismo de acción en humanos se basa en 
la deplección de la sustancia P, principal neurotransmisor del dolor, a través de las 
fibras nerviosas aferentes nociceptivas tipo C (42). El auge del tratamiento de 
capsaicina se basó en un estudio realizado por Ross y Varipapa en 1989 donde 
reportaron dos casos de pacientes diabéticos con dolor neuropático que fueron 
tratados satisfactoriamente con capsaicina tópica (103). A raíz de ahí comenzaron 
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a surgir multitud de estudios en los que analizaban su efectividad como terapia 
tópica al 0.075% y dando resultados realmente positivos en cuanto a alivio del 
dolor, por lo que rápidamente comenzaron a recomendar e incluir su uso como 
tratamiento habitual en la NDD (103–106). Es tal la revolución del tratamiento de 
la NDD con capsaicina que se crea un grupo de estudio denominado “The Capsaicin 
Study Group” formado por profesionales de prestigio en este ámbito, los cuales 
aportan dos estudios destacados en los que mediante ensayos clínicos 
aleatorizados con grupo control analizan el alivio del dolor, la presencia de efectos 
adversos y la influencia del beneficio de la terapia en las actividades de la vida 
diaria. Los resultados que obtienen señalan a la capsaicina tópica al 0.075% como 
un tratamiento, sólo o en combinación con otras terapias, efectivo para la NDD 
(107,108). 
 
En la década de los 90 se siguen desarrollando investigaciones en el tratamiento de 
la NDD. Además de la continua investigación con capsaicina, se realizaron estudios 
destacables como la aplicación de clonidina tópica mediante parches cuyos 
resultados no son muy positivos en términos de alivio del dolor, y sugieren la 
necesidad de realizar mas ensayos clínicos sobre esta terapia para poder 
determinar qué tipo de paciente en concreto puede beneficiarse de ella (109,110). 
La mexiletina, fármaco oral derivado de la lidocaína, es otro de los tratamientos 
analizados en esta época. Existen varios artículos donde se estudia su uso a dosis 
diarias de 10 mg/kg de peso, 225 mg, 550 mg y 675 mg, siendo ésta última la más 
efectiva en cuanto a alivio del dolor se refiere. Dichos artículos destacan también la 
seguridad del fármaco, la escasez de efectos secundarios, y sobre todo la ausencia 
de problemas cardiovasculares asociados (111–114).  
 
Surge también durante esta década los primeros estudios que analizan las terapias 
eléctricas y la acupuntura en los pacientes con NDD. En un primer artículo 
publicado en 1997 por Armstrong y colaboradores se evidenció por primera vez la 
inexistencia de estudios que valorasen la terapia física en pacientes con NDD 
(115). En este estudio piloto se aplicó, mediante electrodos, a 10 pacientes una 
corriente pulsada a 100 Hz, con una intensidad de 50 V durante 10 minutos por 
cada hora de terapia (8 horas por la noche en total). El seguimiento de estos 
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pacientes se realizó durante 4 semanas más 1 mes posterior sin terapia, 
obteniéndose una reducción significativa del dolor mediante escala VAS y 
sugiriendo la necesidad de realizar más ensayos clínicos que certifiquen los 
resultados de este estudio piloto. En un segundo artículo publicado en 1999 por 
Somers se reporta un caso clínico de una paciente de 73 años con NDD severa a la 
que se le aplica la terapia mediante TENS en zona lumbar (116). A dicha paciente 
se la aplica la terapia TENS en fase inicial a 80 Hz durante 20 minutos al día, 
terminando la paciente por auto-administrarse la terapia durante 1-2 horas al día 
con predominio nocturno. Los resultados obtenidos sugieren la efectividad de la 
terapia y la necesidad de más estudios relacionados con ella para aliviar la NDD. 
Un tercer estudio analiza el uso de la acupuntura para el alivio de la NDD en 46 
pacientes aplicándola mediante los puntos acupunturales descritos en la Medicina 
Tradicional China durante 6 sesiones (1 mes aproximadamente) (117). Tras el 
análisis de los resultados se concluye, al igual que en los casos anteriores, la 
necesidad de más estudios de características similares y la presencia de la 
acupuntura como una alternativa terapéutica a las terapias farmacológicas 
convencionales de tratamiento de la NDD.  
 
Otro acontecimiento importante a finales de la década de los 90 es la aparición de 
los primeros estudios que valoran el tratamiento de la NDD con opioides o con 
gabapentina. En el primer caso, los dos estudios más relevantes corren a cargo de 
Harati y colaboradores, y en ellos se valora el tratamiento con tramadol a corto 
plazo (42 días) y largo plazo (6 meses) a dosis diarias (como máximo) de 400 mg 
con resultados positivos en cuanto a alivio de dolor, pero la aparición de algunos 
efectos no deseados como somnolencia o nauseas, aunque según los autores, mejor 
tolerados por los pacientes que los efectos secundarios de antidepresivos y 
antiepilépticos (38,118). En el segundo caso comienzan a aparecer estudios que 
analizan la efectividad de la gabapentina en el tratamiento de la NDD, en concreto 
en el artículo publicado por Gorson y colaboradores se administra gabapentina a 
19 pacientes (21 pacientes placebo) a dosis máxima de 900 mg/día siendo 
mínimamente efectivo en los mismos y reclamando la posibilidad de mayor 
efectividad en estudios que aumenten la dosis diaria (119). Otros artículos 
publicados al respecto analizan lo reclamado en el artículo de Gorson, la 
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administración de gabapentina a dosis superiores (3600 mg/día máximo) 
obteniéndose alivio importante del dolor en los pacientes con NDD (120). 
 
A partir del año 2000 la literatura científica en torno al tratamiento de la NDD 
comienza a ser muy amplia y diversa. Empiezan a proliferar estudios en los que 
analizan todos los tratamientos farmacológicos y/o no farmacológicos para la NDD 
con la finalidad de crear líneas de recomendación al respecto (121–124). También 
comienzan a surgir estudios que analizan la combinación de fármacos para el 
tratamiento de la NDD, como por ejemplo gabapentina y venlafaxina (125), 
paroxetina o citalopran más gabapentina (126) o amitriptilina y duloxetina (127). 
Además de todo ello, siguen surgiendo nuevos estudios sobre terapias no usadas 
anteriormente en la NDD como son por ejemplo la pregabalina (128–130), 
zonisamida (131), parches de lidocaína al 5% (132,133) o compuestos de nitrato 
en forma de parches o sprays (134,135). 
 
Toda esta aparición masiva a lo largo de los años de contenido científico en torno 
al tratamiento de la NDD desemboca en la creación de diversas guías de 
recomendación o revisiones de la literatura por parte de asociaciones o grupos 
especializados en la materia. A día de hoy, se pueden considerar como las más 
relevantes las siguientes: 
 
 Revisiones Cochrane: se han descrito numerosas revisiones sobre el 
tratamiento del dolor neuropático elaboradas y publicadas bajo las 
recomendaciones de este reconocido organismo como es Cochrane. En ellas 
se han revisado tratamientos enfocados no solo para el dolor neuropático 
en general, sino también para la NDD. Entre las revisiones más destacadas 
nos encontramos las siguientes: 
o Opioides para el dolor neuropático (36). 
o Antidepresivos para el dolor neuropático (136). 
o Duloxetina para el tratamiento de la neuropatía dolorosa, el 
dolor crónico o la fibromialgia (137). 
o Inhibidores de la aldosarreductasa para el tratamiento de la 
polineuropatía diabética (138).  
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o Capsaicina tópica (baja concentración) para el dolor 
neuropático crónico en adultos (44). 
o Farmacoterapia combinada para el dolor neuropático en 
adultos (139). 
 
 Revisión sistemática de NeuPSIG: como ya se mencionó 
anteriormente, se trata de una revisión sistemática con meta-análisis 
realizada acorde a GRADE (Grading of Recommendations, Assessment, 
Development and Evaluation) sobre farmacoterapia para el tratamiento del 
dolor neuropático en adultos. Fueron incluidos 229 artículos sobre terapias 
farmacológicas para la NDD, incluidas también las terapias farmacológicas 
combinadas. Los resultados obtenidos se reflejan tabla 3 (30): 
 
Clasificación 
GRADE 
Fármacos Dosis diaria Recomendaciones 
FUERTE PARA Gabapentina  
Gabapentina ER/enacarbil 
Pregabalina  
IRSN duloxetina/venlafaxina 
TCA 
1200 – 3600 mg TID 
1200-3600 mg BID 
300 – 600 mg BID 
60 – 120 QD (duloxetina), 150 – 225 mg QD 
(venlafaxina ER) 
25 – 150 mg QD o BID 
Primera línea 
Primera línea 
Primera línea 
Primera línea 
Primera línea 
DÉBIL PARA Parche capsaicina 8% 
Parche lidocaína 5% 
Tramadol 
Toxina botulínica A (SC) 
Opioides fuertes 
1-4 parches en el área dolorosa durante 30-60 
minutos cada 3 meses 
1-3 parches en el área dolorosa hasta 12 horas 
200 – 400 mg BID (tramadol ER) o TID 
50–200 unidades en el área dolorosa cada 3 
meses 
Dosificación individualizada  
Segunda línea (PNP) 
Segunda línea (PNP) 
Segunda línea 
Tercera línea: uso 
especialista (PNP) 
Tercera línea  
INCONCLUSO Terapia combinada 
Crema capsaicina 
Carbamacepina 
Clonidina tópica 
Lamotrigina 
Lacosamida 
Oxcarbacepina 
Tapentadol 
Topiramato 
Zonisamida  
  
DÉBIL CONTRA Cannabionides 
Valproato  
  
FUERTE CONTRA Levetiracetam  
Mexiletina  
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ER: Extended Release 
QD: dosis única diaria 
BID: dos dosis al día 
TID: tres dosis al día 
PNP: Peripheral Neuropathic Pain 
SC: Subcutáneo 
Tabla 3: Recomendaciones basadas en la clasificación GRADE (30) 
 
 Guía clínica NICE: se trata de una guía clínica elaborada por National 
Institute for Health and Care Excellence (en adelante NICE) sobre 
tratamiento farmacológico del dolor neuropático para personal no 
especialista en dolor (140). Esta guía recoge 115 estudios sobre dolor 
neuropático, de los cuales 11 tienen un origen central, 16 un origen mixto y 
88 un origen periférico. Las recomendaciones otorgadas para este último, 
donde se encuentra la NDD, serían las siguientes: 
 
o Como tratamiento inicial elegir entre los fármacos 
amitriptilina,  duloxetina, gabapentina o pregabalina. 
o Si uno de los tratamientos iniciales elegidos no funciona o no 
es bien tolerado, utilizar otro de los mencionados anteriormente, 
cambiándolo a su vez si sigue sin funcionar el elegido. 
o Considerar el uso de tramadol sólo en los casos agudos donde 
sea necesaria analgesia de rescate. 
o Considerar la capsaicina tópica en forma de crema como 
tratamiento en dolor neuropático periférico localizado en pacientes 
que no deseen o no toleren fármacos orales. 
 
 Guía EFNS: se trata de una guía elaborada por la European Federation 
of Neurological Societies  que recoge un total de 64 ensayos clínicos 
aleatorizados controlados sobre fármacos vs placebo o comparaciones. En 
esta guía se incluye un apartado para polineuropatías dolorosas tanto en 
pacientes diabéticos como no diabéticos cuyas recomendaciones se pueden 
observar en la tabla 4 (13): 
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Etiología Nivel A para 
eficacia 
Nivel B para eficacia Nivel C para 
eficacia 
Nivel A/B para 
ineficacia o 
resultados 
discrepantes 
Recomenda
ciones de 
primera 
línea 
Recomendaciones 
de segunda y 
tercera línea 
Neuropatía 
diabética 
dolorosa 
Duloxetina 
Gabapentina- 
morfina 
TCA 
Agonistas de 
nicotina 
Derivados del 
nitrato 
Oxicodona 
Pregabalina 
Tramadol solo 
o tramadol + 
paracetamol 
Venlafaxina 
ER 
Toxina botulínica 
Dextrometorfano 
Gabapentina/venlafaxina 
Levodopa 
 
Carbamacepina 
Fenitoína 
Crema de capsaicina 
Lacosamida 
Lamotrigina 
Memantine 
Mexiletina 
Antagonistas NK1 
Oxcarbacepina 
IRSS 
Clonidina tópica 
Topiramato 
Valproato 
Zonisamida 
Duloxetina 
Pregabalina 
Gabapentina 
TCA 
Venlafaxina ER 
Opioides 
Tramadol 
Tabla 4: Clasificación de la evidencia según el fármaco en dolor neuropático de 
origen diabético (13). 
 
 Revisión AAN: se trata de una revisión sistemática sobre los 
tratamientos para la NDD realizada por la American Academy of Neurology 
(en adelante AAN), the American Association of Neuromuscular and 
Electrodiagnostic Medicine, y the American Academy of Physical Medicine 
and Rehabilitation (48). Se trata de la única revisión que incluye terapias no 
farmacológicas para el tratamiento de la NDD. En la tabla 5 se puede ver el 
nivel de recomendación de las diferentes terapias analizadas en la revisión: 
 
 Fármaco recomendado y dosis No recomendado 
Nivel A Pregabalina 300-600 mg/día  
Nivel B Gabapentina 900-3600 mg/día 
Valproato sódico 500-1200 mg/día 
Venlafaxina 75-225 mg/día 
Duloxetina 60-120 mg/día 
Amitriptilina 25-100 mg/día 
Dextrometorfano 400 mg/día 
Sulfato de morfina, dosificado hasta 120 
Oxcarbacepina 
Lamotrigina 
Lacosamida 
Clonidina  
Pentoxifilina 
Mexiletina 
Magnetoterapia 
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mg/día 
Tramadol 210 mg/día 
Oxicodona 37 mg (media), 120 mg 
(máximo) 
Capsaicina 0,075% QID 
Spray de dinitrato de isosorbida  
Estimulación eléctrica, estimulación 
nerviosa percutánea, x 3-4 semanas 
Laserterapia a baja intensidad 
Reiki  
Tabla 5: Resumen de recomendaciones según AAN (48) 
 
 Guía de práctica clínica AACE: realizada por American Association Of 
Clinical Endocrinologists (en adelante AACE) y American College Of 
Endocrinology, esta guía de práctica clínica surge para desarrollar un plan 
de cuidados para la comprensión de la DM (69). En ella se hace referencia al 
manejo de la NDD en su pregunta número 11: ¿Cómo se diagnostica y se 
trata la neuropatía en los pacientes con DM?. A esta pregunta la AACE 
responde lo siguiente: 
 
o Antidepresivos tricíclicos, anticonvulsionantes e inhibidores 
de la recaptación de serotonina y noradrenalina deben ser 
considerados para el tratamiento de la NDD, con un grado de 
recomendación A y un nivel 2 de evidencia. 
 
 Recomendaciones ADA: se trata de un documento creado por la 
American Diabetes Association (en adelante ADA) sobre aspectos como la 
prevención, diagnostico evaluación y tratamiento, entre otros, de 
neuropatías diabéticas, fundamentalmente polineuropatía simétrica distal y 
neuropatía cardiovascular autónoma (14). En concreto, en el apartado de 
tratamiento del dolor, la ADA realiza las siguientes recomendaciones: 
 
o Considerar la pregabalina o duloxetina como tratamiento 
inicial de los síntomas del dolor neuropático en DM. Grado de 
recomendación A. 
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o Gabapentina también puede ser usado como tratamiento 
inicial, teniendo en cuenta el estatus socio-económico del paciente, 
comorbilidades y potenciales interacciones farmacológicas. Grado de 
recomendación B. 
o Aunque su uso no está aprobado por la Food and Drug 
Administration (en adelante FDA), los antidepresivos tricíclicos son 
efectivos en el dolor neuropático en DM pero deben ser usados con 
precaución por alto riesgo de efectos adversos serios. Grado de 
recomendación B. 
o Debido al alto riesgo de adicción y otras complicaciones, los 
opioides, incluidos tapentadol y tramadol, no se recomiendan como 
tratamientos de primera ni segunda línea para el dolor en pacientes 
con polineuropatía simétrica distal. 
 
Además de todas las terapias vistas anteriormente cabe destacar otro  tipo de 
terapia que, a pesar de no ser realizada ni manejada por los profesionales de la 
podología sino por facultativos anestesistas y/o neurocirujanos y personal de 
enfermería, constituye un cuerpo de conocimientos interesante para el podólogo 
ya que se trata de una terapia cuyo uso está aumentando notablemente en los 
últimos años. Esta terapia es la neuroestimulación, descrita en apartados 
anteriores, cuya evidencia como tratamiento de la NDD se inicia con el estudio de 
Tesfaye y colaboradores en 1996 donde se aplica en 10 pacientes no 
respondedores a tratamiento convencional para la NDD, donde 8 de los cuales 
refieren un alivio significativo del dolor tras el implante del neuroestimulador 
(141).  A raíz de este estudio han sido diversos los artículos que analizan esta 
terapia en la NDD, sobre todo en los últimos años, y en algunos de ellos se 
evidencia el uso de diferentes tipos de estimulación que mejoren el alivio del dolor 
del paciente (52,142–147). 
 
Una vez conocida la patología de estudio y los tratamientos existentes se 
procederá a revisar, mediante meta-análisis, la efectividad de algunos de los 
tratamientos mencionados anteriormente, con el fin de contribuir a la 
actualización y aumento de conocimientos sobre la NDD que puedan servir de 
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ayuda a los profesionales sanitarios en la toma de decisiones para tratar a los 
pacientes afectados por esta enfermedad. 
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OBJETIVOS 
 
El propósito del estudio fue analizar mediante meta-análisis las alternativas 
terapéuticas existentes para el tratamiento de la NDD, para lo cual se marcaron los 
siguientes objetivos: 
 
Objetivo general 
 Determinar cuáles son las terapias más efectivas para el tratamiento 
de la NDD. 
 
Objetivos secundarios 
 Determinar las líneas de tratamiento según los resultados obtenidos.  
 Analizar las revisiones más importantes existentes para el 
tratamiento de la NDD. 
 Comprobar si existe evidencia sobre tratamientos para la NDD 
mediante terapias combinadas. 
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MATERIAL Y MÉTODO 
 
Pregunta de investigación (PICO) 
 
La base de nuestro estudio es dar resolución a la pregunta de investigación: ¿cuál 
de los tratamientos farmacológicos orales, tópicos y físicos es el más efectivo para el 
alivio del dolor producido por la neuropatía diabética?. Para ayudar en la 
elaboración de esta pregunta y conseguir enfocar más el objeto de estudio es de 
gran utilidad la herramienta PICO. El acrónimo PICO corresponde a los siguientes 
ítems: 
 
 P: Participantes 
 I: Intervenciones 
 C: Comparaciones 
 O: Outcome (resultados) 
 
La adaptación de la pregunta PICO a la pregunta de investigación del estudio 
muestra las siguientes características que se observan en la tabla 6: 
 
P Participantes Personas con neuropatía diabética dolorosa 
I Intervenciones Tratamiento del dolor mediante terapias farmacológicas 
orales, tópicas o físicas únicas 
C Comparaciones Grupo control (placebo) 
O Resultados Nivel de dolor 
Tabla 6: Pregunta PICO del estudio 
 
Diseño de investigación 
 
Se trata de un estudio tipo revisión sistemática con meta-análisis. El meta-análisis  
consiste en el análisis estadístico del conjunto de resultados obtenidos en 
diferentes ensayos clínicos sobre una misma cuestión, con la finalidad de 
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evaluarlos de manera conjunta (148). Este meta-análisis ha sido realizado con 
forme a las normas incluidas en la declaración PRISMA (149). 
 
Este estudio fue llevado a cabo en el Departamento de Podología, dentro de la 
Facultad de Enfermería, Fisioterapia y Podología de la Universidad de Sevilla, en el 
periodo comprendido entre Octubre 2014 a Noviembre 2017. 
 
Criterios de inclusión y exclusión 
 
Para la selección de los estudios clínicos del meta-análisis, en primer lugar se 
siguieron una serie de criterios de inclusión y exclusión a fin de garantizar una 
correcta homogeneidad en la obtención de datos de dichos estudios. Estos criterios 
se desglosan a continuación siguiendo una estructura similar a la herramienta 
PICO anteriormente descrita:   
 
1. Criterios de inclusión: 
a) Tipos de estudio 
 Se incluyeron en la búsqueda ensayos clínicos aleatorizados 
(en adelante ECA). 
 
b) Tipos de participantes 
 Se incluyeron estudios en los que los participantes 
presentaran como patología principal neuropatía diabética dolorosa 
(denominado también como dolor neuropático en paciente con DM). 
 Los pacientes a incluir son mayores de edad, 
indiferentemente del sexo, con indiferencia del tiempo de evolución 
del dolor neuropático. 
 
c) Tipos de intervención 
 Todos aquellos estudios en los que el tratamiento para la 
neuropatía diabética dolorosa fuera de tipo farmacológico oral, 
tópica o terapia física frente a grupo control. 
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d) Tipos de comparaciones 
 Se incluyeron exclusivamente estudios que tuvieran como 
comparación un grupo control (placebo). 
 
e) Tipos de resultados 
 Se incluyeron los estudios cuyos resultados midieran el nivel 
de dolor mediante escalas validadas. 
 
2. Criterios de exclusión 
a) Tipos de estudio 
 Se excluyeron todos los estudios cuya calidad metodológica 
no fuera adecuada tras la valoración mediante escala JADAD.  
 Se excluyeron los estudios que no proporcionaban los 
suficientes datos estadísticos que posibilitaran la realización del 
meta-análisis. 
 
b) Tipos de participantes 
 Los participantes menores de edad, sin historia de diabetes ni 
dolor neuropático provocado por dicha patología, fueron excluidos 
del meta-análisis. 
 
c) Tipos de intervención 
 Los estudios cuya intervención consistió en la aplicación de 
terapias cuyo uso no está acreditado o evidenciado como válido para 
la patología que describimos en al menos uno de los organismos 
oficiales principales (véase Food and Drug Administration (FDA),  
European Medicine Agency (EMA), Agencia Española del Medicamento 
y Productos Sanitarios (AEMPS)), o en alguna de las revisiones más 
destacadas realizadas por sociedades científicas, y aquellos que 
utilizaban terapias combinadas fueron excluidos. 
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d) Tipos de comparaciones 
 Aquellos estudios cuya metodología incluyó un grupo control 
mediante otro tipo de terapia, o sin grupo control, fueron excluidos. 
 
e) Tipos de resultados 
 Se excluyeron los estudios cuyos resultados no expresaban la 
valoración del dolor tras la terapia aplicada o los datos obtenidos no 
eran válidos para el análisis estadístico mediante meta-análisis, 
además de aquellos cuya herramienta para la valoración del dolor no 
se encontrase validada. 
 
Fuentes de información utilizadas 
 
Para la obtención de los estudios que componen el meta-análisis se procedió al uso 
de bases de datos digitales cuyo contenido estuviera relacionado con las Ciencias 
de la Salud. Para acceder a ellas se utilizaron los enlaces digitales ubicados en la 
página web de la biblioteca de Ciencias de la Salud de la Universidad de Sevilla 
(www.bib.es.us/salud) y en la web de la Biblioteca Virtual del Sistema Sanitario 
Público Andaluz (BVSSPA).  Las bases de datos consultadas fueron: 
 
1. Pubmed: se trata de un motor de búsqueda de libre acceso a través del cual 
se accede a la base de datos MEDLINE, producida por la Biblioteca Nacional de 
Medicina de los Estados Unidos, y caracterizada por ser una de las bases de 
datos científicas mas importantes.  
 
2. Web of Science (WOS): servicio en línea generado por la empresa Thomson 
Reuters e integrado en ISI Web of Knowledge, que proporciona acceso a 
recursos científicos relacionados con las Ciencias de la Salud. En la búsqueda 
mediante WOS se integraron por defecto otras bases de datos tales como CCC 
(Current Contents Connect), DIIDW (Derwent Innovation Index), KJD (Korean 
Journal Database), MEDLINE, RSCI (Russian Science Citation Index) y SCIELO. 
 
  47 
Protocolo de búsqueda  
 
a) Paso nº1: 
 
Se realizó una búsqueda en las bases de datos analizadas en el apartado anterior. 
Para ello se usaron la combinación de los términos “pain”, “painful diabetic 
neuropathy”, “diabetic neuropathy”, “peripheral diabetic neuropathic pain”,  
“neuropathic pain”, “treatment”, “therapy”, mediante los operadores boleanos 
AND/OR, y el uso de truncamientos en los casos que fuera necesario. Las 
estrategias de búsqueda para las bases de datos analizadas se muestran en la tabla 
7. 
 
PUBMED WEB OF SCIENCE (WOS) 
Recent queries in pubmed 
#13,"Search (((""painful 
peripheral neuropathy) AND 
diabet*)) AND ((treatment) OR 
therap*)" 
#15 #10 AND #5 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#12,"Search (""painful 
peripheral neuropathy) AND 
diabet*" 
#14 #9 AND #5 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#11,"Search ((((((neuropat*) 
AND pain) AND diabet*)) AND 
peripheral)) AND ((treatment) 
OR therap*)" 
#13 #8 AND #5 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#10,"Search ((((neuropat*) 
AND pain) AND diabet*)) AND 
peripheral" 
#12 #7 AND #5 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#9,"Search ((neuropat*) AND 
pain) AND diabet*" 
#11 #6 AND #5 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
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Idioma de búsqueda=Auto   
#8,"Search (((treatment) OR 
therap*)) AND ((""neuropathic 
pain"") AND diabet*)" 
#10 TEMA: ("peripheral diabetic neuropathic 
pain") 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#7,"Search (treatment) OR 
therap*" 
#9 TEMA: ("peripheral diabetic neuropathy") 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#6,"Search (""neuropathic 
pain"") AND diabet*" 
#8 TEMA: ("peripheral diabetic neuropathy") 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#5,"Search (""diabetic 
neuropathy"") AND (Treatment 
OR therapy)" 
#7 TEMA: ("painful diabetic neuropathy") 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#4,"Search ((""painful diabetic 
neuropathy"") AND treatment) 
AND therapy" 
#6 TEMA: ("diabetic neuropathy") 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#3,"Search ((""painful diabetic 
neuropathy"") AND treatment) 
OR therapy" 
#5 TEMA: (treat* OR therap*) 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#2,"Search (""painful diabetic 
neuropathy"") AND Therapy" 
#4 TEMA: ("diabetic neuropathy" AND (treat* 
OR therap*)) 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#1,"Search ""painful diabetic #3 TEMA: ("peripheral diabetic neuropathic 
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neuropathy""" pain" AND (treat* OR therap*)) 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#2 TEMA: ("painful diabetic neuropathy" AND 
(treat* OR therap*)) 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
#1 TEMA: ("painful diabetic neuropathy") 
Bases de datos= WOS, CCC, DIIDW, KJD, 
MEDLINE, RSCI, SCIELO  
Idioma de búsqueda=Auto   
Tabla 7: Estrategia de búsqueda de las bases de datos analizadas 
 
b) Paso nº 2: 
 
Para obtener resultados más exactos a los criterios de inclusión y exclusión 
utilizados en este estudio se aplicaron filtros con el fin de centrar la búsqueda en 
ensayos clínicos aleatorizados, ya sea mediante la propia base de datos o a través 
del acceso a la biblioteca de Ciencias de la Salud de la Universidad de Sevilla y a la 
BVSSPA. 
 
c) Paso nº3: 
 
Se eliminaron los artículos duplicados tras la búsqueda en las diferentes bases de 
datos. 
 
Selección de los estudios 
 
Tras la realización de la búsqueda y obtención de los resultados se procedió al 
análisis de los mismos con el fin de incluirlos en el meta-análisis. 
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Para ello se procedió a ordenar los estudios seleccionados según el tipo de terapia 
utilizada, ya sea farmacológica oral, tópica o física. Una vez clasificados los estudios 
según terapia, se analizaron individualmente siguiendo la metodología de la 
pregunta de investigación PICO, para a su vez, determinar si se cumplían o no los 
criterios de inclusión y exclusión determinados previamente.  
 
Con respecto a los resultados obtenidos, para evitar la exclusión de algunos 
estudios que se consideraron potencialmente seleccionables y que no se pudieron 
obtener a texto completo o faltaban datos estadísticos relevantes, se recurrió a dos 
estrategias consensuadas con el tutor y directores de tesis: 
 
1. Préstamo interbibliotecario 
 
En los casos que no fue posible el acceso al artículo mediante los recursos 
electrónicos mencionados en apartados anteriores, se procedió a su búsqueda y 
solicitud a través de la Biblioteca de la US, en concreto a través del servicio de 
préstamo interbibliotecario.  
 
Tras el análisis de los artículos solicitados mediante el servicio de préstamo 
interbibliotecario, se decidió que no cumplían los requisitos necesarios para su 
inclusión en el meta-análisis. 
 
2. E-mail autores 
 
Aquellos artículos que fueron determinados potencialmente seleccionables para el 
meta-análisis, pero que no incluían ciertos datos que nos permitían poder realizar 
nuestro análisis estadístico, se obtuvieron las direcciones de correo electrónico de 
los autores para la posterior solicitud a los mismos de los datos ausentes e 
imprescindibles en nuestro estudio. Sin embargo, de todos los e-mail enviados, no 
se obtuvo ninguna respuesta por parte de dichos autores. (Anexo 5) 
 
 
  51 
Extracción de los datos 
 
Para la obtención de los datos, y con la finalidad de facilitar el análisis, se diseñó 
una tabla de recogida de datos en la que se introdujeron los datos de variables de 
cada estudio como son el tamaño de la muestra, terapia aplicada, número de 
mujeres y hombres, dolor inicial y final, entre otras, además de la puntuación 
obtenida por la escala JADAD (Anexo 6). 
 
La escala JADAD es una herramienta creada en 1996 por Alejandro R. Jadad y 
colaboradores cuya finalidad es la medición de la calidad de las publicaciones 
sobre ensayos clínicos que median el alivio del dolor (150). Esta escala se compone 
de 3 ítems a los cuales se les otorga una puntuación en función de su cumplimiento 
o no, teniendo como máximo 5 puntos y como mínimo 0 puntos. Los estudios cuya 
puntuación obtenida fueran inferior a 3 se consideraban estudios de baja calidad, 
por lo que automáticamente eran descartados para la inclusión en nuestro análisis 
estadístico del meta-análisis (150,151). (Anexo 7) 
 
Además de este proceso de extracción, se diseñaron otras 2 tablas de recogida de 
datos (una para el grupo experimental y otra para grupo control) en las cuales 
figuraban los datos propios del estudio que se incluía, tipo de estudio, dosis (en el 
caso que fueran diversos tipos de dosis las estudiadas), tamaño muestral, dolor 
inicial y dolor final (expresados con la desviación estándar (SD) correspondiente). 
La finalidad de esta segunda extracción de datos fue facilitar el manejo estadístico 
de los mismos a la hora de realizar las pruebas estadísticas correspondientes que 
en próximas páginas se detallarán.  
 
Evaluación del riesgo de sesgo para los estudios incluidos 
 
Para la evaluación del riesgo de sesgo de los estudios se siguieron las indicaciones 
del Manual Cochrane Versión 5.1.0. A través de ella podemos analizar el riesgo de 
sesgo que tienen los artículos por sí mismos y el riesgo de sesgo que hay entre 
ellos (152). 
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En estos casos, cuando hablamos de sesgos, según el manual Cochrane podemos 
evaluar principalmente hasta 6 tipos de sesgos diferentes: 
 
a. Sesgo de selección: hace referencia a la existencia o no de 
aleatorización en los grupos estudiados, así como en la existencia de la 
generación de la secuencia de las intervenciones a realizar. También 
hace referencia al proceso de ocultación de la secuencia por parte del 
personal que participa en este proceso inicial de reclutamiento. 
b. Sesgo de realización: hace referencia a la presencia de cegamiento 
por parte de los participantes y personal del estudio en las 
intervenciones realizadas. 
c. Sesgo de detección: hace referencia al proceso de cegamiento de los 
evaluadores para evitar el conocimiento de la intervención que se había 
aplicado. 
d. Sesgo de desgaste: hace referencia a situaciones en las que los datos 
sobre los resultados obtenidos no están disponibles debido al abandono 
del estudio por parte del participante o a la existencia de datos 
incompletos. 
e. Sesgo de notificación: hace referencia a la existencia de datos 
publicados selectivamente, evitando publicar los datos con menor valor 
significativo. Comúnmente es también conocido como “sesgo de 
publicación dentro del estudio”. 
f. Otros sesgos: hace referencia a fuentes de sesgos relevantes en 
ciertas ocasiones y que se pueden encontrar en algunos tipos de 
estudios determinados, como pueden ser por ejemplo intervenciones 
mezcladas entre grupo experimental y grupo control en el caso de 
combinar fármacos entre los participantes. 
 
Para el análisis de riesgo de sesgo de los estudios incluidos se utilizó una 
herramienta informática proporcionada por Cochrane llamada Review Manager 
(RevMan).  En concreto se utilizó la versión RevMan 5.3, en la cual se introdujo 
manualmente todos los datos de los estudios a incluir en el meta-análisis para su 
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posterior análisis de sesgos dentro de la aplicación y la elaboración final de las 
diferentes tablas de resumen. 
 
En dichas tablas los datos obtenidos en función del tipo de sesgo analizado  
aparecen en tres colores diferentes que determinan lo siguiente: 
 
 Color verde: riesgo bajo de sesgo. 
 Color amarillo: riesgo de sesgo no determinado. 
 Color rojo: riesgo alto de sesgo. 
 
Las tablas generadas por esta herramienta informática corresponden a dos tipos:  
1- Gráfico del Riesgo de Sesgo: ilustra la proporción de estudios 
con cada una de sus evaluaciones (Bajo riesgo, Alto riesgo, Riesgo 
poco claro) 
2- Resumen del Riesgo de Sesgo: analiza las evaluaciones 
individualizadas por cada artículo incluido. 
 
Análisis estadístico de los resultados obtenidos 
 
Los datos estadísticos fueron analizados a través del software SSPS 25.0 
detallándose  para el análisis descriptivo la muestra total atendiendo a edad, 
duración de DM, duración de neuropatía, dolor principio y dolor final. Las variables 
numéricas (cuantitativas) se resumieron con medias y desviaciones típicas, o en 
caso de distribuciones asimétricas, mediante medianas y percentiles (P25 y P75). 
 
Se realizaron pruebas no paramétricas para dos muestras independientes (U de 
Man-Withney) para comprobar la heterogeneidad de dos muestras ordinales, 
rechazándose la hipótesis nula (Ho) al obtenerse un valor de significación inferior a 
0.05. 
 
Para el análisis e interpretación de los datos de los estudios seleccionados, se 
calculó el promedio de los resultados de dolor final, así como el tamaño del efecto 
de cada uno de los estudios, y medidas de tendencia central y de dispersión. La 
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desviación típica es el elemento estadístico que toma en cuenta ambos 
componentes, lo que permite ponderar adecuadamente el peso de cada estudio 
que ingresa en el meta-análisis, por ello, se considera como criterio de inclusión 
que tenga el valor medio y el de la desviación típica para el dolor final, tanto en el 
grupo experimental como en el grupo placebo. 
 
Se calculó el tamaño del efecto por cada uno de los artículos seleccionados, así 
como el tamaño del efecto global para cada uno de los tipos de tratamiento. La g de 
Hedges es una medida estandarizada del tamaño del efecto, que permite que se 
puedan comparar evaluaciones realizadas con distintas pruebas y escalas. Esta 
medida del tamaño del efecto no dice cuántas desviaciones típicas mide el efecto. 
La interpretación del tamaño del efecto se realiza de  la siguiente forma:  
 g de Hedges 0-0,5: tamaño del efecto pequeño 
 g de Hedges 0,5 – 0,8: tamaño del efecto mediano 
 g de Hedges > 0.8: tamaño del efecto grande 
 
 
Se utilizó el gráfico forest plot para realizar la representación gráfica de los 
intervalos de confianza de los valores del tamaño del efecto. Se interpretó de tal 
forma que los valores positivos indican una mejoría del dolor. Todos aquellos 
intervalos de confianza que incluyan el cero, no se consideraron significativos en la 
mejoría del dolor. 
 
 
 
 
 
 
 
 
 
 
  55 
RESULTADOS 
 
Proceso de selección de los estudios 
 
Como resultado del proceso de selección de los estudios, a continuación se 
muestra el diagrama de flujo correspondiente a los estudios finalmente incluidos 
(Figura 5), el cual ha sido basado en el diagrama de flujo proporcionado por la 
declaración PRISMA (149). 
 
 
Figura 5: Diagrama de flujo de los estudios incluidos 
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Riesgo de sesgo de los estudios incluidos 
 
En las figuras 6 y 7 se muestran los resultados del análisis de la evaluación del 
riesgo de sesgo de los estudios incluidos en el meta-análisis, concretamente se 
muestran el Gráfico del Riesgo de Sesgo y el Resumen del Riesgo de Sesgo 
respectivamente. En la figura 6 se aprecia el porcentaje, del total de los artículos 
incluidos, del riesgo de los diferentes tipos de sesgos, donde el mayor porcentaje 
de riesgo bajo de sesgo corresponde al sesgo de selección y al sesgo de 
notificación, y un porcentaje pequeño de alto riesgo de sesgo al cegamiento de 
participantes y personal.  La figura 7 muestra el nivel de riesgo obtenido en cada 
uno de los sesgos analizados por cada artículo incluido de forma individualizada. 
 
 
Figura 6: Gráfico del riesgo de sesgo de los estudios incluidos 
 
 
Figura 7: Resumen del riesgo de sesgo de los estudios incluidos 
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Características principales de los estudios incluidos 
 
A continuación se presentan detalladamente, y organizado según tipo de terapia, 
las características de los estudios incluidos tras el proceso de selección, así como 
los datos necesarios para el análisis estadístico realizado. Estos datos fueron 
recogidos mediante tablas de recogida de datos cuyo formato se puede consultar 
en el anexo 6. 
 
Terapias farmacológicas 
 
 Eisenberg y colaboradores, 2001 (153):  
ECA unicéntrico, doble ciego y con grupo control sobre lamotrigina a dosis máxima 
de 400 mg/día, de 6 semanas de duración. Según escala JADAD se obtiene una 
puntuación de 5. 
 
 Goldstein y colaboradores, 2005 (154): 
ECA multicéntrico, doble ciego y con grupo control sobre duloxetina a dosis de 20, 
60 y 120 mg/día, de 12 semanas de duración. Según escala JADAD se obtiene una 
puntuación de 5. 
 
 Raskin y colaboradores, 2005 (155): 
ECA multicéntrico, doble ciego y con grupo control sobre duloxetina a dosis de 60 
y 120 mg/día, de 12 semanas de duración. Según escala JADAD se obtiene una 
puntuación de 5. 
 
 Richter y colaboradores, 2005 (156): 
ECA multicéntrico, doble ciego y con grupo control sobre pregabalina a dosis de 
150 y 600 mg/día, de 6 semanas de duración. Según escala JADAD se obtiene una 
puntuación de 5. 
 
 Donofrio y colaboradores, 2005 (157): 
Estudio abierto de extensión del ECA multicéntrico, doble ciego y con grupo 
control publicado por Raskin y colaboradores en 2004 (158), donde se muestran 
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los resultados totales de ambos estudios en los que se analiza el fármaco 
topiramato a dosis máxima de 600 mg/día durante un periodo total de 38 
semanas. Según escala JADAD se obtiene una puntuación de 4. 
 
 Wernicke y colaboradores, 2006 (159): 
ECA multicéntrico, doble ciego y con grupo control sobre duloxetina  a dosis de 60 
y 120 mg/día, de 12 semanas de duración. Según escala JADAD se obtiene una 
puntuación de 5. 
 
 Rauck y colaboradores, 2013 (160): 
ECA multicéntrico, doble ciego y con grupo control sobre pregabalina y 
gabapentina a dosis de 300 mg/día y 1200, 2400, 3600 mg/día respectivamente, 
de 20 semanas de duración. Según escala JADAD se obtiene una puntuación de 5. 
 
 Niesters y colaboradores, 2014 (161):  
ECA unicéntrico, doble ciego y con grupo control sobre tapentadol a dosis máxima 
de 500 mg/día, de 4 semanas de duración. Según escala JADAD se obtiene una 
puntuación de 5. 
 
Terapias tópicas 
 
 Campbell y colaboradores, 2012 (162): 
ECA multicéntrico, doble ciego y con grupo control sobre clonidina 0,1%, de 12 
semanas de duración. Los pacientes se aplican 3,9 mg de gel al día. Según escala 
JADAD se obtiene una puntuación de 5. 
 
 Kulkantrakorn y colaboradores, 2013 (163): 
ECA unicéntrico, grupos cruzados, doble ciego y con grupo control sobre 
capsaicina 0,025%, de 8 semanas de duración. Los pacientes se aplican dos dosis 
de gel 3 – 4 veces al día. Al ser un estudio de grupos cruzados se decide incluir en 
el meta-análisis solamente la primera fase del estudio, evitando el cruce de los 
grupos. Según escala JADAD se obtiene una puntuación de 5. 
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Terapias físicas 
 
 Weintraub  colaboradores, 2003 (62): 
ECA multicéntrico, doble ciego y con grupo control sobre magnetoterapia estática, 
de 4 meses de duración. La aplicación de la magnetoterapia estática se basó en la 
utilización de plantillas magnetizadas (en el caso del grupo placebo se utilizaron 
plantillas similares pero sin magnetizar) en el calzado de los pacientes durante el 
periodo completo del estudio. Según escala JADAD se obtiene una puntuación de 5. 
 
 Weintraub y colaboradores, 2009 (61): 
ECA multicéntrico, doble ciego y con grupo control sobre magnetoterapia pulsada, 
de 3 meses de duración. La aplicación de la magnetoterapia pulsada se realiza 
mediante sesiones divididas de 10 a 30 minutos (máximo 2 horas diarias) en los 
pies durante el periodo completo del estudio. Según escala JADAD se obtiene una 
puntuación de 5. 
 
 
Todos los datos necesarios para el análisis estadístico obtenidos de los artículos se 
incluyeron en las tablas de recogida de datos, cuyo resultado se muestra en las 
tablas 8, 9 y 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  60 
 
TERAPIAS FARMACOLÓGICAS ORALES 
ESTUDIO TRATAMIENTO N EDAD 
MEDIA 
(Años) 
HOMBRES MUJERES DURACIÓN 
DIABETES 
(Años) 
DURACIÓN 
NEUROPATÍA 
(Años) 
DOLOR 
INICIAL 
DOLOR 
FINAL 
JADAD 
GABAPENTINA 
Rauck 2013 
1200 mg/día 62 57.5 
(10.32) 
34 28 - - 6.64 
(1.47) 
4.09 
(2.535) 
5 
2400 mg/día 56 60.8 
(8.97) 
37 19 - - 6.26 
(1.22) 
4.36 
(2.049) 
3600 mg/día 116 57.5 
(9.87) 
71 45 - - 6.48 
(1.43) 
3.94 
(2.423) 
Placebo 120 60.1 
(10.63) 
73 47 - - 6.49 
(1.26) 
4.4 
(2.069) 
TOTAL 354 58.7 
(10.20) 
215 139 - - - - 
PREGABALINA 
Rauck 2013 
300 mg/día 66 57.7 
(10.59) 
34 32 - - 6.51 
(1.27) 
4.85 
(1.833) 
5 
Placebo 120 60.1 
(10.63) 
73 47 - - 6.49 
(1.26) 
4.4 
(2.069) 
TOTAL 186 58.7 
(10.20) 
107 79 - - - - 
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ESTUDIO TRATAMIENTO N EDAD 
MEDIA 
(Años) 
HOMBRES MUJERES DURACIÓN 
DIABETES 
(Años) 
DURACIÓN 
NEUROPATÍA 
(Años) 
DOLOR 
INICIAL 
DOLOR 
FINAL 
JADAD 
PREGABALINA 
Richter 2005 
150 mg/día 79 56.3 +/- 
9.4 
57 22 8.2 +/- 9.1 - 6.5 +/- 
1.3 
4.9 +/- 
2.2 
5 
600 mg/día 82 57.8 +/- 
9.5 
46 36 9.3 +/- 8.8 - 6.7 +/- 
1.7 
4.3 +/- 
2.7 
Placebo 85 57.1 +/- 
10.3 
46 39 10.6 +/- 8.3 - 6.9 +/- 
1.6 
5.8 +/- 
2.2 
TOTAL 246 57.06 149 97 - - - - 
DULOXETINA 
Raskin 2005 
60 mg/día 116 58.3 
(10.9) 
48 68 14.6 (8.9) 4.5 (4.4) 5.5 (1.1) 3.0 
(0.18) 
5 
120 mg/día 116 59.0 
(9.6) 
61 55 13.9 (9.7) 4.5 (4.6) 5.7 (1.3) 3.23 
(0.18) 
Placebo 116 59.2 
(9.8) 
53 63 12.8 (8.6) 4.0 (3.5) 5.5 (1.3) 3.9 
(0.18) 
TOTAL 348 58.8 
(10.1) 
162 186 13.8 (9.1) 4.3 (4.2) - - 
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ESTUDIO TRATAMIENTO N EDAD 
MEDIA 
(Años) 
HOMBRES MUJERES DURACIÓN 
DIABETES 
(Años) 
DURACIÓN 
NEUROPATÍA 
(Años) 
DOLOR 
INICIAL 
DOLOR 
FINAL 
JADAD 
DULOXETINA 
Goldstein 2005 
20 mg/día 115 60.3 
(10.9) 
75 40 12.1 (9.5) 3.7 (3.7) 5.9 (1.6) 3.54 
(0.21) 
5 
60 mg/día 114 59.2 
(11.6) 
79 35 11.4 (8.2) 3.8 (4.4) 6.0 (1.7) 3.11 
(0.22) 
120 mg/día 113 60.5 
(10.8) 
68 45 10.1 (9.0) 3.5 (2.8) 5.9 (1.4) 2.66 
(0.23) 
Placebo 115 60.4 
(10.5) 
59 56 11.4 (11.3) 4.0 (4.1) 5.8 (1.5) 3.89 
(0.22) 
TOTAL 457 60.1 
(10.9) 
281 176 11.3 (9.6) 3.7 (3.8) - - 
DULOXETINA 
Wernicke 2006 
60 mg/día 114 59.7 
(11.2) 
74 40 9.7 (9.6) 3.6 (3.5) 6.1 (1.6) 3.38 
(0.22) 
5 
120 mg/día 112 61.5 
(9.9) 
61 51 9.9 (10.0) 4.4 (5.9) 6.2 (1.5) 3.36 
(0.23) 
Placebo 108 60.8 
(10.6) 
69 39 11.1 (9.1) 3.5 (3.2) 5.9 (1.4) 4.51 
(0.23) 
TOTAL 334 60.7 
(10.6) 
204 130 10.2 (9.6) 3.8 (4.4) - - 
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ESTUDIO TRATAMIENTO N EDAD 
MEDIA 
(Años) 
HOMBRES MUJERES DURACIÓN 
DIABETES 
(Años) 
DURACIÓN 
NEUROPATÍA 
(Años) 
DOLOR 
INICIAL 
DOLOR 
FINAL 
JADAD 
TOPIRAMATO 
Donofrio 2005 
400 mg/día 117 59.4 
(9.9) 
59 58 10.1 (7.3) 3.4 (2.5) 6.76 
(1.37) 
2.80 
(2.70) 
4 
Placebo 86 59.1 
(10.0) 
47 39 10.5 (8.5) 3.2 (3.4) 6.60 
(1.45) 
3.55 
(2.84) 
TOTAL 203 59.2 106 97 - - - - 
TAPENTADOL 
Niesters 2014 
500 mg/día 12 63 7 5 12 6 6.5 (0.6) 3.9 (0.6) 5 
Placebo 12 64 7 5 11 6.5 6.5 (0.6) 4.8 (0.7) 
TOTAL 24 63.5 14 10 - - - - 
LAMOTRIGINA 
Eisenberg 2001 
400 mg/día 27 52.7 +/- 
2.1 
17 10 13.9 +/- 1.7 3.6 +/- 0.7 6.4 +/- 
0.1 
4.2 +/- 
0.1 
5 
Placebo  26 57.8 +/- 
1.7 
16 10 9.6 +/- 1.1 3.8 +/- 0.6 6.6 +/- 
0.1 
5.3 +/- 
0.1 
TOTAL 53 - 33 20 - - - - 
Tabla 8: Tabla de datos obtenidos de las terapias farmacológicas orales 
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TERAPIAS TÓPICAS 
ESTUDIO TRATAMIENTO N EDAD 
MEDIA 
(Años) 
HOMBRES MUJERES DURACIÓN 
DIABETES 
(Años) 
DURACIÓN 
NEUROPATÍA 
(Años) 
DOLOR 
INICIAL 
DOLOR 
FINAL 
JADAD 
CAPSAICINA 
Kulkantrakorn 
Capsaicina 
0.025% 
17  - -  - 4.41 
+/- 
2.49 
2.88 
+/- 
2.18 
5 
Placebo 17  - -  - 5.0 +/- 
2.93 
3.46 +/- 
2.89 
TOTAL 34 57.96 16 17 11.17 +/- 
7.46 
4.73 +/- 5.13 - - 
CLONIDINA 
Campbell 
Clonidina 0.1% 90  - -  -   5 
Placebo 90  - -  - 6.4 
(1.4) 
4.7 
(1.9) 
TOTAL 180 58.5 86 93 - - 6.5 
(1.5) 
4.2 
(2.2) 
Tabla 9: Tabla de datos obtenidos de las terapias tópicas 
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TERAPIAS FÍSICAS 
ESTUDIO TRATAMIENTO N EDAD 
MEDIA 
(Años) 
HOMBRES MUJERES DURACIÓN 
DIABETES 
(Años) 
DURACIÓN 
NEUROPATÍA 
(Años) 
DOLOR 
INICIAL 
DOLOR 
FINAL 
JADAD 
MAGNETOTERAPIA 
Weintraub 2003 
Magnetoterapia 
estática 
141 62.6 +/- 
11.3 
- - 13.0 +/- 10.8 - 5.8 +/- 
2.3 
4.1 +/- 
2.7 
5 
Placebo 118 63.2 +/- 
11.2 
 
- - 11.6 +/- 10.2 - 5.8 +/- 
2.3 
4.3 +/- 
2.8 
TOTAL 259 62.9 135 124 - - - - 
MAGNETOTERAPIA 
Weintraub 2009 
Magnetoterapia 
pulsada 
90 61.1 +/- 
10.4 
 
- - 3.9 +/- 3.0 - 5.59 +/- 
2.26 
4.05 +/- 
2.71 
5 
Placebo 104 60.6 +/- 
12.4 
- - 4.0 +/- 3.0 - 5.45 +/- 
2.09 
4.13 +/- 
2.47 
TOTAL 194 60.8 - - - - - - 
Tabla 10: Tabla de datos obtenidos de las terapias físicas
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Resultados del análisis estadístico 
 
Análisis descriptivo 
 
Con respecto a los resultados totales nos encontramos con una muestra total de 
pacientes incluidos en los estudios analizados de 2872, de los cuales 1755 
corresponde a los pacientes incluidos en los grupos experimentales y 1117 a los 
incluidos en los grupos placebo. Para los pacientes incluidos en el grupo 
experimental se obtiene una edad media de 59,41 años, una duración media de 
diabetes de 10,85 años y una duración media de neuropatía de 3,86 años. A su vez 
los resultados en cuanto a dolor que se obtienen son de 6,12 sobre 10 en dolor 
inicial y 3,65 sobre 10 en dolor final. Para los pacientes incluidos en el grupo 
placebo se obtiene una edad media de 59,95 años, una duración media de diabetes 
de 10,26 años y una duración media de neuropatía de 3,64 años. Los resultados en 
cuanto a dolor que se obtienen determinan unas cifras de 6,10 sobre 10 en dolor 
inicial y 4,34 sobre 10 en dolor final. Los resultados detallados del análisis 
descriptivo se muestran las tablas 11, 12 y 13. 
Tratamiento agrupado 
Grupo Frecuencia Porcentaje Porcentaje 
válido 
Porcentaje 
acumulado 
Experimental Válido Gabapentina 234 13,3 13,3 13,3 
Pregabalina 227 12,9 12,9 26,3 
Duloxetina 800 45,6 45,6 71,9 
Topiramato 117 6,7 6,7 78,5 
Tapentadol 12 ,7 ,7 79,2 
Lamotrigina 27 1,5 1,5 80,7 
Capsaicina 
0,025% 
17 1,0 1,0 81,7 
Clonidina 
0,1% 
90 5,1 5,1 86,8 
Magnoterapia 231 13,2 13,2 100,0 
Total 1755 100,0 100,0  
Placebo Válido Gabapentina 120 10,7 10,7 10,7 
Pregabalina 205 18,4 18,4 29,1 
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Duloxetina 339 30,3 30,3 59,4 
Topiramato 86 7,7 7,7 67,1 
Tapentadol 12 1,1 1,1 68,2 
Lamotrigina 26 2,3 2,3 70,5 
Capsaicina 
0,025% 
17 1,5 1,5 72,1 
Clonidina 
0,1% 
90 8,1 8,1 80,1 
Magnoterapia 222 19,9 19,9 100,0 
Total 1117 100,0 100,0  
Tabla 11: Análisis descriptivo según tratamiento agrupado 
 
Tipo de tratamiento 
Grupo Frecuencia Porcentaje Porcentaje 
válido 
Porcentaje 
acumulado 
Experimental Válido Fármaco oral 1417 80,7 80,7 80,7 
Terapia física 231 13,2 13,2 93,9 
Fármaco 
tópico 
107 6,1 6,1 100,0 
Total 1755 100,0 100,0  
Placebo Válido Fármaco oral 788 70,5 70,5 70,5 
Terapia física 222 19,9 19,9 90,4 
Fármaco 
tópico 
107 9,6 9,6 100,0 
Total 1117 100,0 100,0  
Tabla 12: Análisis descriptivo según tipo de tratamiento 
 
Estadísticos 
Grupo Edad (en 
años) 
Dolor principio Dolor Final Duración 
diabetes 
(en años) 
Duración 
neuropatía o dolor 
neuropático (en 
años) 
Experimental N Válido 1738 1755 1755 1438 1046 
Perdidos 17 0 0 317 709 
Media 59,4108 6,1238 3,6573 10,856 3,8608 
Desviación estándar 1,84004 ,42351 ,63592 2,5475 ,53713 
Mínimo 52,70 4,41 2,66 3,9 3,00 
Máximo 63,00 6,76 4,90 14,6 6,00 
Percen
tiles 
25 58,3000 5,8000 3,1100 9,700 3,5000 
50 59,4000 6,1000 3,5400 10,700 3,7000 
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75 60,5000 6,5000 4,1000 13,000 4,4000 
Placebo N Válido 1100 1117 1117 860 553 
Perdidos 17 0 0 257 564 
Media 59,9586 6,1018 4,3467 10,266 3,6438 
Desviación estándar 1,66011 ,48312 ,55248 2,4917 ,59710 
Mínimo 57,10 5,00 3,46 4,0 2,90 
Máximo 64,00 6,90 5,80 12,8 6,50 
Percen
tiles 
25 59,1000 5,8000 3,9000 9,600 3,2000 
50 60,1000 5,9000 4,4000 11,100 3,5000 
75 60,6000 6,4900 4,5100 11,600 4,0000 
Tabla 13: Análisis descriptivo de los estadísticos resultantes por cada variable 
 
Tras la realización de la prueba estadística U de Mann-Whitney para muestras 
independientes para el análisis de las hipótesis del estudio de investigación se 
obtienen los siguientes resultados reflejados en las figuras 8, 9, 10 y 11. En ellos se 
analizan las variables del estudio (dolor principio, dolor final, edad, duración 
diabetes y duración neuropatía) de forma global y por cada tipo de terapia. 
 
En el contraste de hipótesis de resultados estadísticos globales se rechazan todas 
las hipótesis nulas, es decir, la distribución de las variables son diferentes entre las 
categorías de grupo. 
 
En cuanto al contraste de hipótesis para las terapias orales, se acepta la hipótesis 
nula en la variable dolor principio, por lo que se entiende que en términos 
estadísticos el dolor principio en los grupos placebo y experimental es semejante. 
En el resto de variables se rechaza, por lo que su distribución es diferente en 
ambos grupos. 
 
Para las terapias físicas se acepta la hipótesis nula en la variable edad, 
entendiéndose por ello que la edad de los individuos de cada grupo es similar. En 
el resto de variables se rechaza salvo en la duración de neuropatía o dolor 
neuropático, que es inviable calcular mediante métodos estadísticos. 
 
En el contraste de hipótesis para las terapias tópicas los resultados son semejantes 
a los globales, por lo que se rechazan todas las hipótesis nulas y se determina que 
los datos de todas las variables son diferentes en los grupos estudiados. 
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Figura 8: Contraste de hipótesis de resultados globales 
 
 
Figura 9: Contraste de hipótesis de terapias orales 
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Figura 10: Contraste de hipótesis de terapias físicas 
 
 
Figura 11: Contraste de hipótesis de terapias tópicas 
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Resultados meta-analíticos 
 
Realizado el análisis estadístico para obtener el valor de la g de Hedges, en las 
tablas 14, 15 y 16 se muestran los resultados del mismo mediante el límite 
superior e inferior, p valor y el tamaño del efecto.  
 
DOLOR FINAL Hedges Límite Inferior Límite superior p-valor Tamaño del efecto 
GABAPENTINA 1200 mg/día 
Rauck 2012 
0,138 -0,188 0,463 ns Sin efecto 
GABAPENTINA 2400 mg/día 
Rauck 2012 
0,019 -0,286 0,324 ns Sin efecto 
GABAPENTINA 3600 mg/día 
Rauck 2012 
0,204 -0,083 0,491 ns Sin efecto 
PREGABALINA 
Rauck 2012 
-0,225 -0,511 0,060 ns Sin efecto 
PREGABALINA 150 mg/día 
Richter 2005 
0,407 0,070 0,744 <0,05 Pequeño 
PREGABALINA 600 mg/día 
Richter 2005 
0,607 0,235 0,980 <0,05 Mediano 
DULOXETINA 60 mg/día 
Raskin 2005 
4,984 4,961 5,007 <0,05 Grande 
DULOXETINA 120 mg/día 
Raskin 2005 
3,710 3,687 3,733 <0,05 Grande 
DULOXETINA 20 mg/día 
Goldstein 2004 
1,622 1,594 1,650 <0,05 Grande 
DULOXETINA 60 mg/día 
Goldstein 2004 
3,534 3,505 3,562 <0,05 Grande 
DULOXETINA 120 mg/día 
Goldstein 2004 
5,448 5,419 5,477 <0,05 Grande 
DULOXETINA 60 mg/día 
Wernicke 2006 
5,007 4,977 5,036 <0,05 Grande 
DULOXETINA 120 mg/día 
Wernicke 2006 
4,983 4,952 5,013 <0,05 Grande 
TOPIRAMATO 
Donofrio 2005 
0,271 -0,109 0,650 ns Sin efecto 
TAPENTADOL 
Niesters 2013 
1,333 1,072 1,594 <0,05 Grande 
LAMOTRIGINA 
Eisenberg 2001 
10,837 10,811 10,864 <0,05 Grande 
Tratamiento oral 1,251 1,227 1,275 <0,05 Grande 
ns: No significativo, p-valor>0,05 
Tabla 14: Análisis de g de Hedges en terapias orales 
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DOLOR FINAL Hedges Límite Inferior Límite superior p-valor Tamaño del efecto 
MAGNETOTERAPIA Weintraub 2009 
Magnetoterapia pulsada 
0,031 -0,333 0,394 ns Sin efecto 
MAGNETOTERAPIA Weintraub 2003 
Magnetoterapia estática 
0,073 -0,262 0,407 ns Sin efecto 
Tratamiento Físico 0,052 -0,194 0,299 ns Sin efecto 
ns: No significativo, p-valor>0,05 
Tabla 15: Análisis de g de Hedges en terapias físicas 
 
DOLOR FINAL Hedges Límite Inferior Límite superior p-valor Tamaño del efecto 
CAPSAICINA 
Kulkantrakorn 2013 
0,221 -0,639 1,082 ns Sin efecto 
CLONIDINA 
Campbell 2012 
0,242 -0,058 0,543 ns Sin efecto 
Tratamiento tópico 0,238 -0,047 0,524 ns Sin efecto 
ns: No significativo, p-valor>0,05 
Tabla 16: Análisis de g de Hedges en terapias tópicas 
 
Para la interpretación de los resultados se realiza representación gráfica mediante 
Forest Plot (Figura 11). Los valores positivos corresponden a los resultados a favor 
de la intervención y los resultados negativos a favor del control, siendo el 0 el 
punto nulo. Las líneas rojas corresponden al intervalo de confianza y su punto 
central a la media. Aquellos resultados cuyo intervalo de confianza crucen el 0 o 
punto nulo, se consideran como no significativos para el estudio. En la figura 11 las 
terapias físicas y tópicas no son significativas al cruzar el punto nulo, sin embargo, 
existen estudios dentro de las terapias farmacológicas orales que sí son 
significativas al existir una diferencia significativa a favor de la intervención.  
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Figura 11: Forest Plot de los resultados obtenidos 
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DISCUSIÓN 
 
La finalidad de este estudio fue analizar, a modo de meta-análisis,  las diferentes 
alternativas terapéuticas existentes para el tratamiento de la neuropatía diabética 
dolorosa, con el fin principal de determinar cuales de ellas son las más efectivas en 
cuanto a alivio del dolor se refiere. Según los resultados analizados previamente 
nos  encontramos con que, en términos estadísticos, las terapias físicas y tópicas 
analizadas no son significativas como para argumentar su uso, mientras que 
determinados tratamientos farmacológicos sí lo son.  
 
Una vez terminado el análisis estadístico y la redacción de los resultados nos 
encontramos en disposición de poder valorar realmente los apartados principales 
de esta tesis y el fundamento de la realización del meta-análisis. Todos estos 
tratamientos que analizaremos a continuación vienen determinados por los 
objetivos marcados al principio del proceso, cuya finalidad es la consecución de los 
mismos. 
 
A continuación se abordará la discusión a través de los resultados obtenidos 
mediante dos vertientes, considerándose por clase de terapia (ya sea física, tópica 
u oral) o por tipo de agente terapéutico. Todo este análisis se realizará en base al 
meta-análisis obtenido, la evidencia científica existente en la literatura, y la 
aplicabilidad de dichos tratamientos en el ámbito de las ciencias de la salud, 
teniendo siempre en cuenta que la finalidad de este estudio es determinar qué tipo 
de tratamiento es más efectivo para la neuropatía diabética dolorosa. Tras este 
análisis se desarrollarán diversos algoritmos de tratamientos que ayuden a los 
profesionales sanitarios en la toma de decisiones ante pacientes que presenten 
dicha patología. 
 
Por ello, se procede al análisis a modo de discusión del estudio realizado, dividido 
en dos secciones: 
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Análisis por clase de terapia 
 
Se analizan 3 clases de terapias como son las terapias farmacológicas orales, las 
terapias físicas y las terapias tópicas. De todos los artículos incluidos en ellas, y 
según los resultados obtenidos, determinamos que las terapias farmacológicas 
orales son las terapias realmente efectivas para el tratamiento de la NDD. Esta 
determinación coincide plenamente con las diversas guías de tratamiento y 
consensos existentes en la literatura científica como son NeuPSIG, NICE, EFNS, 
ADA, AAN, y AACE (13,14,30,48,69,140), en las que los mayores niveles de 
evidencia o las primeras líneas de tratamiento corresponden a farmacoterapia 
oral. En este sentido, el meta-análisis realizado reafirma y coincide en la terapia 
farmacológica oral como base en el tratamiento de la NDD al obtenerse un tamaño 
del efecto grande de los resultados obtenidos de los estudios incluidos.  
 
Otros autores como Rosenborg y Watson realizaron una revisión sistemática de la 
literatura acerca de los tratamientos para la NDD donde encontraron como pilar 
básico el tratamiento farmacológico, considerando así mismo la posibilidad de 
combinar fármacos a la vez que otras terapias como son las terapias tópicas y 
físicas y terapias conductuales para conseguir aliviar de forma efectiva el dolor en 
estos pacientes (164). A su vez, Vinik y colaboradores realizaron una revisión 
donde analizan en profundidad todos los aspectos clínicos de las neuropatías 
diabéticas y determinan según su algoritmo realizado a las terapias farmacológicas 
como eje del tratamiento del dolor neuropático de origen diabético, coincidiendo a 
su vez con Rosenborg y Watson en la posibilidad de realizar combinaciones de 
fármacos u otras terapias para aumentar la efectividad en el alivio del dolor (165). 
 
Con respecto a las terapias físicas y tópicas analizadas en su conjunto, los 
resultados estadísticos obtenidos muestran que son terapias sin efecto. Estos 
resultados no se pueden interpretar como una inefectividad en términos clínicos, 
ya que a pesar del pequeño volumen de estudios que se han podido incluir, existen 
diversas guías de las mencionadas anteriormente que incluyen estos tratamientos 
en sus análisis. En concreto, según la AAN (48), la capsaicina crema en su formato a 
0,075% obtiene un nivel de recomendación B, y según la guía NICE (140) se 
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recomienda su utilización en dolor neuropático localizado cuando el paciente no 
tolere tratamiento farmacológico oral. A pesar de todo ello, la realidad de estos 
tipos de terapias tópicas y físicas es, en primer lugar, la escasa evidencia científica 
para su uso, catalogándose su análisis para capsaicina crema y clonidina crema  
como inconcluso según NeupSIG (30) o incluso no recomendándose la 
magnetoterapia por parte de la AAN (48), y en segundo lugar la falta de más 
revisiones sobre estos tipos de terapias. Las pocas revisiones que se encuentran 
sobre estas terapias para el dolor neuropático periférico y/o diabético 
demuestran, al igual que nuestros resultados obtenidos, la ineficacia de estas 
terapias y la dificultad para poder argumentar su uso debido a que la mayoría de 
los estudios incluidos para su análisis en dichas revisiones se consideran de baja 
calidad al tener ciertos problemas metodológicos, ya sea por deficiencias en el 
diseño del estudio, tamaño muestral pequeño, alto riesgo de sesgos entre otras 
limitaciones (12,15,166,167). Además, revisiones sistemáticas consideradas de 
mayor calidad como son las revisiones sistemáticas de Cochrane Library realizadas 
para el análisis de la efectividad de las terapias TENS, capsaicina a baja 
concentración y clonidina tópica para el dolor neuropático concluye, de forma muy 
similar a las revisiones mencionadas anteriormente. En el caso de TENS y 
capsaicina a baja concentración no existen criterios razonables para indicar su 
efectividad en el dolor neuropático de cualquier tipo (53,168), y para la clonidina 
tópica se puede llegar a recomendar, bajo un nivel de evidencia limitado, su uso 
como segunda línea para la NDD cuando no exista la posibilidad de aplicar otros 
tratamientos con mayor evidencia (169). 
 
Análisis por tipo de agente terapéutico 
 
a) Gabapentina 
 
Los resultados estadísticos del análisis del artículo incluido sobre gabapentina a 
cargo de Rauck y colaboradores (160) a dosis estudiadas de 1200, 2400 y 3600 
mg/día respectivamente muestran un estudio sin tamaño del efecto (p-valor > 
0,05). Sin embargo, el análisis propio del estudio refleja una reducción del dolor 
(diferencia de valor entre dolor final y dolor inicial) a dosis de 1200 mg/día y 3600 
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mg/día de 2.55 y 2.54 respectivamente, siendo dicha reducción de 1.90 para la 
dosis de 2400 mg/día. 
 
Diversas guías clínicas y estudios de revisión coinciden en la eficacia de este 
fármaco ante esta patología, sin embargo el nivel de recomendación difiere en 
algunos casos, aunque siempre manteniendo la dosificación del medicamento 
desde dosis iniciales de 900 mg/día a un máximo de 3600 mg/día. Tanto para 
NeuPSIG, NICE, EFNS y AACE la gabapentina se encuentra como primera línea de 
tratamiento para la NDD, siendo para AAN y ADA un fármaco que debería usarse 
como segunda línea de tratamiento o con grado de recomendación nivel B. Estos 
datos son avalados a su vez por una revisión Cochrane realizada por Wiffen y 
colaboradores en 2017, siendo ésta una actualización de la ya realizada por los 
mismos autores en 2014 (170). Dicha revisión sistemática analizó la evidencia del 
uso de gabapentina en diversas condiciones de dolor neuropático, 
fundamentalmente en pacientes con NDD y neuralgia postherpética, para lo cual 
incluyeron 37 ensayos clínicos a doble ciego de dos semanas de duración como 
mínimo, comparando gabapentina (a dosis mínima de 1200 mg/día o superior) 
con placebo u otro tratamiento activo. Según sus resultados, existe un alto riesgo 
de sesgo en los estudios analizados debido principalmente al tamaño de la 
muestra, sin embargo, determinan que la gabapentina en dosis de 1800 mg/día a 
3600 mg/día puede proveer un nivel óptimo de alivio del dolor en pacientes con 
NDD y neuralgia postherpética.  
 
En términos de seguridad, la gabapentina es un fármaco incluido dentro del grupo 
de los antiepilépticos, con indicación para dolor neuropático periférico, y que como 
contraindicación única se encuentra la hipersensibilidad. Además de ello, hay que 
tener precaución con su uso en pacientes con insuficiencia renal o sometidos a 
hemodiálisis, y tener una vigilancia especial si aparecen reacciones anafilácticas, 
pensamientos e ideas suicidas, depresión respiratoria, o si el paciente presenta 
pancreatitis aguda o hace uso simultáneo de opioides (171).  
 
Según todos estos datos analizados nos encontramos con un fármaco efectivo para 
el tratamiento de la NDD, cuya prescripción por parte de los profesionales de la 
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salud puede considerarse de carácter seguro siempre y cuando no se determinen 
las circunstancias detalladas anteriormente para su no aplicación, y por lo tanto 
pasa a formar parte a su vez del arsenal terapéutico a disposición del profesional 
sanitario para esta patología. 
 
b) Pregabalina 
 
Se incluyeron en nuestro estudio dos artículos sobre pregabalina a dosis 
estudiadas de 150, 300 y 600 mg/día (156,160), donde se obtiene 
estadísticamente un tamaño del efecto pequeño y mediano para el artículo donde 
se analizan las dosis a 150 y 600 mg/día, y sin efecto para el artículo que analiza la 
dosis a 300 mg/día. Los resultados obtenidos reflejan claramente cómo se trata de 
un fármaco eficaz para la NDD, datos que coinciden con las guías y revisiones de 
NeuPSIG, NICE, EFNS, AAN, AACE, y ADA donde la clasifican como el fármaco de 
primera recomendación con un nivel de eficacia A para el dolor neuropático 
crónico y/o NDD. Otras revisiones y/o meta-análisis realizados avalan también su 
uso como vía de primera elección para la NDD. Uno de estos estudios es el de  
Parsons y Li donde comparan la respuesta terapéutica de la pregabalina en 
pacientes con NDD moderada o severa a través de 11 ECAs con pregabalina a dosis 
flexible o fija de 150, 300 y 600 mg/día, concluyendo que la pregabalina es efectiva 
en pacientes con dolor severo y con dolor moderado, siendo aún más efectiva en 
aquellos con dolor severo (172).  Arnold y colaboradores analizaron 14 ECAs de 
pregabalina a dosis fija para las patologías de NDD, neuralgia postherpética y 
fibromialgia, de donde destacan en sus resultados el beneficio de este fármaco en 
la NDD a dosis máxima de 300 mg/día (173). Derry y colaboradores, mediante 
revisión Cochrane, estudiaron la pregabalina en diversas condiciones de dolor 
neuropático, entre ellas la NDD, para lo cual analizaron 45 ensayos clínicos a doble 
ciego con 2 semanas de duración como mínimo y comparándola con placebo u otro 
tratamiento activo, de donde se concluye que la evidencia existente muestra la 
eficacia de la pregabalina para la NDD, neuralgia postherpética y dolor neuropático 
post-traumático mixto o sin clasificar (174). 
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La pregabalina, al igual que la gabapentina, es un fármaco del grupo de los 
antiepilépticos con indicación para el dolor neuropático periférico y central, que 
tiene como única contraindicación la hipersensibilidad al fármaco, y que se debe 
tener precaución en pacientes con  problemas de insuficiencia renal e insuficiencia 
cardiaca. Además, este fármaco puede provocar alteraciones en la agudeza visual, 
somnolencia, visión borrosa, confusión, riesgo de pensamientos y 
comportamientos suicidas, y en administración con sustancias que provoquen 
estreñimiento puede disminuir la funcionalidad del tracto gastrointestinal inferior 
(175). A pesar de ello, la mayoría de las manifestaciones mencionadas 
anteriormente son comunes al uso de antiepilépticos, por lo que nos encontramos 
con un fármaco de uso seguro por los profesionales de la salud, los cuales podrán  
prescribirlo ante pacientes con NDD tras realizar una adecuada anamnesis sobre 
antecedentes médicos y tratamiento actual, y realizando una correcta educación al 
paciente sobre posibles efectos adversos que pueda producir el fármaco para 
actuar ante éstos en el caso de su aparición.  
 
c) Duloxetina 
 
Se analizan en el meta-análisis tres estudios sobre duloxetina a dosis 
correspondientes a 20, 60 y 120 mg/día, con resultados estadísticos positivos en 
cuanto a términos de eficacia se refiere, ya que los tres estudios obtienen un 
tamaño del efecto grande, por lo que se puede considerar, según los resultados 
obtenidos, un fármaco de alta eficacia para la NDD.  
 
Estos datos estadísticos obtenidos coinciden en gran parte con las diversas guías y 
revisiones con las que se están comparando los resultados, ya que según NeuPSIG, 
NICE, EFNS, AACE y ADA obtiene un grado de recomendación A y se trataría de un 
fármaco de primera línea de uso. Sin embargo, para AAN la duloxetina 
pertenecería al grupo de los fármacos de recomendación nivel B. En una revisión 
sistemática de Cochrane a cargo de Lunn y colaboradores se concluye que hay una 
calidad de la evidencia moderada de los estudios incluidos sobre duloxetina en 
cuanto a alivio de dolor de las dosis estudiadas a 60 y 120 mg/día (176). Así 
mismo, otras revisiones ponen de manifiesto la eficacia de este fármaco frente a la 
  81 
NDD: Hossain y colaboradores analizan mediante revisión sistemática 8 ECAs de 
alta calidad sobre duloxetina en pacientes con NDD, determinando el mayor efecto 
beneficioso de este fármaco frente al placebo (177); Rudroju y colaboradores 
realizaron un estudio para comparar efectividad, a modo de meta-análisis, entre 6 
fármacos utilizados para el tratamiento de la NDD (amitriptilina, pregabalina, 
duloxetina, valproato, venlafaxina y gabapentina), de donde se concluye a través de 
los resultados obtenidos, que todos los tratamientos analizados tienen un efecto 
superior al placebo pero sin mostrar una superioridad entre los mismos, por lo que 
se determinada a su vez la efectividad de la duloxetina en esta patología (178); 
Sultan y colaboradores realizan una revisión sistemática de ECAs a doble ciego con 
placebo sobre duloxetina a 60 y 120 mg/día en pacientes con NDD y fibromialgia, 
de donde se obtienen 6 artículos, 3 de los cuales sobre NDD, y  según los resultados 
obtenidos se concluye que la duloxetina es un fármaco eficaz para el tratamiento 
de la NDD (179). 
 
Este fármaco está dentro del grupo de los antidepresivos, siendo en concreto un 
inhibidor de la recaptación de serotonina y noradrenalina. Sus contraindicaciones 
fundamentales se basan en la existencia de hipersensibilidad, enfermedad hepática 
que produzca insuficiencia hepática, insuficiencia renal grave, hipertensión arterial  
no controlada o en combinación con fármacos como los inhibidores de la 
monoamino oxidasa (IMAO), o como fluvoxamina, ciprofloxacino o enoxacino. 
Además, se debe tener especial precaución en pacientes que tomen 
anticoagulantes orales y/o medicamentos que afectan la función plaquetaria o en 
pacientes con riesgo elevado de hiponatremia (180). A pesar de ser un fármaco de 
gran eficacia frente a la NDD como se ha podido comprobar mediante nuestro 
estudio y las diversas revisiones y guías mencionadas que también lo han 
analizado, se concluye que es un fármaco con un elevado número de 
contraindicaciones y precauciones que deben hacer valorar a los profesionales de 
la salud su utilización de primera elección para la NDD frente a otros fármacos 
existentes, coincidiendo así con las recomendaciones de ADA. En el caso de su 
elección ante un paciente que presente NDD, se recomienda hacer un seguimiento 
más exhaustivo hacia ese paciente además de las medidas de educación al paciente 
ante la toma de fármacos de este tipo.  
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d) Topiramato 
 
Los resultados obtenidos del meta-análisis realizado para el fármaco topiramato a 
dosis máxima de 400 mg/día muestran la ausencia del tamaño del efecto y la 
ausencia de significación estadística (g de Hedges: 0,271; p-valor > 0.05). Los datos 
propios del estudio muestran a su vez una reducción para el grupo experimental 
de 3,96 en cuanto a diferencia de dolor final con dolor inicial se refiere. Sin 
embargo, a la hora de analizar los resultados de dicho fármaco se encuentra que 
para NeuPSIG y EFNS los resultados obtenidos del análisis del topiramato son 
discrepantes o inconclusos, por lo que no recomiendan su uso. Al igual que 
nuestros resultados y las revisiones y guías mencionadas anteriormente, una 
revisión sistemática Cochrane a cargo de Wiffen y colaboradores donde analizaron 
ECAs a doble ciego con un periodo superior a dos semanas sobre topiramato en 
diversas condiciones de dolor neuropático crónico, concluye en no poder 
argumentar la eficacia del fármaco en NDD debido a los importantes sesgos que se 
incluían en los artículos analizados y al no existir diferencia significativa entre 
topiramato y placebo (181). De hecho, desde 2013 hasta la fecha actual no se 
encuentran en la literatura científica estudios de cierta relevancia donde se analice 
la eficacia de este fármaco en la NDD. 
 
El topiramato es un fármaco que pertenece al grupo de los antiepilépticos cuyo uso 
común es para crisis epilépticas y migrañas (182), y pese a la existencia de 
estudios sobre su eficacia en la NDD, según la AEMPS no tiene indicación probada 
para el tratamiento de esta patología, por lo tanto, nos encontramos con un 
fármaco que debido a su ineficacia y la falta de indicación terapéutica no puede 
formar parte del arsenal terapéutico de los profesionales de la salud ante los 
pacientes que presenten NDD.  
 
e) Tapentadol 
 
Según el meta-análisis realizado a un artículo sobre tapentadol a dosis máxima de 
500 mg/día se obtiene un tamaño del efecto grande, por lo que estamos ante un 
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fármaco de alta eficacia frente a la NDD. A pesar de que según nuestros resultados 
es un fármaco eficaz, la AAN considera que los resultados de sus análisis son 
inconclusos para este fármaco, y la guía EFNS lo encuadra en el grupo de opioides 
catalogándolo como recomendación de segunda y tercera línea y con resultados 
discrepantes. Además de ello, según las recomendaciones de ADA no se 
recomienda su uso debido al riesgo de adicción y otras complicaciones que derivan 
de este fármaco. Existen a su vez otras revisiones donde coinciden con nuestros 
resultados obtenidos al indicar los beneficios de esta terapia en cuanto a reducción 
del dolor en pacientes con NDD se refiere, como las llevadas a cabo por Schwartz y 
colaboradores que analizan dos estudios sobre el tratamiento mediante tapentadol 
en NDD a dosis de 100-220 mg dos veces al día(183), y Vadivelu y colaboradores 
que realizan una revisión sobre estudios clínicos acerca del mecanismo de acción 
del tapentadol y su eficacia clínica en la NDD (184).  
 
Las reticencias en cuanto al uso de este fármaco radican en dos aspectos 
importantes: 
 La escasez de estudios de cierta calidad que puedan llevar a 
análisis más certeros sobre la eficacia de este fármaco. 
 Se trata de un fármaco perteneciente al grupo de los opioides, 
que no tiene indicación directa para la NDD pero si indirecta por su 
indicación para el dolor crónico en adultos, y que conlleva las 
contraindicaciones y complicaciones propias del grupo al que 
pertenece por la posibilidad de apariciones de hipersensibilidad, 
depresiones respiratorias, problemas gastrointestinales, 
interacciones farmacológicas y problemas de adicción entre otros 
(185). 
 
Es por todo ello, que a pesar de haber obtenido buenos resultados según nuestro 
meta-análisis, para los profesionales de la salud debería considerarse como un 
fármaco de uso muy limitado, restringiéndolo a casos muy concretos en los que los 
pacientes no respondan a otros tratamientos de primera elección, y en cuyo caso 
también debería ser considerada la opción de remitirlo a unidades hospitalarias 
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donde puedan tener una estrecha vigilancia en cuanto a su uso y complicaciones se 
refiere.  
 
f) Lamotrigina 
 
Se incluye en el meta-análisis un artículo sobre lamotrigina a dosis máxima de 400 
mg/día donde se obtiene, en términos estadísticos, un resultado relevante al 
obtener un tamaño del efecto grande. Sin embargo, al igual que ocurre de forma 
muy similar con el fármaco tapentadol, la AAN y la guía EFNS catalogan el análisis 
de este fármaco como inconcluso o con resultados discrepantes, siendo para la 
AAN un fármaco no recomendado. En cambio para la AECC seria un fármaco con 
grado de recomendación A por pertenecer al grupo de los anticonvulsionantes. 
También existe una revisión sistemática de Cochrane por Wiffen y colaboradores 
donde analizan este fármaco en el dolor neuropático crónico y la fibromialgia en 
adultos incluyendo 12 estudios, de los cuales 4 eran sobre NDD, y concluyendo 
según sus resultados que ninguno de los estudios incluidos aportó pruebas 
convincentes de la efectividad del fármaco para dolor neuropático crónico o 
fibromialgia a dosis diarias de 200 a 400 mg (186).  
 
A pesar de los resultados discrepantes en términos de eficacia entre nuestro 
estudio y los demás estudios comparados, nos encontramos con un fármaco cuyas 
indicaciones concretas están basadas en el tratamiento de la epilepsia y la 
prevención de episodios depresivos en adolescentes mayores de 18 años con 
trastorno bipolar (187), por lo que no se podría considerar su presencia como 
alternativa terapéutica para la NDD para los profesionales de la salud. 
 
g) Magnetoterapia 
 
Se analizan dos estudios sobre magnetoterapia, tanto pulsada como estática, 
catalogándose sin efecto el análisis estadístico realizado (p-valor > 0.05). Las 
terapias físicas en el tratamiento de la NDD, como es el caso de la magnetoterapia, 
tienen menor influencia en la literatura científica debido a la escasez de estudios 
relevantes, ausencia de sesgos o calidad metodológica. Es por ello que, salvo las 
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recomendaciones de AAN donde su uso no está recomendado, el resto de guías y 
revisiones analizadas no incluyen estas terapias en sus estudios. Otras revisiones 
concluyen que este tipo de terapia no es efectiva en la NDD, como son la de Stein y 
colaboradores donde analizan mediante revisión sistemática y meta-análisis 
terapias eléctricas y electromagnéticas, de las cuales 4 pertenecen a ECAs 
comparados con placebo sin obtenerse mejoría significativa en el dolor 
neuropático en pacientes diabéticos, y la de Pieber y colaboradores, que realizaron 
una revisión sobre electroterapia en la NDD obteniendo resultados no 
satisfactorios para el uso de magnetoterapia ante esta patología (15,166). En casi 
la totalidad de las revisiones analizadas, coincidiendo a su vez con los datos 
obtenidos mediante nuestro meta-análisis, mantienen la ineficacia en cuanto a 
alivio del dolor se refiere o la imposibilidad de recomendación para esta patología 
por la falta de mayor cantidad de estudios con buena calidad metodológica, con 
mejor diseño y con ausencias de sesgos importantes, argumentando así la 
necesidad de un mayor número de ECAs con rigor metodológico (15,61,62,166). 
 
Sin embargo, la escasez de efectos adversos de esta terapia unido a la capacitación 
del profesional de podología para el uso de terapias físicas en la practica clínica 
diaria, hace que la magnetoterapia pueda considerarse como una herramienta más 
para el tratamiento de la NDD, por la cual a su vez puedan desarrollarse estudios 
de investigación que avalen su eficacia en el ámbito podológico.  
 
h) Capsaicina 
 
A través del análisis estadístico realizado al artículo de capsaicina 0.025% incluido 
en el estudio se determina la ausencia de efecto según el estadístico g de Hedges. A 
pesar de los resultados obtenidos la capsaicina tópica en crema sí obtiene cierto 
grado de recomendación según NICE cuando el paciente no desee o tolere 
fármacos orales. Sin embargo, las revisiones de EFNS y AAN le otorgan un nivel de 
recomendación A/B y B respectivamente (en el caso de AAN se le otorga a la crema 
de capsaicina al 0.075%) por resultados discrepantes o ineficaces. En una revisión 
sistemática Cochrane realizada por Derry y Moore se analizaron 6 ECAs a doble 
ciego controlados por placebo por un periodo mínimo de 6 semanas utilizando 
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capsaicina a baja concentración (< 1%), llegando a la conclusión por parte de los 
autores que la capsaicina tópica a baja concentración carece de efecto significativo 
frente a otras cremas de tipo placebo, siendo esto debido a sesgos potenciales y 
tamaño muestral pequeño que tenían los estudios incluidos (44). 
 
Pese a todo ello, la capsaicina tópica en forma de crema es un fármaco con 
indicación específica para la NDD y autorizado por la AEMPS, cuyos efectos 
adversos posibles son fundamentalmente la hipersensibilidad y la sensación de 
quemazón, y que pese a los resultados obtenidos en nuestro estudio, puede formar 
parte de las alternativas terapéuticas de los profesionales de la salud, y del 
profesional de podología en concreto, a la hora de abordar clínicamente a un 
paciente con NDD (188).  
 
i) Clonidina 
 
Según los resultados del meta-análisis realizado nos encontramos con el fármaco 
clonidina crema al 0,1% sin efecto según el estadístico g de Hedges. La clonidina 
tópica es un fármaco que ha sido analizado por NeuPSIG y EFNS catalogándose 
como inconcluso en el primer caso y con un nivel A/B de recomendación por 
ineficacia o resultados discrepantes en el segundo, coincidiendo de esa manera con 
nuestros resultados obtenidos. Se analiza también su eficacia mediante revisión 
sistemática Cochrane a cargo de Wrzosek y colaboradores a partir de 2 ECAs a 
doble ciego comparados con placebo u otro tratamiento activo de al menos dos 
semanas de duración, aplicando el gel de clonidina 0,1% sobre el área dolorosa 2 o 
3 veces al día. En este estudio se concluye que en base a la limitada evidencia 
existente a cargo de pequeños estudios de calidad media – baja se puede 
determinar la existencia de beneficio con esta terapia en pacientes con NDD (169). 
 
A pesar de que este fármaco tópico se encuentre en una situación similar a la 
capsaicina en cuanto a recomendaciones se refiere, en España no tiene indicación 
terapéutica para la NDD, por lo que no puede formar parte del arsenal terapéutico 
de los profesionales de la salud para el tratamiento de la NDD (189).  
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Aplicabilidad del estudio en la práctica clínica. Algoritmos de 
tratamiento 
 
Una vez analizados todos los tratamientos incluidos en el meta-análisis y 
comparados con diversas revisiones y guías de práctica clínica de relevancia en el 
tratamiento de la NDD, nos disponemos a la realización de diversos algoritmos de 
tratamiento que sirvan como herramientas en el ámbito clínico a los profesionales 
de la salud, y en concreto a los profesionales de Podología, cuando se traten a 
pacientes con esta patología, siendo éste uno de los fundamentos principales del 
estudio. A continuación se muestran los algoritmos en función de la eficacia según 
nuestro estudio (figura 12) y las recomendaciones según el estudio realizado y los 
otros estudios comparados en función de su aplicabilidad clínica y seguridad 
(figura 13): 
Figura 12: Propuesta de tratamiento según resultados obtenidos 
 
 
Tratamientos más 
eficaces en NDD 
según los 
resultados 
obtenidos 
Pregabalina 150 - 600 mg/día 
Duloxetina 60 - 120 mg/día 
Tapentadol 500 mg/día 
Lamotrigina 400 mg/día 
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Figura 13: Propuesta de tratamiento según resultados combinados 
 
Limitaciones  
 
En el proceso de realización del estudio se han ido encontrando diversas 
limitaciones que han podido influir en la consecución final de ésta tesis. En este 
aspecto, las limitaciones fundamentales que se encontraron fueron la ausencia de 
datos estadísticos en gran cantidad de artículos seleccionados, por lo que fue 
imposible su inclusión para la realización del meta-análisis. Dicha dificultad 
intentó corregirse mediante el envío de correos electrónicos a los autores de los 
artículos que se encontraban en esa circunstancia, sin que hubiese respuesta 
alguna por parte de ninguno de ellos. A su vez, artículos potencialmente elegibles 
para el meta-análisis tuvieron que excluirse al no pasar la medida de calidad 
pertinente mediante la escala JADAD, por lo que el número de artículos finales 
disminuyó notablemente. 
 
Otro aspecto importante a destacar en cuanto a limitación es la escasez de estudios 
de calidad en lo que a terapias físicas y tópicas se refiere, ya que la literatura 
científica existente es sensiblemente inferior si se compara con las terapias 
farmacológicas orales, lo que ha conllevado la inclusión de un número muy bajo de 
artículos que han podido ser seleccionados para el meta-análisis. Además, una gran 
cantidad de artículos existentes de todos los tipos de terapias analizaban el dolor 
Primera 
línea 
Pregabalina/Gabapentina 
Duloxetina 
Segunda 
línea 
Tapentadol (u otros 
opioides) 
Terapias 
adyuvantes 
Capsaicina crema 
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neuropático en general y no la NDD en particular, por lo que también tuvieron que 
ser descartados. El propósito fundamental de esta tesis ha sido analizar las 
alternativas terapéuticas para la NDD según tratamientos en monoterapia, es decir, 
no se aceptaban comparaciones entre fármacos o terapias combinadas, por lo que 
también esto ha generado un volumen pequeño de artículos incluidos finalmente. 
Por último, a este suceso se añade que gran cantidad de la literatura científica 
existente y accesible no es del todo reciente, es decir, gran cantidad de revisiones y 
artículos tienen más de 5 años de antigüedad, y no existen estudios y revisiones 
más actualizados que cumplieran los criterios de inclusión que se determinaron 
para esta tesis o con los que se pudieran realizar comparaciones. 
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CONCLUSIONES 
 
1. Las terapias farmacológicas orales son las terapias más efectivas en el 
tratamiento de la NDD. 
2. Los fármacos orales duloxetina, pregabalina, tapentadol y lamotrigina son los 
fármacos más eficaces para la NDD según el meta-análisis realizado. 
3. Las terapias tópicas y físicas no son efectivas para la NDD según el meta-
análisis realizado. 
4. Las vías de primera elección para el tratamiento de la NDD, en términos de 
eficacia y aplicabilidad clínica según los resultados obtenidos y la evidencia 
científica existente, serían la pregabalina, gabapentina o duloxetina.  
5. Las vías de segunda elección para el tratamiento de la NDD, en términos de 
eficacia y aplicabilidad clínica según los resultados obtenidos y la evidencia 
científica existente, serían el tapentadol u otros opiodes. 
6. Según los resultados obtenidos y la evidencia científica existente la capsaicina 
tópica puede considerarse como una vía de tratamiento adyuvante cuando los 
pacientes no pueden o quieren tomar fármacos. 
7. No se ha encontrado en la literatura científica argumentos suficientes para 
restringir el uso de fármacos orales en combinación con terapias físicas o 
tópicas. 
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Anexo 7: Escala JADAD (150) 
 
Lea el artículo e intente responder las siguientes preguntas (consulte las 
instrucciones adjuntas):  
1. ¿Se describió el estudio como aleatorio (esto incluye el uso de palabras 
como randomizado, al azar y aleatorización)?  
2. ¿Se describió el estudio como doble ciego?  
3. ¿Hubo una descripción de los retiros y abandonos? 
 
Puntuación de los artículos: Otorgue una puntuación de 1 punto por cada 
"sí" o 0 puntos por cada "no". No hay puntos intermedios  
Dar un punto adicional si: Para la pregunta 1, el método para 
generar la secuencia de 
aleatorización fue descrito y fue 
apropiado (tabla de números 
aleatorios, generados por 
computadora, etc.). 
Y/o: Si para la pregunta 2 el método de 
doble cegamiento era descrito y fue 
apropiado (placebo idéntico, 
placebo activo, dummy, etc.) 
Deducir 1 punto si: Para la pregunta 1, el método para 
generar la secuencia de 
aleatorización se describió y fue 
inapropiado (los pacientes fueron 
asignados alternativamente, o según 
la fecha de nacimiento, número de 
hospital, etc.) 
Y/o: Para la pregunta 2, el estudio fue 
descrito como doble ciego pero el 
método de cegamiento fue 
inadecuado. (p. ej., comparación de 
comprimidos versus inyección sin 
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doble dummy) 
Pautas para la evaluación 
1. Aleatorización 
 Un método para generar la secuencia de aleatorización se considerará 
apropiado si permitió a cada participante del estudio tener las mismas 
posibilidades de recibir cada intervención y los investigadores no pudieron 
predecir qué tratamiento seguirían. Métodos de asignación utilizando La fecha 
de nacimiento, la fecha de ingreso, los números de hospital o la alternancia no 
deben considerarse apropiados. 
2. Doble cegamiento  
Un estudio debe considerarse doble ciego si se utiliza la palabra "doble ciego". 
El método se considerará apropiado si se afirma que ni la persona que realiza 
las evaluaciones ni el participante del estudio pudo identificar la intervención 
que se está evaluando, o si en la ausencia de tal declaración, se menciona el 
uso de placebos activos, placebos idénticos o dummies. 
3. Retiros y abandonos.  
Participantes que fueron incluidos en el estudio pero no completaron el 
período de observación o quienes no fueron incluidos en el análisis deben ser 
descritos. Hay que hacer constar el número y las razones para la retirada en 
cada grupo. Si no hubiera retiros, debería ser enunciado en el artículo. Si no 
hay una declaración sobre los retiros, este artículo no debe obtener puntos. 
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Anexo 9: Artículos incluidos en el meta-análisis 
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0.025%CapsaicinGel for theTreatment of Painful
DiabeticNeuropathy: ARandomized, Double-
Blind, Crossover, Placebo-Controlled Trial
Kongkiat Kulkantrakorn, MD*; Chakraphong Lorsuwansiri, MD*; Pongsatorn
Meesawatsom, MSc†
*Division of Neurology, Department of Internal Medicine, Thammasat University,
Pathumthani; †Department of Pharmacology, Faculty of Pharmacy, Mahidol University,
Bangkok, Thailand
& Abstract
Background: Topical therapy may provide additional
benefit in patients with painful diabetic neuropathy (PDN).
This study was conducted to study the safety and efficacy of
0.025% capsaicin gel in this condition.
Methods: A 20-week, double-blind, crossover, randomized,
single-center study enrolled subjects with PDN. They received
0.025% capsaicin gel or placebo for 8 weeks, with a washout
period of 4 weeks between the two treatments. Primary
efficacy end point was percent change in visual analog scale
(0–100 mm) of pain severity. Secondary outcomes were score
change in Neuropathic Pain Scale (NPS), short-form McGill
Pain Questionnaires (SF-MPQ), proportion of patients who
had pain score reductions of 30% and 50%, and adverse
event.
Results: Of the 35 subjects screened, 33 were enrolled and
33 completed at least an 8-week treatment period. Intention-
to-treat analysis showed no significant improvement in pain
with capsaicin gel, compared with placebo with visual analog
scale (VAS) score 28.8 mm vs. 34.6 mm (P = 0.53). No signif-
icant difference between the groups was found in SF-MPQ
(7.4 vs. 7.71, P = 0.95), NPS (29.4 vs. 31.3, P = 0.81), and
proportion of patients who had 30% or 50% pain relief.
Capsaicin gel was well tolerated with minor skin reaction.
Conclusions: 0.025% capsaicin gel is safe and well tolerated,
but does not provide significant pain relief in patients with
PDN. &
Key Words: capsaicin, neuropathic pain, diabetic neurop-
athy, topical gel
BACKGROUND
Neuropathy is one of the most common complications
in both type 1 and type 2 diabetes mellitus. The most
common form is a symmetrical, chronic, axonal, length-
dependent sensorimotor polyneuropathy.1 Some
patients are asymptomatic, but many patients have
sensory symptoms, either negative or positive ones.
These symptoms may fluctuate over time. The majority
of them also have pain associated with neuropathy, also
called painful diabetic neuropathy (PDN).2 The diagno-
sis of PDN primarily relies on the patient’s description of
pain. The symptoms are predominantly symmetrical,
distal, and more pronounced at night. Common pain
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symptoms are sharp, lancinating, burning, prickling,
deep aching, cramping, and gnawing. Upon examina-
tion, hyperalgesia and allodynia were frequently
found.3,4 Therefore, it is the most common cause of
neuropathic pain.5 Patients with PDN have a lower
quality of life, especially the physical aspect. This
condition often persists over time and causes more
long-term expenditures.6,7 Despite recent improvements
in chronic neuropathic pain treatment, the pain is often
inadequately controlled.
Capsaicin {6-nonenamide, N-[(4-hydroxy-3-meth-
oxyphenyl) methyl]-8-methyl- (6E)} is a natural alka-
loid, which is extracted from Solanaceae family plants
(red chili peppers). It selectively binds to transient
receptor potential vanilloid 1 receptor (TRPV1), a
ligand-gated, nonselective cation channel, predomi-
nantly expressed on unmyelinated C nerve fibers and
causes substance P release. After repeated exposure to
topical capsaicin, the local substance P and possibly
other neurotransmitters were depleted from sensory
nerve endings. This will reduce painful stimuli trans-
mission from peripheral nerves to the central nervous
system.8,9 Defunctionalization of cutaneous nociceptors
also plays important role in reducing cutaneous hyper-
sensitivity and pain. It is caused by temporary loss of
membrane potential and interruption of neurotrophic
factors’ transportation. Eventually, phenotypic
alteration and reversible retraction of epidermal and
dermal nerve fiber terminals occur.10
Topical capsaicin formulations are widely used to
manage pain. Low-concentration creams, lotions, and
patches intended for daily skin application have been
available in most countries since the early 1980s. Pre-
scriptions are usually not needed for these self-adminis-
tered medicines.10 Previous capsaicin clinical trials in
PDNwere performedwith the concentration of 0.075%,
which showedmoderate efficacy.11–13 Burning sensation
was themost common cause of the drug discontinuation.
Less-concentrated preparations of topical capsaicin may
reduce this skin adverse effect. The authors, therefore,
studied the 0.025% capsaicin gel preparation for its
efficacy and safety in patients with PDN.
METHODS
Trial Design
This was a 20-week, randomized, double-blind, cross-
over, placebo-controlled trial conducted in an outpa-
tient neurology clinic within a tertiary-care university
teaching hospital in a northern suburban area of
Bangkok, Thailand.
Patients were assessed at baseline, followed by
8 weeks of treatment with 0.025% capsaicin gel
(Capsika-25® gel, Bangkok Drug Company, Bangkok,
Thailand) or placebo (vehicle gel) and a 4-week washout
period between the two treatments. They were randomly
allocated, by computer-generated randomization list in
blocks of fours, to 2 groups. The first group received
capsaicin gel during the first period and placebo during
the second period, while the second group received
placebo during the first period and capsaicin during the
second period.
The investigators dispensed the drug and performed
assessment for efficacy and safety at each visit. In case of
adverse event during the study, they were always
available to patients by mobile phone. Telephone
reminder was used for patients due to visit and for
follow-up for missed visits. Demographic characteristics
were recorded, and all measured parameters before and
after treatment were compared. An independent
statistician performed the randomization and assured
blinding of procedures.
This study was an investigator-initiated study. It was
approved by the Ethical Committee of Faculty of
Medicine, Thammasat University and was conducted
following the principles of the Declaration of Helsinki
and Good Clinical Practice guideline. Written informed
consent was obtained from each subject prior to
enrolment. This trial was registered with ClinicalTri-
al.gov (NCT00993070).
Inclusion and Exclusion Criteria
Patients of either sex who had type 2 diabetes for at least
1 year and aged more than 20 years old and who had
PDN for at least 1 month were considered for the study.
They met all of the following PDN diagnostic criteria:
(1) consistent medical history; (2) presence of signs and
symptoms of peripheral sensory neuropathy, such as
numbness, burning pain, sharp pain, loss of pain, or
touch sensation; and (3) a score of more than 4 on the
neuropathic pain diagnostic questionnaire (Thai
DN4).14
The patients were excluded if they had other causes of
neuropathy or unstable medical or psychiatric illnesses;
were being treated with other investigational drug; had
other significant disease or receive medication that may
worsen neuropathy during the trial period; underwent
invasive intervention for pain relief; or were allergic to
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capsaicin.15 In those who took other pain medications
such as anticonvulsants, opioid, local anesthetics, the
dosage must have been stable for at least 4 weeks prior
to enrolment.
Medication
The study drug was capsicum tincture 45.5 g per 100 g
(equivalent to capsaicin 0.025%, Capsika-25® gel) in a
plastic tube containing 100 g of gel. Vehicle gel was
provided in a matching tube. The drug or placebo was
dispensed to patients according to randomized group
assignment. The study drug and placebo were provided
by Bangkok Drug Company Limited (Bangkok, Thai-
land).
Patients applied 2 inches of gel topically around the
foot and other painful area and rubbed it until dry for 3
to 4 times a day. To avoid unintentional irritation,
patients were instructed to wash their hands after
applying the gel. Direct questioning and study medica-
tion tube accounting were used to assess compliance.
Outcomes
Efficacy. The primary end point of the study was the
reduction in the mean pain score from baseline, as
assessed by the patient’s visual analog scale (VAS) by
0–100 mm. Secondary end points were the assessment
of pain by the short-form McGill Pain Questionnaire
(SF-MPQ) and Neuropathic Pain Scale (NPS). All
measurements were taken at baseline, 2nd, 4th, and
8th week. At the end of each treatment period, a pain
intensity score reduction in each individual on the basis
of the VAS of 30% and 50% was calculated.15
Safety. Safety and tolerability were assessed at each
visit. Physical examination, including foot inspection,
was performed every visit. Treatment-emergent adverse
events (TEAEs) were assessed by clinical and laboratory
evaluation as appropriate.
Statistical Methods
Sample Size. The sample size calculation was based on
the two by two crossover design16 with the assumption
from the means and SDs observed for VAS pain scores
in previous trial of capsaicin in PDN.12 To detect at
least 10% reduction in pain score and 90% power at
two-tailed significant level of 0.05, the calculated size
sample was 40 patients in each treatment to detect at
least 10% pain reduction and standard deviation of
9.5.
Statistical Analysis. Intention-to-treat analysis was
used for both the primary and secondary efficacy
analyses. It was defined as patients who received at
least one dose of study medication and had at least one
post-treatment efficacy assessment. Values are expressed
as means ± SD, numbers, and percentages. The pain
scores, that is, VAS, Neuropathic Pain Scale, and the
short-form McGill Pain Questionnaire were compared
using the Student’s t-test. Percentage of patients showing
improvement and incidence of adverse events were
compared using the chi-square test. A P value 0.05 was
considered significant, with 2-tailed analysis. STATA
program (version 10.0) (College Station, Texas, U.S.A.)
was used to perform analysis.
RESULTS
The study was conducted between October 2009 and
October 2011.
Patient demographic information, clinical character-
istics, and flow through the study period are summarized
in Table 1 and Figure 1. Concurrent medications for
neuropathic pain among participants included: gaba-
pentin 27.3%, amitriptyline 9.1%, nortriptyline 9.1%,
tramadol 6.1%, and pregabalin and paracetamol 3.0%.
Table 1. Baseline Patient Characteristics
Characteristics Values
Age (years) (min–max) 57.96 (35–76)
Sex: Female 17 (51.5%)
Height (m) 1.64 ± 0.087
Weight (kg) 69.15 ± 13.76
Visual analog scale (mm) 42.7 ± 27.7
Duration of diabetes (years) 11.17 ± 7.46
Duration of pain (years) 4.73 ± 5.13
Thai DN4 score 5.89 ± 1.85
Diabetic complications
Retinopathy 9 (27.3%)
Nephropathy 6 (18.2%)
Neuropathy 33 (100%)
Comorbidities
Hypertension 26 (78.8%)
Dyslipidemia 28 (84.8%)
Others 14 (42.2%)
Pain medication
Tramadol 2 (6.1%)
Amitriptyline 3 (9.1%)
Nortriptyline 3 (9.1%)
Gabapentin 9 (27.3%)
Pregabalin 1 (3.0%)
Paracetamol 1 (3.0%)
Data are means ± SD, or n (%), n = 33 patients.
VAS, visual analog scale; DN4: neuropathic pain diagnostic questionnaires.
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Of the 35 subjects screened, 33 were enrolled and
33 completed at least an 8-week treatment period.
Intention-to-treat (ITT) analysis showed no significant
improvement in pain with capsaicin gel, compared
with placebo with VAS score of 28.8 mm vs. 34.6 mm
(P = 0.53; Figure 2A and Table 2). No significant
difference between the groups was found in NPS
(29.4 vs. 31.3, P = 0.81; Figure 2B and Table 2) and
SF-MPQ (7.4 vs. 7.7, P = 0.95; Figure 2C and
Table 2). From VAS data, overall pain relief of 30%
was observed in 9/33 (27.3%) and 10/33 (30.3%) of
patients with capsaicin and placebo, respectively, and
50% improvement was seen in 6/33 (18.2%) and 9/33
(27.3%) of patients with capsaicin and placebo,
respectively. They were not statistically significant
(P = 0.786 for 30% pain relief and 0.378 for 50%
pain relief; Table 3).
The recruitment was prematurely stopped due to
unexpected hospital closure for 3 months during the
severe flood crisis in Thailand. The reasons for non-
compliance included frequent follow-up visits and
difficulty in transportation due to long distance from
home to the hospital and severe flood during the study
period. Baseline scores were similar in the 2 groups;
therefore, pooled data were analyzed.
Common TEAEs were local skin reactions (burning,
edema, erythema, papules, and pruritus), which were
found in 5 (15.2%) patients in capsaicin group vs. no
(0.0%) patient in placebo groups. Four patients in the
capsaicin vs. no patient in placebo group withdrew
because of skin adverse event. Regarding systemic
reaction, there was no significant difference in both
groups (Table 4).
Screened for eligibility 
(n= 35) 
Randomised 
(n= 33) 
Excluded  
Due to 
screening 
failure (n= 2)  
A Capsaicin group 
(n= 16) 
B Placebo group 
(n= 17) 
Discontinued treatment 
(n=0) 
Adverse event (n=3) 
Lost to follow-up (n=3) 
Discontinued treatment 
(n=0) 
Adverse event (n=0) 
Lost to follow-up (n=6) 
Complete study (n=10) Complete study (n=11) 
B Placebo (n=10) A Capsaicin (n=11) 
Adverse event (n=0) 
Lost to follow-up (n=4) 
Adverse event (n=1) 
Lost to follow-up (n=4) 
Complete study (n=6) Complete study (n=6) 
Figure 1. CONSORT statement.
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Figure 2. Efficacy of 0.025% capsaicin gel vs. placebo on symp-
toms of painful diabetic neuropathy (PDN) over 8 weeks of
treatment. (A) Visual analog scale (VAS), (B) Neuropathic pain
scale (NPS) and (C) Short-form McGill Pain Questionnaires
(SF-MPQ).
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DISCUSSION
Topical capsaicin preparation, most studied at 0.075%
concentration, has been used in many conditions, such
as rheumatoid arthritis, myofascial pain, post herpetic
neuralgia, and many skin conditions.8 A head-to-head
comparison trial with amitriptyline in patients with
PDN showed comparable efficacy, without systemic side
effects.11 American Academy of Neurology evidence–
based guideline recommended 0.075% capsaicin topical
preparation as an probably effective treatment option in
PDN.17 In contrast to the European Federation of
Neurological Societies recommendation, it did not
include capsaicin cream as an effective treatment for
PDN due to its limited efficacy and discrepant results.5
In our study, the results for the primary and secondary
end points for pain relief were not achieved for 0.025%
capsaicin gel in patients with PDN. However, this
concentration was safe and well tolerated. In contrary,
the same preparation of lower concentration (0.0125%)
provided pain relief greater than vehicle gel with good
tolerability in Thai patients with osteoarthritis.18
Topical preparations also have certain limitations in
variability of pharmaceutical preparation. Several adju-
vants were added for viscosity and permeability
enhancers, emollient, and preservatives during produc-
tion. Variation in individual skin condition affects
absorption and distribution of the topically applied
medication. Moreover, its efficacy also relies on the rate,
amount, and depth of skin penetration.19 Capsaicin is
near water insoluble; therefore, the depth of skin
penetration is minimal. Higher concentrations may be
needed to achieve desirable depth and functional
denervation of sensory nerve fibers.
Although a very high concentration at 8% of capsa-
icin patch was reported to be beneficial in postherpetic
neuralgia and HIV-associated neuropathy, it is not
suitable for PDN due to its difficult usage and the
potential for dangerous side effects. The application of
the patch may be impossible on the feet/toes or hands/
fingers, which are the affected sites. Theoretically, the
application of high concentration of capsaicin may cause
more cutaneous denervation, which leads to less protec-
tive sensation and possibly increased risk of skin injuries.
However, this has not been evident in previous clinical
trials for other indications.10 Episodic application of this
patch results in acute localized extensive denervation,
which provides pain relief for several months. It is
mechanistically different from repeated application of
low-concentration capsaicin preparation. A new deliv-
ery system, such as nanoparticle preparation, may be
more promising. Many new agonists and antagonists of
TRPV1 receptor are also currently being evaluated for
analgesia, which may have future role in PDN.
Patient’s compliance is always an important issue in
the treatment of chronic pain, especially in medically ill
patients. The frequent application of topical treatment
may hinder the compliance. However, this effect in
Table 2. Pain Visual Analog Scale (VAS), Neuropathic
Pain Scale (NPS), and Short-Form McGill Pain Question-
naire After Application of 0.025% Capsaicin Gel in Each
Visit Over 8 Weeks
Outcome
Measurements
0.025%
Capsaicin Gel
(Mean ± SD)
Placebo
(Mean ± SD) P Value
VAS (mm)
Wk 0 44.1 ± 2.49 50.0 ± 2.93 0.55
Wk 2 43.8 ± 3.23 48.8 ± 3.01 0.647
Wk 4 4.91 ± 1.92 48.8 ± 3.01 0.155
Wk 8 2.88 ± 2.18 3.46 ± 2.89 0.531
NPS
Wk 0 38.46 ± 20.76 42.43 ± 21.41 0.630
Wk 2 34.69 ± 23.09 38.79 ± 20.69 0.631
Wk 4 34.92 ± 16.35 31.36 ± 20.43 0.623
Wk 8 29.38 ± 16.07 31.29 ± 21.29 0.805
SF-MPQ
Wk 0 18.06 ± 9.15 19.18 ± 8.89 0.725
Wk 2 10.20 ± 7.08 17.80 ± 11.42 0.091
Wk 4 11.86 ± 6.67 13.30 ± 11.80 0.775
Wk 8 7.40 ± 6.19 7.71 ± 10.16 0.953
VAS, visual analog scale; NPS, Neuropathic Pain Scale; SF-MPQ, short-form McGill Pain
Questionnaire.
Table 3. Proportion of 30% and 50% Pain Relief in Each
Group Based on Visual Analog Scale (VAS) Score
Outcomes Treatment
Number of
Patients
Mean
VAS (SD)
95%
CI P Value
 30%
pain relief
Capsaicin 9 66.57 ± 21.89 49.74–83.39 0.773
Placebo 10 69.25 ± 17.91 65.44–82.06
 50%
pain relief
Capsaicin 6 77.99 ± 17.23 59.91–96.07 0.559
Placebo 9 72.79 ± 14.81 61.41–84.17
Table 4. Treatment-Emergent Adverse Events (TEAEs)
Data Are Expressed as n (%)
Capsaicin Placebo P Value
Any skin reaction 5 (14.7%) 0 (0.0%) < 0.01*
Burning sensation 1 (3.0%) 0 (0.0%) 0.50
Edema 1 (3.0%) 0 (0.0%) 0.50
Erythema 1 (3.0%) 0 (0.0%) 0.50
Papules 1 (3.0%) 0 (0.0%) 0.50
Pruritus 1 (3.0%) 0 (0.0%) 0.50
Systemic reaction
Nausea/vomiting 3 (9.1) 3 (9.1%) 0.69
Hypertension 11 (33.3%) 12 (36.4%) 0.60
Dizziness 1 (3.0%) 0 (0.0%) 0.50
Headache 1 (3.0%) 0 (0.0%) 0.50
*Statistically significant.
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topical therapy vs. oral drugs has not been adequately
studied.19
A limitation of this study is the small sample size, high
dropout rates, and missing data at some time points.
The pooling of results may partially alleviate this issue.
Due to the crossover design, many patients who received
the placebo during the first phase may have dropped out
due to lack of efficacy. Additionally, this trial was
interrupted and terminated due to the severe flood in
Thailand during study period. At that time, the hospital
was closed for several months and land transportation
was not possible. Nonetheless, the duration of the
evaluable treatment period (8 weeks) in this study was
appropriate to evaluate its efficacy. In general neuro-
pathic pain conditions, pain relief was experienced
within 6–12 weeks with a single application of 8%
capsaicin patch or repeated use of 0.075% capsaicin
cream.10 The frequency of application at 3–4 times a day
may also have contributed to noncompliance and
dropouts, but it reflected the real-life practice of this
topical preparation. However, the dropout rate due to
local side effect was low.
In summary, in this crossover study, we found that
topical preparation of capsaicin at 0.025% concentra-
tion provided no significant benefit in providing pain
relief in patients with PDN, but it was safe and well
tolerated with minor skin reaction.
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1.	Introduction	
a		b		s		t		r		a		c		t	
A	length-dependent	neuropathy	with	pain	in	the	feet	is	a	common	complication	of	diabetes	(painful	
diabetic	neuropathy).	It	was	hypothesized	that	pain	may	arise	from	sensitized-hyperactive	cutaneous	
nociceptors,	and	that	this	abnormal	signaling	may	be	reduced	by	topical	administration	of	the	a2-adren-	
ergic	agonist,	clonidine,	to	the	painful	area.	This	was	a	randomized,	double-blind,	placebo-controlled,	
parallel-group,	multicenter	trial.	Nociceptor	function	was	measured	by	determining	the	painfulness	of	
0.1%	topical	capsaicin	applied	to	the	pretibial	area	of	each	subject	for	30	minutes	during	screening.	Sub-	
jects	were	then	randomized	to	receive	0.1%	topical	clonidine	gel	(n	=	89)	or	placebo	gel	(n	=	90)	applied	3	
times	a	day	to	their	feet	for	12	weeks.	The	difference	in	foot	pain	at	week	12	in	relation	to	baseline,	rated	
on	a	0–10	numerical	pain	rating	scale	(NPRS),	was	compared	between	groups.	Baseline	NPRS	was	
imputed	for	missing	data	for	subjects	who	terminated	the	study	early.	The	subjects	treated	with	clonidine	
showed	a	trend	toward	decreased	foot	pain	compared	to	the	placebo-treated	group	(the	primary	end-	
point;	P	=	0.07).	In	subjects	who	felt	any	level	of	pain	to	capsaicin,	clonidine	was	superior	to	placebo	
(P	<	0.05).	In	subjects	with	a	capsaicin	pain	rating	P2	(0–10,	NPRS),	the	mean	decrease	in	foot	pain	
was	2.6	for	active	compared	to	1.4	for	placebo	(P	=	0.01).	Topical	clonidine	gel	signiﬁcantly	reduces	the	
level	of	foot	pain	in	painful	diabetic	neuropathy	subjects	with	functional	(and	possibly	sensitized)	
nociceptors	in	the	affected	skin	as	revealed	by	testing	with	topical	capsaicin.	Screening	for	cutaneous	
nociceptor	function	may	help	distinguish	candidates	for	topical	therapy	for	neuropathic	pain.	
Ó	2012	International	Association	for	the	Study	of	Pain.	Published	by	Elsevier	B.V.	All	rights	reserved.	
	
	
receptor	agonist	that	was	originally	approved	as	an	oral	product	
to	treat	hypertension.	Intrathecally	applied	clonidine	was	later	
A	length-dependent	neuropathy	is	one	of	the	most	common	
complications	of	diabetes.	Pain,	typically	felt	in	the	feet,	is	a	com-	
mon	feature.	The	analgesic	efﬁcacy	of	oral	medications	such	as	pre-	
gabalin	and	duloxetine	in	painful	diabetic	neuropathy	(PDN)	is	
highly	variable,	and	many	patients	have	difﬁculty	with	side	effects	
[25].	It	is	therefore	desirable	to	ﬁnd	alternative	therapies.	Prior	re-	
ports	from	studies	in	animals	and	man	have	suggested	that	cloni-	
dine	may	be	effective	in	relieving	neuropathic	pain	when	applied	
topically	to	the	painful	area	[6,17].	Clonidine	is	an		a2-adrenergic	
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shown	to	produce	analgesia	for	both	acute	and	chronic	pain	[10].	
Alpha-2	receptors	are	also	present	on	nociceptors	in	the	epidermis	
[26].	Activation	of	these	G-protein-coupled	receptors	leads	to	re-	
lease	of	an	inhibitory	G-protein	which,	in	turn,	downregulates	
adenylate	cyclase	and	other	second	messengers	thought	to	play	a	
role	in	initiating	and	maintaining	the	abnormal	excitability	of	noci-	
ceptors	[16].	The	origin	of	neuronal	signals	leading	to	pain	in	PDN	
is	unknown,	though	nociceptors	expressed	in	the	skin	are	a	poten-	
tial	target	[3].	Given	the	robust	expression	of		a2	receptors	in	
cutaneous	nociceptors,	evidence	that	nociceptors	in	the	skin	may	
be	sensitized	in	neuropathic	pain	models,	and	prior	behavioral	
and	clinical	data	indicating	analgesic	effects	of	clonidine,	a	dou-	
ble-blind	randomized	study	was	performed	to	determine	efﬁcacy,	
tolerability,	and	safety	of	topical	clonidine	to	treat	PDN.	In	some	
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patients,	the	skin	is	profoundly	denervated,	and	in	these	cases,	top-	
ical	therapy	is	likely	futile.	In	other	patients,	the	nociceptor	inner-	
vation	of	the	skin	is	preserved	[11,23,32],	and	to	the	extent	that	
abnormal	signaling	in	these	nociceptors	leads	to	pain,	topical	clo-	
nidine	may	have	a	therapeutic	role.	Here	we	provide	evidence	that	
the	analgesic	effect	of	topical	clonidine	varies	with	the	painfulness	
of	 topical	 capsaicin	 applied	 near	 the	 foot.	 This	 supports	 the	
hypothesis	that	the	efﬁcacy	of	this	topical	therapy	depends	on	
the	presence	of	nociceptors	in	the	skin,	and	possibly	on	the	level	
of	sensitization.	
	
2.	Materials	and	methods	
	
2.1.	Design	
	
The	study	was	a	randomized,	double-blind,	placebo-controlled,	
parallel-group	study,	conducted	at	multiple	centers	throughout	the	
United	States,	that	consisted	of	a	screening	phase	(28	±	7	days	prior	
to	the	baseline	visit),	a	baseline	phase	(7	days	prior	to	treatment	
plus	the	baseline	visit	assessments	[day	1]),	a	12-week	double-	
blind	treatment	phase,	and	a	follow-up	period	(Fig.	1).	The	protocol	
and	informed	consent	documents	were	approved	by	the	appropri-	
ate	Institutional	Review	Boards	and	the	trial	was	registered	(Clini-	
calTrials.gov	identiﬁer:	NCT00695565).	Written	informed	consent	
was	 obtained	 from	 each	 patient	 before	 initiation	 of	 study	
procedures.	
	
2.2.	Screening	of	subjects	
	
All	subjects	were	diagnosed	to	have	a	length-dependent	painful	
sensory	neuropathy	affecting	the	feet	attributable	to	type	1	or	type	
2	diabetes	mellitus	based	on	history,	physical	examination,	and	
laboratory	data.	The	symptoms	followed	a	stocking-type	distribu-	
tion.	Subjects	were	excluded	if	they	had	clinical	evidence	of	other	
causes					of					foot					pain					such					as					Morton’s					neuroma,					tarsal					tunnel	
syndrome,	plantar	fasciitis,	lumbar	radiculopathy,	and	arthritis.	
Subjects	were	also	excluded	if	they	had	another	condition	with	
greater	pain	intensity,	an	unstable	medical/psychological	condi-	
tion,	or	an	open	lesion/skin	condition	in	the	area	of	gel	application.	
The	complete	list	of	inclusion	and	exclusion	criteria	is	provided	in	
Table	1.	Physical	examination,	vital	signs,	application	site	assess-	
ment,					complete					medical					history,					clinical					laboratory					specimen	
examination,					electrocardiogram					(ECG),					urine					drug					screen,					and	
pregnancy	test	were	conducted	at	screening.	Participants	also	com-	
pleted	questionnaires	and	underwent	sensory	testing.	Participants	
discontinued	use	of	‘‘as	needed’’	pain	medications	other	than	acet-	
aminophen	(paracetamol).	If	they	were	on	other	daily	pain	medica-	
tions,	they	were	allowed	to	continue	these	as	long	as	they	agreed	
to	continue	stable	daily	dosing	throughout	the	study.	
	
2.3.	Baseline	assessment	
	
Subjects	recorded	the	average	pain	intensity	in	their	feet	over	
the	past	24-hour	period	(average	daily	pain)	using	the	numerical	
pain	rating	scale	(NPRS).	Eligible	subjects	(baseline	pain	rating	
P4	[average	of	7	days	prior	to	treatment];	diaries	>	80%	complete)	
underwent	baseline	measurements	that	included	reassessment	of	
screening	procedures	and	questionnaires,	and	laboratory	assess-	
ments	(including	sampling	of	plasma	levels	of	clonidine).	A	subset	
of	participants	(97)	underwent	a	3-mm	skin	punch	biopsy	6	cm	
above	the	ankle	of	either	leg	in	order	to	quantify	intraepidermal	
nerve	ﬁber	density.	Epidermal	C	ﬁbers	colocalize	with	markers	of	
nociceptors	and	are	thought	to	relate	to	pain	functioning	in	the	
skin					[26].					This					procedure					was					elective,					and					sites					as					well					as	
	
	
	
Screening	
Baseline	 Double-blind	treatment	
CLO-027	TID	
Follow-up	
	
1:1	Randomization		
Day	-28	 Day	-7	 Placebo	TID	 13	 16	
	
Start	Study	Treatment	
1				2	 	
Week	
Study	
Termination	
	
Fig.	1.	Timeline.	CLO,	clonidine;	TID,	3	times	a	day.	
	
Table	1	
Inclusion/exclusion	criteria.	
Inclusion	criteria	
1	 Between	18	and	80	years	of	age	
2	 Established	diagnosis	of	diabetes	(type	I	or	II)	with	pain	attributable	to	a	symmetrical	stocking	distribution	neuropathy	in	the	lower	extremities	
3	 Average	daily	pain	score	P4	on	an	11-point	0–10	numerical	pain	rating	scale	(NPRS)	in	the	area	of	PDN	during	the	baseline	phase	
4	 At	least	a	6-month	history	of	PDN	pain,	but	65	years	(prior	to	screening)	
5	 Stable	glycemic	control	regimen	for	at	least	3	months	
6	 Stable	analgesic	regimen	for	at	least	21	days	prior	to	randomization	
7	 Willing	to	maintain	current	medications	at	their	same	dose	throughout	the	study	
Exclusion	criteria	
1	 Other	chronic	pain	with	greater	intensity	than	their	PDN	pain	
2	 Other	chronic	pain	within	the	region	of	PDN	
3	 Any	serious	or	unstable	medical	or	psychological	condition	
4	 Hypotension	
5	 History	of	illicit	drug	or	alcohol	abuse	within	a	year	
6	 Cognitive	or	language	difﬁculties	that	would	impair	understanding/completion	of	the	assessment	instruments	
7	 Pregnant	or	lactating	females,	planning	to	become	pregnant,	or	using	unreliable	means	of	birth	control	
8	 Received	other	experimental	drugs	within	2	months	of	randomization	
9	 Prior	use	of	topical	clonidine	gel	
10	 Open	lesions	or	skin	conditions	in	the	area	of	gel	application	
11	 Known	sensitivity	or	intolerance	to	clonidine	
PDN,	painful	diabetic	neuropathy.	
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participants	could	opt	out	from	participation	based	on	their	prefer-	
ence.	Labeling	was	performed	with	the	pan	axonal	marker	PGP	9.5,	
and	 density	 assessment	 followed	 validated	 techniques	 [35]	
(Therapath:	http://www.therapath.com).	
	
2.4.	Questionnaires	
	
The	Brief	Pain	Inventory	(BPI)	[4]	was	used	to	assess	pain	and	
functioning.	Subjects	also	underwent	tests	of	sleep	(Chronic	Pain	
Sleep	Inventory;	CPSI)	[13]	and	depression,	along	with	anxiety	
(Hospital	Anxiety	and	Depression	Scale;	HADS)	[40].	Clinician	
and	Patient	Global	Impressions	of	Change	(CGIC,	PGIC,	respec-	
tively)	 were	 assessed	 by	 having	 the	 investigator	 and	 patient	
independently	rate	the	overall	change	in	pain	status	at	the	ﬁnal	
treatment	visit	[8].	
	
2.5.	Psychophysical	assessment	
	
During	screening,	0.1%	capsaicin	was	applied	over	a	1-cm	diam-	
eter	area	on	the	pretibial	area	midway	between	the	calf	and	ankle	
of	both	legs.	The	pretibial	area	was	selected	for	placement	of	the	
capsaicin	stimulus	rather	than	the	foot,	because	the	pretibial	area	
is	typically	also	affected	by	the	length-dependent	neuropathy,	and	
it	was	believed	that	the	pain	from	capsaicin	stimulus	might	other-	
wise	be	confused	with	the	ongoing	pain	in	the	foot.	Notably,	the	
area	selected	was	near	the	area	chosen	for	skin	biopsy	used	to	ana-	
tomically	quantitate	the	severity	of	the	small	ﬁber	neuropathy	
(data	presented	in	Results).	An	occlusive	dressing	(eg,	Tegaderm;	
3M,	St	Paul,	MN,	USA)	was	applied	over	the	capsaicin	application	
site,	and	left	in	place	for	30	minutes.	Subjects	then	rated	the	capsa-	
icin-induced	pain	on	a	0–10	scale	(NPRS)	for	each	leg	indepen-	
dently.	The	responses	from	the	right	and	left	sides	were	highly	
correlated	(r2	=	0.93,	P	=	0.001).	Therefore,	the	mean	pain	rating	
of	the	2	sides	was	used	in	further	analyses.	Vibratory	testing	was	
performed	on	the	dorsum	of	both	large	toes	through	use	of	a	
128-Hz	tuning	fork	[20].	Normal,	reduced,	or	absent	mechanical	
sensation	was	assessed	through	use	of	a	10-g	(5.07)	von	Frey	
monoﬁlament	 (Center	 for	 Specialized	 Diabetes	 Foot	 Services;	
Mid-Delta	Health	Systems,	Inc,	Belzoni,	MS,	USA)	applied	to	the	
dorsum	of	the	great	toe	[20].	An	assessment	of	thermal	discrimina-	
tion	was	conducted	to	test	the	subject’s	ability	to	differentiate	
warmth	from	cold	on	the	dorsum	of	each	foot	using	a	heated	or	
cooled	metal	rod.	
	
2.6.	Randomization	and	blinding	
	
Participants	were	randomized	in	blocks	to	receive	either	0.1%	
topical	clonidine	gel	or	placebo	gel	in	a	1:1	ratio,	double-blinded	
fashion.	Subjects	were	stratiﬁed	with	regard	to	baseline	pain	sever-	
ity,	such	that	similar	numbers	of	patients	with	moderate	and	
severe	pain	were	included	in	the	active	and	placebo	groups.	The	
placebo	 formulation	 was	 identical	 in	 appearance,	 consistency,	
packaging,	and	labeling.	Placebo	and	active	drug	were	supplied	
by	Arcion	Therapeutics	(Baltimore,	MD,	USA).	
	
2.7.	Treatment	period	
	
Throughout	the	study,	participants	recorded	their	average	pain,	
using	the	NPRS,	over	the	last	24	hours	in	a	diary	each	evening	be-	
fore	going	to	bed.	Subjects	returned	to	the	clinic	for	visits	at	weeks	
1,	2,	4,	6,	8,	10,	and	12	for	assessments.	Pharmacokinetics	and	other	
laboratory	tests,	 physical	examination,	 application	 site	 assess-	
ments,	vital	signs,	ECG,	urine	drug	screen,	urine	pregnancy	test,	
HADS,	BPI,	and	CPSI	were	obtained	at	clinic	visits.	Subjects	also	
returned	to	the	clinic	approximately	1	week	after	discontinuation	
of	study	medication	for	a	follow-up	safety	evaluation.	
2.8.	Drug	application	
	
Study	medication	was	self-administered	to	both	feet	in	the	
morning,	afternoon,	and	evening.	A	‘‘dose’’	was	deﬁned	as	the	
amount	of	gel	delivered	with	one	complete	pump	(a	metered	dose)	
of	the	mechanical	dispensing	bottle	per	foot.	Participants	were	
instructed	to	apply	the	gel	evenly	to	the	toes,	between	the	toes,	
and	top	and	bottom	of	the	feet	extending	up	to	the	ankle.	The	clo-	
nidine	bottles	contained	0.1%	clonidine	and	dispensed	0.65	g	of	gel	
(0.65	mg	clonidine)	per	dose.	The	total	daily	clonidine	dose	was	
3.9	mg	(2	feet,	3	times/day;	0.65	mg	Â	6).	Prior	unpublished	stud-	
ies	suggested	that	.05%	is	not	an	effective	dose	of	clonidine,	and	
0.2%	had	no	greater	efﬁcacy	than	0.1%	clonidine.	Safety	was	as-	
sessed	by	tracking	the	frequency	and	severity	of	adverse	events,	
and	comparing	pre-	and	posttreatment	urinalysis,	blood	chemistry,	
and	hematology.	Safety	was	additionally	evaluated	by	assessing	lo-	
cal	dermal	changes	and	changes	in	heart	rate	and	blood	pressure	at	
study	visits.	
	
2.9.	Statistical	analysis	
	
Analyses	of	covariance	were	performed	on	NPRS	change	scores	
(from	baseline	to	12-week	average	daily	diary	ratings;	landmark	
analysis	–	primary	outcome)	and	(continuous)	secondary	outcome	
measures,	controlling	for	baseline	scores	and	treatment-by-study-	
center	interaction.	Secondary	outcomes	of	interest	included	pain	
(BPI),	sleep	(CPSI),	depression	and	anxiety	(HADS),	clinician	and	
patient	global	impressions	of	change	(CGIC	and	PGIC),	as	well	as	
physiological	factors.	CGIC	and	PGIC	categories	were	compared	be-	
tween	active	and	placebo	groups	using	a	generalized	linear	model	
based	on	maximum	likelihood,	with	speciﬁcation	of	the	distribu-	
tion	as	multinomial.	Analyses	were	also	conducted	by	capsaicin	
score	(a	prespeciﬁed	variable	of	interest),	by	separate	analyses	
using	the	intrapatient	capsaicin	scores	as	a	dichotomous,	indepen-	
dent	factor	in	the	analyses	of	covariance.	Missing	data	for	subjects	
who	terminated	early	were	imputed	using	the	baseline	scores.	
	
3.	Results	
	
Of	464	screened	subjects,	182	were	randomized	(Fig.	2).	Of	the	
randomized	subjects,	one	participant	from	each	group	was	found	
to	be	ineligible	after	randomization	(but	before	dosing)	had	oc-	
curred.	In	another	subject,	the	baseline	NPRS	scores	were	lost	after	
treatment	on	day	1	and	the	subject	was	subsequently	lost	to	
follow-up.	Of	the	179	remaining	subjects,	90	received	placebo	gel	
and	89	received	active	gel.	Patient	demographics,	clinical	charac-	
teristics	at	baseline,	summary	questionnaire	data,	and	other	vari-	
ables	of	interest	are	presented	in	Table	2.	
The	2	randomized	groups	were	well	balanced	with	regard	to	
demographic	characteristics	(Table	2).	The	mean	pain	level	at	base-	
line	was	6.5	(n	=	179).	Nine	subjects	were	diagnosed	with	type	1	
diabetes;	one	had	type	1.5,	and	all	remaining	subjects	had	type	2	
diabetes.	The	mean	duration	of	diabetes	was	10	years,	with	a	mean	
pain	duration	of	3	years.	Use	of	concomitant	neuropathic	pain	
medications	was,	overall,	44%	(39%	in	the	active	group	and	48%	
in	the	placebo	group).	
	
3.1.	Efﬁcacy	
	
Pain	in	the	intent-to-treat	population	decreased	with	time	as	
shown	in	Fig.	3.	At	12	weeks,	the	decrease	in	pain	in	the	clonidine	
group	(À2.3;	0–10,	NPRS)	was	greater	than	the	drop	in	pain	in	the	
placebo	group	(À1.7;	D	=	0.6,	P	=	0.07).	The	responder	analysis	
shown	in	Fig.	4A	and	B	demonstrates	the	cumulative	proportion	
of	patients	who	had	speciﬁed	percent	decreases	in	the	NPRS	at	
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Subjects	Screened	(n	=	464)	
	
Excluded	(n	=	282)	
Not	meeting	inclusion	/exclusion	criteria	(n	=	237)	
Refused	to	participate	(n	=	18)	
Other	reasons	(enrollment	ended)	(n	=	27)	
	
Randomized	(n	=	182)	
	
	
	
Allocated	to	Active	(Clonidine)	
(n	=	91)	
Received	allocated	intervention	
(n	=	90)	
Did	not	receive	allocated	intervention	
(n	=	1)	
Reason:	One	subject	found	to	be	
ineligible	after	randomization	
	
Analyzed	(n	=	89)	Intent-to-Treat	
Excluded	from	analysis	(n	=	1)	
Reason:	No	Baseline	NPRS	scores	
were	available	for	one	subject.*	
IENFD	participants,	n	=	53	
	
Discontinued	study	
(n	=	8)	
Reasons:	
Lost	to	follow-up	(n	=	3)	
Subject	withdrew	consent	(n	=	1)	
Protocol	Violation	(n	=	2)	
Adverse	Event	(n	=	1)	
Lack	of	Efficacy	(n	=	1)	
Allocated	to	Placebo	
(n	=	91)	
Received	allocated	intervention	
(n	=	90)	
Did	not	receive	allocated	intervention	
(n	=	1)	
Reason:	One	subject	found	to	be	
ineligible	after	randomization	
	
Analyzed	(n	=	90)	Intent-to-Treat	
Excluded	from	analysis	(n	=	0)	
IENFD	participants,	n	=	44	
	
	
Discontinued	study	
(n	=	13)	
Reasons:	
Lost	to	follow-up	(n	=	4)	
Subject	withdrew	consent	(n	=	1)	
Protocol	Violation	(n	=	4)	
Adverse	Event	(n	=	3)	
Lack	of	Efficacy	(n	=	1)	
	
Fig.	2.	CONSORT	(Consolidated	Standards	of	Reporting	Trials)	diagram.⁄Immediately	after	initial	dosing,	one	patient	left	the	study	site	and	removed	all	pain	rating	
information.	The	patient	could	not	be	reached	subsequently.	NPRS,	numerical	pain	rating	scale;	IENFD,	intraepidermal	nerve	ﬁber	density.	
	
12	weeks.	For	example,	in	the	ITT	population,	48%	of	the	clonidine	
subjects	had	a	30%	drop	in	pain	compared	to	40%	of	the	placebo	
subjects.	Changes	in	the	BPI,	CPSI,	and	HADS	did	not	reach	statisti-	
cal	signiﬁcance	(Table	2).	
To	assess	nociceptor	function,	topical	0.1%	capsaicin	cream	was	
applied	under	occlusion	for	30	minutes	in	the	pretibial	area.	The	
capsaicin	stimulus	evoked	pain	in	45%	of	subjects	(48%	active	
group;	41%	placebo	group).	The	change	in	pain	from	baseline	in	
the	active	vs	placebo	groups	varied	with	the	capsaicin	rating	as	
shown	in	Fig.	3.	In	the	subjects	that	did	not	detect	capsaicin	(rating	
of	0;	n	=	99),	clonidine	had	no	statistically	signiﬁcant	differential	
effect	over	placebo	at	any	time	point.	However,	in	the	subjects	
who	detected	any	level	of	pain	to	capsaicin	(capsaicin	>	0),	cloni-	
dine	was	signiﬁcantly	more	effective	than	placebo	(difference	in	
mean	=	0.9,	95%	conﬁdence	interval	0.01–1.76;	P	<	0.05;	Fig.	3).	
The	 magnitude	 of	 separation	 between	 the	 clonidine-	 and	
placebo-treated	patients	became	more	pronounced	with	increas-	
ing	capsaicin	ratings.	In	subjects	with	a	capsaicin	pain	rating	P2	
(0–10,	NPRS),	the	mean	decrease	in	pain	was	2.6	(0–10,	NPRS)	
for	 active,	 compared	 to	 1.4	 for	 the	 placebo	 (difference	 in	
mean	=	1.2,	95%	conﬁdence	interval	0.21–2.22;	P	=	0.01).	The	re-	
sponder	analysis	in	Fig.	4b	is	shown	for	subjects	with	capsaicin	
pain	ratings	P2.	
Male	and	female	subjects	did	not	differ	with	regard	to	the	
response	to	capsaicin,	nor	were	there	any	identiﬁed	ethnic	or	racial	
differences.	Capsaicin	responders	also	did	not	signiﬁcantly	differ	
from	nonresponders	with	respect	to	duration	of	diabetes,	duration	
of	neuropathic	pain,	baseline	HbA1c,	and	baseline	pain	(NPRS	–	data	
not	shown).	The	analysis	of	secondary	endpoints	demonstrated	a	
similar	pattern	of	efﬁcacy	in	the	capsaicin	responders	(Table	3).	
Among	capsaicin	responders,	PGIC	and	CGIC	were	statistically	sig-	
niﬁcant	in	favor	of	clonidine	(P	=	0.034	and	P	=	0.018,	respectively;	
Fig.	5),	as	was	change	in	sleep	quality	(P	=	0.034).	A	similar	analysis	
was	performed	based	on	the	results	of	nonnociceptor	sensory	func-	
tion	(vibration,	assessment	of	tactile	sensibility,	and	thermal	dis-	
crimination).	No	signiﬁcant	correlations	emerged	between	any	of	
these					measures					and					clonidine					efﬁcacy					or					results					of					capsaicin	
testing.	
Ninety-seven					of					the	179					subjects	underwent	a					3-mm	skin	
punch	biopsy.	Nerve	ﬁber	count	varied	with	capsaicin	response	
(Fig.	6).	The	mean	intraepidermal	nerve	ﬁber	density	was	2.7	ﬁ-	
bers/mm,	SD	3.1	(lower	limit	of	normal	is	5.4	ﬁbers/mm	[15]).	
Those	who	reported	any	level	of	pain	from	the	capsaicin	(re-	
sponses	>	0)	had	signiﬁcantly	greater	intraepidermal	nerve	ﬁber	
densities	(P	=	0.042)	when	compared	with	subjects	rating	‘‘0’’	to	
capsaicin.	
	
3.2.	Pharmacokinetics	
	
The	typical	plasma	level	of	clonidine	for	treating	hypertension	
is	over	1000	pg/mL	[29].	In	the	current	examination,	the	clonidine	
levels	at	2	weeks	were	similar	to	those	at	12	weeks	and	generally	
below	the	level	of	detection	(10	pg/mL).	There	were	2	outliers	with	
levels	>200	pg/mL	(796	pg/mL	and	315	pg/mL).	The	reason	for	
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Table	2	
Demographics,	clinical	characteristics,	and	outcomes	at	baseline,	and	12	weeks	minus	baseline.	
Variable	 Placebo	(n	=	90)	 0.1%	Clonidine	(n	=	89)	 P-	
Baseline	(BL)	 Baseline	(BL)	 value	
	
Age	(in	years),	mean	(SD)	 57.6	(9.5)	 59.4	(9.9)	 0.22	
Sex,	n	(%)	
Female	 48	(53)	 45	(51)	 0.77	
Male	 42	(47)	 44	(49)	
Race,	n	(%)	
Non-Hispanic	white	 46	(51)	 56	(63)	 0.19	
Hispanic	 17	(19)	 7	(8)	
African	descent	 24	(27)	 24	(27)	
Other	 3	(3)	 2	(2)	
Type	of	diabetes	mellitus,	n	(%)	
Type	1	 4	(4)	 5	(6)	 0.56	
Type	1.5	 0	(0)	 1	(1)	
Type	2	 86	(96)	 83	(93)	
Duration	of	diabetes	(in	years),	mean	(SD)	 9.6	(7.8)	 10.7	(8.0)	 0.35	
Duration	of	foot	pain	(in	years),	mean	(SD)	 2.9	(1.3)	 3.0	(1.3)	 0.55	
Nerve	ﬁber	density	(in	ﬁbers/mm),	mean	(SD);	(n)	 3.2	(3.5);	(44)	 2.3	(2.6);	(53)	 0.14	
Concomitant	medications	(%)	 48	 39	 0.25	
Capsaicin	pain	rating,	mean	(SD)	(at	Screening;	0–10	NPRS,	average	of	right	
and	left	legs)	
1.8	(2.7)																														1.8	(2.4)																														0.97	
	
Baseline	
(BL)	
Change	(12	week	
minus	BL)	
Baseline	
(BL)	
Change	(12	week	
minus	BL)		
Average	pain	severity	from	diary,	daily	mean	(SD,	0–10	NPRS)	 6.4	(1.4)	 À1.7	(1.9)	 6.5	(1.5)	 À2.3	(2.2)	 0.07*	
Experienced	>30%	reduction	in	pain,	n	(%)	 36	(40.0)	 43	(48.3)	 0.34	
Experienced	>50%	reduction	in	pain,	n	(%)	 26	(28.9)	 31	(34.8)	 0.49	
HbA1c,	mean	(SD)	 7.5	(1.6)	 0.1	(0.7)	 7.4	(1.6)	 0.03	(0.6)	 0.47*	
BPI	–	Severity	Scale,	sum	(SD)	 25.3	(5.8)	 À6.0	(8.2)	 25.4	(6.4)	 À7.7	(8.9)	 0.23*	
BPI	–	Average	pain,	mean	(SD)	 6.3	(1.4)	 À1.6	(1.9)	 6.5	(1.5)	 À2.2	(2.2)	 0.06*	
BPI	–	Functional	Interference	Scale,	sum	(SD)	 38.8	(15.1)		À11.8	(14.9)	 36.4	(16.9)		À13.5	(17.2)	 0.53*	
CPSI	–	Overall	sleep	quality,	mean	(SD);	(increase	=	improvement)	 37.9	(23.4)		15.9	(32.1)	 39.7	(24.7)		18.1	(30.7)	 0.40*	
HADS	–	Anxiety	Scale,	sum	(SD)	 7.0	(4.1)	 À0.5	(2.5)	 6.2	(4.1)	 À0.7	(3.0)	 0.30*	
HADS	–	Depression	Scale,	sum	(SD)	 5.9	(4.1)	 À0.4	(2.4)	 5.0	(3.7)	 À0.8	(2.1)	 0.11*	
NPRS,	numerical	pain	rating	scale.	
Concomitant	medications	included	anticonvulsants,	antidepressants,	and	opioids;	Brief	Pain	Inventory	(BPI;	Severity	range	0–40,	Average	pain	range	0–10,	Functional	
Interference	range	0–70);	Chronic	Pain	Sleep	Inventory	(CPSI;	range	0–100);	Hospital	Anxiety	and	Depression	Scale	(HADS	Anxiety	range	0–21,	Depression	range	0–21;	<8	is	
normal,	threshold	for	moderate	is	11).	
*	 P-values	represent	analyses	of	differences	from	week	12	to	baseline	in	the	active	compared	to	placebo	group;	no	changes	were	observed	at	baseline	between	groups.	
	
these	outliers	was	not	apparent,	and	neither	subject	had	side	ef-	
fects	or	blood	pressure	changes	consistent	with	or	attributable	to	
excessive	clonidine	exposure.	
	
3.3.	Safety	
	
Adverse	events	are	indicated	in	Table	4.	Skin	site	reactions	were	
mild	and	observed	only	in	the	placebo	group.	No	signiﬁcant	differ-	
ences	were	observed	in	cardiovascular	parameters	(blood	pressure,	
heart	rate,	ECG,	serum	chemistry,	hematology,	urine,	prothrombin	
time,	partial	thromboplastin	time,	or	hemoglobin	A1c)	and	physi-	
cal	examination.	
	
4.	Discussion	
	
The	results	of	this	study	suggest	that	treatment	with	topical	
clonidine	reduces	pain	from	diabetic	neuropathy	and	indicates	that	
efﬁcacy	depends	on	the	relative	level	of	functionality	of	nocicep-	
tors	in	the	skin.	The	primary	endpoint	related	to	the	effects	of	clo-	
nidine	in	the	overall	population.	Though	there	was	a	trend	favoring	
efﬁcacy	(P	=	0.07),	statistical	signiﬁcance	was	not	achieved.	The	
statistical	analysis	plan	stipulated	a	further	analysis	relative	to	
the	innervation	status	of	nociceptors	in	the	skin	as	revealed	by	
testing	with	topical	capsaicin.	
Studies	have	shown	that	the	loss	of	small	ﬁber	function	and	
pain	sensibility	in	the	skin	varies	widely	among	diabetic	patients	
[3,18,33].	The	abnormal	signals	in	the	nociceptive	pathways	that	
lead	to	pain	may,	in	principal,	extend	along	the	neuroaxis	(from	
the	skin	to	the	brain).	If	the	skin	is	severely	denervated	with	regard	
to	nociceptor	function,	then	the	target	for	clonidine,	presumed	to	
be	the		a2-adrenergic	receptor	on	the	epidermal	nociceptors,	would	
be	lost	and	clonidine	would	not	have	efﬁcacy	[2,3,14].	To	test	for	
functioning	of	nociceptors	in	the	skin,	topical	capsaicin	cream	
0.1%	was	applied	to	the	skin	above	the	ankle	for	30	minutes	at	
the	screening	visit.	Analgesic	efﬁcacy	of	clonidine	over	placebo	in-	
creased	with	the	subjects’	response	to	the	capsaicin	stimulus.	Thus,	
these	data	suggest	that	the	analgesic	effect	of	clonidine	depends	on	
the	presence	of	functional	capsaicin-responsive	nociceptors	in	the	
skin,	and	raises	the	broader	issue	that	neuropathic	pain	treatments	
may	be	guided	by	results	of	sensory	testing.	
The	separation	between	clonidine	and	placebo	was	1.2	on	the	
NPRS	scale	in	subjects	with	a	capsaicin	response	of	P2	(0–10	
scale).	In	the	overall	population,	the	separation	was	0.6.	This	sepa-	
ration	is	within	the	range	seen	in	other	approved	therapies.	Pre-	
gabalin	and	duloxetine	are	widely	used	as	oral	therapies	to	treat	
PDN.	Tolle	et	al.	[36]	reported	beneﬁt	of	pregabalin	of	1.1	over	pla-	
cebo	(difference	between	changes	in	pain	in	placebo	vs	active	
group)	with	600-mg	dosing	at	12	weeks.	With	300-mg	dosing,	
the	difference	from	placebo	was	only	0.2.	In	a	recent	study	in	Japan	
[28]	(n	=	317),	the	difference	over	placebo	at	300	mg/day	was	0.6;	
at	600	mg/day,	the	difference	was	0.7.	For	duloxetine	at	the	dose	of	
60	mg/day,	the	difference	over	placebo	was	about	1.3	at	12	weeks	
[38],	but	only	1.0	when	the	imputation	for	missing	data	was	the	
baseline	observation	carried	forward	[9].	
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Fig.	3.	Mean	change	in	pain	by	capsaicin	response	level	[(mean	±	SEM)	Y-axis	=	DNPRS;	X-axis	=	week].	Effects	of	Clonidine	over	Placebo	varied	with	capsaicin	response	
determined	during	screening.	Weekly	means	of	‘‘average	pain	over	the	last	24	hours’’	rated	on	0–10	numerical	pain	rating	scale.	ITT,	intent	to	treat.	
	
4.1.	Other	sensory	and	skin	biopsy	data	
	
Other	tests	of	sensory	functions	(mechanical,	vibration,	ther-	
mal)	did	not	correlate	with	the	responses	to	clonidine.	These	tests	
were	done	as	simple	screens	and	lacked	quantitative	rigor.	More	
sophisticated	tests	of	heat	and	mechanically	induced	pain	have	
been	done	in	specialized	centers	[14],	but	would	be	difﬁcult	to	
perform	in	the	context	of	a	large	multicenter	clinical	trial.	Never-	
theless,	future	studies	aimed	at	assessments	of	other	nociceptor	
functions	and	their	relation	to	efﬁcacy	of	topical	treatment	will	
be	of	value.	The	capsaicin	test	reported	here	was	technically	simple	
to	apply,	took	little	time,	and	did	not	depend	on	the	use	of	special-	
ized	equipment	or	personnel	[34].	
To	test	for	anatomical	evidence	of	cutaneous	C-ﬁber	pathology,	
97	of	the	179	subjects	underwent	a	3-mm	skin	biopsy.	Intraepider-	
mal	nerve	ﬁbers	were	labeled	with	the	pan-axonal	marker	PGP	9.5,	
and	density	of	ﬁbers	was	quantiﬁed.	The	C-ﬁber	density	in	the	epi-	
dermis,	presumed	to	correspond	mainly	to	the	innervation	density	
of	nociceptors	[1,24,26],	was	signiﬁcantly	lower	in	subjects	who	
lacked	a	response	to	capsaicin.	This	anatomical	analysis	simply	as-	
sessed	the	density	of	epidermal	ﬁbers,	not	the	expression	of		a2-	
adrenergic	receptors	or	the	presence	of	sensitization.	The	capsaicin	
response,	in	contrast,	is,	in	a	sense,	a	functional	assay,	and	could	
suggest	sensitization	in	transient	receptor	potential	V1	channel-	
positive	ﬁbers	as	well	as	the	anatomical	presence	of	nociceptors.	
	
4.2.	Mechanism	of	action	
	
The	blood	levels	of	clonidine	in	this	study	were	typically	below	
the	level	of	detection	(10	pg/mL).	Thus,	the	effects	were	almost	
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Fig.	4.	Cumulative	proportion	of	responder’s	analysis	graph	displaying	proportion	of	patients	who	had	a	given	percentage	decrease	in	pain	compared	to	baseline	at	week	12	
with	Clonidine	or	Placebo.	Effects	of	Clonidine	over	Placebo	varied	with	capsaicin	response	determined	during	screening.	Ratings	of	pain	were	obtained	through	0–10	NPRS.	
ITT,	intent	to	treat.	
	
	
	
	
Table	3	
Demographics	and	outcomes	(change	from	baseline	[12	weeks	minus	baseline])	for	capsaicin	responders	(capsaicin	pain	rated	P2;	0–10	NPRS).	
Variable	 Placebo	(n	=	30)	 0.1%	Clonidine	(n	=	33)	 P-	
Baseline	(BL)	 D	from	BL	to	12-week	visit		Baseline	(BL)	 D	from	BL	to	12-week	visit	 value	
	
Duration	of	diabetes	(in	years),	mean	(SD),	 8.8	(5.9)	 12.2	(9.3)	 0.10	
Duration	of	foot	pain	(in	years),	mean	(SD)	 2.7	(1.3)	 2.8	(1.2)	 0.57	
Nerve	ﬁber	density	(in	ﬁber/mm),	mean	(SD);	(n)	 4.3	(4.2);	(18)	 2.9	(3.0);	(24)	 0.20	
Capsaicin	pain	rating,	mean	(SD)	NPRS	 5.2	(2.0)	 4.5	(2.0)	 0.20	
Average	pain	severity	from	diary,	mean	(SD)	NPRS	 6.3	(1.4)	 À1.4	(1.8)	 6.3	(1.5)	 À2.6	(2.0)	 0.01*	
HbA1c,	mean	(SD)	 7.3	(1.5)	 0.26	(0.6)	 7.4	(1.8)	 0.0	(0.6)	 0.17*	
BPI	–	Severity	scale,	sum	(SD)	 25.4	(5.8)	 À5.3	(7.8)	 25.1	(7.3)	 À7.8	(7.2)	 0.18*	
BPI	–	Average	pain,	mean	(SD)	 6.3	(1.5)	 À1.3	(1.7)	 6.5	(1.6)	 À2.2	(1.9)	 0.06*	
BPI	–	Functional	Interference	Scale,	sum	(SD)	 37.2	(17.1)	 À8.7	(13.2)	 37.1	(17.5)	 À13.0	(15.2)	 0.43*	
CPSI	–	Overall	sleep	quality,	mean	(SD);	 37.7	(26.9)					4.4	(32.7)																		44.5	(21.5)					13.4	(30.4)																	0.03*	
(increase	=	improvement)	
HADS	–	Anxiety	Scale,	sum	(SD)	 7.8	(4.5)	 À0.2	(2.2)	 6.4	(4.4)	 À0.6	(2.7)	 0.30*	
HADS	–	Depression	Scale,	sum	(SD)	 6.1	(4.5)	 À0.8	(2.1)	 4.8	(3.5)	 À0.4	(1.8)	 0.60*	
NPRS,	numerical	pain	rating	scale.	
Brief	Pain	Inventory	(BPI;	Severity	range	0–40,	Average	pain	range	0–10,	Functional	Interference	range	0–70);	Chronic	Pain	Sleep	Inventory	(CPSI,	range	0–100);	Hospital	
Anxiety	and	Depression	Scale	(HADS	Anxiety	range	0–21,	Depression	range	0–21;	<8	is	normal,	threshold	for	moderate	is	11).	
*	 P-values	represent	analyses	of	differences	from	week	12	to	baseline	in	the	active	compared	to	placebo	group;	no	changes	were	observed	at	baseline	between	groups.	
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Fig.	5.	Clinician	and	patient	global	impression	of	change	(CGIC;	PGIC)	at	point	of	study	termination	(12	weeks)	for	capsaicin	responders	[(P2);	Y-axis	=	percent	of	patients].	
CGIC	and	PGIC	were	assessed	by	having	the	investigator	and	patient	independently	rate	overall	global	impression	of	change	in	the	subject’s	pain	status	at	the	ﬁnal	treatment	
visit	using	a	7-point	verbal	rating	scale.	The	investigator	and	subject	were	asked:	‘‘Relative	to	Baseline,	please	rate	from	among	the	following	choices	the	subject’s	total	
improvement	whether	or	not,	in	your	judgment,	it	is	due	entirely	to	study	drug	treatment:	‘very	much	improved,’	‘much	improved,’	‘minimally	improved,’	‘no	change,’	
‘minimally	worse,’	‘much	worse,’	or	‘very	much	worse’.’’	Percentages	are	displayed	by	treatment	group	on	the	y-axis,	the	n	for	each	group	is	included	within	each	bar.	ITT,	
intent	to	treat.	
	
Table	4	
Adverse	events	associated	with	treatment	by	group.	
	
System/organ	class	 Placebo	gel	
(n	=	90)	
Clonidine	gel	
(n	=	89)	
	
Number	of	patients	with	P1	related	
adverse	event,	n	(%)	
General	disorders	and	administration	site	
conditions	
Musculoskeletal	and	connective	tissue	
11	(12.2)							3	(3.4)	
2	(2.2)									1	(1.1)	
2	(2.2)									0	(0)	
disorders	
Nervous	system	disorders	 2	(2.2)	 2	(2.2)	
Psychiatric	disorders	 1	(1.1)	 0	(0)	
Respiratory,	thoracic	and	mediastinal	
disorders	
0	(0)											1	(1.1)	
Fig.	6.	Nerve	ﬁber	count	by	capsaicin	response.	Participating	subjects	(n	=	97)	
received	a	3-mm	punch	skin	biopsy	on	the	lower	extremity	6	cm	above	the	ankle.	
Intraepidermal	nerve	ﬁber	density	was	determined	using	the	pan-axonal	marker	
PGP	9.5	by	a	central	laboratory	(Therapath:	http://www.therapath.com).	Sites	were	
selected	for	participation	based	on	willingness	to	do	skin	biopsy	and	a	prespeciﬁed	
intent	to	do	the	biopsy	in	about	one	half	of	the	subjects.	
	
certainly	peripherally	mediated.	Li	et	al.	[17]	studied	clonidine	
treatment	in	a	rodent	neuropathic	pain	model	and	determined	that	
clonidine	reversed	allodynia	and	hyperalgesia	when	applied	to	the	
affected	paw	but	not	when	it	was	applied	to	the	contralateral	side.	
Application	of	the	clonidine	patch	relieved	hyperalgesia	in	patients	
with	complex	regional	pain	syndrome,	but	only	in	the	area	of	
application	[5].	Evidence	indicates	that	clonidine	is	also	efﬁcacious	
in	the	treatment	of	PDN	when	delivered	through	a	transdermal	
patch	applied	remotely	to	the	painful	area	(eg,	shoulder	or	anterior	
chest	region)	[39].	In	this	case,	the	analgesic	mechanism	of	cloni-	
dine	may	be	central	as	well	as	peripheral,	given	that	intrathecally	
administered	clonidine	has	been	shown	to	have	analgesic	proper-	
ties	[7,21,30].	
The	 discovery	 that	 the	 targeted		a2A	 receptor	 is	 expressed	
directly	on	nociceptors	in	the	epidermis	[27]	further	supports	the	
hypothesis	that	clonidine	effects	are	mediated	by	direct	effects	in	
Skin	and	subcutaneous	tissue	disorders				5	(5.6)									0	(0)	
General	disorders,	application	site	irritation/reaction;	Musculoskeletal	and	con-	
nective	tissue	disorders,	muscle	tightness/pain	in	extremity;	Nervous	system	dis-	
orders,	burning	sensation/dizziness/headache;	Psychiatric	disorders,	disorientation;	
Respiratory,	thoracic	and	mediastinal	disorders,	dyspnea;	Skin	and	subcutaneous	
tissue	disorders,	dry	skin/eczema/pruritus/rash.	
	
the	skin.	Clonidine	is	an	agonist	for	an	inhibitory	G-protein-cou-	
pled	receptor	[22,31].	Activation	of	these	receptors	likely	decreases	
levels	of	adenylate	cyclase	and	cAMP.	Increased	levels	of	these	
second	messengers	have	been	identiﬁed	as	a	source	of	increased	
excitability	of	nociceptors	and	as	a	mechanism	of	neuropathic	pain.	
Adenylate	cyclase	upregulation	may	also	lead	to	phosphorylation	
of	the	transient	receptor	potential	V1	channel	and	therefore,	sensi-	
tize	nociceptors	to	capsaicin	stimulation.	This	observation	provides	
further	impetus	to	use	capsaicin	testing	as	a	tool	to	identify	candi-	
dates	for	clonidine	treatment	[12,19,37].	
	
4.3.	Conclusions	
	
Topical	clonidine	gel	signiﬁcantly	reduced	the	level	of	pain	in	
subjects	with	diabetic	neuropathy	in	whom	there	are	functional	
(and	possibly	sensitized)	nociceptors	in	the	affected	skin.	This	
147
C.M.	Campbell	et	al.	/	PAIN	153	(2012)	1815–1823																																																						 1823	Ò	
	
study	provides	support	for	the	view	that	quantitative	sensory	
testing	may	aid	in	identiﬁcation	of	the	appropriate	treatment	for	
a	given	patient.	The	treatment	with	clonidine	was	safe	and	without	
the	problematic	side	effects	typically	associated	with	systemic	
therapies.	Further	research	is	warranted	to	corroborate	the	efﬁcacy	
and	safety	of	topical	clonidine	as	a	treatment	of	PDN	and,	possibly,	
other	neuropathic	pain	states.	Drugs	with	effects	in	preclinical	tri-	
als	targeting	speciﬁc	mechanisms	have	often	failed	in	phase-2	and	
-3	efﬁcacy	trials.	This	could	be	due	in	part	to	the	heterogeneity	of	
mechanisms	in	the	patients.	In	future	drug	trials,	it	may	prove	
useful	to	screen	for	nociceptor	function	in	the	skin	as	a	way	to	
optimize	identiﬁcation	of	effective	topical	therapies.	
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Abstract	
The		aim		of		this		study		was		to		examine		the		efﬁcacy		and		safety		of		duloxetine,		a		balanced		and		potent		dual		reuptake		inhibitor		of		serotonin		and	
norepinephrine,		in		the		management		of		diabetic		peripheral		neuropathic		pain.		Serotonin		and		norepinephrine		are		thought		to		inhibit		pain		via	
descending		pain		pathways.		In		a		12-week,		multicenter,		double-blind		study,		457		patients		experiencing		pain		due		to		polyneuropathy		caused		by	
Type	1	or	Type	2	diabetes	mellitus	were	randomly	assigned	to	treatment	with	duloxetine	20		mg/d	(20		mg	QD),	60		mg/d	(60		mg	QD),	120		mg/d	
(60		mg	BID),	or	placebo.	The	diagnosis	was	conﬁrmed	by	a	score	of	at	least	3	on	the	Michigan	Neuropathy	Screening	Instrument.	The	primary	
efﬁcacy		measure		was		the		weekly		mean		score		of		the		24-h		Average		Pain		Score,		which		was		rated		on		an		11-point		(0–10)		Likert		scale		(no		pain		to	
worst	possible	pain)	and	computed	from	diary	scores	between	two	site	visits.	Duloxetine	60	and	120		mg/d	demonstrated	statistically	signiﬁcant	
greater	improvement	compared	with	placebo	on	the	24-h	Average	Pain	Score,	beginning	1	week	after	randomization	and	continuing	through	the	
12-week		trial.		Duloxetine		also		separated		from		placebo		on		nearly		all		the		secondary		measures		including		health-related		outcome		measures.	
Signiﬁcantly		more		patients		in		all		three		active-treatment		groups		achieved		a		50%		reduction		in		the		24-h		Average		Pain		Score		compared		with	
placebo.		Duloxetine		treatment		was		considered		to		be		safe		and		well		tolerated		with		less		than		20		percent		discontinuation		due		to		adverse		events.	
Duloxetine		at		60		and		120		mg/d		was		safe		and		effective		in		the		management		of		diabetic		peripheral		neuropathic		pain.	
q		2005		International		Association		for		the		Study		of		Pain.		Published		by		Elsevier		B.V.		All		rights		reserved.	
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1.		Introduction	
	
Diabetes		is		commonly		associated		with		a		peripheral	
neuropathy		that		often		results		in		signiﬁcant		pain.		The		pain	
has		been		described		as		an		‘aching,		burning,		stabbing,		or	
tingling’		sensation,		and		often		affects		sleep.		Tricyclic	
antidepressants		(TCAs),		certain		anticonvulsants		(e.g.		gaba-	
pentin),		and		opioid		analgesics		are		currently		used		to		treat		the	
neuropathic		pain		due		to		diabetic		peripheral		neuropathy,		but	
often		are		limited		by		efﬁcacy		or		signiﬁcant		side		effects	
(Kapur		et		al.,		1992;		McQuay		et		al.,		1996).	
	
*	This	work	was	sponsored	by	Eli	Lilly	and	Company	and	PRN	
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E-mail	address:	detke_michael@lilly.com	(M.J.	Detke).	
Serotonin		(5-HT)		and		norepinephrine		(NE)		have		been	
implicated		in		the		modulation		of		endogenous		analgesic	
mechanisms		via		the		descending		inhibitory		pain		pathways		in	
the		brain		and		spinal		cord		(Basbaum		and		Fields,		1984;		Clark	
and		Proudﬁt,		1993;		Fields		and		Basbaum,		1999;		Fields		et		al.,	
1991).		An		imbalance		in		these		inhibitory		mechanisms		may	
contribute		to		central		sensitization		and		hyperexcitability		of	
the		spinal		and		supraspinal		pain		transmitting		pathways	
leading		to		persistent		pain		[reviewed		by		Coderre		and		Katz	
(1997)]		(Ren		and		Dubner,		2002).	
Duloxetine		hydrochloride		[(Cymbaltaw),		(C)-N-methyl-	
g-(1-naphthalenyloxy)-3-(2-thiopene)-propanamine]		is		a	
relatively		balanced		and		potent		dual		reuptake		inhibitor		of	
both		5-HT		and		NE		(SNRI)		transporters		with		weak		afﬁnity	
for		the		dopamine		transporter		and		insigniﬁcant		afﬁnity		at	
more		than		60		neurotransmitter		receptors		including		muscar-	
inic,		histamine,		opioid,		glutamate		and		GABA		receptors	
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and		sodium,		potassium,		and		calcium		channel		sites		(Wong	
and		Bymaster,		2002).	
Duloxetine		is		effective		in		animal		models		of		persistent		and	
neuropathic		pain		(Iyengar		et		al.,		2004)		suggesting		that	
duloxetine		could		be		efﬁcacious		in		the		treatment		of		persistent	
pain		conditions		in		humans.		Since		efﬁcacy		occurs		at		doses	
that		do		not		impair		performance		on		the		rotorod		test		of	
neurological		function,		duloxetine		is		likely		to		be		non-	
sedating		and		non-ataxic		(Iyengar		et		al.,		2004),		making		it		a	
good		clinical		candidate.	
In		several		randomized,		double-blind,		placebo-controlled	
studies,		duloxetine		at		60–120		mg		per		day		(Detke		et		al.,	
2002a,b;		Goldstein		et		al.,		2002;		Nemeroff		et		al.,		2002)		was	
an		effective		treatment		for		major		depressive		disorder		(MDD)	
based		on		traditional		measures		of		efﬁcacy,		such		as		the	
Hamilton		Depression		Rating		Scale.		Duloxetine		also		pro-	
duced		signiﬁcant		improvement		on		visual		analog		scales	
(VAS)		ratings		of		painful		physical		symptoms		associated		with	
depression,		including		overall		pain,		back		pain,		shoulder		pain,	
headache,		and		general		somatic		symptoms,		despite		the		fact	
that		patients		were		not		selected		for		pain		type		or		pain		severity	
and		the		studies		were		not		statistically		powered		for		these	
measures.		Path		analysis		demonstrated		that		greater		than		50%	
of		the		reduction		in		painful		physical		symptoms		of		MDD		was	
a		direct		effect		of		duloxetine,		rather		than		a		secondary		effect	
of		improving		depression.	
Consistent		with		duloxetine’s		effects		on		the		painful	
physical		symptoms		in		MDD		and		the		existing		evidence		that	
dual		5-HT		and		NE		reuptake		inhibitors		are		effective		in	
treating		pure		pain		disorders		such		as		neuropathic		pain	
conditions		(Sindrup		and		Jensen,		1999),		the		potential	
analgesic		efﬁcacy		of		duloxetine		was		evaluated		in		patients	
with		neuropathic		pain		due		to		diabetic		peripheral		neuropathy	
who		did		not		have		depression.		The		current		study		describes	
the		efﬁcacy		and		safety		of		duloxetine		in		reducing		pain	
severity		in		diabetic		peripheral		neuropathic		pain		(DPNP)	
patients.	
	
	
	
2.		Methods	
	
2.1.		Study		design	
	
This		was		a		parallel-group,		double-blind,		randomized,		placebo-	
controlled		study		of		patients		who		met		criteria		for		diabetic	
neuropathy		as		assessed		by		history		and		the		physical		exam		portion	
of		the		Michigan		Neuropathy		Screening		Instrument		(MNSI)	
(Sheehan		et		al.,		1998).		The		primary		objective		was		to		evaluate		the	
efﬁcacy		of		duloxetine		20,		60,		or		120		mg/d		(administered		20		mg	
QD,		60		mg		QD		and		60		mg		BID,		respectively),		on		the		treatment		of	
pain		associated		with		diabetic		neuropathy		as		compared		with	
placebo.		Each		site’s		ethics		committee		approved		the		study		protocol	
in		accordance		with		the		principles		of		the		Declaration		of		Helsinki.	
Patients	provided	written		informed	consent	prior	to		participation	in	
any		study-related		procedures.	
2.2.		Patients	
	
Patients,		at		least		18		years		of		age,		had		daily		pain		due		to	
polyneuropathy		caused		by		Type		1		or		Type		2		diabetes		mellitus,	
which		was		present		for		a		minimum		of		6		months.		This		pain		had		to	
have		begun		in		the		feet		with		relatively		symmetrical		onset.		The	
diagnosis		was		conﬁrmed		by		a		score		of		at		least		3		on		the		MNSI.	
Patients		were		required		to		have		a		minimum		score		of		4		on		the		24-h	
Average		Pain		Score		rated		on		an		11-point		(0–10)		Likert		scale.	
Patients		were		excluded		if,		over		the		past		year,		they		met		Diagnostic	
and	Statistical	Manual	of	Mental	Disorders,	Fourth	Edition	(DSM-	
IV)		criteria		for		Axis		I		diagnosis		of		MDD,		depression-partial	
remission,		dysthymic		disorder,		generalized		anxiety		disorder,	
alcohol		or		eating		disorders		as		determined		by		the		Mini		International	
Neuropsychiatric		Interview		(MINI).		Patients		were		excluded		if		they	
had		any		current		or		historical		DSM-IV		diagnosis		of		mania,		bipolar	
disorder,		or		psychosis		as		determined		by		the		MINI.		Patients		were	
also		excluded		if		they		had		pain		that		could		not		be		clearly	
differentiated		from,		or		conditions		that		might		interfere		with,		the	
assessment		of		the		DPNP,		such		as		peripheral		vascular		disease	
(ischemic		pain);		neurological		disorders		unrelated		to		diabetic	
neuropathy		(e.g.		phantom		limb		pain		from		amputation);		skin	
condition		in		the		area		of		the		neuropathy		that		could		alter		sensation	
(e.g.	plantar	ulcer);	other	painful	conditions	(e.g.	arthritis).	Patients	
were		also		excluded		if		they		had		a		history		of		substance		abuse		or	
dependence		within		the		past		year		or		had		a		positive		urine		drug	
screen,		if		they		received		treatment		within		the		last		30		days		that		had	
not		received		regulatory		approval,		had		taken		excluded		medications	
within		7		days		of		baseline,		received		treatment		with		a		MAOI		or	
ﬂuoxetine		within		30		days		of		baseline,		or		had		used		an		opioid		within	
3	days	of	baseline.	Patients	were	allowed	to	take	a	maximum	of	4		g	
of		acetaminophen		per		day,		but		no		other		analgesic		medication		used	
to		treat		diabetic		neuropathic		pain.	
	
2.3.		Treatments	
	
Patients		(457)		were		randomly		assigned		to		duloxetine		20,		60,	
120		mg/d,		or		placebo		in		a		1:1:1:1		ratio		for		the		12-week		therapy	
phase		(see		Fig.		1)		as		determined		by		a		computer-generated		random	
sequence		using		an		interactive		voice		response		system		(IVRS).	
Patient		numbers		were		assigned		consecutively		at		each		study		site		to	
each		patient		who		entered		the		study.		The		IVRS		was		used		to		assign	
blister		cards		containing		study		drug		to		each		patient		conﬁrmed	
through		IVRS		entry		of		a		conﬁrmation		number		found		on		the		card.	
Patients		were		seen		weekly		for		the		ﬁrst		5		weeks		of		treatment		and	
then		bi-weekly		thereafter.	
	
2.4.		Efﬁcacy		measures	
	
Efﬁcacy		was		assessed		primarily		using		the		weekly		mean		change	
from		baseline		to		endpoint		on		the		24-h		Average		Pain		Score	
[11-point	(0–10)	Likert	scale]	(referred	to	as	the	24-h	Average	Pain	
Score,		hereafter),		computed		from		diary		scores		recorded		at		the		time	
of		the		evening		dose		between		two		site		visits.		In		addition		to		average	
pain		severity,		the		diary		included		ratings		of		worst		pain		severity		over	
the		prior		24		h,		average		pain		during		the		night		once		they		had		gone		to	
bed,		and		acetaminophen		use		over		the		past		24		h.		Secondary	
measures		included		Average		Daily		Severity		and		Average		Night	
Pain		Severity		(weekly		mean		scores		of		the		24-h		Average		Pain	
Severity		and		Average		Night		Pain		Severity),		Worst		Pain		Severity,	
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Study	Period	2	
Therapy	Phase	
	
	
Duloxetine	120	mg/dº	
	
Duloxetine	
80	mg/dº	
Duloxetine	60	mg/d	
	
	
Duloxetine	20	mg/d	
	
	
Placebo	
	
	
Weeklya	
	
Visit:	 1				2				3				4				5	 6									8									10								12	 13	 14		
Week:	 -1				0				1				2	 3	 4	 5							 	7										9 									11	 12	
	
a	Visits	7,	9,	11,	13,	and	15	were	phone	visits	only.	
º	Bi-daily	dosing	administration.	
Fig.	1.	Illustration	of	study	design.	
	
severity	and	interference	portions	of	the	Brief	Pain	Inventory	(BPI)	
(Cleeland		and		Ryan,		1994)		at		each		visit;		Clinical		Global	
Impression		of		Severity		(CGI-Severity)		Scale		(NIMH		1976)		and	
Patients		Global		Impression		of		Improvement		(PGI-Improvement)	
Scale		(Guy,		1976)		at		randomization,		Weeks		4,		8,		and		12;		the	
sensory		portion		of		the		Short-Form		McGill		Pain		Questionnaire		(SF-	
MPQ)		(Melzack,		1987),		Dynamic		Allodynia		at		randomization		and	
Week		12,		the		Short		Form-36		Health		Status		Survey		(Ware		et		al.,	
1993),		and		the		EQ-5D		version		of		the		Euro		Quality		of		Life	
instrument		(Kind,		1996).		Changes		in		mood		and		anxiety		were	
measured		using		the		Beck		Depression		Inventory-II		(BDI-II)		(Beck	
et		al.,		1996)		and		the		Beck		Anxiety		Inventory		(BAI)		(Beck		et		al.,	
1988),		respectively,		at		randomization		and		Week		12.	
	
2.5.		Safety		assessments	
	
Safety		measures		recorded		at		every		visit		included		spontaneously	
reported		adverse		events,		concomitant		medications,		weight,		supine	
heart		rate		and		blood		pressure,		and		the		occurrence		of		signiﬁcant	
hypoglycemic		events.		Blood		chemistry,		hematology,		HgbA1c,		and	
lipids		were		collected		at		Visit		1		and		Week		12.		For		those		who	
discontinued		from		the		study,		those		assessments		were		collected		at	
their		last		visit.	
Sustained		hypertension		was		deﬁned		as		three		consecutive		visits	
with		the		following:	
†		Sitting		systolic		blood		pressure		R130		mmHg		and		an		increase	
from		baseline		of		10		mmHg,		or	
†		Sitting		diastolic		blood		pressure		R85		mmHg		and		an		increase	
from		baseline		of		10		mmHg.	
2.6.		Statistical		analysis	
	
This		study		was		designed		to		enroll		440		patients.		With		110	
patients		per		arm,		this		study		would		have		at		least		90%		power		to	
detect		a		treatment		group		difference		of		K1.20		points		in		the		weekly	
mean		of		24-h		Average		Pain		Severity		between		duloxetine		60		mg	
BID		and		placebo		treatment		groups		after		3		months		of		acute		therapy.	
The		sample		size		was		determined		using		a		2-sided		test		with		aZ0.05	
and		assuming		a		common		standard		deviation		of		2.2		and		a	
discontinuation		rate		of		35%.	
All		analyses		were		conducted		on		an		intent-to-treat		basis.		All	
randomized		patients		were		included		in		safety		analyses		and		all	
randomized		patients		with		at		least		one		post-baseline		assessment	
were		included		in		the		efﬁcacy		evaluations.		After		randomization,	
weekly		average		scores		on		24-h		average		pain,		worst		pain,		and		night	
pain	were		calculated	for	the	diary	entries	collected		in	days	between	
weeks;		the	baseline	for	the	three		variables		was	calculated	by	taking	
the		average		of		last		three		non-missing		diary		data		given		the	
consideration		that		previous		medications		had		effect		on		the		ﬁrst	
few		days		after		the		screening		visit.		For		either		case,		the		mean		score	
was		set		to		be		missing		if		the		number	of		diary	entries		was		less		than		3.	
A		likelihood-based		mixed-effects		model		repeated		measures	
analysis		was		the		protocol-speciﬁed		primary		efﬁcacy		analysis		for	
continuous		efﬁcacy		measures		with		longitudinal		observations.		The	
model		included		the		ﬁxed		categorical		effects		of		treatment,	
investigator,		visit,		and		treatment-by-visit		interaction,		as		well		as	
the		continuous		ﬁxed		covariates		of		baseline		and		baseline-by-visit	
interaction.		An		unstructured		covariance		matrix		was		used		to		model	
the		within-patient		errors.		The		primary		treatment		comparisons		were	
the		contrasts		between		duloxetine		treatment		groups		and		placebo		at	
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Abbreviations:	BDI	-	Beck	Depression	Inventory;	BAI	_	Beck	Anxiety	Inventory	
Fig.	2.	Causal	relationship	in	the	path	analysis	on	24-h	average	pain.	
	
the		last		visit		of		the		study		(Week		12)		on		the		change		scores.	
Satterthwaite’s		approximation		was		used		to		estimate		denominator	
degrees		of		freedom.		The		dose–response		trend		for		the		primary	
efﬁcacy		measure		was		tested		using		a		repeated		measures		analysis	
model		where		therapy		was		replaced		by		dosage		and		placebo		was	
excluded		and		the		overall		dose		effect		was		reported.		For		the	
continuous		efﬁcacy		measures		collected		once		at		baseline		and		once	
at		the		last		visit		of		the		study,		change		from		baseline		to		endpoint		was	
assessed		using		an		ANCOVA		model,		which		contained		terms		of	
treatment,		investigator,		and		baseline.		For		either		statistical		model,	
Type		III		sum-of-squares		for		the		least-squares		mean		was		used		for	
testing		the		differences		between		treatment		groups.	
Path		analysis		(Retherford		and		Choe,		1993)		was		performed		to	
test		the		direct		treatment		effect		on		pain		reduction.		In		this		analysis,	
pre-speciﬁed		pathways		(Fig.		2)		described		the		causal		relationships	
for		the		testing:		the		treatment		has		effect		on		pain		reduction		(direct	
effect),		and		the		treatment		effect		on		mood		or		anxiety		symptoms		has	
impact		on		pain		reduction		(indirect).		The		signiﬁcance		of		the		direct	
treatment		effect		was		tested		by		a		Student’s		t-test		in		the		regression	
model		where		change		in		24-h		average		pain		was		a		dependent	
variable,		and		treatment,		baseline,		investigator,		change		on		BDI,		and	
change		on		BAI		were		regressors.		In		addition,		with		two		other	
regression		models		on		change		on		BDI		and		BAI,		respectively,		the	
indirect		treatment		effect		via		change		in		BDI		(or		BAI)		was		a		result		of	
multiplying		treatment		coefﬁcient		by		the		coefﬁcients		of		the	
corresponding		change		in		the		ﬁrst		described		regression		model.	
The		percentage		of		direct		and		indirect		effects		on		the		total		treatment	
effect		was		computed		and		presented.		When		an		indirect		pathway		had	
no		impact		on		pain		reduction		(i.e.		the		coefﬁcient		between		pain	
reduction		and		change		was		positive)		that		particular		path		was	
removed		from		the		path		analysis.	
Continuous		baseline		measures		and		continuous		safety		measures	
were		evaluated		using		a		ﬁxed		effect		(treatment,		investigator)	
ANOVA.		Categorical		variables		were		analyzed		using		Fisher’s	
exact	test.	Average	daily	dose	of	acetaminophen	use	was	calculated	
over		days		on		therapy		for		each		patient.		Treatment		group		differences	
were		evaluated		using		the		ANOVA		model		on		the		rank-transformed	
data		since		the		distribution		of		the		data		was		skewed.		For		the		same	
reason,		the		rank		transformed		change		from		baseline		to		endpoint,		the	
last		non-missing		observations		during		the		trial,		on		laboratory	
analytes		were		analyzed		using		the		ANOVA		model.	
For		all		the		analyses,		treatment		effects		were		tested		at		a		2-sided	
signiﬁcance		level		of		0.05.		Throughout		this		manuscript,		the		term	
‘signiﬁcant’		indicates		statistical		signiﬁcance		(P%0.05),		and		the	
term		‘mean		change’		refers		to		the		least-squares		mean		change		for		the	
continuous		efﬁcacy		variables.	
	
3.		Results	
	
3.1.		Patient		disposition	
	
Patient		disposition		is		shown		in		Fig.		3.		Of		the		763	
screened		patients,		457		patients		entered		and		344		(75.3%)	
completed		the		study.		The		duloxetine		60		mg/d		(13.2%)	
and		120		mg/d		(19.5%)		treatment		groups		had		more		discon-	
tinuations		due		to		adverse		events		than		the		placebo		treatment	
group		(5.2%;		P!0.001).	
	
3.2.		Demographics	
	
The		patient		demographics		and		baseline		assessments		are	
shown		by		treatment		group		in		Table		1.		Most		patients		had	
Type		2		diabetes		mellitus		(88.4%)		with		a		mean		duration		of	
diabetes		of		11.3		years		and		of		diabetic		neuropathy		for		3.7	
years.		The		majority		of		patients		were		male		with		percentages	
ranging		from		51%		in		the		placebo		group		to		69%		in		the	
60		mg/d		treatment		group.	
	
3.3.		Efﬁcacy	
	
Mean		change		from		baseline		to		each		post-baseline		visit		on	
the		24-h		Average		Pain		Score,		shown		in		Fig.		4,		and		the		mean	
change		from		baseline		to		endpoint		during		the		12-week		study,	
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in	Acute	Therapy	Phase	
(n=24)	
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•	Adverse	Event	(5)	
•	Lack	of	Efficacy	(2)	
(patient/physician	perception)	
•	Lost	to	Follow	Up	(4)	
•	Personal	Conflict	or	
Other	Patient	Decision	(5)	
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•	Sponsor’s	Decision	(1)	
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(n=28)	
	
•	Adverse	Event	(15)	
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•	Lost	to	Follow	Up	(3)	
•	Personal	Conflict	or	
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•	Physician	Decision	(1)	
Discontinued	
in	Acute	Therapy	Phase	
(n=33)	
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•	Adverse	Event	(22)	
•	Lack	of	Efficacy	(2)	
(patient/physician	perception)	
•	Lost	to	Follow	Up	(2)	
•	Personal	Conflict	or	
Other	Patient	Decision	(4)	
•	Physician	Decision	(1)	
•	Protocol	Violation	(2)	
	
	
Bi-daily	dosing	administration	
	
	
	
Table	1	
Demographics	and	baseline	assessments	
Variable	 Placebo	
•	Sponsor’s	Decision	(1)	
•	Protocol	Violation	(2)	
	
	
Fig.	3.	Patient	disposition.	
	
	
	
	
Duloxetine																																																			Total	
	
	
	
	
	
	
	
	
P-value	
(nZ115)	 a	 (NZ457)	
	
Age,	years	(SD)	 60.4	(10.5)	 60.3	(10.9)	 59.2	(11.6)	 60.5	(10.8)	 60.1	(10.9)	 0.786	
Gender	
Female,	n	(%)	 56	(48.7)	 40	(34.8)	 35	(30.7)	 45	(39.8)	 176	(38.5)	 0.033	
Male,	n	(%)	 59	(51.3)	 75	(65.2)	 79	(69.3)	 68	(60.2)	 281	(61.5)	
Race	(origin)	
Caucasian,	n	(%)	 89	(77.4)	 85	(73.9)	 88	(77.2)	 91	(80.5)	 353	(77.2)	
African,	n	(%)	 11	(9.6)	 12	(10.4)	 8	(7.0)	 6	(5.3)	 37	(8.1)	
Hispanic,	n	(%)	 12	(10.4)	 12	(10.4)	 13	(11.4)	 14	(12.4)	 51	(11.2)	 0.915	
Other,	n	(%)	 3	(2.6)	 6	(5.3)	 5	(4.4)	 2	(1.8)	 16	(3.5)	
Height	(cm)	 170	(11)	 172	(11)	 174	(10)	 171	(11)	 172	(11)	 0.046	
Weight	(kg)	 94	(22)	 93	(19)	 99	(24)	 96	(21)	 96	(21)	 0.128	
Type	of	diabetes	mellitus	
Type	I,	n	(%)	 11	(9.6)	 17	(14.8)	 14	(12.3)	 11	(9.7)	 53	(11.6)	 0.565	
Type	II,	n	(%)	 104	(90.4)	 98	(85.2)	 100	(87.7)	 102	(90.3)	 404	(88.4)	
Duration	of	diabetes	(years)	 11.4	(11.3)	 12.1	(9.5)	 11.4	(8.2)	 10.1	(9.0)	 11.3	(9.6)	 0.438	
Duration	of	diabetic	neuropathy	(years)	 4.0	(4.1)	 3.7	(3.7)	 3.8	(4.4)	 3.5	(2.8)	 3.7	(3.8)	 0.695	
MNSI	 5.1	(1.6)	 5.4	(1.6)	 5.1	(1.6)	 5.3	(1.5)	 5.2	(1.6)	 0.555	
Average	24-h	pain	severity	 5.8	(1.5)	 5.9	(1.6)	 6.0	(1.7)	 5.9	(1.4)	 5.9	(1.6)	 0.627	
CGI-Severity	 4.4	(0.9)	 4.4	(0.9)	 4.3	(1.0)	 4.4	(0.9)	 4.4	(0.9)	 0.450	
BDI-II	total	 7.3	(7.8)	 8.1	(6.8)	 7.1	(6.4)	 6.7	(5.5)	 7.3	(6.7)	 0.463	
BAI	total	 8.4	(7.5)	 9.2	(7.4)	 7.8	(6.1)	 8.8	(8.6)	 8.6	(7.4)	 0.556	
MNSI,	Michigan	Neuropathy	Screening	Instrument;	CGI-Severity,	Clinical	Global	Impressions	of	Severity;	BDI-II	total,	Beck	Depression	Inventory	II	total;	
BAI	total,	Beck	Anxiety	Inventory	Total;	SD,	standard	deviation.	
a	Bi-daily	dosing	administration.	
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Fig.	4.	Mean	change	from	baseline	in	24-h	average	pain	severity	for	all	randomized	patients	over	12	weeks	of	double-blind	therapy.	
	
presented		in		Table		2,		demonstrate		dose-related		efﬁcacy	
(PZ0.005		for		testing		of		linear		trend).		Duloxetine		20		mg/d	
demonstrated		a		non-signiﬁcant		decrease		in		pain		severity	
compared		with		placebo.		The		duloxetine		60		and		120		mg/d	
treatments		signiﬁcantly		reduced		pain		severity		beginning		at	
Week		1		and		continuing		throughout		the		study		compared		with	
placebo,		while		there		was		no		signiﬁcant		difference		between	
the		duloxetine		60		and		120		mg/d		groups.		The		mean	
difference		between		60		mg/d		and		placebo		at		endpoint		was	
K1.17		(95%		CI:		K1.84		to		K0.50)		and		that		between	
duloxetine		120		mg/d		and		placebo		was		K1.45		(95%		CI:	
K2.13		to		K0.78).		A		50%		reduction		in		the		24-h		Average	
Pain		Score		was		achieved		by		29		(26%)		in		the		placebo		group,	
46		(41%)		in		the		duloxetine		20		mg/d		group,		55		(49%)		in	
	
Table	2	
Mean	change	in	efﬁcacy	and	health	outcome	measures	
Placebo	 Duloxetine	
20	mg/d	 60	mg/d	 120	mg/d	
N	 Mean	(SE)	 N	 Mean	(SE)	 N	 Mean	(SE)	 N	 Mean	(SE)	
24-h	average	pain	score	a	 88	 K1.91	(0.22)	 91	 K2.36	(0.21)	 88	 K2.89	(0.22)	 80	 K3.24	(0.23)	
24-h	worst	pain	scorea	 111	 K2.09	(0.24)	 111	 K2.78	(0.23)	 112	 K3.31	(0.24)*	 109	 K3.72	(0.24)***	
Night	pain	scorea	 111	 K2.20	(0.23)	 111	 K2.48	(0.22)	 112	 K2.91	(0.23)*	 109	 K3.45	(0.24)***	
BPI	average	pain	severitya	 112	 K2.04	(0.21)	 110	 K2.25	(0.21)	 113	 K2.81	(0.21)**	 109	 K3.07	(0.22)***	
BPI	interference	-	general	activitya	 89	 K1.72	(0.21)	 91	 K1.87	(0.21)	 88	 K2.43	(0.21)*	 81	 K2.54	(0.22)**	
BPI	interferencea	(Avg.	of	7	inter-	 112					K1.73	(0.17)				110				K1.73	(0.17)				113				K2.33	(0.17)**		109				K2.30	(0.18)*	
ference	questions)	
CGI-Severitya	 111	 K0.83	(0.12)	 109	 K1.28	(0.11)*	 109	 K1.42	(0.12)***	 110	 K1.70	(.012)***	
PGI-improvementa	 111	 2.91	(0.12)	 108	 2.68	(0.12)	 111	 2.21	(0.12)	***	 109	 2.24	(.0.12)**	
SF	McGill	total	scoreb	 96	 K5.39	(0.66)	 88	 K7.23	(0.67)*	 95	 K8.25	(0.65)***	 99	 K9.18	(0.64)***	
Dynamic	Allodynia	severityb	 103	 K0.08	(0.03)	 99	 K0.10	(0.03)	 98	 K0.15	(0.03)	 103	 K0.10	(0.03)	
SF36	Health	status	surveyb	
Physical	 102	 3.94	(0.77)	 98	 3.67	(0.78)	 101	 5.86	(0.77)	 101	 5.85	(0.76)	
Mental	 102	 K1.09	(0.75)	 98	 0.02	(0.76)	 101	 0.63	(0.76)	 101	 1.84	(0.75)**	
Bodily	pain	 107	 10.32	(1.89)	 102	 13.22	(1.91)	 104	 18.00	(1.89)**	 105	 18.32	(1.88)**	
General	health	perceptions	 106	 2.03	(1.61)	 100	 3.94	(1.63)	 103	 5.66	(1.62)	 102	 9.56	(1.62)***	
Mental	health	 107	 K2.63	(1.69)	 102	 0.74	(1.68)	 104	 2.99	(1.65)*	 105	 5.14	(1.62)***	
Euro	quality	of	lifeb	 107	 0.08	(0.02)	 101	 0.10	(0.02)	 104	 0.13	(0.02)*	 105	 0.13	(0.02)*	
BDIa	 79	 K1.74	(0.48)	 82	 K2.44	(0.48)	 78	 K2.71	(0.49)	 74	 K3.11	(0.50)*	
BAIa	 80	 K2.36	(0.56)	 88	 K2.37	(0.54)	 82	 K2.78	(0.56)	 83	 K2.50	(0.55)	
*P%0.05	vs.	placebo;	**P%0.01	vs.	placebo;	***P%0.001	vs.	placebo.	BPI,	Brief	pain	inventory;	CGI-Severity,	Clinical	Global	Impressions	of	Severity;	PGI-	
Improvement,	patient’s	global	impression	of	improvement;	SF,	short	form;	BDI,	Beck	Depression	Inventory;	BAI,	Beck	Anxiety	Inventory;	SE,	standard	error.	
a	Results	from	repeated	measures	analysis.	
b	Results	from	ANCOVA;	data	were	only	collected	at	baseline	and	last	visit.	
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Table	3	
Percentage	of	patients	showing	improvement	on	the	McGill	pain	questionnaire—sensory	component	pain	descriptions	
Placebo	 Duloxetine	
20	mg/d	 60	mg/d	 120	mg/da	
N	 n	(%)	 N	 n	(%)	 N	 n	(%)	 N	 n	(%)	
Total	 96	 66	(68.8)	 88	 74	(84.1)*	 95	 80	(84.2)*	 99	 83	(83.8)*	
Throbbing	 106	 45	(42.5)	 100	 47	(47.0)	 104	 52	(50.0)	 105	 59	(56.2)	
Shooting	 104	 41	(39.4)	 101	 46	(45.5)	 104	 56	(53.8)	 105	 65	(61.9)***	
Stabbing	 105	 41	(39.0)	 100	 53	(53.0)	 100	 56	(56.0)*	 105	 68	(64.8)***	
Sharp	 103	 47	(45.6)	 99	 54	(54.5)	 102	 71	(69.6)***	 104	 70	(67.3)**	
Cramping	 105	 46	(43.8)	 97	 47	(48.5)	 103	 50	(48.5)	 103	 52	(50.5)	
Gnawing	 104	 35	(33.7)	 97	 32	(33.0)	 103	 44	(42.7)	 102	 45	(44.1)	
Hot-burning	 104	 47	(45.2)	 101	 59	(58.4)	 103	 60	(58.3)	 105	 66	(62.9)*	
Aching	 103	 49	(47.6)	 100	 54	(54.0)	 103	 59	(57.3)	 105	 60	(57.1)	
Heavy	 103	 41	(39.8)	 99	 46	(46.5)	 103	 51	(49.5)	 104	 51	(49.0)	
Tender	 105	 48	(45.7)	 100	 48	(48.0)	 104	 52	(50.0)	 105	 57	(54.3)	
Splitting	 105	 34	(32.4)	 101	 38	(37.6)	 104	 45	(43.3)	 105	 50	(47.6)*	
*P%0.05	vs.	placebo,	**P%0.01	vs.	placebo,***P%0.001	vs.	placebo.	
a	Bi-daily	dosing	administration.	
	
the		60		mg/d		group,		and		57		(52%)		in		the		120		mg/d		group.	
The		number		of		patients		achieving		a		50%		reduction		in		the		24-	
h		Average		Pain		Score		was		signiﬁcantly		greater		for		all	
three		active-treatment		groups		when		compared		with		placebo	
(P!0.05).	
The		results		of		secondary		efﬁcacy		measures		are		summar-	
ized		in		Table		2.		Both		duloxetine		60		and		120		mg/d		treatment	
groups		produced		signiﬁcantly		greater		improvement		over	
placebo		for		all		pain		measures		(Worst		Pain,		Night		Pain,		BPI	
Average		Pain		Severity,		BPI		Worst		Pain		Severity,		BPI		Least	
Pain		Severity,		BPI		Pain		Severity		Right		Now,		SF-McGill	
total		score),		except		dynamic		allodynia.		The		duloxetine		60	
and		120		mg/d		treatment		groups		also		demonstrated		signiﬁ-	
cant		improvement		on		measures		of		general		illness		severity	
and		improvement		(CGI-Severity		and		PGI-Improvement).	
Patients		treated		with		duloxetine		20		mg/d		were		signiﬁcantly	
better		than		placebo		on		the		measures		of		worst		pain		score,		SF-	
McGill		total		score,		and		CGI-Severity.	
The		analysis		of		the		individual		SF-McGill		sensory		pain	
components		revealed		that		a		signiﬁcantly		higher		percentage	
of		duloxetine		120		mg/d		patients		reported		improvement		in	
shooting,		stabbing,		sharp,		hot-burning,		and		splitting		pain	
sensations		when		compared		with		placebo		patients		(Table		3).	
A		signiﬁcantly		higher		percentage		of		duloxetine		60		mg/d	
patients		reported		improvement		in		stabbing		and		sharp		pain	
sensations		when		compared		with		placebo		patients.	
The		comparison		of		the		average		daily		dose		of		supplemen-	
tal		acetaminophen/analgesic		use		indicated		that		duloxetine-	
treated		patients		had		reduced		pain		severity		and		required	
less		supplemental		analgesic		compared		with		placebo.	
The		duloxetine		60		and		120		mg/d		groups		used		signiﬁcantly	
less		supplemental		analgesic		than		the		placebo		group	
(P%0.01;		see		Fig.		5),		and		the		duloxetine		20		mg/d		group	
used		numerically		less		than		the		placebo		group		(PZ0.080).	
Baseline		dynamic		allodynia		scores		were		very		low		indicating	
that		most		patients		lacked		pain		induced		by		brush		stroking		and	
did		not		show		signiﬁcant		differences		across		the		treatments		at	
endpoint.		Similarly,		baseline		depression		and		anxiety	
symptom		severities,		assessed		by		BDI		and		BAI,		respectively,	
were		low		and		the		decrease		in		these		scores		across		the		study	
and		differences		among		the		treatments		were		not		signiﬁcant	
(see		Table		2).	
Most		health		outcomes		measures,		the		SF-36		Health		Status	
Survey,		BPI		Interference,		and		EQ-5D,		summarized		in	
Table		2,		improved		signiﬁcantly		more		for		patients		treated	
with		duloxetine		60		and		120		mg/d		compared		to		those		treated	
with		placebo.		Exceptions		included		the		SF-36		Physical	
Component		that		lacked		signiﬁcant		difference		across		treat-	
ment		groups		and		the		Mental		Component		and		General		Health	
Perceptions		that		demonstrated		signiﬁcantly		greater	
improvement		for		duloxetine		120		mg/d		treatment		group	
compared		with		the		placebo		treatment		group.	
	
3.4.		Evaluation		of		direct		treatment		effect		on		pain		reduction	
	
From		path		analysis,		duloxetine		60		mg/d		demonstrated		a	
signiﬁcant		direct		treatment		effect		on		average		pain		score	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Fig.	5.	Supplemental	analgesic	use	for	pain—median	average	daily	dose.	
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(PZ0.003		vs.		placebo).		The		total		treatment		effect		of	
duloxetine		60		mg/d		vs.		placebo		observed		on		the		reduction	
in		24-h		average		pain		was		decomposed		into		three		effects		as	
follows:		94.8%		direct		effect,		0.2%		indirect		effect		through	
improvement		on		mood		(change		in		BDI),		and		5.1%		indirect	
effect		through		improvement		on		anxiety		symptoms		(change	
in		BAI).		For		duloxetine		120		mg/d,		there		was		no		effect		of	
improvement		on		the		BAI		on		the		change		in		the		24-h		Average	
Pain		Score.		When		the		anxiety		component		was		removed	
from		the		analysis,		the		direct		treatment		effect		on		24-h	
Average		Pain		Score		was		signiﬁcant		(P!0.001		vs.		placebo)	
and		accounted		for		88.6%		of		the		total		treatment.		The		indirect	
treatment		effect		through		change		in		BDI		accounted		for		11.4%	
of		the		total		effect.	
	
3.5.		Safety	
	
3.5.1.		Adverse		events	
A	total	of	49	(10.7%)	patients	discontinued	due	to	adverse	
events	(Fig.	3).	There	were	group	differences	with	the	fewest	
discontinuations		for		the		duloxetine		20		mg/d		group		(4.3%)	
and		the		most		for		the		duloxetine		120		mg/d		group		(19.5%).	
Treatment-emergent		adverse		events		by		treatment		with		a	
signiﬁcant		difference		in		reporting		frequency		from		placebo	
are		shown		in		Table		4.		Two		adverse		events		(somnolence		and	
constipation)		showed		a		signiﬁcant		difference		between	
duloxetine		60		mg/d		and		placebo.		Most		adverse		events	
were		mild		or		moderate,		except		severe		somnolence,		which	
was		reported		signiﬁcantly		more		frequently		by		the		duloxetine	
120		mg/d		treatment		group		than		the		other		treatment		groups,	
which		had		no		severe		somnolence		reports.	
Some		pain		adverse		events		(back		pain,		arthralgia,		and	
pruritis)		were		reported		signiﬁcantly		less		frequently		by		the	
duloxetine		60		and		120		mg/d		groups		compared		with		placebo.	
Placebo-treated		patients		reported		signiﬁcantly		greater	
incidence		of		lower		limb		edema		and		peripheral		swelling	
A		total		of		19		patients		experienced		serious		adverse		events,	
deﬁned		as		any		event		resulting		in		or		prolonging		hospitaliz-	
ation		or		death,		life		threatening		experience,		severe		or	
permanent		disability		during		the		study.		Among		serious	
adverse		events		reported		as		reason		for		discontinuation,		one	
death		occurred		due		to		accidental		drowning		in		the		placebo	
group.		Serious		adverse		events		occurring		in		more		than		one	
patient		included		chest		pain		(placebo:		1		[0.9%];		duloxetine	
20		mg/d:		1		[0.9%]),		hypergylcemia		NOS		(placebo:		1	
[0.9%];		duloxetine		120		mg/d:		1		[0.9%]),		and		myocardial	
infarction		(duloxetine		20		mg/d:		1		[0.9%];		duloxetine	
120		mg/d:		1		[0.9%]).		There		were		no		signiﬁcant		treatment	
group		differences		in		occurrence.	
	
3.5.2.		Laboratory		data	
Although		mean		changes		in		several		laboratory		analytes	
differed		statistically		signiﬁcantly		across		treatments		groups,	
the		mean		changes		were		small		and		none		were		considered	
clinically		meaningful.		Compared		with		placebo-treated	
patients,		the		duloxetine		120		mg/d		group		had		a		statistically	
signiﬁcant		mean		decrease		in		uric		acid,		chloride,		and	
gamma-glutamyl		transferase		(GGT),		and		increase		in	
bicarbonate.		The		60		mg/d		group		had		decreases		in		sodium,	
chloride,		and		alanyl		leucine		transferase		(ALT).		Alkaline	
phosphatase		showed		a		dose-related		increase.	
There		were		no		statistically		signiﬁcant		treatment-group	
differences		in		the		incidence		of		treatment-emergent		abnor-	
mal		hematology		analytes.		Hematology		analytes		showed	
several		statistically		signiﬁcant		differences;		however,		these	
mean		changes		were		not		considered		clinically		relevant.	
Duloxetine		lacked		adverse		effects		on		glycemic		control		or	
lipids		and,		consistent		with		this		ﬁnding,		had		no		signiﬁcant	
difference		among		treatment		groups		in		number		of		hypogly-	
cemic		events		(Table		5).	
Table	5	
Laboratory	values	
than		duloxetine-treated		patients.	
Table	4	
Treatment-emergent	 adverse	 events	 that	 had	 statistically	 signiﬁcant	
Placebo	
NZ115	
Duloxetine	
20	mg/d	
NZ115	
	
60	mg/d	
NZ114	
	
120	mg/da	
NZ113	
differences	between	duloxetine	120	mg/d	and	placebo	 HgbA1cb						K0.0004			K0.00021		K0.00039				0.00127	
Placebo	
NZ115	
Duloxetine	
20	mg/d	
NZ115	
	
60	mg/d	
NZ114	
	
120	mg/d	
NZ113	
P-value																						0.450								0.432								0.116	
LDL-Cb							K0.036						0.008				K0.034				K0.007	
P-value																						0.442								0.953								0.728	
HDL-Cb							K0.023						0.018				K0.004						0.018	
Nausea	 11	(9.6%)	 16	(13.9%)	 19	(16.7%)	 31	(27.4%)***	
Somnolence	 9	(7.8%)	 9	(7.8%)	 23	(20.2%)**	32	(28.3%)***	
Dizziness	 8	(7.0%)	 7	(6.1%)	 11	(9.6%)	 26	(23%)***	
P-value																						0.075								0.239								0.102	
Triglyceridesb		K0.025				K0.090				K0.332				K0.11	
P-value																						0.529								0.532								0.703	
Consti-	 4	(3.5%)			6	(5.2%)				17	(14.9%)**	12	(10.6%)*	 Hypoglycemic	episodesc	
pation	
Dry	mouth	 7	(6.1%)	 6	(5.2%)	 8	(7%)	 17	(15%)*	
Mean																				0.19									0.13									0.10									0.13	
SD																								0.72									0.58									0.21									0.53	
Sweating	
increased	
Appetite	
3	(2.6%)			7	(6.1%)						4	(3.5%)				10	(8.8%)*	
	
0										3	(2.6%)						3	(2.6%)				14	(12.4%)***	
Median																	0.00									0.00									0.00									0.00	
P-value																			–										0.465								0.867								0.555	
decreased	
Anorexia	 1	(0.9%)	 3	(2.6%)	 3	(2.6%)	 9	(8%)**	
Weakness	 0	 1	(0.9%)	 3	(2.6%)	 8	(7.1%)**	
*P%0.05	vs.	placebo,	**P%0.01	vs.	placebo,	***P%0.001	vs.	placebo.	
P-values					vs.					placebo.					HgbA1c,					urobilinogen;					LDL-C,					microscopic	
examination	of	sediment;	HDL-C,	nitrite;	SD,	standard	deviation.	
a	Bi-daily	dosing	administration.	
b	Mean	change	from	baseline	to	endpoint.	
c	Weekly	average	number.	
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3.5.3.		Vital		signs		and		electrocardiographic		results	
The		incidence		of		sustained		hypertension		was		6		(5%),		9	
(8%),		1		(1%),		and		3		(3%)		for		the		duloxetine		20,		60,	
120		mg/d,		and		placebo		treatment		groups,		respectively.	
There		was		no		difference		between		the		duloxetine		treatment	
groups		and		placebo		in		the		percentage		of		cases		of		sustained	
hypertension.		Compared		with		the		placebo		group,		the	
duloxetine		60		and		120		mg/d		treatment		groups		had		a	
statistically		signiﬁcant		mean		decrease		in		QT		interval	
(K14.25		and		K11.49		ms,		respectively).	
	
	
4.		Discussion	
	
In		this		randomized,		double-blind,		12-week		trial,		dulox-	
etine		at		60		and		120		mg/d		demonstrated		signiﬁcantly		greater	
efﬁcacy		than		placebo		on		most		outcome		measures		in		the	
management	of	pain	due	to	polyneuropathy	caused	by	Type	1	
or		Type		2		diabetes		mellitus.		Speciﬁcally,		pain		reduction		was	
signiﬁcant	for	average	pain,	worst	pain,	least	pain,	night	pain,	
and		pain		‘right		now.’		Patient-		and		clinician-rated		global	
improvement		scores		were		also		signiﬁcantly		improved.		In	
addition,		duloxetine		at		120		mg/d		appeared		to		work		best		on	
pain		described	as	shooting,	stabbing,	sharp,		hot-burning,	and	
splitting.		Patients		treated		with		duloxetine		not		only		reported	
improvement		on		measures		of		pain		but		also		used		signiﬁcantly	
less		supplemental		analgesic		as		well.		Furthermore,		path	
analysis		showed		that		duloxetine		affected		pain		directly		rather	
than		indirectly		through		mood		improvement.	
In		addition		to		relieving		pain,		treatment		with		duloxetine	
was		also		associated		with		signiﬁcant		improvement		in		daily	
functioning.		In		particular,		there		was		a		reduction		of	
interference		with		activity		as		measured		by		the		BPI		and	
improvement		in		quality		of		life,		as		measured		by		the		EQ-5D	
scale.		These		effects		highlight		the		clinical		relevance		of	
duloxetine		management		of		DPNP.	
The		reduction		in		pain		severity		demonstrated		in		this		trial	
is		consistent		with		the		previously		reported		ﬁndings		that	
duloxetine		was		effective		in		treating		pain		in		animal		models	
(Iyengar		et		al.,		2004)		and		extends		the		ﬁnding		of		reduced	
severity		of		painful		physical		symptoms		in		depressed		patients	
treated		with		duloxetine		(Detke		et		al.,		2002a,b;		Nemeroff	
et		al.,		2002).		These		results		are		also		consistent		with		human	
clinical		data		on		5-HT/NE		and		known		5-HT/NE		pathways	
that		suggest		targeting		both		pathways		is		better		than		targeting	
each		individually		(Sindrup		and		Jensen,		1999).	
In		general,		duloxetine		was		well		tolerated		and		safe	
during		this		12-week		study.		There		were		more		discontinu-	
ations		due		to		adverse		events		in		the		duloxetine		60		and	
120		mg/d		treatment		groups		than		in		the		placebo		treatment	
group;		however,		only		two		adverse		events		(somnolence		and	
constipation)		were		reported		more		frequently		by		the	
60		mg/d		treatment		group		than		by		the		placebo		treatment	
group.		With		regard		to		safety		issues		of		central		importance		to	
patients		with		diabetes,		duloxetine		does		not		appear		to	
adversely		affect		glycemic		control,		lipid		proﬁles,		or		QTc	
interval,		or		show		clinically		relevant		changes		in		heart		rate	
and		blood		pressure		(Detke		et		al.,		2002a).		The		lack		of	
signiﬁcant		cardiovascular		changes		due		to		duloxetine	
therapy		in		these		patients		suggests		that		duloxetine-treated	
patients		with		diabetes		mellitus		do		not		require		additional	
cardiovascular		assessments		than		they		do		for		their		under-	
lying		diabetes.	
The		efﬁcacy		of		duloxetine		60		and		120		mg/d		was		similar	
in		this		trial,		but		duloxetine		60		mg/d		produced		fewer	
discontinuations		for		adverse		events		and		a		slightly		reduced	
frequency		of		treatment-emergent		adverse		events.		Dulox-	
etine		is		currently		approved		by		the		FDA		for		the		manage-	
ment		of		DPNP		at		a		dose		of		60		and		120		mg/d.		Although		the	
higher		dose		of		120		mg/d		did		not		produce		signiﬁcantly	
greater		improvement		than		60		mg/d		and		was		less		well	
tolerated,		it		was		safe		and		effective		and		may		be		an	
appropriate		dose		for		patients		who		require		additional		pain	
relief.	
The		exclusion		of		patients		with		depression		and		anxiety		by	
the		MINI		was		conﬁrmed		by		the		low		scores		on		the		BDI		and	
BAI.		As		a		consequence,		antidepressant		or		anxiolytic		effects	
by		duloxetine		could		not		be		demonstrated;		however,		the	
absence		of		depressive		and		anxiety		symptoms		at		baseline,	
conﬁrmed		by		the		results		of		path		analysis,		indicate		that	
analgesic		effects		were		not		dependent		on		improvement		of	
mood		or		anxiety		symptoms.	
	
4.1.		Strengths		and		limitations	
	
In		this		trial,		the		patient		population		was		limited		due		to	
exclusion		of		patients		whose		comorbid		conditions		and		con-	
comitant		medications		might		have		interfered		with		interpret-	
ation		of		efﬁcacy		or		safety;		thus,		further		study		will		be	
required		to		generalize		these		ﬁndings		to		all		patients		with	
DPNP.		In		addition,		this		condition		requires		prolonged	
therapy		and		evaluation		for		a		longer		duration		than		the		12	
weeks		presented.		Finally,		future		studies		with		an		active	
comparator		would		allow		for		a		more		complete		evaluation		of	
the		beneﬁts		of		duloxetine		in		DPNP.		Strengths		of		the		current	
study		include		the		use		of		a		randomized,		prospective		design,	
multiple		clinically		signiﬁcant		measures		related		to		both	
efﬁcacy		and		safety,		and		an		adequate		dose		range		to		assess		the	
dose–response		relationship.		It		is		also		important		to		note		that	
patients		were		not		allowed		to		take		other		drugs		used		to		treat	
neuropathic		pain.	
In		sum,		this		study		demonstrates		that		duloxetine		is	
effective		in		managing		DPNP		and		that		this		is		not		an		indirect	
effect		of		improved		mood.		Presumably,		this		effect		is		due		to	
the		ability		of		duloxetine		to		enhance		both		5-HT		and		NE	
function		in		descending		modulatory		pain		pathways.		Thus,	
duloxetine		has		a		distinct		efﬁcacy		in		managing		the		persistent	
pain		condition		associated		with		diabetic		neuropathy		and	
efﬁcacy		in		treating		the		emotional		and		painful		physical	
symptoms		associated		with		depression.	
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Abstract Objective. Assess efﬁcacy and safety of duloxetine, a selective serotonin and norepinephrine reuptake
inhibitor, on the reduction of pain severity, in patients with diabetic peripheral neuropathic pain
(DPNP).
Methods. This was a multicenter, parallel, double-blind, randomized, placebo-controlled trial that
enrolled 348 patients with pain due to peripheral neuropathy caused by type 1 or type 2 diabetes
mellitus. Patients (N = 116 per group) were randomly assigned to receive duloxetine 60 mg once
daily (QD), duloxetine 60 mg twice daily (BID), or placebo, for 12 weeks. The primary outcome
measure was the weekly mean score of 24-hour average pain severity evaluated on an 11-point
Likert scale. Secondary outcome measures and safety were evaluated.
Results. Compared with placebo-treated patients, both duloxetine-treated groups improved signif-
icantly more (P < 0.001) on the 24-hour average pain score. Duloxetine demonstrated superiority
to placebo in all secondary analyses of the primary efﬁcacy measure. A signiﬁcant treatment effect
for duloxetine was observed in most secondary measures for pain. Discontinuations due to adverse
events were more frequent in the duloxetine 60 mg BID- (12.1%) versus the placebo- (2.6%) treated
group. Duloxetine showed no adverse effects on diabetic control, and both doses were safely
administered and well tolerated.
Conclusions. In this clinical trial, duloxetine 60 mg QD and duloxetine 60 mg BID were effective
and safe in the management of DPNP.
Key Words. Duloxetine; Diabetic Neuropathy; Pain; Antidepressant; Serotonin; Norepinephrine
Introduction
iabetes mellitus is predicted to afﬂict 220
million people worldwide by the year 2010
[1]. The prevalence of diabetes in the adult U.S.
population is estimated to be 7.8%, and may be
as high as 12–14% in people over 40 years [2].
Approximately 30–60% of patients with diabetes
D
develop long-term complications of peripheral
neuropathy, and up to 10–20% of these patients
experience pain [3–5] often described as a steady
aching or burning pain and characterized by hype-
ralgesia, allodynia, and paresthesia [6–8].
Serotonergic and noradrenergic neurons have
been implicated in the mediation of endogenous
pain inhibitory mechanisms via descending inhib-
itory pain pathways in the brain and spinal cord
[9,10]. In pathological pain states, these endoge-
nous pain inhibitory mechanisms may be dysfunc-
tional, contributing to the central sensitization
and hyperexcitability of the spinal and supraspinal
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pain transmitting pathways and manifesting as
persistent pain [11]. In rodents, duloxetine has
demonstrated efﬁcacy in the formalin and capsai-
cin models of persistent pain, the partial sciatic
nerve ligation [12], and L5/L6 spinal nerve liga-
tion models of neuropathic pain [8]. Preclinical
models of central sensitization suggest that dulox-
etine is effective in the treatment of persistent
pain [13]. This is likely due to the effect of dulox-
etine on central sensitization rather than on noci-
ception, suggested by its minimal efﬁcacy in the
tail-ﬂick model of acute nociceptive pain. These
results are indicative of pain inhibitory effects of
duloxetine in the treatment of neuropathic, per-
sistent, and inﬂammatory pain, but not in acute
nociceptive pain. Because central sensitization
and disinhibition mechanisms are believed to be
involved in the development and maintenance of
chronic neuropathic pain, including diabetic
peripheral neuropathic pain (DPNP), duloxetine
was considered to be a good clinical candidate for
evaluating treatment of DPNP.
Duloxetine hydrochloride (Cymbalta®) is a
selective serotonin (5-HT) and norepinephrine
(NE) reuptake inhibitor that is relatively balanced
in its afﬁnity for both 5-HT and NE reuptake
inhibition [14] and it is the ﬁrst U.S. Food and
Drug Administration (FDA)-approved drug for
the management of DPNP. In a randomized, con-
trolled, 12-week trial comparing duloxetine
60 mg once daily (QD) and duloxetine 60 mg
twice daily (BID) or 20 mg QD with placebo in
the management of 477 patients [15] with DPNP
and without depression, duloxetine was found to
be effective and safe for DPNP management.
Based on this evidence [15], two more indepen-
dent studies were conducted to assess the safety
and efﬁcacy of duloxetine 60 mg QD and 60 mg
BID in the management of patients with DPNP.
The ﬁrst of these two studies [16] conﬁrmed ﬁnd-
ings reported earlier [15], and the second study is
reported here.
Methods
Overview
Enrollment for this study extended from Novem-
ber 2003  to  March  2004  and  was  conducted
in 26 centers worldwide. This was a Phase III,
multicenter, parallel, double-blind, randomized,
placebo-controlled trial. The study protocol was
approved in accordance with the principles of the
Declaration of Helsinki, and all patients provided
written informed consent.
Entry Criteria
Patients were eligible for the study if they were
≥18 years, and presented with pain due to bilateral
peripheral neuropathy caused by type 1 or type 2
diabetes mellitus. The pain had to begin in the feet
and with relatively symmetrical onset. The daily
pain must have been present for at least 6 months,
and the diagnosis was to be conﬁrmed by a score
of at least 3 on the Michigan Neuropathy Screen-
ing Instrument (MNSI). Patients had to have a
mean score of ≥4 when assessed for 24-hour aver-
age pain severity on the 11-point Likert scale
(from the patient diary prior to randomization),
and stable glycemic control. Patients were
excluded if they were pregnant or breastfeeding,
had prior renal transplant or current renal dialysis,
or had a serious or unstable illness, symptomatic
peripheral vascular disease, or other medical con-
dition or psychological conditions that might
compromise participation in the study. Patients
were also excluded if they had a current (≤1 year)
Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition (DSM-IV) [17] Axis I diagnosis
of major depressive disorder (MDD), dysthymia,
generalized anxiety disorder, alcohol, or eating
disorders as determined by the Mini International
Neuropsychiatric Interview (MINI) [18], or if they
had a DSM-IV diagnosis or a previous diagnosis
of mania, bipolar disorder, or psychosis. Other
exclusion criteria included historical exposure to
drugs known to cause neuropathy, history of sub-
stance abuse or dependence within the previous
year (excluding nicotine and caffeine), a positive
urine  drug  screen  for  any  substances  of  abuse
or  excluded  medication,  or  a  history  of  a  med-
ical condition including pernicious anemia and
hypothyroidism that could have been responsible
for neuropathy, and treatment with a monoamine
oxidase inhibitor (MAOI) or ﬂuoxetine within
30 days of randomization. Patients were excluded
if they had severe allergic reactions to multiple
medications, and prior participation in a study of
duloxetine.
Concomitant medication exclusions included
chronic use of antidepressants, antiemetics, anal-
gesics with  the  exception  of  acetaminophen  up
to 4 g/day and aspirin up to 325 mg/day. Anti-
manics, antimigraine medications, antipsychotics,
benzodiazepines, capsaicin, chloral hydrate, guan-
ethidine, topical lidocaine, MAOIs, narcotics,
psychostimulants, oral and injectable steroids,
and anticonvulsants were excluded. Concomitant
medication inclusions (chronic and episodic) were
antacids, antiasthma agents, aminophylline, birth
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control medication, cough/cold preparations (that
did not contain dextromethorphan), diuretics,
inhaled and topical steroids, hypoglycemics,
insulin, laxatives, theophylline, anticoagulants,
antibiotics, antidiarrheals, and antihistamines.
Medications including angiotensin-converting
enzyme (ACE) inhibitors, angiotensin II receptor
agonists, antiarrythmics, anticoagulants, calcium
channel blockers, and others were allowed pro-
vided the patient had been on a stable dose for
3 months prior to enrollment.
Study Design
This study was designed to enroll 330 patients to
three treatment groups. With 110 patients per
arm, the study had at least 90% power to detect a
treatment-group difference of −1.20 points in the
baseline-to-endpoint mean change on the weekly
mean of 24-hour average pain severity between
duloxetine 60 mg BID and placebo treatment
groups. The sample size was determined using a
two-sided test with α  = 0.05, and assuming a com-
mon standard deviation of 2.2 and a discontinua-
tion rate of 35%.
Patients who met entry criteria following an up
to 3-week screening phase (study period I) were
randomized to treatment with duloxetine 60 mg
QD, duloxetine 60 mg BID, or placebo, with ran-
domization performed at visit 3 in a 1:1:1 ratio.
Assignment to treatment groups was determined
by a computer-generated random sequence using
an Interactive Voice Response System. Patients
received either of (or a combination of, depending
on their randomly assigned treatment) the follow-
ing: 30 mg capsules of duloxetine hydrochloride
or placebo capsules identical to duloxetine cap-
sules. Patients randomly assigned to all treatment
groups were instructed to take two capsules (by
mouth) every morning and every evening. Study
period II consisted of a 12-week, double-blind
acute therapy period and 1-week study drug taper-
ing period. Visits to the site occurred weekly for
the ﬁrst 2 weeks, biweekly for the next 10 weeks,
and then weekly for the next week. All patients
randomized to duloxetine treatment were treated
initially with 60 mg QD. After 3 days, those
patients randomized to the 60 mg BID treatment
group received 60 mg BID. Patients in the 60 mg
QD  treatment  group  continued  at  60 mg  QD.
At Visit 2 (week prior to randomization) through
Visit 10 (week 12), patients received a diary and
at Visit 3 through Visit 10 (week 12), patients
received study drug. At Visit 10, the patient’s study
drug dose was halved to 30 mg QD and 60 mg QD
for the duloxetine 60 mg QD- and 60 mg BID-
treated group, respectively. The efﬁcacy and safety
evaluation of duloxetine versus placebo was con-
ducted using data from the 12-week acute therapy
period where duloxetine 60 mg was administered
at a full dosage.
Efficacy Measures
The primary efﬁcacy measure was the change in
the weekly mean of the 24-hour average pain
scores (referred to as the 24-hour average pain
score) as measured by an 11-point Likert scale
that was completed daily by the patients in a diary.
At Visit 2, site personnel dispensed daily diaries
and educated patients on proper completion of
the diary. The mean score in a week was deter-
mined by averaging the daily scores (among the
days in the week) on the 24-hour average pain
collected from the diary. Overall study diary com-
pliance was deﬁned as being compliant at each
visit in the study period from Visit 4 through Visit
10. A patient was considered to be compliant with
the diary at a certain visit if the patient completed
at least 80% of the diary over the total days since
the last visit. Scores for 24-hour average pain,
worst pain, and night pain were derived from the
patient diary collected at each visit. Protocol-
speciﬁed response at endpoint was deﬁned as a
30% reduction from baseline to endpoint in the
24-hour average pain score. Responses based on
50%, 75%, and 100% reductions from baseline
were also reported. Sustained response at end-
point was deﬁned as a 30% reduction from base-
line to endpoint in the 24-hour average pain
severity with a 30% reduction from baseline at a
week at least 2 weeks prior to the last, and with at
least a 20% reduction from baseline at every week
in between.
Secondary efﬁcacy measures for pain were the
weekly mean of daily worst pain and night pain on
the 11-point Likert scale (collected from patient’s
diary), Brief Pain Inventory (BPI) [19], the Short-
Form McGill Pain Questionnaire (sensory por-
tion) (SF-MPQ) [20] (sum of 11 pain descriptor
terms—throbbing, shooting, stabbing, sharp,
cramping, gnawing, hot-burning, aching, heavy,
tender, and splitting; the pain intensity for each
pain descriptor was rated on a scale of 0 = none,
1 = mild, 2 = moderate, and 3 = severe), and
dynamic allodynia. Dynamic allodynia was
assessed by the clinician using a brush stroke (to
the same body location at baseline and endpoint)
to elicit pain severity from the patient. The patient
was asked to answer whether a brush swept over
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the skin caused pain. The score range was from a
scale of 0 (no pain) to 3 (severe pain). The inter-
ference portion of the BPI was completed by the
patient to measure how much pain had interfered
with patient outcomes. Other secondary measures
included the 17-item Hamilton Depression Rating
Scale (HAMD17) [21,22], the Clinical Global
Impression of Severity (CGI-Severity) scale [23],
and Patient Global Impression of Improvement
(PGI-Improvement) scale. The average daily
intake of acetaminophen taken for DPNP was
recorded.
Schedule of Assessments
The screening portion of the protocol (Visits 1–3)
included the medical history and the MINI [18]
to determine whether patients met criteria for
excluded primary DSM-IV Axis I diagnoses.
Patients also underwent a physical exam, electro-
cardiogram (ECG), and laboratory tests. At ran-
domization (Visit 3), and at each subsequent visit
the diary was collected, vital signs were checked,
and adverse events and concomitant medication
were reviewed. BPI and CGI-Severity were
completed at Visits 3, 6, 8, and 10. The PGI-
Improvement was measured at Visits 6, 8, and 10.
The HAMD17, SF-MPQ, and dynamic allodynia
were measured at Visits 3 and 10.
Safety Assessments
Safety was evaluated by measuring discontinua-
tion rates, treatment-emergent adverse events
(TEAEs), serious adverse events, vital signs,
weight, laboratory analyses, ECGs, frequency of
signiﬁcant hypoglycemic events, and electrophys-
iology assessments.
Statistical Analysis
All analyses were conducted on an intent-to-treat
basis. Treatment effects were evaluated based on a
two-sided signiﬁcance level of 0.05, and interac-
tion effects at 0.10. The change from baseline to
endpoint (the last nonmissing observation after
randomization) on the continuous efﬁcacy mea-
sures was analyzed using an analysis of covariance
(ancova) model with the terms of treatment, inves-
tigator, treatment-by-investigator interaction, and
baseline scores. When the interaction was not sta-
tistically signiﬁcant, the treatment-group contrasts
were made from the model without interaction.
Type II sum-of-squares for the least-squares
means were used. Repeated measure analysis [24]
was used as the secondary methodology to dem-
onstrate the invariance of the results and the time
course of the treatment effect. The model included
terms of the treatment,  investigator,  visit,  and
treatment-by-visit interaction, as well as the cova-
riate of baseline score and baseline-by-visit inter-
action. The unstructured covariance was used in
the model, and the analysis was implemented using
SAS PROC MIXED. An analysis of variance
(anova) model with the terms of treatment and
investigator was used to analyze the continuous
safety measures or the corresponding rank-
transformed data (labs and daily average of con-
comitant acetaminophen use). Proportions were
analyzed using Fisher’s exact test. Time to ﬁrst
response (30% reduction from baseline) and time
to the ﬁrst visit where sustained response was
observed were analyzed by a log-rank test.
Path analysis [25,26] was used to assess the direct
treatment effect on pain reduction after accounting
for the possible treatment effect on mood. This
analysis tested the null hypothesis that change in
the 24-hour average pain score depended on
change of mood, as measured by HAMD17 total
score, versus the alternative that the reduction in
24-hour average pain score was due to a direct
analgesic effect of the treatment and was indepen-
dent of the treatment effect on mood.
Throughout the article, the term “signiﬁcant”
indicates statistical signiﬁcance, and “mean
change” refers to “least-squares mean change.”
Results
Patient Disposition
A total of 475 patients were screened to enroll 348
patients who met entry criteria and were randomly
assigned to duloxetine 60 mg QD, duloxetine
60 mg BID, or placebo (116 patients in each
group). Fifty-two (15%) patients withdrew for all
reasons during the acute therapy phase, 15 (13%)
from the duloxetine 60 mg QD group, 21 (18%)
from the duloxetine 60 mg BID group, and 16
(14%) from the placebo group. Twenty-two
(6.3%) patients discontinued due to adverse
events, 5 (4.3%) from the duloxetine 60 mg QD
group (P = 0.72 vs placebo), 14 (12.1%) from the
duloxetine 60 mg BID group (P = 0.01 vs placebo),
and 3 (2.6%) from the placebo group.
Baseline Clinical and Demographic Characteristics
The majority of the patients in the study were
Caucasian (99.7%) with a mean age of 58.8 years
(Table 1). The mean duration of diabetes was
13.8 years. Type 2 diabetes was the most prevalent
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(84.5%), and the mean MNSI score at the time of
screening was 5.0. At baseline, there was a signif-
icant difference between treatment groups for the
MNSI score, with placebo-treated patients having
a slightly higher score (P = 0.036). At baseline,
the mean dynamic allodynia score was 0.38 and
HAMD17 total score was 3.89.
Efficacy
In the mean change analyses, duloxetine 60 mg
QD and 60 mg BID were statistically superior to
placebo on the primary and all secondary measures
(Table 2) except for HAMD17 total score and
dynamic allodynia. After adjusting for the baseline
MNSI score, the P value for the primary analysis
did not change. There was no signiﬁcant differ-
ence in efﬁcacy measures between duloxetine
60 mg QD and 60 mg BID. The repeated measure
analysis showed that duloxetine was signiﬁcantly
superior to placebo beginning 1 week after ran-
domization and  continuing  through  the  study
in the analyses of the 24-hour average pain
(Figure 1), worst pain severity, and night pain
scores. Duloxetine was signiﬁcantly better than
placebo in reducing BPI Severity scores for worst
pain, least pain, average pain, and pain right now
using both mean change analysis and repeated
measure analysis (Figure 2). There were no statis-
tically signiﬁcant differences among treatment
groups for study diary compliance.
Both duloxetine groups were superior to pla-
cebo on CGI-Severity and PGI-Improvement
scores, and demonstrated an improvement in the
total score of the sensory component of the SF-
MPQ. The 24-hour average pain severity response
rate at endpoint showed signiﬁcant superiority for
both duloxetine 60 mg QD (68.14%, P < 0.001)
and duloxetine 60 mg BID (64.04%, P = 0.002)
compared with placebo (43.36%). A 50%, 75%,
and 100% reduction in the 24-hour average pain
response rate at endpoint was achieved by 30%,
11%, and 4% of patients, respectively, in the
placebo group, 50%, 20%, and 5% of patients,
respectively, in the duloxetine 60 mg QD group,
and 39%, 22%, and 8% of patients, respectively,
in the duloxetine 60 mg BID group. Duloxetine
60 mg QD (60.18%, P = 0.002) and duloxetine
60 mg BID (57.02%, P = 0.008) also demonstrated
signiﬁcant superiority to placebo (38.94%) at
achieving sustained response at endpoint. Com-
pared with placebo, patients in both of the dulox-
etine treatment groups achieved ﬁrst response
and sustained response in a signiﬁcantly shorter
amount of time (P < 0.001).
The path analysis for the 24-hour average pain
score showed that the direct treatment effect of
duloxetine on pain accounted for the major por-
tion of the total effect (98.0% and 92.7% for
duloxetine 60 mg BID and 60 mg QD vs placebo,
respectively).
Table 1 Demographics and baseline assessments
Variable
Placebo
(N = 116)
Duloxetine
60 mg QD
(N = 116)
Duloxetine 
60 mg BID 
(N = 116)
Total 
(N = 348) P Value
Age, years,* mean (SD) 59.2 (9.8) 58.3 (10.9) 59.0 (9.6) 58.8 (10.1) 0.711
Gender,† N (%) 0.237
Female 63 (54.3) 68 (58.6) 55 (47.4) 186 (53.4)
Race (origin),† N (%) >0.999
Caucasian 116 (100) 115 (99.1) 116 (100) 347 (99.7)
East/Southeast Asian 0 1 (0.9) 0 1 (0.3)
Weight, kg,* mean (SD) 87.2 (16.5) 83.3 (19.6) 87.1 (19.2) 85.9 (18.5) 0.128
Type of diabetes mellitus,† N (%) 0.269
Type 1 14 (12.1) 23 (19.8) 17 (14.7) 54 (15.5)
Type 2 102 (87.9) 93 (80.2) 99 (85.3) 294 (84.5)
Duration of diabetes, years,* mean (SD) 12.8 (8.6) 14.6 (8.9) 13.9 (9.7) 13.8 (9.1) 0.372
Duration of DN, years,* mean (SD) 4.0 (3.5) 4.5 (4.4) 4.5 (4.6) 4.3 (4.2) 0.570
MNSI,* mean (SD) 5.2 (1.6) 4.9 (1.4) 4.8 (1.4) 5.0 (1.5) 0.036
Pain severity at baseline,* mean (SD)
24-hour average pain severity 5.5 (1.3) 5.5 (1.1) 5.7 (1.3) 5.6 (1.2) 0.542
24-hour worst pain severity 6.5 (1.4) 6.7 (1.3) 6.9 (1.3) 6.7 (1.4) 0.213
Night pain severity 6.2 (1.7) 5.9 (1.7) 6.1 (1.6) 6.1 (1.7) 0.523
Mood and general illness at baseline,* mean (SD)
HAMD17 total score 3.8 (3.2) 3.8 (3.7) 4.2 (3.1) 3.9 (3.3) 0.608
CGI-Severity 4.5 (0.9) 4.6 (0.9) 4.5 (1.0) 4.5 (0.9) 0.563
* Means were analyzed using a Type III Sum of squares analysis of variance.
† Frequencies were analyzed using a Fisher’s exact test.
QD = once a day; BID = twice daily; SD = standard deviation; BPI = Brief Pain Inventory; CGI-Severity = Clinical Global Impressions of Severity; DN = diabetic
neuropathy; MNSI = Michigan Neuropathy Screening Instrument; HAMD17 = 17-item Hamilton Depression Rating Scale.
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The  mean  average  daily  dose  for  concomi-
tant use of acetaminophen for DPNP (placebo-
treated  group:  202.52 mg,  duloxetine  60 mg
QD-treated group: 151.88 mg, duloxetine 60 mg
BID-treated group: 121.65 mg) indicated signiﬁ-
cant treatment-group differences between dulox-
etine 60 mg BID and placebo (P = 0.040). The
mean change analysis of 24-hour average pain
Figure 1 Mean change in 24-hour
average pain severity score. **P ≤
0.01 versus placebo; ***P ≤ 0.001
versus placebo.
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Figure 2 Brief Pain Inventory individual severity score. *P ≤ 0.05 versus placebo; **P ≤ 0.01 versus placebo; ***P ≤ 0.001
versus placebo.
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adjusted for the concomitant acetaminophen use
still showed signiﬁcant superiority of both dulox-
etine groups to the placebo group.
In the BPI Interference scale, both duloxetine
doses were signiﬁcantly superior to placebo at
reducing scores in all measures (P < 0.05), except
relationship with other people item (P = 0.146)
and mood item (P = 0.053) for 60 mg QD-treated
patients (Table 2).
Safety
Of the 348 randomly assigned patients, 57 (49.1%)
placebo-, 71 (61.2%) duloxetine 60 mg QD-
(P = 0.086 vs placebo), and 73 (62.9%) duloxetine
60 mg BID- (P = 0.047 vs placebo) treated patients
reported at least one TEAE. Patients in both
duloxetine groups reported treatment-emergent
nausea, somnolence, hyperhidrosis, and anorexia
signiﬁcantly more frequently than placebo-treated
patients. Additionally, vomiting and constipation
were reported by duloxetine 60 mg BID-treated
patients signiﬁcantly more frequently than
placebo-treated patients. Twenty-two patients
discontinued during the therapy phase due to
adverse events (duloxetine 60 mg QD, 5 [4.3%];
duloxetine  60 mg  BID,  14  [12.1%];  placebo
3 [2.6%]), with signiﬁcant differences between
duloxetine 60 mg BID- and placebo-treated
groups (P = 0.010). Eighty-six percent of patients
who discontinued due to adverse events did so
during the ﬁrst 4 weeks of the study. Vomiting
(3.4%) and nausea (1.7%) were reported as rea-
sons for discontinuation in >1% of duloxetine
60 mg BID-treated patients. Ten (2.9%) patients
experienced 13 serious adverse events with no sig-
niﬁcant treatment-group differences. These in-
cluded 4 (3.4%) placebo-treated patients (events:
anemia, cerebrovascular accident, chest pain,
chronic obstructive airways, dyspnea, melaena,
pneumonia), 4 (3.4%) duloxetine 60 mg QD-
treated patients (events: atrial ﬁbrillation, chole-
cystitis, diabetes mellitus, nephrolithiasis), and 2
(1.7%) duloxetine 60 mg BID-treated patients
(events: urinary calculus, ventricular extrasysto-
les). The weekly average of signiﬁcant hypoglyce-
mic events showed no signiﬁcant differences
between treatment groups.
Duloxetine 60 mg QD-treated patients experi-
enced a mean increase in alkaline phosphatase,
aspartate transaminase/serum glutamic oxaloacetic
transaminase, inorganic phosphorous, fasting
glucose, and uric acid compared with placebo-
treated patients. Duloxetine 60 mg BID-treated
patients experienced a mean increase in choles-
terol, alkaline phosphatase, low-density lipopro-
tein cholesterol, and bicarbonate HCO3, and a
mean decrease in urea nitrogen compared with
placebo treated patients. These mean differences
were transient, and generally of low magnitude
and not considered to be clinically relevant. There
were no signiﬁcant treatment-group differences
observed in any of the mean change analyses of
electrophysiology measures.
There was a slight but signiﬁcant mean
decrease in weight from baseline to endpoint for
duloxetine  60 mg  BID-  (mean  change  [SD]:
−0.90 kg [2.39]; P = 0.006) treated patients com-
pared with placebo-treated patients. There was a
signiﬁcant mean increase in heart rate from base-
line to endpoint for duloxetine 60 mg BID- (mean
change [SD] beats/minute: 4.22 [10.72]; P = 0.005
vs duloxetine 60 mg QD; P < 0.001 vs placebo)
treated  patients  compared  with  duloxetine
60 mg QD- (mean change [SD]: 0.47 [9.02]), and
placebo- (mean change [SD]: −0.82 [10.97])
treated patients. These changes were not of clini-
cally relevant magnitude. There were no signiﬁ-
cant treatment-group differences in mean change
of systolic and diastolic blood pressure. Seventeen
patients (7 [6.1%] placebo-, 4 [3.5%] duloxetine
60 mg QD-, and 6 [5.2%] duloxetine 60 mg BID-
treated) experienced sustained elevation of blood
pressure (deﬁned as a sitting diastolic blood pres-
sure ≥85 mm Hg and an increase from baseline of
at least 10 mm Hg, or sitting systolic blood pres-
sure ≥130 mm Hg and an increase from baseline
of at least 10 mm Hg, for three consecutive visits),
but the treatment-group differences were not
signiﬁcant.
Placebo-treated patients experienced mean
increases in QT interval and PR interval com-
pared with duloxetine 60 mg BID-treated patients
who experienced mean decreases in QT interval
(mean change [SD]: −10.44 [25.76]; P < 0.001) and
PR interval (mean change [SD]: −4.14 [14.81];
P = 0.006).
Twenty-three of the 348 patients reported at
least one adverse event that emerged during the
1-week drug taper phase (7 [6.0%] duloxetine
60 mg BID-treated group, 8 [6.9%] duloxetine
60 mg QD-treated group, and 8 [6.9%] placebo-
treated group, all events reported in <1% of
patients except hypertension [1.7%] in duloxetine
60 mg BID-treated patients), with no signiﬁcant
treatment-group differences in the overall inci-
dence of taper-emergent adverse events or in any
single taper-emergent adverse event.
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Discussion
In this randomized, double-blind, 12-week trial,
duloxetine at doses of 60 mg QD and 60 mg BID
had signiﬁcantly greater efﬁcacy than placebo on
most outcome measures in the management of
patients with DPNP. Compared with placebo,
both doses of duloxetine signiﬁcantly reduced
pain, beginning in the ﬁrst week of management
and continuing throughout the 12 weeks of ther-
apy. Response rates demonstrated greater pain
reduction for both duloxetine groups compared
with placebo, and patients in the duloxetine
groups were more likely to achieve a sustained
response over time. Farrar et al. 2001 [27] ana-
lyzed the pooled results of 10 placebo-controlled
studies involving patients with chronic pain syn-
dromes (diabetic neuropathy, postherpetic neural-
gia, chronic low back pain, ﬁbromyalgia, and
osteoarthritis) in order to corroborate the associ-
ation between change in pain intensity numeric
rating scale and an improvement in quantiﬁable
measures of clinical status. Their results indicate
that on average a reduction of approximately two
points from baseline on an 11-point pain rating
scale (shown to be equivalent to a 30% reduction
on pain severity from baseline) corresponds to a
clinically meaningful improvement. In this study,
the 24-hour average pain severity was reduced
about two points and the response rate (deﬁned as
30% reduction from baseline to endpoint) showed
signiﬁcant superiority for both duloxetine 60 mg
QD and duloxetine 60 mg BID compared with
placebo. Signiﬁcant pain reduction was observed
on the 24-hour worst, and night pain scores,
respectively, thus stressing the clinical relevance of
duloxetine in the management of DPNP.
A signiﬁcant treatment effect was observed for
both duloxetine treatment groups for most BPI
Interference items. Duloxetine was not statistically
superior to placebo on the HAMD17 total score
and dynamic allodynia. Given the dynamic allo-
dynia rating at baseline of less than 1 on a scale of
0–3, the patients did not have much room for
improvement on this measure.
Duloxetine is known to be an effective antide-
pressant, raising the question as to how much of
the pain reduction effect may be attributed to
relief of depressive symptoms, and what would be
the impact on mood when the drug was used for
the management of pain on patients who do not
have MDD. The potential confounding relation-
ship between pain and mood was recognized when
this study was designed, which is why patients
with a clinical diagnosis of depression were
excluded. This does not preclude the possibility
that patients had subclinical depression. Thus,
HAMD17 was used to measure the mood change
in the trial and the change in HAMD17 was taken
into account for the evaluation of pain reduction
by the path analysis. A HAMD17 score of ≤7 is
often used as an indicator of remission in the
MDD population. In this study, since patients
with a clinical diagnosis of depression were
excluded, the HAMD17 score at baseline was low
(3.89) and well below the standard remission cri-
terion. This might explain the lack of an antide-
pressant effect observed in this study. The path
analysis showed that the reduction of pain was a
direct treatment effect on pain modulation, and
cannot be attributed to an antidepressant effect.
In addition, the analyses on HAMD17 total
showed that the mean changes from baseline to
endpoint were very similar between duloxetine-
treated patients and placebo-treated patients,
which suggests that duloxetine has a neutral effect
on mood for those patients who do not have clin-
ically diagnosed MDD.
Duloxetine is relatively balanced in its afﬁnity
for both 5-HT and NE reuptake inhibition [14].
These results conﬁrm ﬁndings from previous
studies where duloxetine 60 mg QD and 60 mg
BID demonstrated superiority over placebo in
improving DPNP [15,16], and are consistent with
data  that  suggest  that  drugs  with  inhibition  of
5-HT and NE reuptake are effective in the man-
agement of DPNP [28]. These results are also
consistent with ﬁndings that duloxetine is effective
in treating pain in animal models [13] and in
reducing severity of painful physical symptoms in
depressed patients [29–31]. Since noradrenergic
and serotonergic neurons modulate the endoge-
nous pain inhibitory pathways [9,10], the ability of
duloxetine to exert its effects on both these neu-
rotransmitter systems may explain its effectiveness
in this clinical trial.
In the present study, there were no signiﬁcant
differences between the duloxetine 60 mg QD and
duloxetine 60 mg BID treatment groups in efﬁ-
cacy outcomes. However, the study was not ade-
quately powered to detect a difference between
duloxetine 60 mg QD and duloxetine 60 mg BID
treatment groups. Patients treated with duloxetine
60 mg BID took signiﬁcantly less concomitant
acetaminophen during the study than placebo-
treated patients, and this ﬁnding provided some
evidence of additional efﬁcacy of duloxetine 60 mg
BID.
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Both doses of duloxetine were well tolerated by
most patients and safely administered. Signiﬁ-
cantly more duloxetine 60 mg BID-treated
patients than placebo-treated patients reported
TEAEs, but these events were generally mild to
moderate in severity. Although 17 patients had
sustained elevation in blood pressure, several fac-
tors may explain this rate. The majority of patients
(73.6%) were known to have hypertension as a
secondary condition, and 7.2% of patients were
known to have diabetic nephropathy, which
predisposed them to elevated blood pressure.
Although observed, sustained elevations in blood
pressure were not likely to result from duloxetine
use, as four placebo- versus one duloxetine 60 mg
QD- and two duloxetine 60 mg BID-treated
patients experienced sustained elevation in blood
pressure. Duloxetine treatment did not result in
QTc prolongation. The lack of signiﬁcant cardio-
vascular changes due to duloxetine therapy in
these patients and other studies [29,30,32,33] sug-
gests that patients with diabetes mellitus do not
require more intensive assessment of their cardio-
vascular status when treated with duloxetine than
they require for their underlying diabetes. There
were no treatment-group differences in any of
the electrophysiology measures of nerve function,
indicating that the reduction in pain was not
related to deterioration of nerve function. Clinical
laboratory assessments, vital signs, and physical
ﬁndings were stable relative to baseline and no
clinically relevant differences were detected
between treatment groups.
Signiﬁcantly more patients in the duloxetine
60 mg BID group than the placebo group discon-
tinued treatment due to adverse events. Most
patients who discontinued due to adverse events
did so within the ﬁrst 4 weeks of the study. This
could be due to the titration of duloxetine in which
patients were started on 60 mg QD and under-
went titration to 60 mg BID over just 3 days, sug-
gesting that some patients would have better
tolerability with a lower duloxetine starting dose
and slower titration.
Several limitations of this study should be con-
sidered. The results are based on an acute treat-
ment trial of 12 weeks, and may not generalize to
a longer duration of treatment, and DPNP, a
chronic condition, likely requires management for
more than 12 weeks. Further evaluation of the
long-term efﬁcacy of duloxetine on DPNP would
be required to assess the effects on progression of
neuropathy. Since patients were selected from
among those with very limited or stable medical
conditions, and stable doses of concomitant med-
ications, the generalizability of the results to typ-
ical outpatients is limited.
In summary, this randomized, placebo-
controlled study provides substantial evidence and
conﬁrms previously reported ﬁndings that treat-
ment with duloxetine 60 mg QD and 60 BID for
up to 12 weeks is safe and effective in the manage-
ment of DPNP.
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A randomized controlled trial of
duloxetine in diabetic peripheral
neuropathic pain
J.F. Wernicke, PhD, MD; Y.L. Pritchett, PhD; D.N. D’Souza, PhD, MBA; A. Waninger, BS; P. Tran, MD;
S. Iyengar, PhD; and J. Raskin, MD, FRCPC
Abstract—Background: Serotonin (5-HT) and norepinephrine (NE) are involved in pain modulation via descending
inhibitory pathways in the brain and spinal cord. Objective: To assess the efficacy of duloxetine, a dual reuptake inhibitor
of 5-HT and NE, on the reduction of pain severity, as well as secondary outcome measures in patients with diabetic
peripheral neuropathic pain (DPNP). Methods: In this double-blind study, patients with DPNP and without comorbid
depression were randomly assigned to treatment with duloxetine 60 mg once daily (QD), duloxetine 60 mg twice daily
(BID), or placebo for 12 weeks. The primary outcome measure was the weekly mean score of 24-hour average pain severity
on the 11-point Likert scale. Secondary measures and health outcome measures were also assessed. Results: Duloxetine 60
mg QD and 60 mg BID demonstrated improvement in the management of DPNP and showed rapid onset of action, with
separation from placebo beginning at week 1 on the 24-hour average pain severity score. For all secondary measures for
pain (except allodynia), mean changes showed an advantage of duloxetine over placebo, with no significant difference
between 60 mg QD and 60 mg BID. Clinical Global Impression of Severity and Patient’s Global Impression of Improve-
ment evaluation demonstrated greater improvement on duloxetine- vs placebo-treated patients. Duloxetine showed no
notable interference on diabetic controls, and both doses were safely administered. Conclusions: This study confirms
previous findings that duloxetine at 60 mg QD and 60 mg BID is effective and safe in the management of diabetic
peripheral neuropathic pain.
NEUROLOGY 2006;67:1411–1420
Diabetes mellitus is a condition that is often associ-
ated with painful neuropathy. Diabetes affects ap-
proximately 17 million people in the United States,
and it has been predicted that 220 million people
worldwide will be afflicted by 2010.1 The lifetime
incidence of distal neuropathy was estimated to be
37% to 45% for patients with type 2 diabetes and
54% to 59% for patients with type 1 diabetes.2 Pa-
tients often report superficial pain presenting as al-
lodynia, sharp, stabbing, or burning pain in the feet,
numbness, and tingling.3 Various agents have been
evaluated in randomized controlled clinical trials
and are currently used to treat diabetic peripheral
neuropathic pain (DPNP). These include tricyclic an-
tidepressants (TCAs) such as amitriptyline,4 imipra-
mine,5 and desipramine,6 believed to potentiate CNS
activity of serotonin (5-HT) and norepinephrine (NE)
projections in nociceptive modulatory circuits,7 and
certain anticonvulsants such as gabapentin.8 How-
ever, these drugs are often limited by their anticho-
linergic, -adrenergic-blocking, and CNS side effects.
Both noradrenergic and serotonergic neurons are
involved in modulating nociceptive transmission in
the brain and spinal cord,9,10 thereby indicating that
they modulate the endogenous pain inhibitory path-
ways. An imbalance in these inhibitory mechanisms
may contribute to the central sensitization and hy-
perexcitability of the spinal and supraspinal pain
transmitting pathways. This imbalance may mani-
fest as persistent pain11 similar to that experienced
by patients with DPNP.
Duloxetine hydrochloride, hereafter referred to as
duloxetine, is a selective 5-HT and NE reuptake in-
hibitor that is relatively balanced in its affinity for
both 5-HT and NE reuptake inhibition12 and is the
first Food and Drug Administration–approved pre-
scription drug for the management of DPNP. In clin-
ical trials, duloxetine has been shown to be safe and
effective in the treatment of depression13-15 and can
significantly reduce painful physical symptoms asso-
ciated with major depressive disorder (MDD).16
Based on preclinical17 and clinical16 studies of du-
loxetine, this compound was tested in an earlier
study to explore its effects in humans with DPNP.18
Patients with DPNP and without comorbid depres-
sion were randomly assigned to treatment with du-
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loxetine 20 mg once daily (QD), 60 mg QD, or 60 mg
twice daily (BID) or placebo for 12 weeks.18 Based on
evidence that duloxetine was safe and effective in
the management of DPNP,18 two independent confir-
matory studies, the first of which is reported here,
were conducted to assess the safety and efficacy of
duloxetine in patients with DPNP. In the present
study, patients with DPNP and without comorbid
depression were randomly assigned to treatment
with duloxetine 60 mg QD, duloxetine 60 mg BID, or
placebo for 12 weeks.
Methods. Overview. Enrollment for this study, which was con-
ducted in 28 study centers, began in October 2002 and ended in
August 2003. This was a Phase III, multicenter, parallel, double-
blind, randomized, placebo-controlled trial. The ethical review
board (ERB) provided approval of the study protocol in accordance
with the principles of the Declaration of Helsinki. The ERB was
composed of medical professionals and nonmedical members
whose responsibility was to verify that the safety, welfare, and
human rights of the patients participating in the clinical trial
were protected. Investigators were responsible for monitoring the
safety of patients who entered the study, and various safety mea-
sures were evaluated during the study. This study had no planned
interim analysis. All patients provided written informed consent
after the study was explained and before the performance of any
protocol procedures and administration of the study drug.
Entry criteria. Female and male patients were eligible for the
study if they were aged 18 years or older and presented with
DPNP caused by type 1 or type 2 diabetes mellitus. The pain had
to begin in the feet and with relatively symmetric onset. The daily
pain must have been present for at least 6 months, and the diag-
nosis was to be confirmed by a score of at least 3 on the Michigan
Neuropathy Screening Instrument (MNSI). Patients had to have a
mean score of 4 (between Visit 2 and Visit 3 before randomiza-
tion), when assessed by 24-hour average pain severity on the
11-point Likert scale from the patient diary, a stable glycemic
control assessed by a physician investigator, and a glycosylated
hemoglobin (HbA1c) 12% (high HbA1c [9.0% to 9.5%] is associ-
ated with rapid progression of microvascular complications). Only
patients who were judged to be reliable and had an educational
level and degree of understanding that allowed them to communi-
cate intelligibly were included in the study. Patients were ex-
cluded if they were pregnant or breastfeeding, had previous renal
transplant or current renal dialysis, or had a serious or unstable
cardiovascular, hepatic, renal, respiratory, or hematologic illness,
symptomatic peripheral vascular disease, or other medical condi-
tions or psychological conditions that might compromise participa-
tion in the study. Patients were also excluded if they had a
current (1 year) Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV), Axis I diagnosis of MDD,
dysthymia, generalized anxiety disorder, alcohol, or eating disor-
ders as determined by the Mini International Neuropsychiatric
Interview (MINI),19 or if they had a previous diagnosis or a
DSM-IV diagnosis of mania, bipolar disorder, or psychosis deter-
mined either by patient history or by diagnosis using specific
MINI modules. Other exclusion criteria were historical exposure
to drugs known to cause neuropathy, history of substance abuse or
dependence within the previous year (excluding nicotine and caf-
feine), a positive urine drug screen for any substances of abuse or
excluded medication, or a history of a medical condition, including
pernicious anemia and hypothyroidism, or treatment with a mono-
amine oxidase inhibitor (MAOI) or fluoxetine within 30 days of
randomization. Patients were excluded if they had severe allergic
reactions to multiple medications and prior participation in a
study of duloxetine.
Concomitant medication exclusions included chronic use of an-
tidepressants, antiemetics, and analgesics with the exception of
acetaminophen up to 4 g/day and aspirin up to 325 mg/day. Anti-
manics, antimigraines, antipsychotics, benzodiazepines, capsaicin,
chloral hydrate, guanethidine, topical lidocaine, MAOIs, narcotics,
psychostimulants, oral and injectable steroids, and anticonvul-
sants were excluded. Concomitant medication inclusions (chronic
and episodic) were antacids, antiasthma agents, aminophylline,
birth control medication, cough/cold preparations (that did not
contain dextromethorphan), diuretics, inhaled and topical ste-
roids, hypoglycemics, insulin, laxatives, theophylline, anticoagu-
lants, antibiotics, antidiarrheals, and antihistamines. Medications
including angiotensin-converting enzyme inhibitors, angiotensin
II receptor agonists, antiarrhythmics, anticoagulants, calcium
channel blockers, and others were allowed provided the patient
had been on a stable dose for 3 months before enrollment.
Patients were excluded if they had frequent or severe allergic
reactions with multiple medications, had an alanine aminotrans-
ferase laboratory value  1.5 times the upper limit of normal
(ULN), and a serum creatinine laboratory value  1.5 times ULN.
Study design. Visit 1 and Visit 2 occurred before randomiza-
tion where entry criteria were evaluated for the patients. Those
who continued to meet all inclusion criteria and no exclusion
criteria proceeded to randomization at Visit 3. Randomization was
performed at the site level in that randomization codes were as-
signed to sites in blocks, but there was no further stratification.
After a 3-week assessment and screening period, patients with
DPNP and without comorbid depression were randomly assigned
to treatment with duloxetine 60 mg QD, duloxetine 60 mg BID, or
placebo in a 1:1:1 ratio. Assignment to a treatment group was
determined by a computer-generated random sequence using an
interactive voice response system (IVRS). The IVRS was used to
assign blister cards containing study drug to each patient. Site
personnel confirmed that they had located the correct blister card
by entering a confirmation number found on the card into the
IVRS. Throughout the course of the study, enrollment and patient
progress was tracked using the IVRS. Patients were instructed to
begin treatment the morning after randomization. The placebo-
controlled, double-blind treatment phase lasted for 13 weeks. The
first 12 weeks of the study period was considered the acute ther-
apy phase, and the last week was used for drug tapering. The
duloxetine 60 mg QD treatment group was started at 60 mg QD,
and at the last week of the study period, the patients’ dose was
decreased to 30 mg QD. Patients who were randomized to dulox-
etine 60 mg BID were started initially at 60 mg QD for 3 days,
and dosage was increased to 60 mg BID. At the last week of the
study period, the patients’ dose was decreased to 60 mg QD. Pa-
tients, investigators, and all other personnel involved with the
conduct of the study were blinded to individual treatment assign-
ments for the duration of the study.
Efficacy measures. The primary efficacy measure for this
study was the reduction in weekly mean of the 24-hour average
pain scores (computed from diary scores between two site visits),
as measured by an 11-point (0  no pain, 10  worst possible
pain) Likert scale that was completed daily by the patients in a
diary. A reduction of approximately 2 points or approximately
30% in the 11-point pain intensity numerical rating scale repre-
sents a clinically important difference.20 Protocol-specified re-
sponse at endpoint was defined as a 30% reduction from baseline
to endpoint in the 24-hour average pain score. Sustained response
was defined as a 30% reduction from baseline to endpoint in the
24-hour average pain severity with a 30% reduction from baseline
at a week at least 2 weeks before the last, and with at least a 20%
reduction from baseline at every week in between. The amount of
acetaminophen that was used to relieve pain over the past 24
hours was also recorded in the patients’ diary. The secondary
efficacy measures collected were pain severity for worst pain (re-
ferred to as 24-hour worst pain score hereafter) and night pain
(recorded daily by patients in a diary) as measured by the 11-point
Likert scale, the Patient’s Global Impression of Improvement
(PGI-Improvement) scale21 recorded at weeks 4, 8, and 12, the
Brief Pain Inventory (BPI) (severity),22 and the Clinical Global
Impression of Severity (CGI-Severity)21 scales recorded at random-
ization, weeks 4, 8, and 12, and the Sensory Portion of the Short
Form McGill Pain Questionnaire (SF-MPQ),23 the 17-item Hamil-
ton Depression Rating Scale (HAMD17)24,25 and dynamic allodynia
that was recorded at randomization and week 12.
Health outcomes measures. The impact of duloxetine com-
pared with placebo on patient-reported health outcomes was mea-
sured by the interference portion of the BPI, Short Form 36
(SF-36),26 and European Quality of Life Instrument 5D version
(EQ-5D).27 The SF-36 was completed by the patient and measured
how the patient perceived general status. The SF-36 consisted of
36 items that calculated eight health domains: bodily pain, gen-
eral health, mental health, physical functioning, role–physical,
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role–emotional, social function, and vitality. The EQ-5D was com-
pleted by the patient to measure how severe the patient perceived
general health. The interference portion of the BPI was completed
by the patient to measure how much pain had interfered with
several patient outcomes, such as general activity, mood, walking
ability, sleep, and relationships with other people.
Pharmacokinetic evaluation. Blood samples were collected for
pharmacokinetic evaluation of plasma duloxetine concentrations
at steady state.
Safety assessments. Safety measures evaluated during the
study were discontinuations, treatment-emergent adverse events
(TEAEs), vital signs (sitting blood pressure and heart rate),
weight, electrocardiograms, and laboratory analyses. Electrophys-
iology assessment was performed using nerve conduction studies
to determine whether duloxetine degraded motor and large sen-
sory nerve (ulnar motor and sensory nerves, and peroneal motor
nerve) function. The frequency of significant hypoglycemic events
was elicited by a questionnaire derived from the results of the
Diabetes Control and Complications Trial. A patient considered to
have sustained elevation in blood pressure after randomization
met the following criteria: sitting diastolic blood pressure  85
mm Hg and increase from baseline of 10 mm Hg for three consec-
utive visits, or sitting systolic blood pressure  130 mm Hg and
increase from baseline of 10 mm Hg for three consecutive visits.
Statistical analysis. This study was designed to enroll 330
patients in 1:1:1 ratio to the three treatment groups (placebo,
duloxetine 60 mg QD, and duloxetine 60 mg BID). With 110 pa-
tients per arm, this study would have at least 90% power to detect
a treatment group difference of 1.20 points in the baseline-to-
endpoint mean change on the weekly mean of 24-hour average
pain score between duloxetine 60 mg BID and placebo treatment
groups. The sample size was determined using a two-sided test
with   0.05 and assuming a common SD of 2.2 and a discontin-
uation rate of 35%.
An intent-to-treat principle was used in the analyses of all
efficacy variables, i.e., patients were analyzed based on their ran-
domized treatment assignment, even if the patient did not take
the assigned treatment, did not receive the correct treatment, or
did not follow or complete the protocol. For each efficacy variable,
the analysis included all randomized patients with a baseline and
at least one nonmissing postbaseline observation.
Baseline was defined as the last nonmissing observation at or
before randomization, and endpoint was defined as the last non-
missing observation in the acute therapy phase. For the efficacy
measures, the treatment group differences in change from base-
line to endpoint were evaluated using the analysis of covariance
(ANCOVA) model (with the terms of treatment, investigator, and
the baseline). As specified in the protocol, the primary treatment
contrast was to compare duloxetine 60 mg BID with placebo using
the Type III sum of squares for the least-square means, and thus,
no adjustments for multiple pairwise comparisons were made. The
treatment-by-investigator interaction was evaluated using the
above model with the addition of the interaction term using
the Type II sum of squares. Significant interaction was evaluated
at the significance level of 0.10. The longitudinal observations on
the efficacy variables were also analyzed using a repeated-
measures analysis. The statistical inferences from the two differ-
ent analytical methodologies demonstrated a high degree of
consistency for all of the efficacy variables. Therefore, results from
the ANCOVA were presented for the majority of the variables
except for the primary efficacy measure, for which the results
from both methodologies were presented. The weekly mean scores
for the three pain scores (24-hour average pain, night pain, and
24-hour worst pain) were computed from patients’ daily diaries. If
the nonmissing diary count was 3, the mean score was set as
missing.
Proportions were analyzed using the Fisher exact test. The
average daily dose of acetaminophen used for DPNP relief was
calculated from dosage collected from the patient’s diary during
the acute therapy and was analyzed using an analysis of variance
(ANOVA) model on the rank-transformed data, because the distri-
bution was skewed. The same approach was applied to the evalu-
ation of weekly average number of significant hypoglycemic
episodes.
Changes in vital signs, EKGs, and electrophysiology variables
were evaluated using an ANOVA model with the terms of treat-
ment, investigator, and treatment-by-investigator interaction,
whereas laboratory analytes were evaluated in the rank-
transformed format, because the distribution of raw data for most
of the analytes was skewed.
Throughout the manuscript, the term significant indicates sta-
tistical significance, and when presenting efficacy results, the
mean change refers to least-squares mean change.
Results. Patient disposition, demographics, and disease
characteristics. The flow of patient progress through the
trial is shown in figure 1. A total of 561 patients were
screened to identify 334 patients who were randomized to
study treatment. One-hundred eight patients received pla-
cebo, 114 patients received duloxetine 60 mg QD, and 112
patients received duloxetine 60 mg BID. Patient demo-
graphics and clinical characteristics at baseline are shown
in table 1. The majority of patients were male (61.1%) and
Figure 1. Flow diagram of patient
progress through the trial. QD  once
daily; BID  twice daily.
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white (78.1%). The mean patient age was 60.7 years. The
mean duration of diabetes in all patients was 10.2 years,
with type II diabetes being the most prevalent (91%). The
mean MNSI score was 5.6 out of a possible maximum score
of 10, with a higher score indicating a greater degree of
neuropathy.
Eighty-six patients withdrew from the study during the
acute therapy phase: 29 (25%) from the duloxetine 60 mg
QD-treated group, 34 (30%) from the duloxetine 60 mg
BID-treated group, and 23 (21%) from the placebo-treated
group (figure 1).
At baseline, a significant difference among treatment
groups was observed for the BPI average interference
score. The mean BPI average interference score was high-
est in the duloxetine 60 mg BID treatment group (5.0),
followed by the duloxetine 60 mg QD treatment group (4.7)
and the placebo treatment group (4.2).
Efficacy. The mean change from baseline to week 12 on
the 24-hour average pain score is presented in table 2, and
the mean change from baseline to each postbaseline visit is
shown in figure 2. Both duloxetine 60 mg QD and 60 mg BID
were significant compared with placebo, thereby demonstrat-
ing a highly significant treatment effect of duloxetine on the
management of DPNP as measured by the primary efficacy
variable. A treatment-by-investigator interaction was ob-
served (p  0.007) on the 24-hour average pain score. The
interaction was mainly caused by Investigator 004. The re-
sults from Investigator 004 showed that mean changes of
24-hour average pain scores for duloxetine 60 mg BID and
placebo were opposite to the direction postulated: dulox-
etine 60 mg BID–treated patients got worse compared with
baseline, whereas placebo-treated patients improved com-
pared with baseline. The effect seen by Investigator 004 is
qualitatively different from all other investigators. When
Investigator 004 was excluded from the analysis, the
treatment-by-investigator interaction was no longer signif-
icant, and both duloxetine 60 mg BID and duloxetine 60
mg QD remained significant compared with placebo (p 
Table 1 Demographics and clinical characteristics at baseline
Duloxetine
Variable
Placebo
(n  108)
60 mg QD
(n  114)
60 mg BID
(n  112)
Total
(n  334)
Mean age (SD), years 60.8 (10.6) 59.7 (11.2) 61.5 (9.9) 60.7 (10.6)
Sex, n (%)
Female 39 (36.1) 40 (35.1) 51 (45.5) 130 (38.9)
Male 69 (63.9) 74 (64.9) 61 (54.5) 204 (61.1)
Race (origin), n (%)
White 86 (79.6) 90 (78.9) 85 (75.9) 261 (78.1)
African descent 5 (4.6) 3 (2.6) 3 (2.7) 11 (3.3)
Hispanic 17 (15.7) 16 (14.0) 21 (18.8) 54 (16.2)
Other 0 (0.0) 5 (4.4) 3 (2.7) 8 (2.4)
Weight (SD), kg 104.4 (24.8) 99.9 (22.0) 98.7 (24.9) 101 (24.0)
Type of diabetes mellitus, n (%)
Type I 11 (10.2) 10 (8.8) 9 (8.0) 30 (9.0)
Type II 97 (89.8) 104 (91.2) 103 (92.0) 304 (91.0)
Duration of diabetes (SD), years 11.1 (9.1) 9.7 (9.6) 9.9 (10.0) 10.2 (9.6)
Duration of diabetic neuropathy (SD), years 3.5 (3.2) 3.6 (3.5) 4.4 (5.9) 3.8 (4.4)
Michigan Neuropathy Screening Score, mean (SD) 5.9 (1.5) 5.5 (1.5) 5.6 (1.5) 5.6 (1.5)
Pain severity at baseline, mean (SD)
24-Hour average pain severity 5.9 (1.4) 6.1 (1.6) 6.2 (1.5) 6.1 (1.5)
24-Hour worst pain severity 7.0 (1.5) 7.3 (1.7) 7.2 (1.6) 7.2 (1.6)
Night pain severity 6.2 (2.3) 6.3 (2.1) 6.2 (2.3) 6.3 (2.2)
BPI average interference score* 4.2 (2.2) 4.7 (2.5) 5.0 (2.4) 4.7 (2.4)
Total of SF-McGill 16.2 (7.5) 15.9 (7.7) 16.8 (6.7) 16.3 (7.3)
Dynamic allodynia 0.2 (0.5) 0.3 (0.6) 0.3 (0.7) 0.3 (0.6)
Mood and general illness, mean (SD)
HAMD17 total score 3.4 (2.7) 3.3 (3.4) 3.6 (3.0) 3.4 (3.1)
CGI-Severity 4.6 (0.8) 4.5 (0.9) 4.6 (0.8) 4.6 (0.8)
* p  0.05.
QD  once daily; BID  twice daily; n  number of randomized patients; BPI  Brief Pain Inventory; SF  Short Form; HAMD17 
17-item Hamilton Rating Scale for Depression; CGI-Severity  Clinical Global Impression of Severity.
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0.001). Therefore, with or without Investigator 004, the
results demonstrated a highly significant treatment effect
of duloxetine in the management of DPNP as seen on the
primary efficacy variable. Duloxetine 60 mg QD and 60 mg
BID treatment groups showed a significant decrease in
pain severity compared with placebo beginning at week 1
and continuing throughout the study, with no significant
difference between the duloxetine 60 mg QD and 60 mg
BID treatment groups. The mean difference from placebo
at endpoint was 1.32 (95% CI 1.95 to 0.69) for the
duloxetine 60 mg QD treatment group and 1.44 (95% CI
2.08 to 0.81) for the duloxetine 60 mg BID treatment
group.
In the mean change analyses, duloxetine 60 mg QD and
60 mg BID were significant compared with placebo on all
secondary measures (table 2) except for HAMD17 total
score and dynamic allodynia. Analyses of the 24-hour
worst pain severity revealed that both duloxetine 60 mg
QD and 60 mg BID were significant compared with pla-
cebo. Mean change analysis in night pain score showed
that both duloxetine 60 mg QD and 60 mg BID were signif-
icant compared with placebo, beginning 1 week after ran-
domization and continuing through the study. Both
duloxetine 60 mg QD and 60 mg BID were significant
compared with placebo on all BPI-Severity, CGI-Severity,
and PGI-Improvement scale scores, as well as in improving
the total score of the SF-MPQ.
A treatment-by-investigator interaction (p  0.10) was
observed for 24-hour worst pain severity, night pain sever-
ity, BPI individual severity score, and SF-MPQ total score.
This interaction was no longer significant when Investiga-
tor 004 was excluded from the analyses, while the signifi-
cance of the differences between duloxetine treatment
group and placebo remained the same.
For the HAMD17 total score, placebo was significant com-
pared with duloxetine 60 mg BID. This finding, however, was
likely due to noise of the data and was not clinically relevant
because at baseline, due to exclusion criteria, patients dem-
onstrated extremely low mean baseline HAMD17 total scores
(range of 3.31 to 3.55), as patients with depression were ex-
cluded from this study. Significant differences were observed
Table 2 Mean change (SE) from baseline to endpoint: Efficacy measures
Duloxetine
Placebo 60 mg QD 60 mg BID
n Mean (SE) n Mean (SE) n Mean (SE)
Weekly mean of
24-Hour average pain score 106 1.39 (0.23) 110 2.72 (0.22)‡ 111 2.84 (0.23)‡
24-Hour worst pain score 106 1.94 (0.25) 110 3.21 (0.25)‡ 111 3.39 (0.26)‡
Night pain score 106 1.83 (0.24) 109 2.95 (0.25)† 111 3.08 (0.25)‡
BPI pain severity
Average pain 104 1.48 (0.23) 112 2.66 (0.23)‡ 107 3.05 (0.24)‡
Worst pain 104 1.98 (0.28) 112 3.33 (0.27)‡ 107 3.50 (0.28)‡
Least pain 104 0.86 (0.22) 112 1.88 (0.22)† 108 2.30 (0.22)‡
Pain right now 104 1.38 (0.23) 112 2.48 (0.22)‡ 108 2.67 (0.23)‡
CGI-Severity 102 0.98 (0.12) 111 1.37 (0.11)* 106 1.47 (0.12)†
PGI-Improvement (at endpoint)§ 105 3.17 (1.44) 112 2.61 (1.44)† 107 2.40 (1.29)‡
SF-MPQ 91 4.18 (0.73) 97 7.23 (0.70)† 100 7.98 (0.71)‡
HAMD17 95 0.64 (0.26) 97 0.65 (0.26) 101 0.19 (0.26)*
Dynamic allodynia 98 0.07 (0.04) 106 0.11 (0.04) 102 0.17 (0.04)
* p  0.05 vs placebo.
† p  0.01 vs placebo.
‡ p  0.001 vs placebo.
§ For Patient’s Global Impression of Improvement (PGI-Improvement), endpoint was analyzed and the mean (SD) is provided.
QD  once daily; BID  twice daily; n  number of patients who had a baseline score and at least one nonmissing postbaseline score
for that particular variable; BPI  Brief Pain Inventory; CGI-Severity  Clinical Global Impression of Severity; SF-MPQ  Short Form
McGill Pain Questionnaire; HAMD17  17-item Hamilton Rating Scale for Depression.
Figure 2. Weekly mean change in 24-hour average pain
severity score. *** p  0.001 vs placebo. QD  once daily;
BID  twice daily.
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for both duloxetine 60 mg QD and 60 mg BID in the 24-hour
average pain response rate at endpoint. A 30% reduction in
the 24-hour average pain response, as specified by the proto-
col as the criterion for response, was achieved by 42% of
patients in the placebo-treated group, 63% in the duloxetine
60 mg QD–treated group (p  0.003 vs placebo), and 69% in
the duloxetine 60 mg BID–treated group (p  0.001 vs pla-
cebo). A 50% reduction in the 24-hour average pain response
was achieved by 27% of patients in the placebo-treated
group, 43% in the duloxetine 60 mg QD–treated group (p
 0.05 vs placebo), and 53% in the duloxetine 60 mg
BID–treated group (p  0.001 vs placebo). Duloxetine 60
mg QD (p  0.004) and 60 mg BID (p  0.001) demon-
strated significance compared with placebo at achieving
sustained response. Sustained response was achieved by
54% of duloxetine 60 mg QD– and 62% of duloxetine 60
mg BID–treated patients compared with 34% of placebo-
treated patients.
Concomitant acetaminophen use during the acute ther-
apy phase. The median average daily dose for concomi-
tant acetaminophen used for DPNP collected from the
patient diary during the acute therapy phase indicated
that patients treated with duloxetine 60 mg BID used a
significantly lower median daily dose of concomitant acet-
aminophen compared with patients treated with dulox-
etine 60 mg QD or placebo-treated patients (figure 3).
Figure 3. Supplemental analgesic use for pain: median
average daily dose of concomitant acetaminophen use.
*** p  0.001 vs placebo,  p  0.05 vs duloxetine 60 mg
QD, p value based on analysis of covariance for rank-
transformed data. QD  once daily; BID  twice daily.
Table 3 Mean change (SE) from baseline to endpoint: Health outcome measures
Duloxetine
Placebo 60 mg QD 60 mg BID
n Mean (SE) n Mean (SE) n Mean (SE)
SF-36
Physical functioning 101 3.64 (1.90) 109 11.96 (1.81)† 108 11.20 (1.86)†
Social functioning 101 3.68 (2.14) 109 7.50 (2.06) 108 7.61 (2.09)
Role–physical 101 12.14 (3.77) 109 22.85 (3.63)* 108 25.01 (3.67)*
Role–emotional 100 2.13 (3.44) 108 10.66 (3.32) 108 9.00 (3.35)
Bodily pain 101 12.17 (2.10) 109 15.30 (1.98) 107 20.59 (2.04)†
General health 101 2.39 (1.42) 108 5.64 (1.38) 107 7.73 (1.39)†
Vitality 101 2.79 (1.78) 108 8.47 (1.73)* 108 6.36 (1.74)
Mental health 101 0.31 (1.52) 108 1.63 (1.48) 108 3.82 (1.49)*
Physical component score 100 3.67 (0.78) 107 6.85 (0.76)† 106 7.46 (0.77)‡
Mental component score 100 0.29 (0.83) 107 0.77 (0.81) 106 1.09 (0.82)
Euro Quality of Life (EQ-5D) 99 0.08 (0.02) 108 0.15 (0.02)* 105 0.15 (0.02)*
BPI Interference
General activity 104 1.79 (0.23) 111 2.40 (0.23) 107 2.57 (0.23)*
Mood 104 1.37 (0.21) 111 1.95 (0.21)* 107 2.48 (0.21)‡
Walking ability 104 1.74 (0.25) 111 2.50 (0.24)* 107 2.96 (0.25)‡
Normal work 104 2.03 (0.24) 111 2.49 (0.23) 107 2.93 (0.24)†
Relationship with other people 104 0.88 (0.19) 111 1.44 (0.18)* 107 1.81 (0.19)‡
Sleep 104 2.34 (0.26) 111 3.02 (0.26) 107 3.17 (0.26)*
Enjoyment of life 104 2.24 (0.23) 111 2.58 (0.23) 107 3.42 (0.23)‡
Average of interference scores 104 1.72 (0.19) 111 2.36 (0.19)* 107 2.79 (0.19)‡
* p  0.05 vs placebo.
† p  0.01 vs placebo.
‡ p  0.001 vs placebo (pairwise comparison of least square means).
QD  once daily; BID  twice daily; n  number of patients who had a baseline score and at least one nonmissing postbaseline score
for that particular variable; SF-36  Short Form 36; EQ-5D  European Quality of Life Instrument 5D version; BPI  Brief Pain
Inventory.
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Health outcomes analyses. In the SF-36 health survey,
duloxetine 60 mg QD was significantly better than placebo
in the physical component summary and the domains of
physical functioning, role limitations due to physical prob-
lems, and vitality (table 3). Duloxetine 60 mg BID was
significantly better than placebo in the physical component
summary and domains of bodily pain, general health per-
ceptions, mental health, physical functioning, and role lim-
itations due to physical problems. In the analysis of the
EQ-5D, duloxetine 60 mg QD and 60 mg BID were both
significantly better than placebo. Duloxetine 60 mg BID
was significant compared with placebo at reducing scores
in all BPI interference scales.
A significant treatment-by-investigator interaction was
observed for physical functioning and bodily pain on the
SF-36 and the EQ-5D index score. The interaction was no
longer significant when Investigator 004 was excluded,
and the results of statistical comparison remained the
same.
Pharmacokinetic evaluation. Plasma duloxetine con-
centrations in patients taking duloxetine 60 mg BID were
96.6 (SD  83.3) ng/mL, and those in patients taking du-
loxetine 60 mg QD were 41.3 (SD  37.4) ng/mL.
Safety. Adverse events. Of the 334 randomly as-
signed patients, 79 placebo-treated patients (73.1%), 102
duloxetine 60 mg QD–treated patients (89.5%) (p  0.002
vs placebo), and 96 duloxetine 60 mg BID–treated patients
(85.7%) (p  0.029 vs placebo) reported at least one TEAE.
Table 4 shows the top 10 TEAEs by decreasing frequency.
Patients in both duloxetine-treated groups reported
treatment-emergent nausea, fatigue, somnolence, increased
sweating, and dry mouth significantly more frequently than
placebo-treated patients. Additionally, compared with
placebo-treated patients, dizziness and diarrhea were re-
ported significantly more frequently by duloxetine 60 mg
QD–treated patients, and constipation, insomnia, decreased
appetite, asthenia, erectile dysfunction, and tremor were re-
ported significantly more frequently by duloxetine 60 mg
BID–treated patients. Forty-five patients (13.5%) dis-
continued during the therapy phase because of adverse
events (duloxetine 60 mg QD, 17 [14.9%]; duloxetine 60
mg BID, 20 [17.9%]; placebo, 8 [7.4%]), with differences
between duloxetine 60 mg BID– and placebo-treated
groups (p  0.025). Nausea (5.3%) and dizziness (2.6%)
were reported as reasons for discontinuation in 1% of
duloxetine 60 mg QD–treated patients. Nausea (5.4%),
fatigue (2.7%), and somnolence (2.7%) were reported as
reasons for discontinuation in 1% of duloxetine 60 mg
BID–treated patients.
A serious adverse event was defined as any adverse
event from the study resulting in one of the following out-
comes (or was significant for any other reason): death,
initial or prolonged inpatient hospitalization, a life-
threatening experience, persistent or significant disability/
incapacity, or congenital anomaly/birth defect. No deaths
were reported during the study. Twelve patients (3.6%)
experienced serious adverse events with no significant
treatment group differences. These included 5 duloxetine
60 mg QD–treated patients (4.4%) (events: congestive car-
diac failure, coronary artery stenosis, hip fracture, pros-
tate cancer, hypokalemia, hyponatremia), 2 duloxetine 60
mg BID–treated patients (1.8%) (events: blood calcium in-
creased, concussion), and 5 placebo-treated patients (4.6%)
(events: atrioventricular block second degree, carcinoma,
chronic obstructive airways disease exacerbated, diabetic
ulcer, fatigue, hypertension).
Twenty-eight (8.4%) of the 334 patients reported at
least one adverse event that emerged during the 1-week
drug taper phase (7 duloxetine 60 mg QD–treated patients
[6.1%], 10 duloxetine 60 mg BID–treated patients [8.9%],
and 11 placebo-treated patients [10.2%]; no events oc-
curred in 1% of patients in either duloxetine treatment
group, and in the placebo-treated group, the events re-
ported by 1% of patients were headache [2.8%] and ar-
thralgia [1.9%]). There were no significant treatment
group differences in the overall incidence of taper-
emergent adverse events or in any single taper-emergent
adverse event.
Table 4 Top 10 treatment-emergent adverse events of all randomized patients, by decreasing frequency
Duloxetine
Placebo
(n  108), n (%)
60 mg QD
(n  114), n (%)
60 mg BID
(n  112), n (%)
Total
(n  334), n (%)
Nausea 7 (6.5) 32 (28.1)‡ 36 (32.1)‡ 75 (22.5)
Dizziness 6 (5.6) 18 (15.8)* 12 (10.7) 36 (10.8)
Headache 7 (6.5) 12 (10.5) 15 (13.4) 34 (10.2)
Constipation 2 (1.9) 8 (7.0) 21 (18.8)‡ 31 (9.3)
Fatigue 3 (2.8) 14 (12.3)* 14 (12.5)* 31 (9.3)
Somnolence 1 (0.9) 9 (7.9)* 17 (15.2)‡ 27 (8.1)
Diarrhea 2 (1.9) 13 (11.4)† 5 (4.5) 20 (6.0)
Nasopharyngitis 5 (4.6) 8 (7.0) 7 (6.3) 20 (6.0)
Insomnia 2 (1.9) 6 (5.3) 11 (9.8)* 19 (5.7)
Sweating increased 1 (0.9) 10 (8.8)* 8 (7.1)* 19 (5.7)
* p  0.05 vs placebo.
† p  0.01 vs placebo.
‡ p  0.001 vs placebo (Fisher exact p values).
QD  once daily; BID  twice daily; n  number of randomized patients.
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Laboratory data, vital signs, and electrocardiographic
data. Although duloxetine-treated patients showed
changes in chemistry laboratory assessments, these
changes were of low magnitude and not considered clini-
cally relevant. Duloxetine 60 mg QD– and 60 mg BID–
treated patients experienced a significant mean increase in
alkaline phosphatase (ALKPH) compared with placebo-
treated patients. Duloxetine 60 mg BID–treated patients
experienced a significant mean decrease in chloride and
uric acid and duloxetine 60 mg QD–treated patients expe-
rienced a significant mean increase in inorganic phospho-
rous compared with placebo-treated patients. Bilirubin
was elevated in association with elevation of aspartate
transaminase/serum glutamic oxaloacetic transaminase in
one duloxetine 60 mg QD–treated patient and with eleva-
tion of creatine phosphokinase (CPK) in one placebo-
treated patient. In this 12-week study, duloxetine did not
seem to adversely affect lipid profiles (table 5) or glycemic
control (table 6).
There were no significant mean changes in ulnar and
peroneal nerve function measures from baseline to end-
point in patients receiving duloxetine 60 mg QD, dulox-
etine 60 mg BID, or placebo. Duloxetine did not prolong
the QT interval. There were no significant treatment
group differences in mean change of systolic and diastolic
blood pressure. Patients treated with duloxetine 60 mg
BID experienced a slight but significant mean increase in
heart rate (2.41 beats per minute [bpm]) compared with
duloxetine 60 mg QD–treated patients (0.35 bpm) and
placebo-treated patients (0.99 bpm), and patients in both
duloxetine-treated groups experienced a slight but signifi-
cant mean decrease in weight (1.37 kg in each group)
compared with placebo-treated patients (0.01 kg). How-
ever, neither of these effects was considered clinically
relevant.
Discussion. Diabetes mellitus is common in the
United States, and it is estimated that the preva-
lence of neuropathy in diabetic patients is 30% in
hospital patients and 20% in community patients.28
Over time, neuropathic pain can become a common
complication. The first line of management of DPNP
has involved administration of TCAs with reuptake
inhibitory activity for both 5-HT and NE and anti-
convulsants.4,6,29,30 However, because this condition
primarily affects the elderly, these patients may be
more susceptible to the -adrenergic blocking, anti-
cholinergic, and cardiac conduction effects associated
with TCAs. Other treatments have involved capsa-
icin cream and isosorbide dinitrate spray.
Although head-to-head comparison studies have
not been conducted, a great deal of evidence suggests
that dual 5-HT and NE reuptake inhibitors provide
better efficacy, whereas randomized trials of selec-
tive serotonin reuptake inhibitors (SSRIs) overall
have shown minimal efficacy of SSRIs in relieving
DPNP.31-33 Treatment with the 5-HT and NE re-
uptake inhibitor venlafaxine at high doses resulted
in lower pain intensity and greater pain relief.34 Var-
ious other studies have shown that venlafaxine may
be useful in treating pain associated with diabetic
neuropathy.35-37 However, at low doses, it is predom-
inantly serotonergic, whereas higher doses add sub-
stantial noradrenergic effects.36 Duloxetine has a
higher affinity for both 5-HT and NE transporters38
and is relatively balanced in its affinity for both
5-HT and NE reuptake inhibition.12 It is effective in
treating pain in animal models.17,39 It is also effective
Table 5 HbA1c and lipid profile: Mean change from baseline to endpoint
Duloxetine
Placebo (n  82–101) 60 mg QD (n  88–105) 60 mg BID (n  95–108)
HbA1c, % 0.0005 0.0018 0.0004
p Value 0.967 0.259
LDL-cholesterol, mmol/L 0.017 0.023 0.113
p Value 0.689 0.177
HDL-DX, mmol/L 0.002 0.033 0.062
p Value 0.183 0.009
Triglycerides, mmol/L 0.265 0.136 0.394
p Value 0.169 0.070
p values vs placebo (least-squares mean option, using mean squares for error).
QD  once daily; BID  twice daily; n  total number of patients in each treatment group having the variable in both baseline and
postbaseline visits; HbA1c  glycosylated hemoglobin; LDL-C  low-density lipoprotein cholesterol; HDL-DX  high-density lipoprotein
cholesterol-dextran precip.
Table 6 Weekly average number of significant hypoglycemic
episodes
Duloxetine
Placebo
(n  106)
60 mg QD
(n  112)
60 mg BID
(n  111)
Mean 0.08 0.06 0.12
SD 0.39 0.19 0.43
Median 0.00 0.00 0.00
p Value vs placebo
(rank-transformed data)
— 0.198 0.109
QD  once daily; BID  twice daily.
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in reducing the severity of painful physical symp-
toms associated with depression in patients with
MDD.16,40 Because noradrenergic and serotonergic
neurons may modulate the endogenous pain inhibi-
tory pathways,9,10 the ability of duloxetine to exert its
effects on both these neurotransmitter systems may
explain its effectiveness in this clinical trial.
This study confirms previous findings that dulox-
etine at 60 mg QD and 60 mg BID was safe and
demonstrated robust evidence of efficacy in the man-
agement of DPNP.18 Both studies were adequately
designed and powered a priori to ensure that a sta-
tistical comparison of efficacy between placebo- and
duloxetine-treated groups could be undertaken. In
both studies, beginning in week 1, duloxetine was
significant compared with placebo in improvement of
a priori–declared primary outcome measure, the 24-
hour average pain score. An earlier study conduct-
ed18 also included a dose of duloxetine 20 mg to
establish a subtherapeutic dose in the management
of DPNP. The 20 mg QD dose of duloxetine did not
show significant separation from placebo on the pri-
mary efficacy measure and many secondary efficacy
measures. Effect size presentation for 24-hour aver-
age pain score, response rate, and sustained re-
sponse rate clearly and consistently demonstrated
that duloxetine 60 mg QD was more efficacious than
duloxetine 20 mg QD. In the study presented here,
significant pain reduction was demonstrated on the
24-hour average pain score, worst pain score, night
pain score, and various health outcome measures.
This demonstrates the clinical relevance of the
changes in pain severity observed.
Although the HAMD17 rating scale showed that
placebo was significant compared with duloxetine 60
mg BID, this difference was not clinically relevant
because patients had low mean baseline HAMD17
scores (3.4) due to exclusion criteria. A HAMD17
score of 7 is often used as an indicator of remission
in the MDD population. These patients were normal
with regard to mood disorder; thus there was mini-
mal room for improvement in mood.
The incidence of serious adverse events was low,
and no deaths occurred during the study. The only
adverse events leading to discontinuation in 1% of
duloxetine-treated patients were nausea, dizziness,
somnolence, and fatigue. Although nausea was the
most frequently reported adverse event, it usually
occurred at the beginning of treatment and de-
creased quickly over time. Patients in the present
study were started on duloxetine 60 mg QD and un-
derwent titration to 60 mg BID over just 3 days.
Results from a previous study in patients with MDD
suggest that initiating duloxetine treatment at 30
mg QD for 1 week, followed by escalation to 60 mg
QD, may reduce the risk of treatment-emergent nau-
sea when compared with starting at 60 mg QD.41
These results suggest that some patients would have
better tolerability with a lower duloxetine starting
dose and slower titration. In this study, no adverse
effects on glycemic control or lipid profiles were de-
tected. Duloxetine did not prolong the QT interval or
cause a significant change in blood pressure com-
pared with placebo. There were no clinically relevant
changes in heart rate or weight that were experi-
enced by patients taking duloxetine 60 mg QD or 60
mg BID in this trial. The lack of significant
treatment-group differences in any of the electro-
physiology measures indicated that duloxetine did
not alter motor and large sensory nerve fiber func-
tion in DPNP patients. The safety findings reported
in this study are in general agreement with the find-
ings in other studies that indicate that duloxetine-
treated patients with depression do not experience
clinically relevant changes in heart rate and blood
pressure.13,15 In summary, duloxetine was generally
well tolerated, although it is not without side effects.
The efficacy of duloxetine 60 mg QD and that of
duloxetine 60 mg BID were similar, and the numeric
advantage of the higher dose on many outcome mea-
sures was not significant. Previous studies have
shown that duloxetine exhibits linear pharmacoki-
netics with regard to dose and duration of treat-
ment,42 and the results of the trial presented here
show that plasma concentrations in patients taking
duloxetine 60 mg BID were slightly more than twice
those in patients taking duloxetine 60 mg QD. Be-
cause duloxetine 60 mg QD represents the lowest
consistently effective total daily dose and considering
the advantage of a once-daily regimen and adminis-
tration of a lower total daily dose, the recommended
dose of duloxetine in the management of DPNP is 60
mg QD. Although a higher dose may be less well
tolerated, some patients may obtain an additional
benefit from doses up to 60 mg BID.
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& Abstract
Background: Gabapentin enacarbil (GEn), a transported
prodrug of gabapentin, provides sustained, dose-propor-
tional gabapentin exposure. The purpose of this study was to
investigate the dose response of GEn to select the optimal
dose(s) for clinical use in subsequent diabetic peripheral
neuropathy (DPN) trials.
Methods: This was a multicenter, randomized, double-
blind, double-dummy, parallel group, placebo-controlled
trial with a study duration of approximately 20 weeks
(Clinicaltrials.gov database, Identifier # NCT00643760). Pre-
gabalin (PGB) (Lyrica®; Pfizer Inc.) was used as an active
control to provide assay sensitivity of the trial. A total of 421
adult subjects with DPN were randomized in a ratio of
2:1:1:1:2 to receive oral GEn 3,600 mg/day, GEn 2,400 mg/
day, GEn 1,200 mg/day, PGB 300 mg/day, or matching pla-
cebo, respectively. The primary efficacy endpoint was change
from baseline to end of maintenance treatment with respect
to the mean 24-hour average pain intensity score based on an
11-point Pain Intensity Numerical Rating Scale (PI-NRS).
Safety and tolerability assessments included treatment-emer-
gent adverse events (TEAEs), laboratory evaluations, vital
signs, electrocardiograms (ECG), neurological examination,
and pedal edema.
Results: The adjustedmean difference vs. placebo at the end
of maintenance treatment with respect to the mean 24-hour
average PI-NRS pain intensity score for GEn 1,200 mg (0.35;
[95% CI: 1.02, 0.31]; P = 0.295), GEn 2,400 mg (0.02; [95%
CI: 0.71, 0.66]; P = 0.946), and GEn 3,600 mg (0.55; [95%
CI: 1.10, 0.01]; P = 0.105) was not statistically significant.
The active control, PGB (300 mg/day), did not differentiate
from placebo.
Conclusion: Overall, none of the GEn treatment groups
differentiated from placebo. Analyses of the secondary
endpoints showed comparable results across treatment
groups. However, the majority of the endpoints, including
all of the pain endpoints, showed the largest numerical
treatment difference was between GEn 3,600 mg and
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placebo. The active control, PGB (300 mg/day), did not
differentiate from placebo. &
Key Words: gabapentin enacarbil, diabetic peripheral
neuropathy, neuropathic pain, PXN110448
INTRODUCTION
Diabetes mellitus, particularly type 2 diabetes, is a
common condition in the developed world and its
prevalence is increasing rapidly. Diabetic peripheral
neuropathy (DPN) is a common complication of
diabetes mellitus and can occur in 34–90% of the
diabetic population, depending on the diagnostic criteria
used1–6. While not all DPN is painful, pain can develop
as a symptom of DPN. It is estimated that between 16%
and 26% of diabetic subjects experience chronic neuro-
pathic pain associated with DPN7.
Neuropathic pain associated with DPN is caused by
lesions or dysfunction of the peripheral and/or central
nervous system and does not require receptor stimula-
tion. Painful sensations are most commonly relayed via
small primary afferents, the A-d fibers, and unmyeli-
nated C fibers to the dorsal horn of the spinal cord
where a synaptic junction in the outer part of the
dorsal horn subsequently relays sensations to the
spino-parabrachial-amygdaloid pathway and spinotha-
lamic tract7. Neuropathic pain is a paradox, in that
there is development of pain in the area where the
subject experiences sensory deficit due to nerve injury.
Neuropathic pain results from plastic changes in the
nervous system of some, although not all, subjects that
leads to increased excitability of the remaining and
surrounding neurons and results in the experience of
pain.
Since 1999, the United States (US) Food and Drug
Administration (FDA) has approved two medications
for the management of neuropathic pain associated with
DPN: pregabalin (Lyrica®; Pfizer Inc., New York, NY,
USA) and duloxetine (Cymbalta®; Eli Lilly & Co.,
Indianapolis, IN, USA). Other nonapproved pharma-
cotherapies commonly used for treatment include
gabapentin, tricyclic antidepressants, and opioids. In
clinical trials, pregabalin and duloxetine have both been
shown to improve pain scores in DPN subjects.
However, less than half of subjects in the clinical trials
with pregabalin and duloxetine experienced at least
50% reduction in pain score from baseline8,9. Both the
degree and variability of effectiveness of the currently
approved medicines suggests that there are patients with
neuropathic pain associated with DPN who might
benefit from a new treatment option.
Gabapentin enacarbil (GEn [XP13512/GSK18382
62]) is a prodrug of gabapentin designed to overcome
the pharmacokinetic limitations of gabapentin. Unlike
orally administered gabapentin, which is absorbed by
low capacity transporters expressed in a limited region
of the upper intestine, GEn is designed to be absorbed by
high-capacity transport mechanisms located throughout
the intestinal tract, including the colon10. GEn is well
absorbed and provides rapid and extended delivery of
gabapentin into the systemic circulation, offering pre-
dictable absorption, dose-proportional gabapentin
exposure, and the opportunity to optimize gabapentin
exposure to patients. Additionally, GEn has been
formulated as an extended release (ER) formulation,
thereby providing less frequent dosing compared with
gabapentin.
The current study, PXN110448, explored the efficacy
of GEn in the treatment for neuropathic pain associated
with DPN. Study medication included different doses of
GEn, pregabalin (PGB), and placebo.
METHODS
This study (PXN110448, Clinicaltrials.gov Identifier
#NCT00643760) was conducted at 85 centres in the US,
from March 2008–February 2009, in accordance with
“good clinical practice” (GCP) and all applicable subject
privacy requirements, the guiding principles of 21 Code
of Federal Regulations parts 312, 50, and 56, and of the
Declaration of Helsinki. The study protocol, the
informed consent, and other information that required
preapproval were reviewed and approved by applicable
institutional review boards or ethics committees.Written
informed consent was obtained from each subject prior
to the performance of any study-specific procedures.
Study Population
Men and women at least 18 years of age who were
diagnosed with diabetes mellitus (type 1 or 2) and had
pain attributed to DPN, defined as painful distal
symmetric sensorimotor polyneuropathy, for at least
6 months and no greater than 5 years were considered
for inclusion. Subjects must have had pain attributed to
their DPN of at least moderate intensity, defined as an
average pain intensity score of  4 on an 11-point pain
intensity numerical rating scale (PI-NRS) where 0 = no
pain and 10 = worst possible pain. During the 7 days
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preceding randomization, subjects recorded pain scores
at least 4 of 7 days in a daily pain diary.
Enrolled subjects were required to have stable glyce-
mic control 3 months prior to randomization and
glycosylated hemoglobin (HbA1c) levels < 8% at the
time of randomization (levels were permitted to range
between 8–11% if attempts to control diabetes had
failed). Women of childbearing potential were required
to have a negative pregnancy test and were willing to use
an effective method of contraception throughout the
study. Acetaminophen, up to 3 g/day, was allowed as
rescue medication for pain throughout the trial but was
not allowed within 24 hours of any site visit for
assessments.
Key exclusion criteria included the following:
 Subjects with chronic pain due to neuropathy or
lower extremity pain not related to DPN. How-
ever, subjects with chronic pain conditions not
associated with DPNwere not excluded if the pain
was located at a different region of the body, the
pain intensity was not greater than the pain
intensity of the DPN pain, and the subject was
able to assess DPN pain independently of other
pain conditions.
 Subjects with conditions (eg unstable depression,
alcohol, substance abuse) or medications (eg acute
pain medications, hypnotics, antidepressants) that
could possibly have interfered with the assessment
of pain improvement following the use of Gen.
 Subjects with pre-existing liver, renal, cardiovas-
cular, disease, epilepsy or seizure disorders, or any
other medical condition or treatment that could
have interfered with the accurate assessment of
the efficacy, safety, or absorption of Gen.
 Subjects who were currently participating in other
clinical trials or who had been recently exposed
to, or had an allergic reaction to, GEn or its
components or acetaminophen or compounds
closely related to acetaminophen.
Study Design
This was a multicenter, randomized, double-blind,
double-dummy, parallel group, placebo-controlled,
and active-controlled study to investigate the dose
response of GEn in subjects with neuropathic pain
associated with DPN.
The duration of the study was approximately
20 weeks, divided into six phases: screening (up to
4 weeks); baseline (including randomization, 1 week);
up-titration (1 week); maintenance phase (dose main-
tained at fixed level, 12 weeks); down-titration
(1 week); and follow-up phase (1 week after last inves-
tigational product dose; 16 days for females of child
bearing potential).
Subjects were randomized to receive GEn 3,600 mg/
day, GEn 2,400 mg/day, GEn 1,200 mg/day, PGB
300 mg/day, or matching placebo in a 2:1:1:1:2 ran-
domization ratio according to a computer-generated
schedule. Gabapentin enacarbil was provided as 600 mg
tablets with identical-in-appearance placebo tablets to
ensure blinding of subjects and investigators; PGB was
provided as 50 mg and 100 mg with identical-in-
appearance placebo capsules and was administered in
accordance with the recommended dose for the man-
agement of neuropathic pain associated with DPN
specified in the FDA approved package label8. To
maintain blinding during the maintenance phase, all
subjects were instructed to take the study medication as
indicated in Table 1 in the morning, afternoon, and
evening. All GEn and matching placebo tablets were
provided in Medisets that were filled by an unblinded,
third-party pharmacist; all PGB and matching placebo
capsules were provided in blister cards.
Table 1. Treatment Cohorts
Cohort
Randomization
Ratio
(n = Planned
Number of
Randomized
Subjects)
Maintenance Treatment
Total Daily Regimen
Placebo (PBO) 2
(n = 112)
GEn PBO X 6
(3 tablets twice daily);
PGB PBO X 3
(1 capsule 3 times daily)
GEn 1,200 mg/day 1
(n = 56)
GEn 600 mg X 2
(1 tablet twice daily);
GEn PBO X 4
(2 tablets twice daily);
PGB PBO X 3
(1 capsule 3 times daily)
GEn 2,400 mg/day 1
(n = 56)
GEn 600 mg X 4
(2 tablets twice daily);
GEn PBO X 2
(1 tablet twice daily);
PGB PBO X 3
(1 capsule 3 times daily)
GEn 3,600 mg/day 2
(n = 112)
GEn 600 mg X 6
(3 tablet twice daily);
PGB PBO X 3
(1 capsule 3 times daily)
PGB 300 mg/day 1
(n = 56)
PGB 100 mg X 3
(1 capsule 3 times daily);
GEn PBO X 6
(3 tablets twice daily)
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Study Assessments
The primary objective of the study was to investigate the
dose response of GEn using improvement in pain
intensity scores to select the optimal dose(s) for clinical
use in subsequent DPN trials.
Additional (secondary) objectives included charac-
terizing the effect of GEn on improvement in pain
parameters, physical and emotional function, and global
improvement; investigating the safety of GEn; and
estimating the systemic exposure of gabapentin associ-
ated with GEn doses of 1,200 mg/day, 2,400 mg/day,
and 3,600 mg/day.
The primary efficacy assessment instrument was the
11-point PI-NRS as completed by subjects in their daily
pain diary. Subjects described their pain during the
previous 24 hours by choosing the appropriate number
from 0 (“no pain”) to 10 (“pain as bad as you can
imagine”). The primary analysis compared the change
from baseline to end of maintenance treatment
(EOMT) with respect to the mean 24-hour average
pain intensity score. The baseline score was the
calculated mean of the daily 24-hour average pain
scores for each subject during the last 7 days prior to
randomization. The EOMT score was the calculated
mean of the daily 24-hour average pain scores for each
subject during the last seven days of the maintenance
phase.
The secondary efficacy endpoints included the change
from baseline in the mean: 24-hour average pain
intensity score, daytime average pain intensity score,
nighttime average pain intensity score, current pain
intensity score, daytime worst pain intensity score,
nighttime worst pain intensity score, sleep interference
score, and rescue analgesia consumption (mg), each of
which was analyzed at each week of treatment and post-
treatment.
Other efficacy endpoints included: the Neuropathic
Pain Scale (NPS); Short-Form McGill Pain Question-
naire (SF-MPQ); pre- and post-50-foot (15 meter) walk
pain scores; proportion of subjects who were “much
improved” or “very much improved” on the Patient
Global Impression of Change (PGIC) and Clinician
Global Impression of Change (CGIC) questionnaires;
proportion of subjects achieving various levels of
reduction in the 24-hour average pain intensity score;
time to onset of sustained improvement in the 24-hour
average pain intensity score; Profile of Mood State
(POMS); and Short-Form-36 (SF-36) health-related
quality of life questionnaire.
The safety assessments included treatment-emergent
adverse events (TEAEs), possible suicidality-related
adverse events (PSRAEs), laboratory evaluations (blood
chemistry, hematology, immunology, urinalysis, preg-
nancy), vital signs (blood pressure, heart rate), electro-
cardiograms (ECG), and a neurological exam, including
a detailed examination of sensory and motor systems,
body weight, and pedal edema. The investigator was
responsible for the detection and documentation of
events meeting the criteria and definition of an AE or a
serious adverse event (SAE) as defined in the study
protocol; adverse events were collected at each study
visit.
The objective of the population PK analysis was to
derive the daily area under the gabapentin plasma
concentration curve (AUC0-24) in each subject with
neuropathic pain associated with DPN. A Bayesian
approach was applied to estimate individual PK param-
eters assuming the population PK model previously
estimated with data from healthy subjects and subjects
with RLS as priors. A population PK/PD model,
describing the relationship between gabapentin systemic
exposure and pain intensity scores, was then developed.
In addition, the potential effects of covariates (age, body
weight, height, body mass index, sex, concomitant
medications, and baseline pain score) on the defined
exposure–response relationship were investigated.
Statistical Methods
The study was originally designed to assess dose
response from an anticipated Emax distribution. Con-
sequently, there was an unequal randomization to the
different treatment arms. However, the primary statis-
tical analysis (per-protocol amendment 3) was designed
to test each potential dose (GEn 3,600 mg/day, GEn
2,400 mg/day, or GEn 1,200 mg/day) against placebo.
A planned sample size of 336 subjects, randomized in a
2:1:1:2 ratio (GEn 3,600 mg/day:GEn 2,400 mg/day:
GEn 1,200 mg/day:Placebo) (112:56:56:112), provided
power ranging between 71 and 96% to detect a
treatment effect of 1.2 points in mean pain intensity
score as compared to placebo, assuming a standard
deviation of 2.45. Additionally, 56 subjects were to be
randomized to PGB (300 mg/day) as an active control
to provide a descriptive assessment of the assay sensi-
tivity of the study. To protect the experiment-wise alpha
level of 0.05, a combination of sequential methods and
a Hochberg procedure was used for the primary
endpoint.
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Based on a simulation of the Hochberg method for
adjusting for multiple comparisons, if both GEn
3,600 mg/day and GEn 2,400 mg/day were effective,
there would be approximately 96% power to detect a
difference for at least one of the comparisons, GEn
3,600 mg/day vs. placebo and GEn 2,400 mg/day vs.
placebo. If only GEn 3,600 mg/day was effective, there
would be 88% power to detect a difference between
GEn 3,600 mg/day and placebo at an alpha level of
0.025. If only GEn 2,400 mg/day was effective, there
would be 71% power to detect a difference between
GEn 2,400 mg/day and placebo at an alpha level of
0.025.
The GEn 1,200 mg/day dose was to be compared
with placebo only if both of the higher doses were
statistically significant at an alpha level of 0.05. Formal
statistical testing of PGB to placebo was not conducted.
The Safety Population, used to assess safety end-
points, was composed of all subjects who took at least
one dose of investigational product. The Intent-to-Treat
(ITT) Population, used to assess all efficacy endpoints,
comprised all randomized subjects who took at least one
dose of investigational product and provided at least one
postbaseline efficacy measurement. The Per-Protocol
(PP) Population was defined as all subjects in the ITT
Population who had no major protocol deviations. The
PK Population was defined as all randomized subjects
who took at least one dose of investigational product
and provided at least one PK sample.
The primary efficacy analysis used the last observa-
tion carried forward (LOCF) approach for imputation
of data for subjects who did not complete the study.
Sensitivity analyses using baseline observation carried
forward (BOCF), BOCF/LOCF Hybrid and observed
cases (OC) data for noncompleters, were also per-
formed. Finally, a mixed-model repeated measures
(MMRM) analysis was performed as an additional
sensitivity analysis for the primary efficacy variable
using the OC data for the ITT population.
For endpoints assessed as a change from baseline,
including the primary efficacy endpoint, each dose of
GEn was compared with placebo using an Analysis of
Covariance (ANCOVA) model, with body mass index
(BMI), baseline score for the endpoint being analyzed,
grouped centre, and randomized treatment as terms in
the model. The proportion endpoints (eg proportion of
subjects who are “much improved” or “very much
improved” per the PGIC and CGIC) were analyzed
using logistic regression with grouped centre and ran-
domized treatment as terms in the model (PGIC), or
with randomized treatment as the only term in the
model (CGIC).
RESULTS
Subject Disposition and Baseline Characteristics
There were 421 subjects randomized in a 2:1:1:1:2 ratio
(GEn 3,600 mg/day:GEn 2,400 mg/day:GEn 1,200 mg/
day:PGB 300 mg/day:Placebo) in the study (n = 117
GEn 3,600 mg/day, n = 56 GEn 2,400 mg/day, n= 62
GEn 1,200 mg/day, n = 66 PGB 300 mg/day, n = 120
placebo). One subject in the GEn 3,600 mg group, who
was randomized in error, did not take study medication
and therefore was excluded from the Safety population.
Of the 420 subjects in the Safety population, all were
included in the ITT population.
The majority of subjects enrolled in the study were
white (80%) and male (59%). Mean age ranged from
57.5–60.8 years across treatment groups. Across treat-
ment groups, the majority of subjects (61% [GEn
2,400 mg/day], 66% [GEn 3,600 mg/day], 74% [GEn
1,200 and PGB], and 78% [PBO]) were obese as defined
by a BMI > 30 kg/m2.
Demographics and baseline characteristics were sim-
ilar among treatment groups (Table 2).
Efficacy—Pain Measures
The primary efficacy endpoint was the change from
baseline to EOMT for the mean 24-hour average
pain intensity score based on an 11-point PI-NRS.
A decreased mean 24-hour average pain intensity score
at EOMT, as compared to baseline, was noted in all
treatment groups (Table 3, Figure 1).
For the primary analysis (using LOCF data), there
were no statistically significant differences when
comparing each active daily dose of GEn (1,200 mg,
2,400 mg, and 3,600 mg) vs. placebo, P = 0.295,
0.946, and 0.105, respectively, at EOMT. The unad-
justed P-values (ie not adjusted for multiple compari-
sons of active treatment vs. placebo) were 0.295, 0.946,
and 0.052, respectively.
Consistent with the primary LOCF analysis, the
supportive analyses of the ITT population using BOCF,
BOCF/LOCF hybrid, OC, the MMRM analysis of the
ITT population using OC data, and the PP population
analyses all resulted in a decreased 24-hour pain
intensity score at EOMT, as compared with placebo
(Table 4). When considering the BOCF and MMRM
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analysis, the magnitude of the improvement was greater
in the GEn 3,600 mg/day treatment group than in the
placebo treatment group, with the confidence intervals
(not multiplicity-adjusted) indicating a benefit for GEn
3,600 mg/day over placebo.
Per the predefined testing strategy, GEn 1,200 mg vs.
placebo was only to be tested if both GEn 2,400 mg and
GEn 3,600 mg were significantly better than placebo at
an alpha (a) level of 0.05. Thus, the results for the
1,200 mg group are included in Table 4 for reference
and should only be considered descriptive. The active
control, PGB (300 mg/day), did not differentiate from
placebo. Neither the method of imputation, statistical
analysis technique, nor the population had a significant
impact on the primary efficacy measure.
The secondary efficacy analyses were performed on
the ITT population, and as shown in Tables 5 and 6,
overall, the analyses of the secondary endpoints showed
comparable results across treatment groups. Addition-
ally, the time to sustained improvement was defined as
the time to the first of two or more consecutive days of at
least 2-points reduction in the 24-hour average pain
intensity score relative to baseline. Fifty percent of
subjects in the GEn 3,600 mg treatment group achieved
sustained improvement within 15 days of first dose of
investigational product as compared to PBO (24 days),
Table 3. Change from Baseline in 24-Hour Average Pain
Intensity Score at End of Maintenance Treatment (ITT
Population, LOCF Imputation)
Time Period Parameter
PBO
N = 120
GEn
1,200 mg
N = 62
GEn
2,400 mg
N = 56
GEn
3,600 mg
N = 116
PGB
300 mg
N = 66
Baseline Mean 6.49 6.64 6.26 6.48 6.51
Change
from
Baseline
to
EOMT1
Mean 2.09 2.55 1.90 2.54 1.66
SD 2.069 2.535 2.049 2.423 1.833
Median 1.59 1.71 1.61 2.15 1.54
Min 7.5 8.4 6.1 8.0 7.1
Max 1.8 1.0 4.3 4.3 2.2
End of maintenance treatment.
Figure 1. Adjusted mean (95% CI) change from baseline in 24-
hour average pain intensity by week and at the EOMT (ITT, LOCF).
Table 2. Demographics and Baseline Characteristics (Safety Population)
Number (%) of Subjects
PBO
N = 120
GEn 1,200 mg
N = 62
GEn
2,400 mg
N = 56
GEn 3,600 mg
N = 116
PGB 300 mg
N = 66
Total
N = 420
Age
Mean (SD)
Range
60.1(10.63)
29–85
57.5 (10.32)
32–77
60.8 (8.97)
33–78
57.5 (9.87)
35–79
57.7(10.59)
35–79
58.7 (10.20)
29–85
Age group
 65 years 82 (68%) 44 (71%) 39 (70%) 90 (78%) 50 (76%) 305 (73%)
> 65 years 38 (32%) 18 (29%) 17 (30%) 26 (22%) 16 (24%) 115 (27%)
Sex
Female 47 (39%) 28 (45%) 19 (34%) 45 (39%) 32 (48%) 171 (41%)
Male 73 (61%) 34 (55%) 37 (66%) 71 (61%) 34 (52%) 249 (59%)
Race
White* 98 (82%) 46 (74%) 47 (85%) 90 (79%) 52 (81%) 333 (80%)
BMI
 30 27 (23%) 16 (26%) 22 (39%) 39 (34%) 17 (26%) 121 (29%)
> 30 93 (78%) 46 (74%) 34 (61%) 77 (66%) 49 (74%) 299 (71%)
Baseline 24-hour pain score
Mean
(SD)
Range
6.49
(1.26)
4.0–10.0
6.64
(1.47)
4.0–9.4
6.26
(1.22)
4.0–9.6
6.48
(1.43)
4.0–10.0
6.51
(1.27)
4.0–9.3
N/A
Baseline 24-hour pain score
4 to < 6.5 61 (51%) 25 (40%) 32 (57%) 63 (54%) 33 (50%) 214 (51%)
6.5 to 10 59 (49%) 37 (60%) 24 (43%) 53 (46%) 33 (50%) 206 (49%)
Creatinine Clearance, est. (mL/min)
Mean
(SD)
Range
111.3
(38.09)
45–296
115.3
(40.49)
31–262
107.1
(39.35)
43–222
119.6
(41.94)
45–249
121.5
(47.57)
47–299
N/A
*Other races were primarily African American/African Heritage.
N/A, not applicable
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GEn 1,200 mg (25 days), GEn 2,400 mg (22 days), and
PGB 300 mg (29 days) treatment groups.
Safety and Tolerability
The majority of subjects across all treatment groups
reported at least one TEAE. Overall, the rate of AEs (any
event) reported across the GEn groups and the PGB
group was comparable. The most commonly reported
TEAEs that occurred at a rate  5% in any active
treatment group included dizziness, somnolence, nau-
sea, and peripheral edema (Table 7).
The majority of subjects in each treatment group
completed the study. A slightly higher percentage of
subjects in the GEn daily doses of 2,400 mg and
3,600 mg withdrew from the study, as compared with
the other treatment groups (Figure 2). This difference
was driven by a higher rate of AE withdrawals in
the higher dose GEn treatment groups (21% in the
GEn 2,400 mg treatment group and 18% in the
GEn 3,600 mg treatment group). The GEn 3,600 mg
treatment group had the smallest proportion of subjects
withdraw from the study due to protocol deviations.
For all other categories of withdrawal, the treatment
groups were comparable in the percentage of subjects
withdrawn.
No AE led to the withdrawal of > 5% of subjects in
any treatment group. Additionally, there was no con-
sistent pattern of AEs related to dose or treatment across
treatment groups. There was one report of suicidal
ideation in the study; it occurred in the GEn 3,600 mg
group. It was reported as moderate in severity, not
serious, and was considered to be related to the
investigational product by the investigator. The subject
had no history of psychiatric conditions including
suicidal ideation, behavior, or self-harm. Reported
stressors included job loss and domestic stress. The
event occurred 51 days after starting GEn and lasted
1 day. GEn treatment was discontinued, and the like-
lihood of reoccurrence was reported as unlikely.
During the study, 22 subjects reported 29 nonfatal
SAEs and no clear differences were noted between
treatment groups. No deaths occurred during this study.
There were no clinically significant mean changes in
blood pressure or HR in the GEn, PGB, or placebo
treatment groups. At the end of maintenance treatment,
subjects in the PGB treatment group experienced the
most weight gain. Of the GEn groups, weight gain
increased by dose with subjects in the GEn 3,600 mg/
day group experiencing the most weight gain and
subjects in the GEn 1,200 mg/day group experienced
the least gain. Subjects in the placebo group showed the
least change in weight across all treatment groups. The
proportion of subjects who had weight gain of at least
7% at any visit postrandomization was greatest in the
PGB group (15%), followed by the GEn 3,600 mg
group (11%) compared with the GEn 2,400 mg (7%),
GEn 1,200 mg (5%) and PBO (3%). There were no
systematic changes noted in laboratory parameters or
ECG findings across the treatment groups.
Pharmacokinetics/Pharmacodynamics
Gabapentin plasma concentration data in DPN subjects
were collected in accordance with the protocol. Only
four subjects were excluded from the PK analysis. The
distribution of sampling times during the treatment was
homogeneous between doses, which allowed capture of
Table 4. Treatment Difference vs. Placebo for Change
from Baseline in Mean 24-Hour Average Pain Intensity
Score at End of Maintenance Treatment (LOCF, BOCF,
BOCF/LOCF Hybrid, OC, MMRM, PP Population)
Population
(Imputation
Method)
GEn
1,200 mg
N = 62
GEn
2,400 mg
N = 56
GEn
3,600 mg
N = 116
PGB
300 mg
N = 66
ITT (LOCF)
n 62 56 116 66
Adj. mean diff vs.
Placebo
0.35 0.02 0.55 0.43
95% CI (1.02, 0.31) (0.71, 0.66) (1.10, 0.01) (0.22, 1.08)
Adj. P-value* 0.295 0.946 0.105 NA
ITT (BOCF)
n 62 56 116 66
Adj. mean diff vs.
Placebo
0.29 0.02 0.58 0.41
95% CI (0.96, 0.37) (0.67, 0.70) (1.13, 0.02) (0.24, 1.07)
ITT (BOCF/LOCF hybrid)
n 62 56 116 66
Adj. mean diff vs.
Placebo
0.36 0.03 0.56 0.43
95% CI (1.03, 0.30) (0.71, 0.66) (1.12, 0.01) (0.22, 1.08)
ITT (OC)
n 59 53 115 65
Adj. mean diff vs.
Placebo
0.37 0.01 0.56 0.43
95% CI (1.05, 0.31) (0.71, 0.70) (1.12, 0.01) (0.23, 1.09)
Per-protocol (LOCF)
n 49 42 93 53
Adj. mean diff vs.
Placebo
0.39 0.07 0.69 0.42
95% CI (1.15, 0.37) (0.88, 0.73) (1.32, 0.06) (0.33, 1.16)
MMRM (OC)
n 59 53 115 65
Adj. mean diff vs.
Placebo
0.37 0.03 0.50 0.45
95% CI (0.92, 0.19) (0.60, 0.55) (0.97, 0.04) (0.1. 0.99)
A negative treatment difference indicates benefit, relative to placebo.
*Adjusted P-values are valid for inference of the LOCF analysis. Adjustments to P-values
were made based on multiple treatment arms.
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the PK profile of gabapentin during the dosing interval at
steady state.
An exposure–pain reduction response was established
for gabapentin following administration of GEn. The
pharmacodynamic effects of GEn were modelled as a
linear function of daily gabapentin exposure (AUC0-24).
After placebo correction, the net drug effect was small,
as shown in Figure 3. For the highest gabapentin
AUC0-24ss (312–758 µg*h/mL) obtained in the study,
the median net effect was a 0.9-point reduction in pain
score on a [0–10] scale. The net drug response ranged
0.4 to 3; four subjects had a net drug effect > 3.
However, these subjects were considered outliers.
DISCUSSION
In this randomized clinical study of patients with
neuropathic pain associated with DPN, all treatment
groups experienced a reduction in pain intensity scores
(baseline to EOMT) as measured on the 11-point
PI-NRS with scores ranging from 1.66 with PGB to
2.54 with GEn 3,600 mg. However, comparisons
Table 6. Responder Rates for 24-Hour Average Pain Intensity at EOMT (LOCF), n (%)
Percentage Reduction from Baseline
Placebo
(N = 120)
GEn 1,200 mg
(N = 62)
GEn 2,400 mg
(N = 56)
GEn 3,600 mg
(N = 116)
PGB 300 mg
(N = 66)
 0 103 (86%) 55 (89%) 50 (89%) 101 (87%) 55 (83%)
 10% 86 (72%) 43 (69%) 42 (75%) 91 (78%) 42 (64%)
 20% 73 (61%) 36 (58%) 34 (61%) 78 (67%) 36 (55%)
 30% 57 (48%) 31 (50%) 25 (45%) 66 (57%) 28 (42%)
 40% 46 (38%) 28 (45%) 19 (34%) 55 (47%) 20 (30%)
 50% 35 (29%) 26 (42%) 15 (27%) 46 (40%) 14 (21%)
 60% 26 (22%) 21 (34%) 11 (20%) 41 (35%) 9 (14%)
 70% 15 (13%) 17 (27%) 6 (11%) 25 (22%) 5 (8%)
 80% 11 (9%) 11 (18%) 5 (9%) 17 (15%) 4 (6%)
 90% 4 (3%) 5 (8%) 2 (4%) 8 (7%) 3 (5%)
100% 3 (3%) 4 (6%) 1 (2%) 5 (4%) 3 (5%)
Table 7. Most Common (at Least 5%) Treatment-Emergent Adverse Events (Safety Population)
Preferred Term
Number (%) of Subjects
Placebo
N = 120
GEn 1,200 mg
N = 62
GEn 2,400 mg
N = 56
GEn 3,600 mg
N = 116
PGB 300 mg
N = 66
Any event 79 (66) 45 (73) 38 (68) 86 (74) 47 (71)
Dizziness 7 (6) 9 (15) 8 (14) 16 (14) 9 (14)
Somnolence 5 (4) 2 (3) 7 (13) 14 (12) 9 (14)
Nausea 9 (8) 7 (11) 4 (7) 7 (6) 3 (5)
Peripheral edema 5 (4) 2 (3) 0 11 (9) 11 (17)
Headache 9 (8) 3 (5) 4 (7) 4 (3) 6 (9)
Muscle spasms 4 (3) 6 (10) 0 11 (9) 3 (5)
Diarrhea 6 (5) 3 (5) 2 (4) 6 (5) 5 (8)
Urinary tract infection 5 (4) 3 (5) 4 (7) 6 (5) 4 (6)
Constipation 4 (3) 3 (5) 4 (7) 4 (3) 6 (9)
Fatigue 3 (3) 3 (5) 3 (5) 5 (4) 4 (6)
Arthralgia 5 (4) 1 (2) 2 (4) 5 (4) 3 (5)
Nasopharyngitis 5 (4) 1 (2) 2 (4) 4 (3) 3 (5)
Pain in extremity 2 (2) 1 (2) 4 (7) 6 (5) 2 (3)
Vision blurred 5 (4) 0 3 (5) 2 (2) 3 (5)
Weight increased 1 (< 1) 0 2 (4) 5 (4) 5 (8)
Back pain 3 (3) 1 (2) 1 (2) 3 (3) 3 (5)
Increased appetite 4 (3) 0 3 (5) 1 (< 1) 3 (5)
Dry mouth 4 (3) 0 4 (7) 1 (< 1) 1 (2)
Disturbance in attention 2 (2) 2 (3) 0 2 (2) 3 (5)
Vomiting 3 (3) 3 (5) 1 (2) 2 (2) 0
Bronchitis 1 (< 1) 3 (5) 1 (2) 0 1 (2)
Excoriation 0 1 (2) 1 (2) 1 (< 1) 3 (5)
Hypoesthesia 1 (< 1) 1 (2) 1 (2) 0 3 (5)
Paresthesia 0 2 (3) 1 (2) 0 3 (5)
Fall 0 3 (5) 1 (2) 1 (< 1) 0
All AEs occurred more frequently than placebo in at least one active treatment arm.
Gabapentin Enacarbil in DPN  493
188
between GEn and placebo failed to reach statistical
significance with adjusted mean differences ranging
from 0.02 (GEn 2,400 mg; P = 0.946) to 0.55
(GEn 3,600 mg; P = 0.105). The results were consistent
across multiple methods of adjusting for missing values
(ie LOCF, BOCF, BOCF/LOCF hybrid, OC [ITT, Per-
protocol and MMRM]). When compared to placebo,
the active-control arm of the study, PGB 300 mg, also
failed to reach statistical significance with the adjusted
mean difference actually favouring the placebo treat-
ment group.
Gabapentin, which is approved for the treatment of
postherpetic neuralgia (PHN), has been prescribed
extensively over the past 15+ years for the treatment of
neuropathic pain and has been investigated in numerous
neuropathic and nonneuropathic pain conditions11.
While gabapentin has demonstrated efficacy in reduc-
tion in perioperative pain and opioid use, several reviews
of pharmacological management in neuropathic pain
have concluded that gabapentin should be considered a
first-line drug in neuropathic pain conditions12,13. In a
well-designed prospective, randomized, double-blind,
placebo-controlled study, Backonja et al. examined the
Figure 2. Summary of subject disposition and reasons for premature withdrawal (randomized population).
Figure 3. Drug effect (corrected for placebo) estimated as a
function of gabapentin systemic exposure (PK population).
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efficacy of gabapentin in neuropathic pain associated
with diabetic peripheral neuropathy (DPN). Gabapentin
demonstrated significant efficacy in this study of 165
patients with DPN; pain in the gabapentin group
decreased from 6.4 to 3.9 (Likert scale: 0–10) vs.
placebo, 6.5 to 5.1 (P < 0.001), and all secondary
endpoints statistically favored gabapentin over
placebo14.
A study of DPN patients (n = 40), by Gorson et al.,
failed to show efficacy in a placebo-controlled, double-
blind, crossover design. A secondary endpoint, the
McGill pain questionnaire, demonstrated statistically
significant benefit of gabapentin vs. placebo (P = 0.03).
The dose of gabapentin did not exceed the daily dose of
900 mg15.
Numerous drugs studied in neuropathic pain have
reported negative outcomes. It has often been difficult to
interpret these results when juxtaposed with other
positive trials or clinical practice12,13. Are there differ-
ences in neuropathic disease states that might explain
the conflicting reports? Dworkin et al. recently com-
pared clinical trial results in the two most commonly
studied neuropathic disease states: DPN and PHN. The
authors found that the placebo group improvements
were greater in painful DPN trials when compared with
PHN trials. When compared with results in groups
receiving active medication, the placebo benefits could
not be attributed to greater overall improvement in
subjects with DPN12.
Pregabalin and duloxetine have both received regu-
latory approval for the treatment of DPN. As stated
above, gabapentin had mixed efficacy trials in two
well-designed RCTs. However, gabapentin is listed as
first-line treatment for DPN in several guideline publi-
cations. Many clinicians, following these guidelines,
have reported and discussed the benefits of gabapentin
in their patients with DPN.
Given the backdrop described above, one should be
well acquainted with the nuances of clinical trials and
drug development. These nuances appear enhanced in
the particular population of patients with DPN. The
current trial of gabapentin enacarbil (GEn) clearly failed
to meet its primary efficacy endpoint or any of its
secondary endpoints. An active comparator, pregabalin
(approved for the indication of DPN), performed as
poorly or worse compared to the study drug. How does
one interpret these results? Does this represent a failed
trial or a failed drug (negative trial)?
In the current study of GEn, subjects receiving
placebo reported possibly significant pain relief (> 2
point reduction on a 0–10 point Likert scale) at the end
of the maintenance phase (13 weeks of double-blind
conditions). While this level of placebo response has
occurred in other chronic pain trials, it presents an
enormous burden for an active drug to overcome. There
may be several reasons to explain this degree of placebo
response.
First, the natural history of painful diabetic periph-
eral neuropathy waxes and wanes. Some patients
develop spontaneous improvements in their pain, more
commonly early in the disease process. If more of these
patients happen to be receiving placebo, they will
accurately report significant improvements in their pain,
despite the lack of a pharmacologically active com-
pound being received. Results would expect to skew in
favor of the placebo group.
Second, there are differences between PHN and DPN
regarding underlying pathophysiologic mechanisms.
DPN is a disease of the peripheral nervous system while
PHN patients often have lesions in the dorsal horn of the
spinal cord. It has been hypothesized that intact
descending inhibitory pathways in the spinal cord dorsal
horn are required for the placebo response16. This could
explain the differences in placebo responses seen
between these two study groups and further explain
the placebo response seen in the current trial.
Third, the current study randomized subjects into one
of five treatment groups. Randomization occurred such
that subjects had only a two in seven chance of receiving
placebo. As this information was provided in the
informed consent form, subjects knew that the chances
of receiving an active compound were greater than 70%.
A familiar maxim states, “Results follow expectations.”
Unknowingly, subjects receiving placebo could over-
state the analgesic efficacy they perceived during the
trial.
The current study was designed with a placebo group,
three fixed doses of GEn, and the active comparator,
pregabalin (PGB) for various reasons. The US FDA
routinely wants to know the minimum effective dose of
a drug. Phase II clinical trials are commonly designed to
study doses and are often referred to as dose ranging
studies. Earlier work had suggested that 1,200 mg/day
of GEn would be inferior to the higher doses. Maximally
tolerated dose is another concept often explored in
Phase II studies. The 3,600 mg daily dose of GEn was
thus included in the current trial as the highest dose. To
adequately explore the dose response of GEn in subjects
with DPN, it was necessary to include several groups in
the study design.
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The active comparator, PGB, was included in the
current trial to provide a descriptive assessment of the
assay sensitivity of the study. However, this added an
additional treatment group who received a pharmaco-
logically active drug and possibly increased the placebo
response stated above. In retrospect, the decision to
include pregabalin may have emphatically demonstrated
the failed aspect of this trial. Pregabalin has performed
very well in DPN and has an FDA approved indication
in DPN. The fact that pregabalin performed worse than
placebo in the current trial further supports the idea of
flaws in either the trial design or the specific population
included in the trial.
In conclusion, one will never unequivocally know
whether the current results represent a failed trial or a
failed drug. Previous studies of gabapentin in DPN and
the overwhelming clinical impression of analgesic effi-
cacy of this compound in treating patients with DPN
support the notion that these results support a failed
trial. Previous pharmacologic information of GEn sup-
ports that gabapentin would have been in the plasma in
similar and higher concentrations to studies with the
parent compound. Future research will undoubtedly
help answer these lingering questions.
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Lamotrigine reduces painful diabetic
neuropathy
A randomized, controlled study
E. Eisenberg, MD; Y. Lurie, MD; C. Braker, MD; D. Daoud, MD; and A. Ishay, MD
Article abstract—Objective: To study the efficacy of lamotrigine in relieving the pain associated with diabetic neuropa-
thy. Methods: The authors randomly assigned 59 patients to receive either lamotrigine (titrated from 25 to 400 mg/day) or
placebo over a 6-week period. Primary outcome measure was self-recording of pain intensity twice daily with a 0 to 10
numerical pain scale (NPS). Secondary efficacy measures included daily consumption of rescue analgesics, the McGill Pain
Questionnaire (MPQ), the Beck Depression Inventory (BDI), the Pain Disability Index (PDI), and global assessment of
efficacy and tolerability. Results: Twenty-four of 29 patients (83%) receiving lamotrigine and 22 of 30 (73%) patients
receiving placebo completed the study. Daily NPS in the lamotrigine-treated group was reduced from 6.4 6 0.1 to 4.2 6 0.1
and in the control group from 6.5 6 0.1 to 5.3 6 0.1 (p , 0.001 for lamotrigine doses of 200, 300, and 400 mg). The results
of the MPQ, PDI, and BDI remained unchanged in both groups. The global assessment of efficacy favored lamotrigine
treatment over placebo, and the adverse events profile was similar in both groups. Conclusions: Lamotrigine is effective
and safe in relieving the pain associated with diabetic neuropathy.
NEUROLOGY 2001;57:505–509
Abnormal neural firing may be a major cause of neu-
ropathic pain.1 Spontaneous activity of primary af-
ferent neurons was found in diabetic rats2 and in the
dorsal horn of rats with experimental peripheral
neuropathy.3 Furthermore, there is now evidence
that excitatory amino acids, particularly glutamate,
play a key role in dorsal horn spinal hyperexcitabil-
ity by acting at the NMDA receptor.4,5
The antiepileptic agent lamotrigine has at least
two antinociceptive properties: it stabilizes the neu-
ral membrane through blocking activation of voltage-
sensitive sodium channels and it inhibits the
presynaptic release of glutamate.6 Animal studies
have demonstrated the ability of lamotrigine to re-
duce hyperalgesia in rats with streptozotocin-
induced diabetes.7,8 Open studies in humans have
suggested that lamotrigine may reduce painful dia-
betic neuropathy,9 trigeminal neuralgia,10 symptoms
of complex regional pain syndrome type 1,11 and
chronic refractory neuropathic pain of mixed etiolo-
gies.12 Painful HIV-associated neuropathy and cen-
tral poststroke pain have been relieved by
lamotrigine but not by placebo in recent controlled
trials.13,14 We report a trial of the analgesic efficacy of
lamotrigine in painful diabetic neuropathy. Prelimi-
nary results were reported earlier.15
Methods. Patients. The study was approved by the
Ethics Committee of Rambam Medical Center in Haifa,
Israel. All patients provided written informed consent be-
fore enrollment. Patients were considered eligible if 1) they
had an established diagnosis of diabetes mellitus (type 1 or
2); 2) no change had been made in their antihyperglycemic
medications within 3 weeks before screening; 3) evidence
of peripheral neuropathy was indicated by at least two of
the three following measures: a) medical history, b) neuro-
logic examination, or c) abnormal nerve conduction test
results; 4) pain attributed to diabetic neuropathy had been
present for at least 6 months; and 5) a mean pain intensity
of at least 4 on an 11-point numerical pain scale (NPS; 0 to
10; 0 means no pain, 10 means the worst imaginable pain)
was recorded twice daily (morning and evening) during the
week before randomization. Exclusion criteria included 1)
age younger than 18 or older than 75 years; 2) impaired
renal or liver function; 3) known epilepsy; 4) presence of
other painful conditions; 5) receipt of anticonvulsants, an-
tidepressants, or membrane-stabilizing agents for reasons
other than pain relief, or use of opioids; and 6) participa-
tion in any clinical trial within 30 days before screening.
Design. The study was a randomized, double-blinded,
placebo-controlled, parallel- group, single-center trial and
consisted of three phases: a 7-day screening phase, an
8-week, double-blinded treatment phase, and a 2-week
post-treatment phase.
Screening phase. Letters providing information about
the study were sent to primary care physicians, neurolo-
gists, diabetes clinics, and pain clinics in northern Israel.
Ads were published in the local newspapers informing the
public about the opportunity for self-referral. Study eligi-
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bility was determined in the first two visits: during the
first visit, informed consent and medical history were ob-
tained, medical and neurologic examinations were per-
formed, and blood samples for liver and kidney function
tests, hemoglobin A1c (HbA1c), and fasting glucose levels
were drawn. Subjects meeting the initial inclusion criteria
were instructed to record their pain intensity and their
consumption of rescue analgesics in a daily diary. Patients
who were taking analgesics (including anticonvulsants, an-
tidepressants, membrane stabilizers, and opioids) were re-
quested to discontinue the use of these drugs for at least 3
days before beginning the use of the diary. In the second
visit, final eligibility was determined by reviewing the dia-
ries and the results of the blood tests.
Randomization. Only patients who met all inclusion
criteria were randomly assigned to receive either lam-
otrigine or a placebo. Randomization was done in blocks of
four according to a computer-generated random code in a
double-blinded fashion.
Treatment phase. Treatment was initiated at a daily
dose of 25 mg for 2 weeks, increased to 50 mg/day for 2
more weeks, and subsequently to 100, 200, 300, and 400
mg/day, each dose for an additional week. The dosing
schedule was once daily during the first 2 weeks and twice
daily for the remaining 6 weeks. Patients in the placebo
group received equal numbers of identical-looking placebo
tablets according to the same schedule. Both the lam-
otrigine and the placebo tablets were kindly supplied by
Glaxo-Wellcome, USA. Patients were allowed to use rescue
medications, including simple analgesics (paracetamol or
dipyrone) and nonsteroidal anti-inflammatory drugs.
Post-treatment phase. After the 8-week treatment pe-
riod, study medications were discontinued. Patients were
allowed to continue the use of rescue medications and were
requested to continue the daily diary for an additional 2
weeks.
Efficacy and safety measures. The primary efficacy pa-
rameter was a pain intensity score recorded by patients
twice daily (morning and evening), using the 0 to 10 NPS.16
Patients were instructed to record their “present pain in-
tensity” and not to take any rescue medication for at least
2 hours before the recording time. Secondary efficacy pa-
rameters included the daily recording of rescue analgesic
consumption, as well as completion of the McGill Pain
Questionnaire (MPQ),17 the Beck Depression Inventory
(BDI),18 and the Pain Disability Index (PDI),19 both before
and at the end of the treatment phase. In addition, pa-
tients were requested at the end of the treatment phase to
complete a global assessment of both efficacy and tolerabil-
ity of the drug that they were receiving, using a 0 to 10
scale. For each parameter, a score of 8 to 10 was regarded
as high, 4 to 7 as moderate, and 0 to 3 as low. Plasma
glucose and HbA1C levels also were measured before and
at the end of the treatment phase. Patients were seen at
four separate office visits during the treatment period and
at the end of the post-treatment phase for dispensing/
collecting the study medications and diaries as well as for
assessment of adverse effects.
Statistical analysis. Based on previous studies with
painful diabetic neuropathy, a 20% to 25% difference in
efficacy between lamotrigine and placebo was considered
to have clinical significance. A sample size of 25 subjects
per group was found to be large enough to provide 80%
power for detecting such a difference according to the Lehr
formula.20 Statistical analysis was performed with SAS
(SAS Institute, Cary, NC). The daily NPS were averaged
across weeks and were analyzed by repeated-measures
analysis of variance. Comparisons of the pretreatment
(baseline) week with each subsequent week of the treat-
ment and the post-treatment phases were performed using
Dunnett’s test. MPQ, BDI, and PDI, as well as glucose and
HbA1C levels, were evaluated by paired t-test, comparing
baseline with end-of-treatment scores. Sex differences and
global assessment scores were compared by chi-square.
Statistical significance was assigned at the p 5 0.05 level.
Data are presented as mean 6 SEM.
Results. Patients. Fifty-nine of 160 screened patients
were randomized to receive either active treatment (29) or
placebo (30). In the lamotrigine-treated group, two pa-
tients were withdrawn because of lack of compliance (in-
complete daily diaries) and were not included in the final
analysis. Three other patients withdrew consent: two be-
cause of the occurrence of adverse events, and one who
requested to leave the study after 4 weeks of treatment for
“personal reasons.” Data on efficacy (NPS) from those
three subjects were included in the analyses up to the
point of their leaving the study. In the placebo-treated
group, four patients were withdrawn from the study and
were not included in the final analysis, three because of
lack of compliance (incomplete diaries) and one because of
protocol violation (opened the emergency blinding code).
Four other subjects did not complete the treatment phase
for the following reasons: one had a car accident in the
fifth week of treatment, two because of adverse events, and
one asked to stop her participation in the study for “per-
sonal reasons” during the fifth week of treatment. Data
from those four subjects up to the point of leaving the
study were included in the analyses. Thus, data related to
baseline diabetes and pain measures, demographics, pri-
mary outcome measures, and adverse events were avail-
able from 53 subjects (lamotrigine, 27; placebo, 26). The
analysis of the secondary outcome measures (MPQ, PDI,
BDI, and global assessment) included only the 46 subjects
(lamotrigine, 24; placebo, 22) who completed the entire
treatment period.
The two groups were not significantly different from
each other in the number of patients enrolled, sex ratio,
weight, type of diabetes, and initial diabetes severity, as
measured by HbA1c and fasting blood glucose. However,
the duration of diabetes in the lamotrigine-treated group
was significantly longer than that in the placebo-treated
group (13.9 6 1.7 years versus 9.6 6 1.1 years). All pa-
tients had distal symmetric pain involving the legs in a
stocking-like distribution. Loss of sensation was noted by
24 subjects in the lamotrigine-treated group and by 21 in
the placebo-treated group. Tingling sensation was reported
by 23 patients in the lamotrigine-treated group and by 21
in the placebo-treated group. Abnormal neurologic exami-
nation results, indicative of peripheral neuropathy (e.g.,
diminished ankle reflexes, sensory loss), were found in all
patients. Nerve conduction tests were performed on nine
subjects in each group and were positive in all cases. The
baseline diabetes and pain data are presented in table 1.
Efficacy. Mean pain intensity gradually dropped from
6.4 6 0.1 in the pretreatment week to 4.2 6 0.1 during
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treatment in the lamotrigine group, and from 6.5 6 0.1 at
pretreatment to 5.3 6 0.1 during treatment in the placebo
group (figure 1). The differences in mean pain intensities
between the two groups were significant at lamotrigine
doses of 200, 300, and 400 mg. The maximal reduction of
pain from baseline was 37% in the lamotrigine-treated
group, versus 20% in the control group. A 50% reduction in
pain during the last 3 weeks of treatment was detected in
12 patients receiving lamotrigine and only in 5 receiving
the placebo (p 5 0.05).
Seven patients in the lamotrigine-treated group re-
corded daily intake of at least one tablet of an analgesic (a
minimum of seven tablets/week) during the baseline
phase, whereas only two were using a similar amount of
rescue analgesics during the last 4 weeks of the treatment
phase. In the placebo-treated group, only three required at
least one tablet daily at baseline, but all three were still
using the same amount at the end of the treatment phase.
The MPQ, BDI, and PDI scores did not change signifi-
cantly from baseline to the end of the treatment phase in
any of the groups (table 2). The global assessment of effi-
cacy performed by the patients at the end of the treatment
phase shows that seven of the 22 subjects (32%) in the
lamotrigine-treated group regarded the drug as highly effi-
cacious, nine (41%) regarded it as moderate, and six (27%)
as low (figure 2). In the placebo-treated group, 2 of 21
subjects (10%) considered it as highly efficacious, 7 (33%)
as moderate, and 12 (57%) as low (p 5 0.07, chi-square). In
contrast, 18 subjects in each group (lamotrigine, 81%; pla-
cebo, 86%) noted that the drug received was highly
tolerable.
Adverse events. Seventeen adverse events were re-
corded in the lamotrigine-treated group and 21 in the
placebo-treated group (table 3). Altogether, four patients
were withdrawn from the study owing to adverse events,
with two from each group. In the lamotrigine-treated
group, rash developed in two patients during the fourth
and the seventh weeks of the treatment period, both of
which resolved shortly after lamotrigine use was discontin-
ued. In the placebo-treated group, one subject had impo-
Figure 1. Weekly pain intensity
(mean 6 SEM) in the lamotrigine-
treated (dark labels) and in the placebo-
treated (open labels) groups. *p ,
0.001. Numbers in brackets represent
the number of patients who were in-
cluded in the analysis at each dose
level. L 5 lamotrigine; P 5 placebo.
Table 1 Demographic and baseline diabetes pain data
Characteristic
Lamotrigine,
n 5 27
Placebo,
n 5 26 p Value
Age, y 52.7 6 2.1 57.8 6 1.7 NS
Men/women 17/10 16/10 NS
Weight, kg 82.1 6 2.3 81.4 6 2.6 NS
Diabetes type
Type 2 24 24 NS
Type 1 3 2
Duration of diabetes 13.9 6 1.7 9.6 6 1.1 0.04
Fasting glucose, mg/dL 215 6 15 196 6 13 NS
Hemoglobin A1c, % 8.2 6 0.3 8.4 6 0.4 NS
Pain duration 3.6 6 0.7 3.8 6 0.6 NS
Previous treatment*
Antidepressants 8 10
Anticonvulsants 7 8
Capsaicin cream 4 2
Other 2 3
Pain score, NPS 6.4 6 0.1 6.6 6 0.1 NS
MPQ
Words 11.9 6 0.7 11.4 6 0.7 NS
Score 28.1 6 2.0 29.6 6 1.6
PDI, total score 4.0 6 0.6 4.6 6 0.6 NS
BDI, total score 12.9 6 1.5 16.1 6 2.0 NS
Data expressed as mean 6 SEM.
* Number of patients who have used each treatment for control
of neuropathic pain.
MPQ 5 McGill Pain Questionnaire; PDI 5 Pain Disability Index;
BDI 5 Beck Depression Inventory; NS 5 not significant; NPS 5
numerical pain scale.
August (1 of 2) 2001 NEUROLOGY 57 507
195
tence during the first week of treatment, and the other had
diarrhea in the fifth week.
Discussion. The results of this study clearly show
that lamotrigine attenuates painful diabetic neurop-
athy at a daily dosage of 200 to 400 mg, and has a
significantly superior analgesic effect compared with
placebo. The same range of lamotrigine dosages was
suggested as efficacious in several other trials of dia-
betic neuropathy,9 trigeminal neuralgia,10 complex re-
gional pain syndrome type 1,11 chronic refractory
neuropathic pain of mixed etiologies,12 painful HIV-
associated neuropathy,13 and central poststroke pain.14
Not all subjects in this study responded to treatment.
Six patients regarded lamotrigine as having a low de-
gree of efficacy, and can probably be categorized as
“nonresponders.” A similar group of nonresponding pa-
tients with painful diabetic neuropathy also was iden-
tified in a previous open-label trial.9 A second category
consists of nine patients who regarded lamotrigine as
moderately effective. The third category consists of the
seven patients who considered lamotrigine to be highly
efficacious. It is possible that if insufficient analgesia
has been achieved at a daily dose of 300 to 400 mg,
increased titration of the dose still can be safe21 and
effective. A superior analgesic effect of higher lam-
otrigine doses, however, has not been confirmed yet by
controlled clinical trials.
The magnitude of pain relief achieved with lam-
otrigine in the current study is comparable with that
found in recent studies with gabapentine22 and tram-
adol.23 In all three studies, the active drug reduced
pain scores roughly by 40% to 45%, and the placebo
by 15% to 20%. In addition, the adverse events pro-
file of lamotrigine was similar to that of the placebo
(with the exception of the two patients in whom rash
developed). Lamotrigine therefore can be regarded as
an effective and a safe agent for the treatment of
painful diabetic neuropathy, provided it is slowly
titrated.
The pathophysiologic process of neuropathic pain
is not entirely clear. One of the suggested mecha-
nisms for such pain is the generation of spontaneous
activity in regenerating small-caliber primary affer-
ents. Such activity has been shown in rat models of
both nerve injury1 and diabetes.2 This activity re-
quires the flow of sodium into the nerve. In addition,
there now is evidence that by releasing excitatory
amino acids, particularly glutamate, which, in turn,
act at the NMDA receptor, the activity of small-
caliber afferents may induce hyperexcitability in dor-
sal horn spinal neurons.3,4 Lamotrigine inhibits the
release of glutamate, possibly by stabilizing the neu-
Figure 2. Global assessment of efficacy completed by pa-
tients at the end of the treatment phase. Data are pre-
sented as percentages of patients in each group. Dark bars
represent lamotrigine-treated patients (n 5 22), and open
bars represent the placebo-treated group (n 5 21).
Table 3 Number of patients reporting adverse events
Adverse event Lamotrigine Placebo
Rash 2 0
Nausea 4 4
Epigastric pain 3 1
Headache 2 2
Drowsiness 1 4
Dizziness 3 4
Other 2*† 6*‡§¶
Total 17 21
* Falling down.
† Constipation.
‡ Pancreatitis.
§ Impotence during first week of placebo treatment.
¶ Irritability.
Table 2 Secondary and biochemical parameters
Adverse event
Lamotrigine, n 5 24 Placebo, n 5 22
p ValuePretreatment Posttreatment Pretreatment Posttreatment
MPQ, words 12.0 6 0.8 12.5 6 0.9 11.1 6 0.8 10.7 6 1.0 NS
BDI, total score 14.1 6 1.5 14.5 6 2.1 17.1 6 2.2 15.9 6 2.2 NS
PDI, total score 4.0 6 0.8 3.8 6 0.7 4.4 6 0.9 4.3 6 0.8 NS
Fasting glucose, mg/dL 212 6 15 206 6 13 185 6 13 175 6 17 NS
Hemoglobin A1c, % 8.4 6 0.3 8.2 6 0.3 8.4 6 0.4 7.8 6 0.4 NS
MPQ 5 McGill Pain Questionnaire; PDI 5 Pain Disability Index; BDI 5 Beck Depression Inventory; NS 5 not significant.
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ral membrane through blocking activation of voltage-
sensitive sodium channels.6 It therefore is likely that
the antinociceptive action of lamotrigine takes place
at both peripheral (e.g., primary afferent) and cen-
tral (e.g., spinal cord) levels. The unchanged glucose
and HbA1C levels also indicate that lamotrigine an-
algesia is mediated by neural rather than biochemi-
cal mechanisms.
Recent reports suggest that lamotrigine may have
mood-stabilizing action and antidepressant proper-
ties in patients with bipolar affective disorder.24,25
The unchanged BDI scores in the lamotrigine-
treated group indicate that lamotrigine exerts its an-
algesic effect independent of its mood-stabilizing
effect. The lack of improvement in the MPQ and the
PDI possibly can be attributed to the fact that most
of the patients had long-lasting, intractable pain.
The relatively short treatment period at an effective
dose (practically, only 3 weeks) was too short to pro-
duce an improvement that would be reflected by
those parameters. It is possible that a longer treat-
ment period could lead to an improvement in those
parameters as well.
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Relief			of			Painful			Diabetic			Peripheral			Neuropathy			With	
Pregabalin:			A			Randomized,			Placebo-Controlled			Trial	
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Abstract:		This		was		a		6-week,		randomized,		double-blind,		multicenter		study		evaluating		the		efﬁcacy		of	
pregabalin		in		the		treatment		of		painful		diabetic		neuropathy.		Two		hundred		forty-six		men		and		women	
with		painful		diabetic		neuropathy		received		pregabalin		(150		or		600		mg/day		by		mouth)		or		placebo.		The	
primary		efﬁcacy		variable		was		mean		pain		score		at		the		end		of		treatment.		Efﬁcacy		results		indicate		that	
pregabalin		600		mg/day		signiﬁcantly		decreased		mean		pain		score		to		4.3		(vs		5.6		for		placebo,		P	 .0002)	
and		increased		the		proportion		of		patients		who		had		a		>50%		decrease		from		baseline		pain		(39%		vs		15%	
for		placebo,		P	 .002).		Pregabalin		also		signiﬁcantly		reduced		sleep		interference,		past		week		and		present	
pain		intensity,		sensory		and		affective		pain		scores,		and		bodily		pain		and		decreased		by		>50%		the		number	
of		patients		describing		their		pain		as		gnawing,		sickening,		fearful,		and		punishing–	cruel.		More		patients	
receiving		pregabalin		600		mg/day		than		placebo		showed		improvement,		as		rated		on		the		Clinical		and	
Patient		Global		Impression		of		Change		scales,		73%		vs		45%		and		85%		vs		47%,		respectively.		Pregabalin	
150		mg/day		was		essentially		no		different		from		placebo.		Dizziness		was		the		most		common		side		effect.	
These		study		results		show		pregabalin		600		mg/day		to		be		safe		and		effective		in		reducing		the		pain		and	
other		associated		symptoms		of		painful		diabetic		neuropathy.	
Perspective:		Painful		diabetic		peripheral		neuropathy		is		a		challenging		neuropathic		pain		syndrome.	
This	randomized	controlled	trial	demonstrates	that	pregabalin,	a	new	drug	that	interacts	with	the	 2-	
protein		subunit		of		the		voltage-gated		calcium		channel,		is		an		efﬁcacious		and		safe		treatment		for		the		pain	
of		this		condition.	
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regabalin		is		a		selective,		high-afﬁnity		ligand		for		the	
2-	protein	subunit	of	voltage-gated	calcium	chan-	
nels,12		which		plays		a		role		in		development		of		patho-	
logic	changes	believed	to	be	associated	with	neuropathic	
pain		in		humans.11,15		Pregabalin		reduces		calcium		inﬂux	
and		diminishes		release		of		several		neurotransmitters.5,9		It	
shows		analgesic		effects		in		animal		models		of		neuropathic	
pain8		and		has		analgesic7,14		and		antianxiety22		effects		in	
humans.		This		proﬁle		suggests		pregabalin		might		be		an	
effective		new		treatment		for		neuropathic		pain.	
The	highly	prevalent	and	heterogeneous	neuropathies	
caused		by		diabetes		are		often		complicated		by		pain.3,10	
Pharmacotherapy		is		the		mainstay		approach		to		treat-	
ment,		and		controlled		studies		have		demonstrated		poten-	
tial		effectiveness		of		opioid		drugs,13		varied		antidepres-	
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sants,16,25		gabapentin,2		tramadol,24		and		mexiletine.21	
Clinical	responses	vary,	and	treatment	of	painful	diabetic	
neuropathy,		like		other		neuropathic		pains,		continues		to	
evolve.		In		this		study,		pregabalin		was		compared		to		pla-	
cebo		for		its		effect		on		pain		and		a		variety		of		associated	
symptoms		that		commonly		accompany		diabetic		neuropa-	
thy.	
	
Materials		and		Methods	
This		was		a		randomized,		double-blind,		placebo-con-	
trolled,		parallel-group		study		in		patients		with		diabetes	
and	painful	diabetic	neuropathy.	An	Institutional	Review	
Board		or		Ethics		Committee		for		each		of		29		participating	
US		and		Canadian		centers		approved		the		protocol,		and	
each		subject		provided		informed		consent.	
Patients		were		recruited		between		March		1998		and	
March		1999.		Individuals		with		diabetes		and		painful		distal	
symmetrical		sensorimotor		polyneuropathy		for		1		to		5	
years		were		potentially		eligible		to		enter		into		the		study.	
Neuropathy		was		conﬁrmed		by		history		and		detailed		neu-	
rologic		examination.		Inclusion		criteria		included		age		18	
years,		hemoglobin		A1C		levels		11%,		and		the		ongoing	
experience	of	moderate	to	severe	pain.	Exclusion	criteria	
included		neurologic		disorders		unrelated		to		diabetic		neu-	
ropathy,	any	condition	that	could	confound	study	assess-	
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Figure		1.	Patient	disposition.	Of	396	patients	who	entered	the	baseline	period,	150	were	withdrawn:	135	who	did	not	meet	study	
criteria,	3	who	experienced	AEs,	and	12	others.	Of	those	randomized	to	pregabalin	150	or	600	mg/day	or	placebo	(N	 246),	219	
completed	the	6-week	study	period.	PGB,	pregabalin.	
	
ments,		recent		treatment		with		any		investigational		drug,	
or	serious	medical	problems.	Women	could	not	be	lactat-	
ing	and	were	required	to	have	a	negative	pregnancy	test	
result		and		to		use		appropriate		contraception		if		of		child-	
bearing		potential.	
Eligible		patients		had		to		meet		additional		criteria		for	
poorly		controlled		pain,		including		a		score		of	 40		mm		on	
the		visual		analog		scale		(VAS)		of		the		Short		Form-McGill	
Pain	Questionnaire20	(SF-MPQ)	and	an	average	daily	pain	
score	 4		for		4		or		more		days		during		baseline.		Phenothia-	
zines,	antiarrhythmic	agents,	and	pteridine	and	the	com-	
bination		of		antihistamines		and		macrolide		antibiotics	
were		prohibited		during		the		study		owing		to		their		proar-	
rhythmic		activity.		Other		medications		that		could		affect	
efﬁcacy		or		safety		were		to		be		discontinued		either		14		days	
(antiepileptic		drugs,		nonsteroidal		anti-inﬂammatory	
drugs)		or		30		days		(opioids,		tricyclic		antidepressants,		ben-	
zodiazepines,		muscle		relaxants,		capsaicin,		mexiletine,	
dextromethorphan)		before		being		administered		study	
drug.		Aspirin		(for		prophylaxis		of		myocardial		infarction	
and		transient		ischemic		attacks),		acetaminophen		(		3	
g/day),		and		stable		doses		of		serotonin		reuptake		inhibitors	
were		allowed.	
Patients	were	randomly	assigned	to	pregabalin	(150	or	
600		mg/day)		or		placebo.		Randomization		was		computer-	
generated		and		conducted		within		sequential		blocks		of		6	
patients.		Eighty		patients		per		treatment		group		was		esti-	
mated	to	give	90%	power	to	detect	a	difference	of	1.3	in	
end		point		mean		pain		score		between		placebo		and		600	
mg/day	pregabalin,	assuming	2-sided	testing	at	the	0.025	
level.	
After		a		1-week		baseline,		eligible		patients		entered		a	
6-week		(2-week		titration/4-week		ﬁxed		dose)		double-	
blind		treatment		phase.		The		dose		of		pregabalin		was		ti-	
trated		from		25		mg/day		to		150		mg/day		or		from		100		mg/	
day		to		600		mg/day		during		the		2-week		titration		period	
and		ﬁxed		thereafter.		Pregabalin		was		provided		as		2		dif-	
ferently	sized	capsules.	To	assure	blinding,	study	medica-	
tion		was		provided		in		2		bottles,		one		with		small-sized		cap-	
sules		containing		25		mg		pregabalin		or		placebo		and		the	
other		with		large-sized		capsules		containing		100		mg		pre-	
gabalin		or		placebo.		Patients		took		2		capsules		from		each	
bottle	3	times	daily.	At	each	stage	of	the	study,	including	
titration,		all		patients,		regardless		of		treatment		group,	
took		the		same		number		of		capsules		from		each		bottle		per	
day.		The		blind		was		maintained		until		completion		of		study	
and		data		evaluability		determination.		Visits		occurred		at	
the		start		of		baseline		(week		–1)		and		double-blind		phases	
(week		0)		and		then		biweekly		(weeks		2,		4,		and		6).	
The		primary		efﬁcacy		parameter		was		pain.		Each		day		on	
awakening,		patients		recorded		their		pain		during		the		pre-	
vious		24-hour		period		by		circling		the		appropriate		number	
on		a		numeric		scale		of		0		(no		pain)		to		10		(worst		possible	
pain)		in		a		daily		diary.		Secondary		efﬁcacy		parameters		as-	
sessed	pain	characteristics,	sleep	interference,	health	sta-	
tus,		psychologic		state,		and		global		improvement.		The	
SF-MPQ,20		a		well-validated		multidimensional		pain		ques-	
tionnaire,		recorded		past		week		pain		intensity		on		a		VAS	
ranging		from		0		mm		(no		pain)		to		100		mm		(worst		possible	
pain),		present		pain		intensity		(PPI)		on		a		numeric		scale		of		0	
(none)		to		5		(excruciating),		and		past-week		intensity		of	
each		of		11		sensory		and		4		affective		descriptors		of		pain		on	
a		numeric		scale		from		0		(none)		to		3		(severe).		The		latter	
were		summed		to		yield		sensory		and		affective		scores		and	
added	for	total	score.	Sleep	interference	was	recorded	in	
daily		diaries		on		a		numeric		scale		of		0		(did		not		interfere	
with		sleep)		to		10		(completely		interfered,		unable		to		sleep	
because		of		pain).		The		36-Item		Short-form		Health		Sur-	
199
	
ORIGINAL		REPORT/Richter		et		al	
Table		1.	Baseline		Demographic		and		Disease		Characteristics	
	
	
PLACEBO	
255	
	
	
PREGABALIN	
	
150	MG/DAY																						600	MG/DAY	
CHARACTERISTIC	 (n			85)																								(n			79)																								(n			82)	
	
Men/women,	N	 46/39	 57/22	 46/36	
White/black/hispanic/other,	N	 67/7/8/3	 74/3/2/0	 65/9/8/0	
Age	(y),	mean	 SD	 57.1	 10.3	 56.3	 9.4	 57.8	 9.5	
Weight	(kg),	mean	 SD	 90.81	 20.40	 97.96	 18.37	 96.55	 19.77	
Diabetes	characteristics	
Type	1,	N	 14	(16.5%)	 7	(8.9%)	 2	(2.4%)	
Type	2,	N	 71	(83.5%)	 72	(91.1%)	 80	(97.6%)	
HbA1c	values,	mean	 SD	 8.1	 1.4	 8.2	 1.5	 8.2	 1.4	
Duration	(y),	mean	 SD	 10.6	 8.3	 8.2	 9.1	 9.3	 8.8	
Distribution	of	neuropathic	pain	
Lower	extremities,	N	 85	(100%)	 79	(100%)	 82	(100%)	
Upper	extremities,	N	 30	(35.3%)	 28	(35.4%)	 26	(31.7%)	
Antidiabetic	medication,	N	 81	(95.3%)	 74	(94.9%)	 77	(93.9%)	
	
Abbreviation:	SD,	standard	deviation.	
	
	
vey27	(SF-36),	a	commonly	used	measure	of	health	status,	
and		Proﬁle		of		Mood		States17		(POMS),		a		well-validated	
measure		of		psychologic		state,		were		administered		at	
week		0		and		the		ﬁnal		visit.		Clinician		and		Patient		Global	
Impression		of		Change		(CGIC,		PGIC)		were		each		scored	
from		1		(very		much		improved)		to		7		(very		much		worse)		at	
the		ﬁnal		visit.	
Safety		was		evaluated		by		adverse		events		(AEs);		clinical	
laboratory		determinations;		electrocardiogram;		and		gen-	
eral		medical,		neurologic,		and		ophthalmologic		examina-	
tions.		The		neurologic		examination		included		a		clinician-	
rated		question		assessing		the		presence		or		absence		of	
allodynia.		Changes		from		baseline		to		the		end		of		the		dou-	
ble-blind		phase		in		examination		data		were		recorded		as	
AEs		if		they		were		deemed		clinically		signiﬁcant		by		the		in-	
vestigators.	
Plasma		pregabalin		concentrations		from		blood		col-	
lected	at	weeks	0,	2,	4,	and	6	were	determined	by	using	a	
validated		high-performance		liquid		chromatographic	
method	with	ultraviolet	detection.	Predicted	(based	on	a	
pharmacokinetic		model		of		pregabalin		constructed		from	
data		rich		[serial		plasma		collections]		single-		and		multiple-	
dose		studies		in		healthy		volunteers,		including		a		single-	
dose		tolerance		and		pharmacokinetic		study,		2		multiple-	
dose		tolerance		and		pharmacokinetic		studies,		and		a	
single-dose,	food-effects	study)	versus	observed	pharma-	
cokinetic	values	were	analyzed	by	using	nonlinear	mixed	
effects		modeling		(NONMEM		Version		V;		University		of		Cal-	
ifornia		at		San		Francisco,		San		Francisco,		Calif).	
Analyses		were		conducted		on		the		intent-to-treat		popu-	
lation	(all	randomized	patients	who	received	at	least	one	
dose		of		study		medication).		Analysis		of		covariance		main	
effects		models,		with		baseline		as		covariate		and		95%		con-	
ﬁdence		intervals		(CIs),		were		constructed		on		the		differ-	
ence		in		least		square		(LS)		means		between		each		of		the		two	
dosages		of		pregabalin		and		placebo		to		evaluate		group	
differences	in	pain	scores	from	daily	pain	diaries,	SF-MPQ	
scores,		sleep		interference		scores,		POMS		scales,		and		scores	
on		the		SF-36		domains.		Generalizability		of		results		among	
centers		was		tested		by		repeating		the		analysis,		including		a	
treatment-by-center		interaction		term.		PGIC,		CGIC,		and	
the		proportion		of		patients		with		at		least		a		50%		reduction	
in	mean	pain	score	(baseline	to	end	point)	were	analyzed	
by		using		the		Cochran-Mantel-Haenszel		test.		Patients	
with	missing	data	for	a	given	parameter	at	baseline	or	at	
the		time		point		to		be		analyzed		were		automatically		ex-	
cluded		from		that		analysis.	
	
Results	
Patient		disposition		is		shown		in		Fig		1,		and		demographic	
and		baseline		characteristics		are		summarized		in		Table		1.	
At		end		point,		patients		receiving		600		mg/day		pregabalin	
had	a	signiﬁcantly	lower	mean	pain	score	than	did	patients	
receiving		placebo		(P			.0002)		(Table		2),		and		signiﬁcantly	
more		had		a		50%		reduction		from		baseline		pain		(P		.002)	
(Fig		2).		Starting		at		week		2,		when		they		were		receiving		the	
full		600		mg/day		dosage		of		pregabalin,		these		patients		had	
signiﬁcantly		greater		weekly		decreases		from		baseline		mean	
pain		scores		(P		.05		vs		placebo)		(Fig		3).	
VAS,		PPI,		sensory,		affective,		and		total		scores		on		the	
SF-MPQ	were	all	signiﬁcantly	lower	after	treatment	with	
600	mg/day	pregabalin	(P		.01	vs	placebo)	(Table	3).	The	
percentage		of		patients		who		reported		gnawing,		sicken-	
ing,		fearful,		and		punishing-cruel		pain		was		more		than	
halved.		Decreases		from		baseline		VAS,		PPI,		and		total	
scores		were		greater		starting		at		week		2,		the		ﬁrst		assess-	
ment	of	these	parameters	during	the	treatment	phase	(P	
.05		vs		placebo).	
Patients		receiving		600		mg/day		pregabalin		had		signiﬁ-	
cantly		lower		sleep		interference		scores		starting		at		week		1	
(Fig		3)		and		at		end		point		(least		square		mean		difference,	
1.152;	95%	CI,		1.752	to		0.551;	P		.0004	vs	placebo).	
These		patients		also		had		signiﬁcantly		better		CGIC		and	
PGIC		assessments		(P			.002		for		either		vs		placebo),		and	
more		were		rated		as		improved		(Fig		4).	
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Figure	2.	Percentage	of	patients	responding	to	treatment	with	
a		50%	decrease	in	baseline	daily	pain.	Decrease	in	pain	was	
signiﬁcantly	greater	for	those	who	received	600	mg/day	pre-	
gabalin	compared	with	those	who	received	placebo	(P	 .002).	
PGB,	pregabalin;	PBO,	placebo.	
	
There		were		no		treatment-related		differences		in		mood	
assessed		by		the		POMS		or		in		health		status		assessed		by		the	
SF-36,		except		for		bodily		pain,		which		was		signiﬁcantly		im-	
proved		by		both		doses		of		pregabalin		(P	 .0106		for		either	
dose		vs		placebo).		Pregabalin		150		mg/day		was		not		signif-	
icantly		different		from		placebo		on		any		other		efﬁcacy		pa-	
rameter.	
There		were		no		clinically		signiﬁcant		changes		in		deep	
tendon		reﬂexes		or		peripheral		sensory		examination		(pin	
prick,		vibration		perception)		among		treatment		groups,	
but		among		patients		with		allodynia		at		baseline,		most		no	
longer		reported		allodynia		after		pregabalin		(18/28	
[64.3%]		600-mg/day		and		13/23		[56.5%]		150-mg/day		vs	
5/22		[22.7%]		placebo).	
A		summary		of		treatment-associated		and		not-associ-	
ated	AEs	by	decreasing	frequency	appears	in	Table	4.	The	
most		common		treatment-associated		AEs		in		the		600-mg/	
day		group		were		dizziness		(30.5%		of		patients),		somno-	
lence		(18.3%		of		patients),		and		headache		(13.4%),	
whereas	in	the	150-mg/day	group,	the	most	common	AEs	
were		dizziness		(6.3%),		somnolence		(5.1%),		and		asthenia	
(3.8%).		In		the		placebo		group,		headache		(7.1%)		and		som-	
nolence,		asthenia,		and		amblyopia		(3.5%		each)		were		the	
most		commonly		observed		treatment-associated		AEs.	
Most		AEs		were		of		a		maximum		intensity		of		mild		or		mod-	
erate.		AEs		considered		severe		that		occurred		in		more		than	
1		patient		in		the		600-mg/day		group		were		dizziness		(3		pa-	
tients),		somnolence		(2		patients),		and		asthenia		(2		pa-	
tients).	No	AEs	considered	severe	were	reported	by	more	
than		1		patient		in		the		150-mg/day		pregabalin		group.		To-	
gether,		dizziness,		somnolence,		and		headache		caused		9	
patients		to		discontinue		the		study		(6		pregabalin		600-mg/	
day,	1	pregabalin	150-mg/day,	2	placebo).	There	were	no	
clinically		signiﬁcant		differences		among		treatment	
groups		in		ophthalmologic		examinations,		physical		exam-	
ination		parameters,		including		orthostatic		hypotension	
and		electrocardiogram,		and		no		evidence		of		worsening	
glucose		control		or		diabetic		ketoacidosis.	
Steady-state		plasma		pregabalin		concentrations		associ-	
ated	with	150	and	600	mg/day	ranged	from	0.141	to	3.53	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.	Reduction	in	mean	pain	score	(top	panel)	and	in	mean	
sleep-interference	score	(bottom	panel)	over	time	assessed	by	
daily	pain	and	by	daily	sleep	diaries.	PGB,	pregabalin;	PBO,	pla-	
cebo.	
	
g/mL		and		from		0.174		to		17.6		g/mL,		respectively.		There	
was		a		linear		relationship		between		predicted		and		ob-	
served		values		(Fig		5).	
	
Discussion	
Painful		neuropathy		is		highly		prevalent		in		the		diabetic	
population		and		can		profoundly		undermine		quality		of	
life.10	Pain	management	is	an	essential	component	in	the	
comprehensive		care		of		these		patients.	
Several		controlled		studies		have		demonstrated		that	
painful		diabetic		peripheral		neuropathy		can		be		relieved	
by		antidepressants,19		anticonvulsants,18		tramadol,24	
agonist		opioids,28		and		topical		application		of		capsaicin,29	
and	recent	meta-analyses4,26	support	those	ﬁndings.	Un-	
fortunately,	the	use	of	these	agents	can	be	limited	by	the	
extent		of		pain		relief		provided		and		the		occurrence		of		sig-	
niﬁcant		side		effects.		Thus,		a		need		exists		for		additional	
safe		and		effective		agents		for		painful		diabetic		peripheral	
neuropathy.	
In		this		study,		patients		who		received		pregabalin		600	
mg/day		experienced		signiﬁcantly		less		pain		than		those	
who		received		placebo.		The		average		reduction		in		pain	
score		from		baseline		was		2.4		on		a		0		to		10		numeric		scale,	
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MEAN	 SD	PAIN	SCORE	
	
	
TREATMENT	 N	
	
BASELINE	
END	
POINT	
LS	MEAN	
SE	
END	POINT	
LS	MEAN	DIFFERENCE	
(95%	CI)	
PREGABALIN-PLACEBO	
P	
VALUE	
	
Placebo	 82*	 6.9	 1.6	 5.8	 2.2	 5.55	 0.23	
Pregabalin	
150	mg/day	 79	 6.5	 1.3	 4.9	 2.2	 5.11	 0.24	 0.440	(	 1.080	to	0.199)	 .1763	
600	mg/day	 82	 6.7	 1.7	 4.3	 2.7	 4.29	 0.26	 1.264	(	 1.890	to		0.639)	 .0002	
	
Abbreviations:	SD,	standard	deviation;	LS,	least	square;	SE,	standard	error;	CI,	conﬁdence	interval.	
*85	at	baseline.	
	
	
with		39%		of		patients		having	 50%		reduction		in		their	
pain.		This		degree		of		response		is		widely		considered		to	
be		clinically		meaningful		and		corresponds		with		the	
highest		degree		of		improvement		assessed		by		PGIC.6,7	
Treatment	with	pregabalin	at	600	mg/day	also	reduced	
sleep		interference		and		signiﬁcantly		improved		all		compo-	
nents		of		the		SF-MPQ		by		week		2.		A		lower		prevalence		of	
allodynia,		improvement		in		bodily		pain,		and		substantial	
global		improvement		were		observed		at		study’s		end.		Pre-	
gabalin		showed		predictable		pharmacokinetics		and		was	
well		tolerated,		as		evidenced		by		the		low		rates		of		study	
discontinuation.	
Although		direct		comparisons		of		pregabalin		with		tricy-	
clic		antidepressants		and		gabapentin		have		not		been		con-	
ducted,	the	ﬁndings	in	this	study	suggest	that	pregabalin	
produces		clinically		signiﬁcant		improvement		in		the		range	
observed		with		these		other		drugs.		Pregabalin		is		structur-	
ally		and		mechanistically		related		to		gabapentin		but		dif-	
fers		from		gabapentin		in		exhibiting		linear		pharmacoki-	
netics		with		increasing		dose		and		low		intersubject	
variability.		These		properties		might		make		pregabalin		eas-	
ier		to		prescribe		and		might		impart		a		better-deﬁned		effec-	
tive		dose		range.	
In		another		controlled		trial,		pregabalin		300		mg/day		also	
signiﬁcantly		improved		pain,		sleep		interference,		and		mood	
in		patients		with		painful		diabetic		neuropathy.23		Together,	
these		2		independent,		randomized		clinical		trials		constitute	
evidence		that		pregabalin		at		300		or		600		mg/day		produces	
signiﬁcant		improvement		of		pain,		sleep,		and		at		least		some	
aspects		of		health		status		and		mood.		Consistent		with		clini-	
cally		recognized,		dose-dependent		effects		of		anticonvul-	
sants		in		neuropathic		pain,		best		characterized		with		gabap-	
entin,1	pregabalin	150	mg/day	did	not	differ	from	placebo.	
Despite		substantial		advances		in		pharmacotherapy		of	
neuropathic		pain,		outcomes		are		often		unsatisfactory.	
Many	drugs	are	tried	despite	a	lack	of	evidence	for	safety	
or		efﬁcacy		in		the		diabetic		population,		emphasizing		the	
need		for		controlled		clinical		trials		of		new		pharmacother-	
	
	
Table		3.	Short-Form		McGill		Pain		Questionnaire		Scores	
LS	MEAN	 SE	
	
LS	MEAN	DIFFERENCE	(95%	CI)	
	
P	
SCORE	 TREATMENT	 N	 END	POINT	 PREGABALIN-PLACEBO	 VALUE	
	
VAS	 Placebo	 82	 58.05	 2.68	
Pregabalin	
150	mg/day	 79	 53.27	 2.75	 4.78	(	 12.20	to	2.64)	 .2058	
600	mg/day	 82	 43.38	 2.70	 14.67	(	 21.92	to		7.41)	 .0002	
PPI	 Placebo	 82	 1.96	 0.11	
Pregabalin	
150	mg/day	 79	 1.78	 0.12	 0.17	(	 0.49	to	0.14)	 .2836	
600	mg/day	 82	 1.30	 0.12	 0.66	(	 0.97	to		0.35)	 .0002	
Sensory	 Placebo	 82	 14.61	 0.73	
Pregabalin	
150	mg/day	 79	 12.65	 0.76	 1.97	(	 3.99	to	0.06)	 .0570	
600	mg/day	 82	 10.07	 0.74	 4.54	(	 6.53	to		2.56)	 .0002	
Affective	 Placebo	 82	 3.35	 0.29	
Pregabalin	
150	mg/day	 79	 2.78	 0.30	 0.57	(	 1.38	to	0.24)	 .1664	
600	mg/day	 82	 2.04	 0.30	 1.31	(	 2.10	to		0.51)	 .0028	
Total	 Placebo	 82	 17.97	 0.96	
Pregabalin	
150	mg/day	 79	 15.48	 0.99	 2.49	(	 5.14	to	0.16)	 .0651	
600	mg/day	 82	 12.14	 0.97	 5.83	(	 8.43	to		3.23)	 .0002	
	
Abbreviations:	LS,	least	square;	SE,	standard	error;	CI,	conﬁdence	interval;	VAS,	visual	analog	scale;	PPI,	present	pain	intensity.	
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Figure		4.	CGIC	and	PGIC	scores	at	study	end	point.	A	signiﬁcantly	greater	percentage	of	patients	who	received	pregabalin	600	
mg/day	vs	placebo	had	improved	scores	on	both	scales	(P	 .002).	CMH,	Cochran-Mantel-Haenszel.	
	
	
apies		to		expand		treatment		options		and		further		the		goal	
of		evidence-based		decision		making.		The		present,		6-week	
study		establishes		that		pregabalin		600		mg/day		is		safe		and	
effective		in		patients		with		painful		diabetic		neuropathy.	
Although		no		conclusions		about		the		durability		of		re-	
sponse		or		AE		proﬁle		during		long-term		administration	
can		be		drawn		from		this		study,		75		patients		(91%)		treated	
with		600		mg/day		pregabalin		and		73		patients		(92%)	
treated		with		pregabalin		150		mg/day		entered		the		open-	
label		extension,		and		73		patients		(86%)		treated		with		pla-	
cebo		were		converted		to		pregabalin		treatment		for		the	
open-label		extension.		Additional		studies		are		needed		to	
further		explore		dose		response		at		higher		doses,		provide	
comparative		efﬁcacy		data		against		other		treatments,		as-	
sess		value		of		combination		therapies,		and		conﬁrm		long-	
term		treatment		effectiveness.	
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%	PATIENTS	
	
PREGABALIN	
	
	
ADVERSE	EVENT	
PLACEBO	
(n	
85)	
150	MG/	
DAY	(n	
79)	
600	MG/	
DAY	(n	
82)	
	
Dizziness	 2.4	 10.1	 37.8	
Somnolence	 3.5	 5.1	 22.0	
Peripheral	 4.7											3.8												17.1	
edema	
Headache	 10.6	 7.6	 15.9	
Asthenia	 3.5	 3.8	 12.2	
Accidental	injury	 5.9	 2.5	 9.8	
Weight	gain	 0	 1.3	 9.8	
Amblyopia	 5.9	 2.5	 8.5	
Dry	mouth	 2.4	 0	 8.5	
Pain	 8.2	 3.8	 7.3	
Constipation	 4.7	 3.8	 6.1	
Infection	 9.4	 12.7	 6.1	
Diarrhea	 3.5	 5.1	 2.4	
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Tapentadol potentiates descending pain inhibition in chronic
pain patients with diabetic polyneuropathy
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Editor’s key points
† Tapentadol is a m-opioid
agonist and also inhibits
norepinephrine reuptake.
† This study evaluates the
main analgesic
mechanisms of
tapentadol in diabetic
neuropathy.
† Conditioned pain
modulation and offset
analgesia were used to
investigate the
endogenous pain
pathways.
† Tapentadol’s analgesic
effect in diabetic
neuropathy is mainly via
activation of descending
inhibitory pathways.
Background. Tapentadol is an analgesic agent for treatment of acute and chronic pain that
activates the m-opioid receptor combined with inhibition of neuronal norepinephrine
reuptake. Both mechanisms are implicated in activation of descending inhibitory pain
pathways. In this study, we investigated the influence of tapentadol on conditioned pain
modulation (CPM, an experimental measure of endogenous pain inhibition that gates
incoming pain signals as a consequence of a preceding tonic painful stimulus) and offset
analgesia (OA, a test in which a disproportionally large amount of analgesia becomes
apparent upon a slight decrease in noxious heat stimulation).
Methods. Twenty-four patients with diabetic polyneuropathy (DPN) were randomized to
receive daily treatment with tapentadol sustained-release (SR) [average daily dose 433 (31)
mg] or placebo for 4 weeks. CPM and OA were measured before and on the last day of
treatment.
Results.Before treatment, none of the patients had significant CPM or OA responses. At week 4
of treatment, CPM was significantly activated by tapentadol SR and coincided with significant
analgesic responses. CPM increased from 9.1 (5.4)% (baseline) to 14.3 (7.2)% (placebo) and
24.2 (7.7)% (tapentadol SR, P,0.001 vs placebo); relief of DPN pain was also greater in
patients treated with tapentadol than placebo (P¼0.028). Neither placebo nor tapentadol
SR treatment had an effect on the magnitude of the OA responses (P¼0.78).
Conclusions. Tapentadol’s analgesic effect in chronic pain patients with DPN is dependent on
activation of descending inhibitory pain pathways as observed by CPM responses.
Clinical trial registration. The study was registered at trialregister.nl under number NTR2716.
Keywords: chronic pain, diabetic polyneuropathy; conditioned pain modulation; morphine;
neuropathic pain, offset analgesia; pain, tapentadol
Accepted for publication: 31 December 2013
Endogenous pain modulatory pathways are important regula-
tors of human pain perception. Both inhibitory and facilitatory
descending pathways, originating at higher centres, modulate
the activity of nociceptive neurones at the level of the spinal
dorsal horn, enhancing or inhibiting noxious signal propaga-
tion to the brain.1 A shift in the balance between pain inhibition
and facilitation has been suggested to underlie the develop-
ment or maintenance of many chronic pain syndromes, such
as fibromyalgia, irritable bowel syndrome, chronic pancreatitis,
and neuropathic pain syndromes.2 – 5 Animal studies show that
effective engagement of descending inhibition protects
against chronic neuropathic pain development. Various neuro-
transmitter systems are involved in the descending pain path-
ways, including endogenous opioid peptides, norepinephrine,
and serotonin. Release of endogenous opioids and norepin-
ephrine underlie pain inhibition, whereas the serotonergic
pathway has both pain inhibitory and facilitatory proper-
ties.6 – 8 The new analgesic tapentadol is a centrally acting
drug with a combined mechanism of action. Tapentadol is a
m-opioid receptor (MOR) agonist (its affinity for the MOR is 50
times less than that of morphine) and inhibits neuronal re-
uptake of norepinephrine.6 9 Both mechanisms act synergistic-
ally to produce analgesia.10 Animal studies indicate that the
opioidergic component is more important in the treatment of
acute pain, whereas the noradrenergic component is largely
involved in the treatment of chronic neuropathic pain.8
As tapentadol modulates opioidergic and noradrenergic
pathways simultaneously, the analgesic effect of tapentadol
is thought to rely on the enhancement of descending pain
inhibitory activity.11 However, up to now, no studies have
been conducted to confirm the presence of such an effect in
humans. In the current study, the effects of tapentadol on
British Journal of Anaesthesia 113 (1): 148–56 (2014)
Advance Access publication 8 April 2014 . doi:10.1093/bja/aeu056
& The Author [2014]. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Downloaded from https://academic.oup.com/bja/article-abstract/113/1/148/2919841/Tapentadol-potentiates-descending-pain-inhibition
by guest
on 02 October 2017
206
two experimental paradigms, conditioned pain modulation
(CPM) and offset analgesia (OA), were tested in chronic pain
patients with diabetic polyneuropathy (DPN). CPM is an experi-
mental measure of endogenous pain modulation that gates
incoming pain signalling as a consequence of a preceding
or simultaneous tonic painful stimulation.12 – 17 OA is a test
in which a disproportionally large amount of analgesia be-
comes apparent upon a slight decrease in noxious heat stimu-
lation.18 19 Both tests have been used previously to evaluate
the engagement of pain modulatory pathways.4 14 19
We performed a randomized, parallel-design, placebo-
controlled study in chronic pain patients with DPN on the
effect of a 4-week tapentadol treatment on CPM, OA, and
pain relief. We hypothesize that tapentadol’s analgesic efficacy
relies, in part, on the engagement of endogenous pain inhibi-
tory pathways.
Methods
Chronic pain patients were recruited to participate in the study
performed at the Leiden University Medical Center over the
period January 2012–October 2012, after approval of the
protocol was obtained from the local Medical Ethics Committee
and the Central Committee on Research involving Human
Subjects (CCMO, The Hague, The Netherlands). The study was
registered at trialregister.nl under number NTR2716 and has
EudraCT number 2010-012175-26. The study was registered
as an addendum to an earlier trial on the effects of a single
dose of tapentadol and morphine on CPM. All participants
gave written informed consent and underwent a physical
examination before enrolment in the study.
Patients were recruited via an advertisement in the journal
of the national diabetic society. All recruited patients had dia-
betes and chronic pain in hands and/or legs and feet. They
were included in the study when they were 18–75 yr, had a
BMI below ≤40 kg m22, and had: (i) presence of at least two of
the following symptoms in legs, arms, or both (in a stocking-
glove distribution): (a) symmetrical dysesthesias or paresthe-
sias, (b) burning or painful feet with nighttime worsening, or (c)
peripheral tactile allodynia; and (ii) an abnormal warm or cold
detection threshold, an abnormal warm or cold pain threshold,
or allodynia observed with quantitative sensory testing (QST).
Exclusion criteria included: indication of the presence of severe
medical diseases (e.g. liver function elevation); allergy to
opioids; current use of benzodiazepines and/or other sedatives;
present or past use of illicit/recreational substances; present or
past alcohol abuse; history of mental illness or epilepsy; preg-
nancy and/or lactation; current use of strong opioids; and inabil-
ity to understand the purpose and instructions of the study. The
patients were allowed to continue the following pain medica-
tions as long as they used a constant dose for the 8 weeks
before the study and the dosage could be kept constant during
the whole study period: acetaminophen, non-steroidal anti-
inflammatory drugs, amitriptyline, gabapentin, and pregabalin.
Patients who had been using opioids previously (and terminated
treatment due to the absence of efficacy or side-effects) were
eligible for inclusion.
Study design
This randomized, double-blind, placebo-controlled study was
performed in 24 DPN patients (see Consort flow chart, Fig. 1).
Assessed for eligibility
n=87
Enrolled/randomized
n=25
Excluded, n=62
– Rejected participation, n=31
– Co-morbidity, n=7
– Age >75, n=8
– BMI >40, n=2
– No pain, n=4
– No neuropathy, n=3
– No diabetes, n=2
– Use of opioids, n=2
– Included in other clinical trial, n=2
– Blind, n=1
Allocated to intervention
n=24
Excluded, n=1
– Rejected participation
4-week placebo treatment
n=12
Analysed
n=12
Analysed
n=12
4-week tapentadol treatment
n=12
Fig 1 Consort study flow chart.
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Twelve patientswere treated orally for 4 weeks with tapentadol
slow release (SR), 12 others with placebo. The dose of tapenta-
dol SR was titrated to effect starting with 100 mg twice daily in
week 1, followed by 200 mg twice daily in week 2, and 250 mg
twice daily in weeks 3 and 4. In the case of the presence of side-
effects unacceptable to the patient, the tapentadol dose was
decreased to a dose where side-effects were absent or accept-
able. All patients were tested twice, once 1 day before the treat-
ment period and once on the last day of treatment. On each
study day, the subjects were familiarized with the test proce-
dures. Next, the CPM and OA responses were obtained. Spon-
taneous pain scores [using an 11-point numerical rating
scale (NRS) from 0 (corresponding with no pain) to 10 (cor-
responding with most imaginable pain)] and side-effects
[presence of nausea, vomiting, drowsiness, dizziness, and dry
mouth, using a dichotomous scale (yes/no)] were monitored
on a weekly basis.
To get an indication of the nerve-fibre involvement in the
patient population, QST was performed according to the stan-
dardized protocol of the German Research Network on Neuro-
pathic Pain.20 In short, this protocol assesses cold, heat, and
mechanical detection and pain thresholds; paradoxical heat
sensations; mechanical pain sensitivity; allodynia; wind-up
and vibration; and pressure pain thresholds. Sensory testing
was performed on the hand and foot of all pain patients
included in the study.
Application of nociceptive stimuli for CPM and OA
testing
Heat pain was induced on the lower part of the non-dominant
arm with a 3×3 cm thermal probe connected to the Pathway
Neurosensory Analyzer (Medoc Ltd, Ramat Yishai, Israel). The
probe was calibrated according to the specifications of the
manufacturer. During the heat pain stimulation, subjects con-
tinuously quantified the pain intensity level of the stimulus
using a slider on a computerized potentiometer that ranged
from 0 (no pain) to 100 (worst pain imaginable). This allowed
for continuous monitoring of the visual analogue scale
(eVAS). To overcome sensitization, the thermode was moved
between different zones on the forearm and ample time was
incorporated between the different heat stimuli. On each of
the two study days (i.e. before treatment and at 4 weeks of
treatment), the individual test temperature was determined
by applying a series of heat stimuli. First, the temperature
was increased from 328C (baseline temperature) by 1.58C s21
to a target temperature of 428C and kept constant for 10 s. If
the eVAS was ,50 mm, a next test was performed increasing
the target temperature in steps of 18C. The cut-off temperature
for these series was 498C. The temperature evoking an eVAS of
at least 50 mm was used during the remainder of the study.
Cold pain was induced using a cold-water reservoir pro-
duced by a rapid water-cooling system (IcyDip, IcySolutions
BV, Delft, The Netherlands). The subject’s foot and lower leg
was immersed into the cold water reservoir, which could be
set at different temperatures ranging from 68C to 188C. The
temperature that produced an eVAS of at least 30 mm was
used in the remainder of the study. After the exposure to cold
water, the subject’s extremity was warmed to normal tem-
perature using warm water collected from the counter-current
outlet of the IcyDip system.
CPM and OA
The method to induce CPM has been published previously.2 4 14
In short, to measure CPM, two series of three pain tests were
performed. One series included stimulation of the forearm
with the experimental stimulus (heat pain). For this, the tem-
perature of the heat probe gradually increased from baseline
temperature (328C) to the earlier set test temperature (at
1.58C s21) and remained constant for 30 s. Next, the tempera-
ture rapidly returned (at 68C s21) to baseline. The second series
included stimulation with both the experimental stimulus and
the conditioning stimulus (CS) (cold pain). The CS was applied
25 s before the start of the experimental stimulus and ended
simultaneously with the end of the experimental stimulus. In
both sessions, the subjects only rated the pain intensity level
of the experimental stimulus (heat pain on the arm). There
were 3 min intervals between single tests.
OA was studied by applying a three-temperature paradigm
as described by Grill and Coghill.18 The temperature was
ramped at 1.58C s21 from baseline temperature to the previ-
ously set test temperature. The test temperature was kept con-
stant for 5 s after which it was raised by 18C for 5 s and next
decreased by 18C for 20 s. At the end of the test, the tempera-
ture quickly returned (68C s21) to baseline. This temperature
paradigm was applied three times with a 3-min interval
between tests.
Randomization and blinding
Randomization and allocation was performed by the local
pharmacy using a computer-generated randomization list.
Placebo tablets were fabricated by the pharmacy and were
identical to the tapentadol tablets in form, size, and taste.
The tablets were repackaged into unmarked containers and
delivered to the research team and subsequently by the
research team to the patients. The research team remained
blinded to treatment until all CPM and OA responses had
been analysed.
Data analyses
To quantify the magnitude of CPM, the peak eVAS scores were
used in the analyses. For each subject, the average peak eVAS
without and with CS were calculated. Next, relative CPM
responses were calculated to correct for variations in peak re-
sponse between sessions and subjects using the formula:2 21 22
[(mean eVAS without CS stimulus–mean eVAS with CS)/
(mean eVAS without CS)]×100%.
OA responses were quantified as previously described.14 19
In short, the decrease in eVAS from the peak eVAS value to
the eVAS nadir after the 18C decrease in the test stimulus was
measured (DeVAS) and corrected for the value of the peak
eVAS: DeVASC¼[DeVAS/(peak eVAS)]×100%.
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Sample size and statistical analysis
A sample size of 24 (12 per treatment level) was calculated by
assuming an increase in CPM of 20% (15%) [mean (SD)] with
a¼0.05 and b.0.95. An effect of 20% was chosen as this con-
stitutes the ‘average’ value of CPM in healthy volunteers and
is probably the maximum magnitude of CPM attainable in
humans.14
The effect of the CS on the relative eVAS responses was
tested by two-tailed paired t-test. Treatment effects were
assessed by two-way repeated-measures analysis of variance
(factors: time and treatment). For all analyses, the software
package SigmaPlot version 12.5 for Windows (Systat Software
Inc., San Jose, CA, USA) was used. Data are presented as mean
(SEM) unless otherwise stated and P-values of ,0.05 were con-
sidered significant.
Results
Eighty-seven patients responded to the advertisement (Fig. 1).
Thirty-one decided not to participate after they were informed
on the nature of the study. Thirty-one others were excluded
because of the absence of pain, diabetes, or neuropathy (as
assessed by QST), not meeting age- or BMI-related inclusion
criteria, the use of strong opioids, or their inclusion in another
trial. Twenty-five subjects were enrolled in the study and
randomized. One patient retracted her consent after ran-
domization; she was replaced by another subject. The patient
characteristics of the participating patients are given in
Table 1. All patients completed the study without major side-
effects. QST measurements obtained from affected hands
and feet are presented in Figure 2. The patients presented
with a mixed small and large fibre neuropathy as evidenced
Table 1 Patient characteristics
Tapentadol Placebo
Men/women (n) 7/5 7/5
Age [yr; median (range)] 63 (58–67) 64 (57–66)
Weight [kg; median (range)] 95 (56–140) 97 (71–125)
Height [cm; median (range)] 177.5 (169–196) 178 (168–194)
Duration of disease
Diabetes mellitus [yr;
median(range)]
12 (3–35) 11 (2–45)
Neuropathic pain [yr;
median (range)]
6 (1–10) 6.5 (2–25)
Affected limbs
Legs (n) 8 8
Legs+arms (n) 4 4
Medication
Insulin 8 6
Metformin 11 7
Pregabalin 3 2
Duloxetin 2 0
Amitriptyline 1 1
Steroid 0 2
Paracetamol 1 1
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Fig 2 Results of the QSTs obtained on the affected skin areas (hand/feet). The data are the populations mean z-scores (SEM). z-Scores were calcu-
lated in relation to a population of healthy subjects as determined by Rolke and colleagues.20 z-Values above the broken line indicate a gain of
function, whereas values below this line are indicative for a loss of sensory function. CDT, cold detection threshold; WDT, warm detection threshold;
TSL, thermal sensory limen; PHS, paradoxal heat sensations; CPT, cold pain threshold; HPT, heat pain threshold; MDT, mechanical detection thresh-
old; MPT, mechanical pain threshold; MPS, mechanical pain sensitivity; ALL, dynamic mechanical allodynia; WUR, wind-up ratio; VDT, vibration
detection threshold; PPT, pressure pain threshold.
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by reduced cold and warm detection thresholds and paradox-
ical heat sensation (signs of small fibre involvement) and a
reduced vibration detection threshold (on the feet more than
on the hands; a sign of large fibre involvement). Importantly,
allodynia was observed in seven (of 24) patients. During the
study period, the daily drug dose wastitrated to a level with suf-
ficient analgesic effect and acceptable side-effects to the
patients. In the placebo group, the maximum daily dose of
500 mg day21 was reached in all subjects compared with an
average of 433 (31) mg day21 in the tapentadol SR group.
Reported side-effects were nausea (placebo:n¼4; tapentadol:
n¼3), vomiting (placebo: n¼0; tapentadol: n¼2), sedation
(placebo: n¼2; tapentadol: n¼6), dizziness (placebo: n¼2;
tapentadol: n¼6), and dry mouth (placebo: n¼1; tapentadol:
n¼5).
Before treatment, significant CPM responses were not de-
tectable as the effect of the CS was not significant [CPM¼9.1
(5.4)%, P¼0.09, Fig. 3]. After both treatments, CPM responses
increased to significant levels [placebo: CPM¼14.3 (7.2)%,
P¼0.04; tapentadol SR: CPM¼24.2 (7.7)%, P,0.01]. A clear
treatment effect was present with tapentadol SR CPM
responses greater than placebo responses (P,0.001, Fig. 3).
Weekly pain scores after tapentadol and placebo treatments
are given in Figure 4A. It shows a clear distinction in pain reduc-
tion in weeks 3 and 4 of treatment with greater analgesia in
patients treated with tapentadol SR [pain scores at baseline
6.5 (0.6) reduced to 4.8 (0.7) after placebo and 3.9 (0.6) after
tapentadol; 4-week treatment effect, P¼0.03]. Plotting pain
relief vs CPM responses shows that greater pain relief from
tapentadol SR coincided with enhanced CPM responses (Fig. 4B).
OA responses before tapentadol treatment and at week 4 of
treatment are given in Figure 5. As contrast, an example of an
OA response in age- and sex-matched healthy volunteer is
added in Figure 5A (data from Niesters and colleagues).19
DeVAS values in healthy volunteers in the age cohort 40–80
years range between 90% and 100%, irrespective of sex.19
Before treatment, DeVAS was 40.7 (7.4)%. Neither placebo
[change from baseline +2.6 (11.6)%] nor tapentadol SR treat-
ment [change from baseline 20.8 (3.7)%] had an effect in the
magnitude of OA (treatment effect, P¼0.78).
Discussion
Tapentadol is a new centrally acting analgesic agent for
treatment of acute and chronic pain,11 23 – 26 which acts
through MOR agonism and neuronal norepinephrine reuptake
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Fig 3 Relative CPM responses at baseline (before treatment), in
patients receiving a 4-week placebo treatment, and patients re-
ceiving a 4-week tapentadol treatment. At baseline, the effect of
the CSwas not significant (P¼0.09). During placebo and tapentadol
treatment, the effect of the CS was significant (placebo P¼0.04,
tapentadol P,0.01). A treatment effect was present with greater
increase in CPM responses during tapentadol treatment than
during placebo treatment (*P,0.001 vs placebo).
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Fig 4 (A) Average spontaneous pain scores of DPN patients during the 4-week treatment period. There was a significant treatment effect with
greater pain relief during tapentadol treatment (P¼0.03). (B) Relative CPM responses vs pain scores. Values are mean (SEM).
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inhibition (NRI).8 – 9 21 Through this combined mechanism of
action, it is thought that tapentadol engages and potentiates
descending pain inhibitory pathways,11 although there are
no human studies to substantiate this. We studied tapenta-
dol’s effect on two experimental paradigms of endogenous
pain modulation (CPM and OA) in chronic pain patients with
DPN. The main findings of our studies are that in DPN patients,
tapentadol SR caused significant pain relief that coincided with
enhanced CPM responses. No effect of tapentadol was
observed on OA responses. Taking these results, we reason
that relief of chronic pain in DPN patients by tapentadol is asso-
ciated with engagement and potentiation of descending in-
hibitory pain pathways.
Conditioned pain modulation
Modulation of pain in humans involves activation of higher cor-
tical centres (prefrontal cortex, anterior cingulate cortex,
insula), brainstem (periaquaductal gray, rostral ventromedial
medulla), and descending pathways projecting to the dorsal
horn of the spinal cord.1 22 27 These descending pathways
may be inhibitory or excitatory. Consequently, nociceptive
input that enters the spinal dorsal horn will undergo some
form of modulation, either facilitation or inhibition, which
results in an amplified or inhibited pain sensation at central
sites. Various chronic pain syndromes show loss of descend-
ing pain inhibition, including fibromyalgia, irritable bowel
syndrome, chronic tension headache, temperomandibular dis-
order, complex regional pain syndrome, and chronic pan-
creatitis.2 – 5 Of importance is the finding by De Felice and
colleagues28 who showed in rodents that a genetic predispos-
ition to activate descending inhibition protects against the
development of chronic pain after peripheral nerve damage.
In humans, examples of efficacious engagement of descending
inhibitory pain modulation include placebo analgesia, stress-
induced analgesia, and CPM.15–17 29 30 CPM is an experimental
and consequently surrogate tool used to quantify descending
pain inhibition in humans. Central inhibition of a focal noxious
stimulus is induced by the administration of a noxious stimulus
at a remote area (CS), thereby reducing the perception of the
focal or test pain stimulus (‘pain inhibits pain’).12 15 The central
nature ofCPM has beenascertainedby the observation that spe-
cific brainregions involved in descending inhibitionare activated
during CPM tests in volunteers.31 32
Volunteer studies show that CPM engagement is less effect-
ive in women relative to men and that CPM efficacy is reduced
in elderly people (starting at middle-age).33 34 Indeed, in our
middle-aged DPN patient population (mean age 59 yr), CPM
was not present before the intake of study medication.
Whether this is related to the underlying disease or an
age-effect is unknown. Irrespective, individuals that are less
able to activate CPM may have a higher probability of chronic
pain development after a specific insult such as peripheral
nerve damage from diabetes (cf. De Felice and colleagues)28
or surgery. Yarnitsky and colleagues16 showed that patients
with less efficient CPM responses were at risk for development
of chronic post-thoracotomy pain. The method of induction of
CPM has been validated previously by us in healthy volunteers
and is applied by others in chronic pain patients.14 16
Taking its mechanisms of action, tapentadol will interact
within the descending modulatory system by activation of
MORs and inhibition of neuronal norepinephrine reuptake.7 8
Both neurotransmitter systems play an important role in the
activation of descending inhibitory pain pathways at suprasp-
inal sites and in the spinal dorsal horn (at pre- and postsynaptic
sites). See Ossipov and colleagues1 for an excellent review on
this topic. For example, animal studies show that activation
of MORs on brainstem nociceptive ‘on-cells’ will release the
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Fig 5 OA responses. (A) An example of a healthy volunteer (female, 60 yr). Data taken from Niesters and colleagues.19 (B) Absence of tapentadol
treatment on OA in painful diabetic neuropathy patients.
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inhibition of brainstem nociceptive ‘off-cells’ that project to the
spinal dorsal horn where nociceptive signal propagation is sub-
sequently inhibited.1 Activation of spinal dorsal horn pre- and
postsynaptic a2-adrenergic receptors will cause potent anal-
gesic responses by inhibiting nociceptive afferent input. Such
analgesic effects are observed after the intrathecal adminis-
tration of the postsynaptic a2-adrenergic receptor agonist clo-
nidine.35 Although tapentadol displays weak MOP-receptor
affinity in chronic pain, animal studies show that its synergistic
effect at MOP- and adrenergic-receptor systems will cause
potent analgesic responses.6 9 21 Indeed, animal studies and
clinical trials show that tapentadol is an effective analgesic in
a variety of chronic pain syndromes (e.g. osteoarthritis pain,
low back pain, neuropathic pain).8 11 26 36 37
We observed that the analgesic efficacy of analgesic treat-
ment (tapentadol/placebo) was coupled to its effect on CPM
(Fig. 4). A 4-week treatment with placebo caused small anal-
gesic effects (DNRS¼1.7 cm) coupled to a modest increase in
CPM (+14.3%), while tapentadol treatment caused a largeran-
algesic response (DNRS¼3.9) coupled to a large CPM response
(+24.2%). This later CPM value is similar to those observed in
young healthy volunteers.13 These findings support a mechan-
istic role for the endogenous analgesia system in producing ef-
fective pain relief by tapentadol, possibly by its synergistic
effect at MOP and a2-adrenergic receptors (see above). Yar-
nitsky and colleagues17 showed a coupling between drug effi-
cacy and magnitude of CPM responses for duloxetine, a
serotonin-norepinephrine reuptake inhibitor (SNRI), in DPN
patients with initially less effective CPM responses. While our
small patient population, with initially minor or absent CPM
responses, benefited from the 4-week tapentadol SR treat-
ment, we remain uninformed on the efficacy of tapentadol in
chronic pain patients with ‘normal’ CPM responses (i.e.
responses of similar magnitude to those observed in young
and healthy volunteers). Extrapolating the duloxetine data
from Yarnitsky and colleagues would suggest that tapentadol
is less effective in these patients. There is now ample evidence
to argue that in painful neuropathy patients with absent or
reduced CPM, CPM responses may be reactivated or poten-
tiated byanalgesic treatment that targets one or more compo-
nents of the endogenous pain modulatory system.4 17
In chronic pain patients, the effect of tapentadol SR requires
several weeks to develop (Fig. 3). Similar observations have
been made for other S(N)RI-type of analgesics and tricyclic
antidepressants.38 Hence, it is recommended to evaluate the
start of pain therapy with these agents not earlier than after
2 weeks of treatment.39 Taking the similarities of mechanisms
of action among these analgesics, we argue that the slow ac-
cumulation of norepinephrine at its putative effector sites
may be held responsible for its slow onset of action. Our find-
ings stress the importance of the noradrenergic component
in inducing tapentadol analgesia in chronic pain as was
earlier observed in animal studies.8
Two patients in the tapentadol group used duloxetine (dur-
ation of treatment .1 yr), a serotonin and norepinephrine re-
uptake inhibitor, without opioidergic activity. Theoretically, the
use of this drug may have enhanced the CPM responses
induced by tapentadol. However, before tapentadol treatment,
these patients had no detectable CPM response and the mag-
nitude of their CPM response after the 4-week tapentadol treat-
ment was well within the range observed in patients not on
duloxetine. We argue that these two patients did not confound
the results of our study.
Offset analgesia
OA is a relatively novel model of endogenous analgesia that
produces temporal alterations in pain processing. The phe-
nomenon occurs when a small decrease (18C) in temperature
during noxious stimulation evokes a disproportionately large
decrease in pain perception.18 19 We previously assessed OA
responses in a large population of volunteers aged 6–88 yr
and observed response values ranging from 92% to 99%. It
has been suggested that OA is of central origin as functional
imaging studies show that OA activation coincides with activa-
tion of brain regions involved in the central modulation of
pain.40 However, it cannot be excluded that OA is initiated by
dynamic responses of primary afferents or spinal processes.
For example, Darian-Smith and colleagues41 reported that in
monkeys, the discharge of heat-sensitive nerve fibres inner-
vating the skin was nearly completely suppressed during a
10 s 18C cooling pulse from a baseline temperature of 398C. A
similar mechanism may occur during OA activation. A peri-
pheral origin of OA is further supported by the observa-
tion that central acting drugs such as opioids (tapentadol,
morphine, remifentanil), opioid antagonists (naloxone), and
N-methyl-D-aspartate receptor antagonists (ketamine) are
unable to affect OA responses in volunteers and neuropathic
pain patients.14 19 42 Finally, a recent observation that while
OA is present on the forearm of healthy volunteers, it is
absent on the palm of the hand further suggesting that periph-
eral mechanisms are important in the development of OA.43
We reproduce our earlier observation that OA responses are
absent or reduced in patients with peripheral neuropathy.19
The DeVAS values observed in the DPN patients were about
40% of those previously observed by us in healthy volunteers
of the same age and sex.19 No improvement or alteration of
OA responses was observed after the 4-week tapentadol treat-
ment, which indicates that this phenomenon of endogenous
analgesia is without opioidergic or noradrenergic involvement.
However, it may well be that the large and small nerve fibre
damage that was present in our current population prevented
their ability to discern small changes in skin temperature and
consequently prevented peripheral activation of OA.
In conclusion, our results show that patients with DPN that
display absent CPM responses benefit from tapentadol causing
pain relief coupled to (re)activation of descending inhibitory
pain pathways.
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ABSTRACT 
Objective: The aim of this study was to further as- 
sess the long-term safety and effectiveness of open-label 
topiramate therapy in subjects with moderately to se- 
verely painful diabetic peripheral neuropathy (DPN). 
Methods: Adults aged 18 to 75 years received open- 
label topiramate (25-600 mg/d for 26 weeks) in an ex- 
tension of a previously published randomized, ouble- 
blind trial comparing topiramate with placebo. Safety 
analyses included adverse vent (AE) reports and clin- 
ical laboratory tests. Metabolic end points included 
body weight and glycosylated hemoglobin (HbAlc). 
Effectiveness analyses included a 100-mm pain visual 
analog (PVA) scale, worst and current pain severity, 
and sleep disruption. 
Results: Two hundred five subjects participated in 
this open-label extension study (118 formerly treated 
with topiramate and 87 who formerly received place- 
bo). The groups did not differ in baseline demo- 
graphics or disease characteristics. One hundred twenty- 
four (60.5%) subjects (68.6% of former topiramate 
recipients and 49.4% of former placebo recipients) 
completed the extension study; the most common rea- 
son for discontinuation was an AE (27.3% of subjects). 
AEs among subjects who received _>1 dose of topira- 
mate (n = 298) included upper respiratory tract infec- 
tion (16.1%), anorexia (15.1%), diarrhea (12.8%), 
nausea (12.8%), paresthesia (10.7%), and headache 
(10.1%). Baseline pain scores were lower in those for- 
merly treated with topiramate (n = 117) than in the 
former placebo group (n = 86) (PVA: 43.3 vs 52.5, 
P = 0.014; worst pain: 1.9 vs 2.5, P < 0.001; current 
pain: 1.6 vs 1.9, P = 0.026; sleep disruption: 3.6 vs 
4.6, P = 0.021). At the final visit, PVA, current pain, 
and sleep disruption scores were not significantly differ- 
ent between the former topiramate and former placebo 
groups, but worst pain differed significantly (1.4 vs 
1.8; P = 0.025). Mean weight loss from the start of 
topiramate therapy was 5.2 and 5.3 kg in the former 
topiramate and former placebo groups, respectively 
(P < 0.001 vs baseline). Mean HbAlc values before 
and after topiramate treatment were 7.7% and 7.4%, 
respectively, in the former topiramate group (P = 
0.004 vs baseline), and 7.6% and 7.1%, respectively, 
in the former placebo group (P < 0.001 vs baseline). 
Conclusion: Although 39.5% of subjects discontin- 
ued, most often due to AEs, the results of this 26-week, 
open-label extension study with topiramate (up to 
600 mg/d) in subjects with moderately to severely 
painful DPN suggest that pain relief was effective and 
durable. (Clin Ther. 2005;27:1420-1431) Copyright 
© 2005 Excerpta Medica, Inc. 
Key words: topiramate, painful diabetic neuropa- 
thy, adverse ffects, pain, body weight. 
INTRODUCTION 
Painful diabetic peripheral neuropathy (DPN) is a 
common and progressive complication of diabetes 
mellitus. 1,2 Meta-analyses have reported that anticon- 
vulsants uch as gabapentin, lamotrigine, and sodium 
*A list of CAPSS-141 Study Group participants is provided in 
the Acknowledgments. 
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valproate may provide greater elief of painful DPN 
compared with placebo, 3 4 but a search of MEDLINE 
(all years through May 2005) for clinical trials with 
the terms pain*, diabet*, and neuropath* did not iden- 
tify any studies of anticonvulsants for the manage- 
ment of painful DPN lasting beyond 12 weeks. Of the 
166 publications identified by the search, 2 reported 
that the long-term use of capsaicin (48 weeks) s or tra- 
madol (6 months) 6 was associated with effective relief 
of painful DPN. Additional ong-term studies report- 
ed that experimental therapy with an aldose reductase 
inhibitor for 24 to 52 weeks (epalrestat 7 or tolrestat8), 
acupuncture for 52 weeks, 9 or acetyl-L-carnitine for 
52 weeks 1° relieved the pain of DPN effectively, but 
other long-term studies reported that 52 weeks of 
therapy with a neurotrophic peptide 11 or tolrestat 12 
did not relieve pain. 
The anticonvulsant topiramate was associated with 
improved pain control in an 8-week, open-label study of 
11 patients with painful DPN 13 and a 3-month, double- 
blind pilot study of 27 patients with painful DPN) 4 
In a 12-week, randomized, double-blind, placebo- 
controlled, multicenter trial of 323 patients with mod- 
erately to severely painful DPN, significant reductions 
in pain intensity, sleep disruption, and body weight 
were observed in the topiramate group compared with 
the placebo group, is Mean scores on a 100-ram pain 
visual analog (PVA) scale decreased from 68.0 to 46.2 mm 
in the topiramate group and from 69.1 to 54.0 mm in 
the placebo group (P = 0.038, topiramate vs placebo). 
Mean scores at the final visit were similar in the topi- 
ramate and placebo groups for current pain severity 
(1.7 vs 1.9 on a scale from 0 to 4; P = NS). Worst pain 
severity over the past week (2.1 vs 2.5 on a scale from 0 
to 4; P = 0.003) and sleep disruption scores (3.9 vs 4.6 
on a scale from 0 to 10; P = 0.020) were significantly 
lower in the topiramate group. Body weight decreased 
by 2.6 kg in the topiramate group and increased by 
0.2 kg in the placebo group (P < 0.001). 
The protocol for the 12-week, multicenter t ial in- 
cluded this 26-week, openqabel extension to further 
assess the long-term safety and effectiveness of open- 
label topiramate monotherapy in subjects with mod- 
erately to severely painful DPN. 
METHODS 
Study Participants 
Adults aged 18 to 75 years were eligible for the ini- 
tial double-blind, placebo-controlled trial if they had 
symmetric painful DPN and stable glycemic ontrol 
for ->3 months, and pain severity in the lower extrem- 
ities ->40 mm on a 100-mm PVA scale (0 -- no pain; 
100 = worst possible pain) after washout of analgesic 
medications. Exclusion criteria included contraindica- 
tions to topiramate therapy and conditions or medica- 
tions (eg, antidepressants, anticonvulsants, analgesics) 
that might interfere with effectiveness analyses. Sub- 
jects were randomly allocated to 12 weeks of double- 
blind topiramate or placebo in a 2:1 fashion. 
Subjects could enroll in this open-label extension if
they completed the double-blind trial or if they discon- 
tinued the double-blind trial due to lack of effectiveness 
after ->8 weeks of blinded treatment with topiramate or 
placebo. Thirty-nine investigators ( ee Acknowledgments) 
recruited subjects at sites throughout the United States. 
The appropriate independent ethics committee or institu- 
tional review board at each site approved the study pro- 
tocol. All subjects provided written informed consent to 
participate, and the study was conducted in accordance 
with the 1989 version of the Declaration of Helsinki. 16 
Interventions 
Open-label treatment with topiramate was begun at 
25 mg/d and increased to a maximum of 400 rag/d, as 
tolerated by the subject (Table I). The double-blind 
regimen (topiramate or placebo) from the initial study 
was tapered simultaneously, in the same increments by 
which the open-label medication was increased. This 
approach enabled subjects to switch from double- 
blind topiramate or placebo to open-label treatment 
with topiramate without revealing the original study 
medication assignment to subjects or investigators. 
After the initial 8-week dose-titration period, open- 
label topiramate was administered without conceal- 
ment; the dose could be titrated up to 600 mg/d at the 
discretion of the investigator. Concomitant use of other 
medications for pain relief (including antidepressants 
and anticonvulsants) was prohibited. After 26 weeks of 
open-label treatment, or at the time of discontinuation, 
the topiramate dose was tapered by approximately one 
third every 4 days based on the recommended schedule 
for the use of topiramate inepilepsy, because it was un- 
known whether abrupt discontinuation would precipi- 
tate rebound symptoms. 17,18 
Outcomes 
Follow-up study visits were scheduled to occur after 
2, 4, 8, 14, 20, and 26 weeks of open-label treatment, 
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Table I. Dose-titration schedule for open-label extension of  double-blind study comparing topi- 
ramate with placebo for painful diabetic peripheral neuropathy, is 
Downward Titration of Double-Blind Upward Titration of Open-Label 
Week Topiramate or Placebo* Topiramate as Toleratedt 
1 Double-blind dose - 25 mg To 
2 Double-blind dose - 50 mg To 
3 Double-blind dose - 7.5 mg To 
4 Double-blind dose - 100 mg To 
5 Double-blind dose - 150 mg To 
6 Double-blind dose - 200 mg To 
7 Double-blind dose - 300 mg To 
8 Double-blind close - 400 mg To 
~wamate 25 mg 
~lramate 50 mg 
~wamate 75 mg 
~lramate 100 mg 
~wamate 150 mg 
~lramate 200 mg 
~lramate 300 mg 
~iramate 400 mg 
*Double-blind regimen from a previous tudy (from which subjects for the present study were selected) was 
tapered simultaneously to allow subjects to switch from double-blind topiramate orplacebo to open-iabei 
treatment with topiramate without revealing original study medication assignment. Downward titration of 
the double-blind medication regimen (topiramate orplacebo) from the original study was continued untii 
the dose reached 0 rag/d; the double-blind ose varied by patient at the start of open-label treatment, due 
to variations in tolerability of the double-blind medication regimen. 
*Upward titration of open-label topiramate in the present study continued until the dose reached 400 mg/d 
or the maximum dose that each patient could tolerate. 
and after discontinuation f study treatment. Adverse 
event (AE) reports were collected at each visit, either 
spontaneously or in response to nondirected question- 
ing. The investigator categorized each event by rela- 
tionship to topiramate treatment (not related, doubtful, 
possible, probable, or very likely). Investigators catego- 
rized AEs as serious if they were fatal or life-threatening, 
or if they resulted in hospitalization or disability. 
Cognitive function and central nervous ystem effects 
were not evaluated with specific assessment tools. 
Other measures included vital signs at all visits (ie, 
pulse, blood pressure, and weight); clinical laboratory 
tests performed by a central aboratory at weeks 0, 4, 
8, and 26 (ie, glucose, total bilirubin, alanine amino- 
transferase, aspartate aminotransferase, total choles- 
terol, albumin, blood urea nitrogen, calcium, creat- 
inine, uric acid, alkaline phosphatase, red blood cell 
count, hemoglobin, hematocrit, platelet count, white 
blood cell count, and differential); hepatic panel at 
weeks 0, 12, and 20; urine pregnancy test in women 
at weeks 0, 8, 20, and 26; and physical examination, 
neurologic examination, urinalysis, and glycosylated 
hemoglobin (HbAlc) at weeks 0 and 20. 
At each follow-up visit through 26 weeks, subjects 
completed a 100-mm PVA scale, 19 5-point scales for 
worst pain severity over the past week and current 
pain severity (0 = none, 1 = mild, 2 = moderate, 3 = se- 
vere, 4 = extreme), 2°and an 11-point sleep-disruption 
scale (0 = does not interfere, 10 = completely inter- 
feres). 2° Subjects recorded their overall assessment of
topiramate on a 5-point scale (1 = poor, 2 = fair, 3 = 
good, 4 = very good, 5 = excellent) at the end of study 
treatment. 
Statistical Analysis 
The safety population included subjects who re- 
ceived >1 dose of topiramate, including subjects who 
participated in this open-label extension after receiv- 
ing either placebo r topiramate in the original double- 
blind study; subjects who received topiramate in the 
double-blind trial but did not enter this open-label 
extension were also included in the safety analysis. 
AEs during topiramate treatment were summarized by 
number and percentage overall, relationship to topi- 
ramate, and association with discontinuation. Body 
weight and HbAlc were summarized by mean change 
from baseline in the safety population. 
The effectiveness population included subjects who 
received >1 dose of open-label topiramate and com- 
pleted >1 effectiveness assessment during open-label 
treatment. Descriptive statistics were generated for 
baseline demographic and clinical characteristics. 
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Mean values for effectiveness measures were deter- 
mined at each study visit. If subjects discontinued the 
study, their subsequent effectiveness values were as- 
sumed to be equal to the last values recorded before 
discontinuation (the last-observation-carried-forward 
method). Power calculations were not possible be- 
cause it was unknown how many patients would enter 
this open-label extension study; a sample size of 300 
patients was estimated to provide >90% power to de- 
tect a difference of 17 mm in PVA scores between 
treatment groups in the original double-blind study. 
Statistical comparisons of the incidence of AEs 
were not performed. Mean values for pain scores and 
metabolic end points at the final visit were compared 
with baseline values using simple Student t tests. 
Mean values for pain scores were compared between 
treatment groups before double-blind treatment, be- 
fore open-label treatment, and after open-label treat- 
ment using simple Student  tests. 
RES U LTS 
Study Participants 
Between November 2000 and September 2002, a 
total of 323 subjects enrolled in the initial double- 
blind study, 15 and 205 subjects participated in the 
open-label extension (118 former topiramate recipi- 
ents and 87 former placebo recipients; Figure 1). One 
hundred twenty-four (60.5%) subjects who enrolled 
in the open-label extension completed the study 
(68.6% [n = 81] of former topiramate subjects and 
49.4% [n = 43] of former placebo subjects); the most 
common reason for discontinuing open-label treat- 
ment before the end of the study was an AE (21.2% 
In = 25] and 35.6% In = 31], respectively). (See next 
subsection for details of AEs.) There were no statisti- 
cally significant differences in baseline characteristics 
between groups (Table II). 
Tolerability 
The safety population included 298 subjects who 
received any dose of topiramate, including 211 sub- 
jects who received ouble-blind topiramate (regard- 
less of whether they entered the open-label extension) 
and 87 subjects in the former placebo group who re- 
ceived open-label topiramate (Figure 1). The mean 
(SD) dose of topiramate in the safety population was 
204.1 (116.4) mg/d overall; the mean (SD) dose dur- 
ing the maintenance phase of open-label treatment 
was 312.1 (137.3) mg/d. 
Two hundred seventy-four (91.9 %) subjects report- 
ed _>1 treatment-emergent AE after the first dose of 
topiramate. The most commonly reported treatment- 
emergent AEs were upper respiratory tract infection 
(16.1% In = 48]), anorexia (15.1% In = 45]), diarrhea 
(12.8% [n = 38]), nausea (12.8% [n = 38]), paresthe- 
sia (10.7% [n = 32]), and headache (10.1% [n = 30]) 
(Table III). 
Serious AEs occurred uring double-blind or open- 
label topiramate therapy in 33 (11.1%) subjects, in- 
cluding 25 (11.8 %) of 211 subjects originally assigned 
to double-blind topiramate and 8 (9.3%) of 86 subjects 
originally assigned to placebo. Serious AEs included 3 
cases each of back pain, injury, and basal cell carcino- 
ma; 2 cases each of prostate disorders, cellulitis, chest 
pain, syncope, convulsions, neoplasm, infection, vascu- 
lar disorders, and retinal detachment; and 1 case each 
of asthenia, taxia, pituitary neoplasm, abdominal pain, 
nausea, pancreatitis, complete atrioventricular block, 
cardiac arrest, hyperglycemia, hyponatremia, ketosis, 
colon carcinoma, malignant skin neoplasm, agitation, 
vaginal hemorrhage, bronchitis, pleural pain, urinary 
retention, urinary tract infection, and unspecified AE. In 
addition, 1 subject in the former topiramate group died 
of cardiac arrest after 171 days of open-label topira- 
mate therapy (255 total days of topiramate therapy); 
the subject's medical history included hypertension, hy- 
percholesterolemia, heart murmur, and angina, and the 
death was not considered by the investigator to be re- 
lated to topiramate treatment. 
Four subjects had serious AEs that the investigator 
considered possibly or probably related to study treat- 
ment; A subject with no history of seizure disorder 
experienced seizure-like activity on day 18 of double- 
blind therapy; topiramate was discontinued the same 
day and the AE resolved within 6 days. A second subject 
with a history of bradycardia, coronary artery disease, 
and hypertension experienced moderate bradycardia 
and marked syncope on day 42 of the double-blind 
study, 1 day after discontinuing topiramate, and both 
events resolved the following day. A subject in the for- 
mer placebo group with a history of myocardial infarc- 
tion experienced marked atypical chest pain on day 36 
of open-label treatment; study medication was discon- 
tinued the same day, and the subject experienced 2 
seizures 2 days after discontinuation and another 
marked seizure 3 days after discontinuation; all seizures 
responded to fosphenytoin treatment, but the types of 
seizures were not reported. Another subject in the for- 
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Figure 1. Flow diagram for subjects in open-label extension of 12-week, double-blind study comparing topiramate 
with placebo for painful diabetic peripheral neuropathy. *Nine subjects originally assigned to double- 
blind topiramate discontinued due to serious adverse events. ~l-hree subjects in the former placebo 
group discontinued open-label topiramate due to serious adverse events. 
mer placebo group with a history of hypertension expe- 
rienced marked ataxia on day 27 of open-label topira- 
mate therapy; study medication was discontinued on 
day 33 and the AE resolved 59 days later. 
AEs that led to discontinuation for >2% of subjects 
included nausea (4.0%), abnormal vision (3.4%), 
fatigue (3.0%), and difficulty with concentration/ 
attention (2.3%). No cases of acute-angle glaucoma 
were reported. 
Effectiveness 
The effectiveness population included 203 subjects 
(117 former topiramate recipients and 86 former 
placebo recipients). In the double-blind study, the mean 
reduction in PVA scale scores was previously reported 
to be significantly greater in topiramate-treated subjects 
than in placebo recipients (P = 0.038). is By the final 
visit of the open-label extension, mean scores on the 
PVA scale had decreased significantly compared with 
scores before open-label treatment in the former topira- 
mate group and the former placebo group (both, P < 
0.001; Figure 2). There was no significant difference in 
PVA scores between groups at the end of the open-label 
extension (Table IV). 
Mean scores in both groups for the secondary end 
points of worst pain severity in the past week, current 
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Table II. Baseline demographic and clinical characteristics of subjects in open-label extension of double-blind 
study comparing topiramate with placebo for painful diabetic peripheral neuropathy (DPN). is 
Former Topiramate Former Placebo 
Group Group 
Characteristic (n = 117) (n = 86) P 
Age, mean (SD), y 59.4 (9.9) 59.1 (10.0) 0.864 
Sex, no. (%) 0.572 
Male 59 (50.4) 47 (54.7) 
Female 58 (49.6) 39 (45.3) 
Race, no. (%) 1.00 
White 102 (87.2) 76 (88.4) 
Black 13 (11.1) 9 (10.5) 
Other 2 (1.7) 1 (1.2) 
Height, mean (SD), cm 171.1 (9.8) 170.1 (11.0) 0.512 
Weight, mean (SD), kg 100.5 (21.8) 96.2 (21.0) 0.160 
Duration of diabetes mellitus, mean (SD), y 10.1 (7.3) 10.5 (8.5) 0.684 
Duration of painful DPN, mean (SD), y 3.4 (2.5) 3.2 (3.4) 0.694 
HbAlo mean (SD), % 7.8 (1.2) 7.6 (1.2) 0.215 
HbAlc = glycosylated hemoglobin. 
pain severity, and sleep disruption also decreased sig- 
nificantly during open-label topiramate treatment (all, 
P < 0.001; Table IV). Although worst pain severity 
decreased significantly during open-label topiramate 
therapy in both treatment groups, it remained signifi- 
cantly higher in the former placebo group than in the 
former topiramate group at the end of treatment (P = 
0.025; Table IV). At the final visit, 99 (49.3%) of 
201 subjects had worst pain severity of mild or none, 
and 126 (62.7%) of 201 subjects had current pain 
severity of mild or none. Patients' overall assessments 
of topiramate treatment at the final visit were good, 
very good, or excellent for 143 (71.9%) of 199 sub- 
jects (80.3% [94/117] in the former topiramate group 
and 59.8% [49/82] in the former placebo group). 
Metabolic Effects 
Body weight and HbAlc values at the end of open- 
label treatment were compared with the values from 
the start of double-blind treatment in the former topi- 
ramate group and from the start of open-label treat- 
ment in the former placebo group. Weight loss oc- 
curred in 223 (76.4%) of 292 subjects. Subjects who 
were weighed before topiramate therapy and after 
26 weeks of open-label treatment experienced mean 
weight loss of 5.2 and 5.3 kg in the former topiramate 
and former placebo groups, respectively (P < 0.001 vs 
start of topiramate therapy). Mean body weight re- 
ported at each study visit is shown in Figure 3. Mean 
change in body mass index (BMI) was -1.5 kg/m 2 
among subjects with baseline BMI >30 kg/m 2, -0.8 kg/m 2 
among those with baseline BMI >27 and ___30 kg/m 2, 
and -0.4 kg/m 2 among those with baseline BMI 
_<27 kg/m 2. No subject was underweight (BMI 
<18.5 kg/m 2) before, during, or after topiramate treat- 
ment. In the former topiramate group, mean (SD) val- 
ues for HbA k before and after topiramate treatment 
were 7.7% (1.2%) and 7.4% (1.4%), respectively (P = 
0.004 vs baseline). In the former placebo group, mean 
(SD) values for HbAlc before and after topiramate 
treatment were 7.6% (1.2%) and 7.1% (1.3%), re- 
spectively (P < 0.001 vs baseline). 
DISCUSSION 
In this study, the high dropout rates due to AEs may 
have been the result of aggressive dosing. Open-label 
topiramate was titrated up to the target dose slowly, 
based on evidence that slower titration improved tol- 
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Table III. Treatment-emergent adverse events report- 
ed by >5% of all subjects during double- 
blind, placebo-controlled is or open-label 
topiramate treatment (N = 298). 
No. (%) of 
Event Subjects 
Any 274 (91.9) 
Upper respiratory 
tract infection 48 (16.1) 
Anorexia 45 (15.1) 
Diarrhea 38 (12.8) 
Nausea 38 (12.8) 
Paresthesia 32 (10.7) 
Headache 30 (10.1 )
Fatigue 29 (9.7) 
Dizziness 29 (9.7) 
Somnolence 28 (9.4) 
Injury 26 (8.7) 
Hypoesthesia 26 (8.7) 
Abnormal vision 26 (8.7) 
Arthralgia 25 (8.4) 
Weight decrease 24 (8.1) 
Sinusitis 23 (7.7) 
Altered taste 22 (7.4) 
Constipation 20 (6.7) 
Urinary tract infection 19 (6.4) 
Pain 18 (6.0) 
Difficulty with 
concentration/attention 18 (6.0) 
Difficulty with memory 18 (6.0) 
Back pain 17 (5.7) 
Hypoglycemia 17 (5.7) 
Nervousness 17 (5.7) 
erability without lessening efficacy in patients with 
epilepsy, 21 but a high target dose of 400 to 600 mg/d 
was used. In previous reports, lower doses of topira- 
mate (150-300 mg/d) were effective for the manage- 
ment of neuropathic pain. 22-2s Conversely, higher 
doses were associated with a greater risk of AEs such 
as cognitive dysfunction and central nervous system 
effects, 26 both of which contributed to withdrawal 
from this study. Several subjects discontinued treat- 
ment due to abnormal vision, including 2 subjects 
with retinal detachment, but retinopathy is a common 
microvascular complication of diabetes mellitus, and 
these 2 events were considered unrelated to topira- 
mate. No subject had angle-closure glaucoma, a seri- 
ous AE that has been reported rarely with topiramate. 27 
The most commonly reported AEs included upper es- 
piratory tract infection, anorexia, diarrhea, nausea, 
paresthesia, nd headache. A similar safety profile was 
reported during topiramate therapy in the double- 
blind phase of the study, is 
Anorexia and weight decrease were commonly re- 
ported, and 223 (76.4%) of 292 subjects experienced 
weight loss from the beginning to the end of topira- 
mate treatment. Weight loss was most pronounced in
obese subjects, and no subject became underweight due 
to topiramate treatment. Topiramate was previously 
associated with analgesic effects and weight loss in pa- 
tients with painful DPN in placebo-controlled stud- 
ies, 14 including the initial 12-week, randomized, 
double-blind phase of this study) s A pooled analysis 
of 3 other controlled trials did not observe significant 
weight loss differences between topiramate and placebo 
during 22 weeks of double-blind treatment. 28 Aspects 
of the design of the latter trials may have confounded 
their efficacy results and have been discussed in detail 
previously, is In future placebo-controlled trials of 
long-term topiramate therapy for painful DPN, titra- 
tion to a lower target dose and prohibition of rescue 
analgesia may permit identification of the minimum 
effective dose and the optimal balance between anal- 
gesic effects, metabolic effects, and AEs. 
In this open-label xtension of a randomized, ouble- 
blind clinical trial, up to 9 months of treatment with 
the anticonvulsant topiramate was associated with 
durable pain relief in subjects with moderately to se- 
verely painful DPN. A worst pain severity scale was 
used to measure the severity of painful flares, whereas 
PVA and current pain severity scales were used to pro- 
vide estimates of underlying pain severity. 29 All sub- 
jects had moderately or severely painful DPN at base- 
line, according to a 100-mm PVA scale, but at the 
final pain assessment, 99 (49.3%) of 201 subjects re- 
ported worst pain severity of mild or none, and 126 
(62.7%) of 201 subjects had current pain severity of 
mild or none. Topiramate monotherapy was associat- 
ed with durable relief, as measured by statistically sig- 
nificant improvements in all measures of pain severity 
during open-label topiramate reatment (all, P < 0.001 
vs baseline). One hundred forty-three (71.9%) of 199 
subjects rated the effectiveness of long-term topiramate 
treatment as good, very good, or excellent overall. 
The openqabel study design and the inclusion/ 
exclusion criteria could limit extrapolation of these 
results to other populations. In addition, the study was 
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Figure 2. Mean 100-mm pain visual analog (PVA) scores among subjects in open-label extension of 12-week, double- 
blind study comparing topiramate with placebo for painful diabetic peripheral neuropathy. Data points 
represent the mean of all observed values at that visit; n values for each treatment group appear below 
the graph. 
designed to assess the tolerability of therapy with 
topiramate, not the comparative ffectiveness of 
switching from placebo to topiramate versus contin- 
uing topiramate therapy. Regardless of whether sub- 
jects received placebo or topiramate during the 
double-blind phase of the study, pain intensity and 
sleep interference scores improved uring up to 26 weeks 
of open-label topiramate treatment (P < 0.001). Be- 
fore beginning the double-blind, placebo-controlled 
study, pain scores and sleep interference scores were 
not significantly different between the treatment 
groups, but by the end of double-blind treatment, 
topiramate-treated subjects had achieved significant- 
ly lower pain intensity and sleep interference scores 
than placebo subjects, as reported previously. Is By 
the end of this open-label extension study, subjects 
who switched from double-blind placebo to open- 
label topiramate reported final scores for pain inten- 
sity and sleep interference that were no longer signifi- 
cantly different from the final scores in the subjects 
who received topiramate throughout both phases of 
the study. 
Subjects in the former topiramate group continued 
to report improvement in pain intensity and sleep dis- 
ruption during the open-label extension (P < 0.001). 
One possibility is that topiramate therapy was associ- 
ated with progressive pain relief. It is also possible 
that subjects with the least pain relief were the most 
likely to discontinue treatment and therefore be ex- 
cluded from effectiveness evaluations at later time 
points. Alternately, subjects in the former topiramate 
group may have believed that they were switching 
from double-blind placebo to open-label topiramate, 
and thus may have anticipated even greater pain relief 
with open-label topiramate treatment than they had 
experienced with double-blind topiramate therapy. 
Meta-analyses of controlled clinical trials have re- 
ported that anticonvulsants such as gabapentin, lamo- 
trigine, and sodium valproate may be effective for the 
management of painful DPN. 3,4 However, no previ- 
ously published trial evaluated >12 weeks of anticon- 
vulsant treatment for painful DPN. An open-label 
extension of a controlled trial comparing abapentin 
600, 1200, or 2400 mg/d with placebo in 325 subjects 
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Table IV. Mean (SD) pain and sleep disturbance scores among subjects in open-label extension of" double-blind 
study comparing topiramate with placebo for painful diabetic peripheral neuropathy, is grouped by visit 
and double-blind trial group. 
Former Topiramate Group Former Placebo Group 
Measure (Possible Range of Scores) (n = 117) (n = 86)* P 
PVA score, mm (0-100) 
Baseline of double-blind period 
Baseline of open-label period 
End of open-label period 
Worst pain severity score (0-4) 
Baseline of double-blind period 
Baseline of open-label period 
End of open-label period 
Current pain severity score (0-4) 
Baseline of double-blind period 
Baseline of open-label period 
End of open-label period 
Sleep disruption score (0-10) 
Baseline of double-blind period 
Baseline of open-label period 
End of open-label period 
67.6 (13.7) 66.0 (14.5) 0.409 
43.3 (26.4) 52.5 (26.2) 0.014 
28.0 (27.0)t 35.5 (28.4)t 0.057 
3.0 (0.7) 3.1 (0.7) 0.705 
1.9 (1.0) 2.5 (1.0) <0.001 
1.4 (1.0)t 1.8 (1.1)f 0.025 
2.2 (0.7) 2.2 (0.8) 0.961 
1.6 (0.9) 1.9 (1.0) 0.026 
1.2 (1.0)t 1.4 (1.0)t 0.200 
6.6 (2.3) 6.1 (2.4) 0.101 
3.6 (2.9) 4.6 (2.9) 0.021 
2.7 (2.7)t 3.0 (2.7)t 0.393 
PVA = pain visual analog. 
*PVA score at end of-open-label period, n = 84; worst pain severity at end of'open-label period, n = 84; current pain severity at 
end of'open-label period, n = 84; sleep disruption at end of-open-label period, n = 83. 
fp < 0.001 For difference versus baseline of'open-label period among patients with data at both time points. 
with painful DPN was not published in full, but the 
key findings were summarized in a review of 
gabapentin dosing. 3° In the 7-week, double-blind 
phase, gabapentin failed to achieve statistical separa- 
tion from placebo; these results were consistent with 
the negative findings of a placebo-controlled trial of 
gabapentin, 31 but contradicted findings from other 
controlled trials in which relief was greater with 
gabapentin than with placebo and not significantly 
different from that with amitriptyline.32, 33 During the 
4-month, open-label extension phase in an undisclosed 
number of subjects, pain intensity and sleep interfer- 
ence scores decreased by -25% to -30%. 30 Twenty- 
four percent of subjects had treatment-related AEs 
during open-label gabapentin treatment, most com- 
monly asthenia, dizziness, and somnolence; HbAlc 
values remained well controlled, but body weight 
changes were not described. 3° 
A literature search identified only 2 fully published, 
long-term, open-label extension studies with designs 
similar to this study. In those studies, long-term treat- 
ment with the analgesics capsaicin s and tramadol 6 was 
associated with effective relief of painful DPN. The re- 
suits of this study were similar; as in the capsaicin 
study, s approximately one half of the subjects experi- 
enced partial or complete relief of their worst pain by 
the final visit, and as in the tramadol study, 6pain inten- 
sity was reduced similarly by 6 months of open-label 
treatment, regardless of treatment assignment in the 
original double-blind study. The rate of discontinuation 
due to treatment failure was lower in the current study 
(7%) and the tramadol study (3%) compared with the 
capsaicin study (28% over the first 24 weeks), but this 
was offset by a higher rate of discontinuation due to 
AEs in this study (27% vs 11% and 16%, respectively). 
CONCLUSIONS 
Although 39.5% of subjects discontinued, most often 
due to AEs, the results of this 26-week, open-label 
extension study with topiramate (up to 600 mg/d) in 
subjects with moderately to severely painful DPN 
suggest that pain relief was effective and durable. 
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Figure 3. Body weight by study visit. Among subjects in open-label xtension of 12-week, double-blind study com- 
paring topiramate with placebo for painful diabetic peripheral neuropathy. Data points represent the 
mean of all observed values at that visit; n values for each treatment group appear below the graph. 
Significant improvements in body weight and HbA k 
were also noted. The most frequently encountered 
AEs were nausea, abnormal vision, fatigue, dizziness, 
and difficulty with concentration/attention. The most 
common AEs while on treatment were upper espira- 
tory tract infection, anorexia, diarrhea, nausea, pares- 
thesia, and headache. Serious AEs were experienced 
by 11.1% of all patients. 
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ORIGINAL ARTICLE
Pulsed Electromagnetic Fields to Reduce Diabetic Neuropathic
Pain and Stimulate Neuronal Repair: A Randomized
Controlled Trial
Michael I. Weintraub, MD, David N. Herrmann, MD, A. Gordon Smith, MD, Misha M. Backonja, MD,
Steven P. Cole, PhD
ABSTRACT. Weintraub MI, Herrmann DN, Smith AG,
Backonja MM, Cole SP. Pulsed electromagnetic fields to
reduce diabetic neuropathic pain and stimulate neuronal
repair: a randomized controlled trial. Arch Phys Med Reha-
bil 2009;90:1102-9.
Objective: To determine whether repetitive and cumulative
exposure to low-frequency pulsed electromagnetic fields
(PEMF) targeting painful feet can reduce neuropathic pain
(NP), influence sleep in symptomatic diabetic peripheral neu-
ropathy (DPN), and influence nerve regeneration.
Design: Randomized, double-blind, placebo-controlled par-
allel study.
Setting: Sixteen academic and clinical sites in 13 states.
Participants: Subjects (N225) with DPN stage II or III
were randomly assigned to use identical devices generating
PEMF or sham (placebo) 2 h/d to feet for 3 months.
Interventions: Nerve conduction testing was performed
serially.
Main Outcome Measures: Pain reduction scores using a
visual analog scale (VAS), the Neuropathy Pain Scale (NPS),
and the Patient’s Global Impression of Change (PGIC). A
subset of subjects underwent serial 3-mm punch skin biopsies
from 3 standard lower limb sites for epidermal nerve fiber
density (ENFD) quantification.
Results: Subjects (N225) were randomized with a dropout
rate of 13.8%. There was a trend toward reductions in DPN
symptoms on the PGIC, favoring the PEMF group (44% vs
31%; P.04). There were no significant differences between
PEMF and sham groups in the NP intensity on NPS or VAS.
Twenty-seven subjects completed serial biopsies. Twenty-nine
percent of PEMF subjects had an increase in distal leg ENFD
of at least 0.5 SDs, while none did in the sham group (P.04).
Increases in distal thigh ENFD were significantly correlated
with decreases in pain scores.
Conclusions: PEMF at this dosimetry was noneffective in
reducing NP. However neurobiological effects on ENFD,
PGIC and reduced itching scores suggest future studies are
indicated with higher dosimetry (3000–5000 G), longer dura-
tion of exposure, and larger biopsy cohort.
Key Words: Electromagnetic fields; Rehabilitation.
© 2009 by the American Congress of Rehabilitation
Medicine
REPETITIVE TRANSCRANIAL magnetic stimulation atthe prefrontal,1 motor,2 and somatosensory cortex3 is
emerging as a promising alternative therapy for disabling and
refractory NP. Short-term analgesic and antinociceptive effects
have also been achieved with direct stimulation of the spinal
cord4 and lumbar nerve roots.5 Both low-frequency and high-
frequency magnetic stimulation can influence thermal and pain
thresholds in both normative and symptomatic subjects for a
short time, yet the specific mechanisms of action are yet to be
determined.6-10 Despite these preliminary data with small co-
horts receiving isolated treatments only at academic clinics,
there has been no information regarding its efficacy in painful
DPN, which is one of the most common causes of NP. It has
been estimated that 40% to 50% may experience NP.11 DPN
begins insidiously in the feet with preferential involvement of
unmyelinated C fibers and small myelinated A delta fibers.12
From a pathophysiological standpoint, DPN symptoms are
believed secondary to ectopic firing of nociceptive afferent
axons that are undergoing degeneration, with dysregulated
expression of sodium, calcium, and potassium channels.13-15
Skin biopsies reveal prominent cutaneous denervation with
length-dependent reductions in ENFD.16,17 The mechanisms of
DPN and NP are considered multifactorial.18 Impaired produc-
tion of neurotrophic factors (NGF, IGF-I, IGF-II, fibroblast
growth factor, and so forth),19-21 impaired Schwann cells,19,22
macrophage dysfunction,19,23 microangiopathy with ischemia
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List of Abbreviations
DPN diabetic peripheral neuropathy
ENFD epidermal nerve fiber density
HbA1C glycosylated hemoglobin
IGF-I insulin-like growth factor I
IGF-II insulin-like growth factor II
NGF nerve growth factor
NP neuropathic pain
NPS Neuropathy Pain Scale
PEMF pulsed electromagnetic fields
PGIC Patient’s Global Impression of Change
VAS visual analog scale
VEGF vascular endothelial growth factor
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and reduced VEGF,19,24 impaired voltage-gated channels (so-
dium, potassium, calcium),13,15,25 protein kinase C dysregula-
tion,19,26 and oxidative stress19,27,28 are believed to be contrib-
utory. Data from cell culture, animal, and human studies
suggest that exogenous application of weak, nonthermal elec-
tromagnetic fields upregulates NGF, IGF-I, IGF-II, fibroblast
growth product, and VEGF29-31; reorients Schwann cells32;
enhances macrophage activity33 and endoneurial blood flow34;
reduces nociceptive afferent signal transduction35-38; reduces
free radicals37,39 and oxidative stress33,40; and promotes neurite
outgrowth.35,41 Thus, magnetic stimulation may be an appro-
priate noninvasive intervention that could reduce DPN symp-
toms and produce disease modification.35,37
METHODS
Enrollment Criteria
The design and conduct of the randomized controlled trial is
described in the accompanying consort flow diagram (fig 1).
Subjects from 18 to 87 years of age with painful DPN (Dyck
stage II or III)38 with moderate-severe constant pain of 4 or
higher on a 0 to 10 VAS, with a duration of at least 6 months,
were recruited at 16 investigative sites in 13 states within the
United States (appendix 1) between August 2005 and March
2007. Pregnant women and subjects with mechanical insulin
pumps or cardiac pacemakers were excluded. Subjects could
remain on their stable drug medications for diabetes and pain
relief, but no new analgesics or dosing increases were permit-
ted during the trial. Subjects were enrolled only if they were on
a stable analgesic regimen. Before randomization, subjects
were instructed on how to tabulate VAS (0–10) pain scores (3
times a day) and a sleep interference score (VAS 0–10, once
daily). All participants provided written informed consent. Two
university centers performed skin-punch biopsies at random-
ization and at conclusion of the study that were shipped to the
University of Rochester for immunohistochemistry and mea-
surement of ENFD.
Randomization
Demographic data (age, height, weight, sex, glycosylated
hemoglobin [HbA1C], family history, duration of diabetes,
concomitant medications) were collected for each enrolled
subject. After entry and baseline quantification of pain and
sleep interruption scores, eligible patients were randomized (1:1
via computer assignment) to receive an active coded magne-
tized or a sham device, identical in all characteristics except for
the demagnetization procedure. Subjects agreed to use the
device a maximum of 2 hours a day in divided sessions of 10
to 30 minutes for 3 months. Subjects recorded daily VAS pain
and sleep scores; other outcome measures (see below) were
evaluated at monthly study visits. All subjects agreed not to
break the blinding of the devices. A consecutive subset of
patients from 2 university sites volunteered to participate in an
ENFD exploratory substudy. Three-millimeter punch skin bi-
opsies were harvested from the proximal and distal lateral
thigh, and the distal leg at baseline and after 3 months of PEMF
or sham exposure. The skin biopsies were fixed, cryoprotected,
sectioned, and immunostained with polyclonal antibodies to
the panaxonal marker, protein gene product 9.5, according to
previously published methods.42,43 A single blind observer
assessed both the linear density (fibers/mm) of nerve fibers
crossing the dermal-epidermal junction ENFD (crossings) and
the total linear density including intraepidermal fragments
ENFD (total) from three to five 50-M thick sections selected
at random from each biopsy specimen, using previously pub-
lished techniques.44,45
Fig 1. The CONSORT diagram revealing enrollment and outcomes. A total of 245 subjects were screened, and 225 were randomized and
enrolled. A 13.8% dropout occurred (31/225) with no safety issues.
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Device
This device (fig 2) uses 6 individual (1800-G) magnetic
sphere units, 3 under each foot, that are driven individually by
a 6-V DC motor. A speed control circuit allows a range of 500
to 1500 revolutions per minute. The magnetic spheres turn on
one axis generating magnetic lines of force (flux), and simul-
taneously, turn on a second axis perpendicular to the first axis
(biaxial), causing the moving flux lines to cut across tissues at
varying periodic angles, inducing varying intensities of force
and polarity changes, resulting in static and time-varying mag-
netic fields. Precise placement on the foot plates with socks
allows penetration of the magnetic fields up to 5 feet as mea-
sured by an ENF meterb (model UHS). There is exponential
decay of field strength with distance from magnetic source
(310,000 mG). Supersaturation of the target area from every
angle at 25 times a second at maximum 1500 revolutions per
minute is achieved. The barium ferrite-nylon bonded spheres
do not induce any discernable sensory effects on the feet to
suggest device activity.
Outcome Measures
Pain is a complex experience, and none of the existing pain
scales appears to be ideal for all situations. Thus, we chose a
priori to employ 3 of the most commonly used validated NP
measures as outcomes for the trial.
Primary outcome. The primary outcome was a VAS (rang-
ing from 0, no pain to 10, worst possible pain),38 3 times daily
at the same time to represent a mean daily pain level.
Secondary outcomes. NPS assessed 10 pain descriptors
collected at baseline and the end of the study.43 NPS composite
(NPS 10) scores range from 0 to 100.
PGIC46 required subjects to select 1 of 7 options describing
response to treatment, ranging from “very much improved” to
“very much worse.”
VAS measure of sleep disruption38 secondary to pain was
collected once on arising each morning.
Other secondary outcomes compared baseline and 12-week
values of the neurologic examination (sensory, motor, reflex
functions). Standardized nerve conduction velocities and am-
plitudes of common peroneal nerve (recording from the exten-
sor digitorum brevis muscle) and sural nerves were monitored
at baseline and the end of the study for abnormalities consistent
with distal polyneuropathy. At the end of the study, both
patients and investigators were asked for their perception of
device activity.
Statistical Analyses
Based on prior pilot VAS pain data,38 a sample size of 200
patients was calculated to yield a power of 80% to detect a 25%
superiority of PEMF over sham placebo with alpha equal to
0.05 and beta equal to 0.20. We allowed for a dropout rate of
20% of subjects enrolled. For the NPS, 10 composite scores
(range, 0–100) were used. In addition, 2 NPS items most
salient to C-fiber involvement, itchy pain and burning pain
(ranges, 0–10), were analyzed separately. ENFD change scores
were computed by subtracting the baseline value from the
3-month value; a positive change score indicated an increase in
ENFD. Change scores as continuous measures were used for
correlation analyses. To assess treatment effects on ENFD, 3
categories were constructed based on a 0.5 SD of the baseline
value: (1) 0.5 SD change (indicating increase in ENFD), (2)
0.5 to 0.5 (no or little change) and (3)  0.5 SD change
(decrease). The 0.5 SD criterion was chosen to be sensitive to
the different levels of variability of the ENFD measures. As-
sociations between treatment and ENFD groups were assessed
with chi-square tests.
Two (PEMF, sham)  2 (baseline to month 3) repeated-
measures analyses of variance were used to assess change in
pain scores and ENFD values over the course of the study. A
statistically significant treatment group  time interaction in-
dicated greater change from baseline to the end of month 3 for
1 of the treatment groups. Independent sample t tests were used
to test for possible baseline differences in mean scores and for
the PGIC at 3 months.
For the a priori statistical tests of the primary outcome
measure, the level of significance was set at P.05. For the 3
secondary outcome measures, a Bonferroni correction adjusted
the statistical significance level to .017. For the Pearson prod-
uct moment correlation analyses between ENFD values and
pain measures, the researchers controlled for familywise error
rate using a sequential Bonferroni approach: significance was
set at P.008. All tests were 2-sided. All analyses were con-
ducted in an intent-to-treat manner (expectation maximization
method). The Statistical Package for the Social Sciences (ver-
sion 15.0c) was used to analyze the data.
RESULTS
The flow of patients through the clinical trial is depicted in
figure 1 (CONSORT diagram). Of the 245 subjects enrolled in
this study, 20 cases were initially excluded because of a low
Fig 2. Device: Body Energizer.a (A), PEMF and/or identical sham
demagnetized device. (B), Subject with feet in place.
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baseline score. Of the 225 patients randomized, there was a
dropout of 31 subjects (13.8%). These included 5 because of
protocol violations, 6 from diabetic complications, 16 lost to
follow-up, and 4 who did not complete the study because of
allodynia. Three of these 4 cases had significant premorbid
burning feet syndrome with pressure allodynia. Of the 107
patients allocated to the magnet group, 90 (84.1%) completed
the 3-month study, whereas 104 of the 118 allocated to the
sham group (88.1%) completed the study. The dropout rate and
withdrawal pattern were similar for both groups. Baseline
demographics (table 1) were similar for both groups. Women
represented 56.7% of the PEMF group and 55.8% of the sham
group. Mean  SD ages were 63.68.6 years and 63.59.5
years for the PEMF and sham groups, respectively. HbA1c data
were similar for both groups at 3 months. There were also no
changes in motor or sensory conductions or the sensory/motor
neurologic examination at 3 months. Seventy-four percent of
patients who completed the study took at least 1 analgesic
medication for pain, and 47% took at least 2 agents. There were
no group differences in number of antiepileptic drugs, narcot-
ics, tricyclics, selective serotonin reuptake inhibitors, or non-
steroidal anti-inflammatory drug medications taken by patients.
For the biopsy cohort (CONSORT diagram) (fig 3), of the 37
subjects enrolled in the study, 10 (27.0%) were lost to fol-
low-up (3 magnet, 7 sham). Of the remaining 27 cases, 14 had
received active magnets, and 13 had received sham devices.
Women represented 64.3% of the PEMF group and 38.5% of
the sham group. Mean ages were 63.6 and 63.5 years for the
PEMF and sham groups, respectively.
Primary and Secondary Outcomes
Results for study outcomes are presented in table 2. There
were no statistically significant group differences in baseline
pain measures. For PGIC at 3 months, 43.7% of PEMF and
30.6% of sham group subjects reported very much or much
improvement (P.04). This result was considered a nonsignif-
icant trend. Group differences from baseline to 3 months were
not significant for VAS (P.96), NPS 10 (P.58), sleep scores
(P.49), or electrodiagnostic studies. Analyses controlling for
baseline HbA1c (PEMF mean,7.5; sham mean,7.4) and whether
subjects were taking insulin (10% PEMF; 28% sham) also did
not reveal significant group differences. However, for subjects
with moderate to severe itchy pain, there was a 53.7% reduc-
tion in mean itchy pain scores for the PEMF group from
baseline to 3 months, whereas there was a 33.8% reduction for
the sham group (P.048). Subjects who reported higher levels
of itching also reported higher levels of burning at baseline
(r.32; P.001) and at 3 months (r.33; P.001).
Correlations Between Pain Measures
At baseline, the correlations between NPS 10 (only the total
composite score was analyzed) and VAS was significant
Table 1: Baseline Demographics and Clinical Characteristics of the
Enrolled Patients
Characteristic
PEMF Group
(n90)
Sham Group
(n104)
Age (y)
Mean 61.110.4 60.612.4
Range 33–87 21–83
Weight (lb) 217.955.6 215.154.6
Height (in) 66.64.54 67.44.42
Female (%) 56.7 55.8
Years since onset of diabetes 3.93.0 4.03.0
HbA1c 7.51.8 7.41.8
Subjects with abnormal
nerve conduction (%)
87.7 89.9
NOTE. Values are mean  SD unless otherwise noted.
Fig 3. Biopsy consort.
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(r.57; P.001). At 3 months, there were significant correla-
tions between NPS 10 and VAS (r.77; P.001). NPS 10 and
PGIC (r.50; P.001), and VAS and PGIC (r.53; P.001).
Biopsy Study
There were no statistically significant group differences in
baseline ENFD measures. At the distal leg site, there was a
nonsignificant trend for an increase in mean  SD ENFD
(crossings) from baseline (1.332.04) to 3 months (1.562.34)
for the PEMF group, while there was a decrease in ENFD
crossings from baseline (1.051.64) to 3 months (0.831.54)
for the sham group (P.10). Similarly, there was a nonsignif-
icant trend for an increase in ENFD total from baseline
(1.832.93) to 3 months (2.213.43) for the PEMF group,
while there was a decrease in ENFD total from baseline
(1.282.10) to 3 months (1.031.99) for the sham group
(P.08). At the distal leg site, 4 (28.6%) of the magnet group
and none of the sham group had greater than 0.5 SD increase
in ENFD crossings (2 P value.04; Fisher exact test.07)
(fig 4). No significant group differences were noted between
baseline and 3-month values for ENFD (crossings) and ENFD
(total) at the distal and proximal thigh biopsy sites. At the distal
thigh, Pearson correlation coefficients for all 27 cases revealed
moderate associations between 3-month PGIC scores and
changes in ENFD crossings (r.40; P.04) and changes in
ENFD total (r.41; P.04); higher nerve density was re-
lated to global improvement. Over the 3 months, an increase in
distal thigh ENFD crossings was moderately associated with a
decrease in NPS 10 scores (r.49; P.010); an increase in
distal thigh ENFD total was significantly associated with a
decrease in NPS 10 scores (r.53, P.006) (fig 5). There
were no significant correlations between changes in distal leg
or proximal thigh ENFD and VAS scores.
Blinding
At the end of the study, the perception of patients and
physicians, regarding device activity was erroneous in 20% of
the PEMF group and 26% of the sham group. In the absence of
objective changes in neurologic examination and conduction
studies, physician investigators tended to agree with the re-
sponses of their patients.
Safety
There were no safety issues or complications except that 4 cases
experienced allodynia leading to dropout (shamPEMF).
DISCUSSION
To our knowledge, this is the first multicentered, random-
ized, double-blind, placebo-controlled trial of cumulative ex-
posure of PEMF targeting painful feet in subjects with NP from
DPN. The results indicate that the key outcomes related to
change in pain or sleep disruption were not improved by
PEMF. However, there are some provocative data suggesting
that neurobiological changes occurred in the epidermal inner-
vation exploratory substudy. First, PEMF appeared to affect
Table 2: Results of Pain and Sleep Scales
PEMF (n90) Sham (n104)
Measures Baseline Month 3 Baseline Month 3
PGIC (% much or very much improved) 43.7 30.6*
VAS 5.592.26 4.052.71 5.452.09 4.132.47
Sleep 4.633.14 3.273.08 4.233.14 2.962.85
NPS 10 60.3517.83 45.2021.18 56.5318.25 44.2120.85
NOTE. Values are mean  SD unless otherwise noted.
*P.05.
Fig 4. Number of ENFD distal leg crossings in (A) PEMF and (B)
sham groups. Dark lines indicate increase in density from baseline
to 3 months; light lines indicate decrease or no change.
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DPN symptoms, despite the enrollment of patients with rela-
tively advanced DPN (Dyck stage II or III), of whom many
subjects were markedly deafferented, particularly at the distal
leg site (table 3). Mean SD ENFD total for the PEMF cohort
at baseline was 1.832.93 (normative, 16.65.3).47 This sug-
gests that cutaneous deafferentation does not preclude a bene-
ficial effect of PEMF on NP. Second, we observed no delete-
rious effect of 12 weeks of PEMF on ENFD, indicating that
any effects of PEMF on DPN symptoms are not mediated via
injury to nociceptive afferents. Third, we found that 29% of
those receiving active PEMF showed at least a 0.5 SD increase
in ENFD between the pretreatment and posttreatment time
points at the distal leg skin site, while none of the sham group
demonstrated such an increase. The exact significance of these
changes in ENFD is uncertain and should be cautiously inter-
preted because of the small cohort size, but it suggests the
possibility of a regenerative effect. It was unfortunate that
almost one third of subjects failed to return for second biopsy.
The significance of reduced itchy pain scores is also unclear but
was felt to represent a C-fiber function.
There are several strengths of this study. These include a
large homogeneous cohort with stage II and stage III DPN.
Additional strengths include the use of 3 validated pain scoring
methods representing a composite of the pain experience. The
high rate of study completion supports device tolerability. The
inclusion of a biologic endpoint (ENFD) in a subset as another
measure of neurologic safety is a strength.
Study Limitations
It is difficult to blind subjects reliably given the ease of
detecting the presence of magnetism. We believe the placebo
effect was as fully controlled as possible using an inert, non-
active demagnetized sham device rather than a weak magnet
because biological responses have been reported. At comple-
tion of the study, the PEMF subjects (48%) reported not
knowing whether they had an active or sham device; 32%
believed they had an active while 20% believed they had a
sham device. For the sham subjects, 56% reported not knowing
whether they had an active or sham device; 26% believed they
had an active device while 18% believed they had a sham
device. Another limitation is that the pain reduction was re-
flected only in PGIC pain scales and was not significantly
different in 3 of the 4 other outcome measures. This could
suggest that PEMF may be influencing other aspects of neuro-
pathic dysfunction such as paresthesiae, dysesthesiae, itching,
burning, and so forth. Andre-Obadia et al2,48 believe that pain
scores after stimulation are variable and inconsistent, with their
reliability increasing in the subsequent 3 to 4 days. Thus the
PGIC data reflecting a cumulative response may be more
meaningful than VAS and NPS.49,50 Last, the specific struc-
tures potentially influenced in the microenvironment and spe-
cific tissue dosimetry at target areas also remain unknown.
CONCLUSIONS
This randomized controlled trial failed to demonstrate a
positive effect on pain modulation at this current dosimetry and
duration of exposure. However, the potential neurobiologic
effects noted from PGIC and skin biopsy data (ENFD) suggest
that future studies using a higher dosimetry (3000–5000 G)
with a longer duration of exposure and a larger biopsy cohort
is warranted to determine whether NP can be modulated by
PEMF51 and influence nerve regeneration.
APPENDIX 1: INVESTIGATORS
The site investigators are listed alphabetically with the prin-
cipal investigator listed first.
● Misha M. Backonja, MD, Department of Neurology, Uni-
versity of Wisconsin, Madison, WI, Theresa Guiliani, RN
(study coordinator)
● Frank DiPalma, DPM, Five County Foot Care, Athens,
GA, Stephanie Miller (study coordinator)
● John England, MD, Billings Clinic, Billings, MT, Howard
Knapp, MD, Diane Gouine, RN (study coordinator)
● Anthony Geraci, MD, Lutheran Medical Center, Queens,
NY, Samara Khorchid, RN (study coordinator)
● Ghazala Hayat, MD, Department of Neurology, St. Louis
University, St. Louis, MO, Susan Eller, MA, RN (study
coordinator)
● David Herrmann, MD, BCH, Director of Peripheral Neu-
ropathy Clinic and Cutaneous Innervation Laboratory,
University of Rochester Medical Center, Rochester, NY,
Janet Sowden, RN (study coordinator)
● Eve Holzemer, N.P. Administrative Director
● Jeffrey Jensen, DPM, Diabetic Foot and Wound Center,
Denver, CO, Patricia Nelson, RN (study coordinator)
Fig 5. Scatterplot of total distal thigh ENFD: increase in ENFD was
significantly associated with a decrease in NPS 10 (difference)
scores (r.53; P.006).
Table 3: Epidermal Nerve Fiber Density at Baseline and 3 Months
PEMF Sham
Measure Baseline Month 3 Baseline Month 3
Distal leg
Crossings 1.332.04 1.562.34 1.051.64 0.831.54
Total 1.832.94 2.213.43 1.282.10 1.031.99
Distal thigh
Crossings 5.001.68 4.762.21 4.491.40 4.442.30
Total 6.512.44 6.262.91 5.952.08 6.273.14
Proximal thigh
Crossings 7.323.11 7.182.06 6.581.83 7.032.41
Total 9.123.81 10.283.06 8.692.83 9.433.19
NOTE. Values are mean  SD.
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● Sam Kabbani, MD, East Tennessee Neurology Clinic,
Knoxville, TN, Tara Jenkins, RN (study coordinator)
● Javier LaFontaine, DPM, Department of Orthopedics/
Podiatry, University of Texas Health Science Center at
San Antonio, San Antonio, TX, Vanessa Duenez, RN
(study coordinator)
● Neil Lava, MD, Department of Neurology, Albany Med-
ical Center, Albany, NY, Kathy McCabe, RN (study co-
ordinator)
● Mamatha Pasnoor, MD, Department of Neurology, Uni-
versity of Kansas Medical Center, Kansas City, KS, Rich-
ard Barohn, MD, Maureen Walsh, RN (study coordinator),
Laura Herbelin, RN (study coordinator)
● Armon Sabet, MD, Department of Neurology, University
of Kentucky, Lexington, KY, Karen Arrowwood, MPH
(study coordinator), Shirley Warren, RN (data manager)
● David S. Saperstein, MD, Phoenix Neurological Associ-
ates, Phoenix, AZ, Lynne Flynn, RN (study coordinator)
● A. Gordon Smith, MD, Department of Neurology and
Pathology, University of Utah School of Medicine, Salt
Lake City, UT, Rob Singleton, MD, Jennie Wade, CRC
(study coordinator)
● Keith Tyson, DPM, Jeffrey Dunkerley, DPM, Martin Foot
and Ankle, Yorke, PA, Martha Martin (study coordinator)
● Michael I. Weintraub, MD, Briarcliff Manor, NY, Susan
Pines Wolert (study coordinator), Christine Dee (data
manager)
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Static Magnetic Field Therapy for Symptomatic Diabetic
Neuropathy: A Randomized, Double-Blind,
Placebo-Controlled Trial
Michael I. Weintraub, MD, FACP, FAAN, Gil I. Wolfe, MD, Richard A. Barohn, MD, Steven P. Cole, PhD,
Gareth J. Parry, MD, Ghazala Hayat, MD, Jeffrey A. Cohen, MD, Jeffrey C. Page, DPM,
Mark B. Bromberg, MD, Sherwyn L. Schwartz, MD, and the Magnetic Research Group
ABSTRACT. Weintraub MI, Wolfe GI, Barohn RA, Cole
SP, Parry GJ, Hayat G, Cohen JA, Page JC, Bromberg MB,
Schwartz SL, and the Magnetic Research Group. Static
magnetic field therapy for symptomatic diabetic neuropathy: a
randomized, double-blind, placebo-controlled trial. Arch Phys
Med Rehabil 2003;84:736-46.
Objective: To determine if constant wearing of multipolar,
static magnetic (450G) shoe insoles can reduce neuropathic
pain and quality of life (QOL) scores in symptomatic diabetic
peripheral neuropathy (DPN).
Design: Randomized, placebo-control, parallel study.
Setting: Forty-eight centers in 27 states.
Participants: Three hundred seventy-five subjects with
DPN stage II or III were randomly assigned to wear constantly
magnetized insoles for 4 months; the placebo group wore
similar, unmagnetized device.
Intervention: Nerve conduction and/or quantified sensory
testing were performed serially.
Main Outcome Measures: Daily visual analog scale scores
for numbness or tingling and burning and QOL issues were
tabulated over 4 months. Secondary measures included nerve
conduction changes, role of placebo, and safety issues. Anal-
ysis of variance (ANOVA), analysis of covariance (AN-
COVA), and chi-square analysis were performed.
Results: There were statistically significant reductions dur-
ing the third and fourth months in burning (mean change for
magnet treatment,12%; for sham,3%; P.05, ANCOVA),
numbness and tingling (magnet, 10%; sham, 1%; P.05,
ANCOVA), and exercise-induced foot pain (magnet, 12%;
sham, 4%; P.05, ANCOVA). For a subset of patients with
baseline severe pain, statistically significant reductions oc-
curred from baseline through the fourth month in numbness
and tingling (magnet, 32%; sham, 14%; P.01, ANOVA)
and foot pain (magnet, 41%; sham, 21%; P.01,
ANOVA).
Conclusions: Static magnetic fields can penetrate up to
20mm and appear to target the ectopic firing nociceptors in the
epidermis and dermis. Analgesic benefits were achieved over
time.
Key Words: Diabetic neuropathies; Magnetics; Rehabilita-
tion.
© 2003 by the American Congress of Rehabilitation Medi-
cine and the American Academy of Physical Medicine and
Rehabilitation
D IABETIC PERIPHERAL NEUROPATHY (DPN) is acommon and often disabling complication of diabetes
mellitus (DM). Depending on criteria, DPN is estimated to
occur in 50% to 90% of individuals with diabetes for more than
10 years.1-4 As many as half of the 16 million diabetics in the
United States will experience neuropathic pain at some point in
their lives.5-9 DPN begins insidiously, presenting as a symmet-
rical sensory polyneuropathy that follows a stocking-glove
pattern. Selective involvement of unmyelinated C fibers and
small myelinated A delta fibers produces pain of the burning
dysesthetic type and is often accompanied by hyperalgesia and
allodynia in the feet.7,10-12 Neuropathic pain symptoms fluctu-
ate and can be described as superficial, deep, aching, lancinat-
ing, constant, or episodic. Complaints are often worse at night.
Although initial symptoms and the course of DPN vary, once
neuropathic pain is established, it is almost always progressive,
leading to increased discomfort and disability.6,13-15 Further-
more, individuals with DPN are at augmented risk for foot
trauma and infections that may necessitate amputative proce-
dures.2,16
From a pathophysiologic standpoint, these symptoms are
believed to be secondary to ectopic firing of nociceptive affer-
ent axons that are undergoing degeneration.7,9-12 This ectopic
depolarization appears to be related to dysregulated expression
of sodium and calcium channels17-19 and a deficit in the potas-
sium-internal rectifying channel.20-22 Neurons at the level of the
dorsal root ganglion (DRG) also become hyperexcitable after
peripheral nerve injury, presumably because of loss of periph-
eral inhibitory influences.23 Currently, there are no treatments
that reverse or arrest progressive diabetic polyneuropathy.24 A
variety of standard oral therapies used for symptomatic neuro-
pathic pain include tricyclic antidepressants,25 antiepileptic
medications,26 and narcotic analgesics.27,28 Additionally, topi-
cal products such as capsaicin29,30 have been applied and have
produced incomplete pain relief and significant side effects.
Overall, the results have been disappointing and associated
with significant side effects.15,31,32 The search for reliable, safe,
and effective mainstream treatments for the neuropathic pain of
DPN remains a major challenge,13,15,25-27,31-34 and, not surpris-
ingly, patients have explored a variety of alternative ap-
proaches, including homeopathy, acupuncture, and magnetic
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therapies. Spurred on by anecdotal reports, the use of perma-
nent magnets for relief of pain has become extremely popular
in recent years, with consumer spending exceeding $500 mil-
lion in the United States and Canada and $5 billion world-
wide.35,36 The idea that magnetic energy from commercially
available, weak magnets applied locally to the feet could in-
fluence chronic neuropathic pain may seem absurd, and yet this
approach is not new.37-41 In the absence of randomized, place-
bo-controlled trials, the medical community has been under-
standably skeptical, which has limited the acceptance of mag-
nets as a valid option for pain relief.42,43 However, 2 prior pilot
studies successfully showed reduced neuropathic pain in 75%
and 90% of patients with refractory DPN over a 4-month
period, with constant application of commercial multipolar foot
magnets (450G).35,36 These surprising and unexpected favor-
able results prompted the present study—a nationwide, ran-
domized placebo-controlled investigation into the legitimacy of
static magnetic fields in the relief of pain from DPN.
METHODS
Enrollment Criteria
From August 1999 through January 2001, 375 subjects with
symptomatic symmetrical sensory and motor diabetic periph-
eral neuropathy (DPN stages II or III), as defined by Dyck et
al,44,45 were recruited from 48 sites in 27 states. Consecutive
patients from neurologic, podiatric, and diabetic clinics or
private practice were enrolled. A few centers advertised their
participation in this nationwide study to attract eligible volun-
teers. The primary providers were skilled clinicians who had
previously participated in pharmacologic studies of diabetes
and/or pain management. Enrollment criteria required that all
subjects have at least 2 abnormalities on neurologic examina-
tion (sensory, motor, reflex), moderate (II) to severe (III)
neuropathic pain, abnormal nerve conduction or quantitative
sensory testing, and/or symptoms of autonomic dysfunction.
Symptoms had to be constant and present over 6 months and
refractory to various medications. Subjects included persons
with insulin-dependent diabetes mellitus (IDDM) and those
who were not insulin dependent (NIDDM). Subjects were
excluded if other systemic diseases could potentially explain
their symptoms. As a safety precaution, pregnant women and
subjects who had mechanical insulin pumps or cardiac pace-
makers were also excluded. Subjects tabulated validated46-50
daily pain scores and similar, but unvalidated, quality of life
(QOL) scores for 4 months and agreed that they would not
attempt to break blinding of the foot devices. They also agreed
to wear the devices constantly, 24 hours per day. Moderate pain
was defined as scores of 5.0 to 6.99 and severe pain was
defined as 7 and higher. No new analgesic drugs were allowed
during the study, but individuals could remain on (or reduce)
their current regimen of neuropathic pain medication. The
randomized, placebo-controlled, parallel design study was fully
explained to all subjects and voluntary withdrawal was allowed
without prejudice.
Randomization
Demographic data (age, height, weight, gender, race, glyco-
sylated hemoglobin [Hb A1c], family history, duration of DM,
complications of DM, treatment of DM) were collected at each
site. Subjects completed a 2-week baseline Likert visual analog
scale (VAS) quantification of their pain symptoms 3 times
daily to establish a reliable mean pain score. QOL scores were
recorded once daily to measure (1) sleep disturbance secondary
to foot pain and (2) exercise-induced foot pain after a 10-
minute exertion such as walking or other physical activity.
After eligibility was confirmed and written informed consent
accepted, subjects were randomized consecutively (1:1 via
computer assignment) to receive an active magnetic shoe insole
or a sham insole of similar appearance. Randomization was
stratified by center and gender. Neither the subject nor the
research staff was aware of the treatment allocation. If correc-
tive trimming of the device was necessary to provide a com-
fortable fit in the shoe, a noninvolved secretary or nurse would
trim them along identifiable lines around the margins. The
subjects and site investigators were not present if trimming was
necessary. All data were submitted to a central data bank under
the supervision of the statistician who was aware of the assign-
ments.
Magnetic Devices
The devices used in the present study are comprised of a
reinforced and flexible magnetic rubber compound pressed into
a sheet and cut into the shape of a shoe insole for men and
women. Strontium ferrite powder is mixed into this rubber
binder and magnetized with a patented pattern of alternating
magnetic poles. Each pole is adjacent to and contiguous with
another triangular-shaped magnetic pole of opposite polarity on
each of the 3 sides of the triangle. This pattern produces a
continuous array of alternating magnetic poles in every direc-
tion across the insole (fig 1).
The strength of the magnetic field is 450G, as measured with
a conventional gauss meter on the surface of the insoles at the
center of the triangle (10,000G1T). The field depth of pen-
etration is 20mm and is reduced inversely with the square of
the distance. By far, the simple, most direct method of deter-
mining field strength at various distances from the insole sur-
face is by instrument measurement. For example, using a
Lakeshore 420 gauss meter with a flat transverse probea has an
accuracy of .25%. The effective field of the magnet from the
insole surface is 20mm. Beyond 20mm, the magnetic field
measures in the range of the ambient magnetic field of the earth
at about 0.5G. The maximum surface field strength of the
magnetic insole is 450G. At a 1-mm distance from the surface,
the field strength drops to 249G. At 2mm, the field strength is
measured at 150G. At 3mm (approximately 1⁄8in), the field
strength is 90G. Flux density at the target area may be more
clinically relevant than the magnetic reading at the surface of
the magnet. The specific flux density, however, at the target
area is unknown. At 13mm above the surface of the magnetized
insole, the reading is only 1.5G. The sham insole’s gauss meter
readings did not exceed the 0.5G of the earth’s magnetic field.
Both sham and active magnetic shoe insoles could not be
distinguished in terms of appearance, consistency, or weight.
The magnetic insoles used in the present study were manufac-
tured by Nu-Magnetics Inc,b and are commercially sold under
the brand name of Magsteps by Nikken Inc.c
Outcome Measures
Pain was measured on an 11-point numeric pain rating scale
(VAS; scale range: 0, no pain; 10, worse possible pain). The
primary efficacy measure was the reduction in neuropathic pain
scores at week 16 compared with baseline scores. We also
compared month-to-month changes. We looked specifically at
2 of the most common pain symptom scores of numbness or
tingling and burning. Each symptom was recorded 3 times
daily so to reduce any new variables (VAS range, 0–10).
Similarly, QOL issues were considered primary efficacy mea-
sures with reduction of exercise-induced foot pain and sleep
interruption secondary to pain (VAS range, 0–10). These were
recorded once daily. Secondary outcomes compared baseline
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and 16-week values of neurologic examinations, nerve conduc-
tion velocity (NCV), quantitative sensory testing (QST) thresh-
olds (Neurometer51d or Case IV52), and other electrophysi-
ologic tests.53,54 Safety measures with tabulation of adverse
events were monitored as was cause for dropouts. Additionally,
an interim study performed before the end of this study at
selected sites assessed masking and bias by asking patients and
investigators whether they believed that a placebo or active
device was used or whether they had no opinion.
Sites
There were 48 investigative sites in 27 states. They included
11 university-based centers and 37 private practices. A neuro-
logic examination was performed before entry to identify the
presence of a sensory peripheral polyneuropathy in the feet that
met the Dyck45 criteria of moderate (II) to severe (III) DPN.
NCVs of the peroneal and/or posterior tibial (motor) and sural
nerves (sensory) were performed in a standardized manner to
confirm the presence of neuropathy. Selected sites performed
forced-choice QST by using Neurometer (CPT) or Case IV
equipment and other neurophysiologic tests, such as biothesi-
ometry and sympathetic skin response (SSR). Because no stan-
dard, validated device exists and controversy about their merits
surrounds the various devices, we let each site use their stan-
dard analysis technique.
Investigational Review Board
Phelps Memorial Hospital Investigational Review Board
(IRB) reviewed and approved the protocol, as did IRBs at
individual university centers. Phelps Memorial served as a
central IRB for many investigative sites and appropriate safety
and progress data were submitted to this IRB in a timely
fashion. All patients provided written informed consent to
participate in this study.
Statistical Analyses
For each of the 4 outcome measures (burning, numbness and
tingling, foot pain, sleep scores), a 2 (treatment, sham) 5
(baseline, 1mo, 2mo, 3mo, 4mo) repeated-measures analysis of
variance (ANOVA) was used to assess possible differences
between treatment and sham groups over the course of the
study. These analyses were followed by a 2 (treatment, sham)
2 (2mo, 4mo) analysis of covariance (ANCOVA) with base-
line score as the covariate to explore treatment effects during
the last 2 months of the study. Furthermore, for each outcome
measure, we grouped patients into 3 categories of severity
based on baseline scores. Ratings of 1 to 4 corresponded to
mild pain; 5.0 to 6.99, to moderate pain; and 7 to 10, to severe
pain.55 ANOVAs were used to compare the mean changes
separately for each severity group. For each of the outcome
measures, chi-square tests for independence were used to as-
sess magnet versus sham group differences in the percentage of
patients who had at least a 30% reduction in severe pain.
Finally, ANOVAs and ANCOVAs were used to assess treat-
ment effects for subgroups defined by measures known to
previously affect outcomes in this population. For all tests, a P
value of .05 or less was considered to indicate statistical
significance. Subjects with any missing data for an endpoint
were excluded for that analysis.
On the basis of published results of clinical trial placebo
responses for painful diabetic neuropathy,26 at an  level of .05
and a power of .80, with 150 subjects per group, it was
estimated that a difference between treatment and sham group
responses of 17% or more would be statistically significant.56
Analyses were conducted with SPSS.e
Fig 1. Magnetic field visualization with superimposed magne-view
film. The microencapsulated colloidal nickel particles congregate in
alignment with the magnetic flux lines producing a 2-dimensional
image of the pole pattern.
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Adverse Events
Potential injury to the sole producing ulcer or abrasion or
infection was monitored. Mechanical allodynia because of sen-
sitive feet was also tabulated.
Role of Funding Source
This study was initially funded by Nu-Magnetics and sup-
plemented by Nikken Inc. The grant recipients had complete
independence regarding study design, data analysis, and manu-
script preparation. The study’s protocol was approved by the
National Institutes of Health, but not funded.
RESULTS
The flow of patients through the clinical trial is depicted in
figure 2. Three hundred seventy-five subjects were randomly
assigned to treatment and sham groups, and 259 subjects (69%)
successfully completed this 4-month trial. Of the 90 dropouts,
74% in the treatment group and 71% in the sham cohort
dropped out before the second month. Of the total group, 45%
were lost to follow-up, 24% dropped because of allodynia, and
9% dropped for nonstudy complications. Twenty-six subjects
were dropped by the statistician for missing or questionable
data. The baseline characteristics for the remaining 259 sub-
jects were similar for treatment and sham groups (table 1). The
t tests for independent samples revealed no baseline differences
between the treatment and sham groups for the primary end
points (table 2). Racial-ethnic proportions at enrollment were a
representative cross-section of the US population. In addition,
a series of ANOVAs revealed no baseline differences or dif-
ferences over the study period between patients at university
centers and in private practice settings.
Primary Outcomes
Burning. Burning scores decreased 30% for the treatment
group from baseline (mean  standard deviation, 5.132.29)
to month 4 (3.612.44) and decreased 24% for the sham group
from baseline (5.272.40) to month 4 (4.012.81) (P.000,
ANOVA; fig 3). There was a larger decrease in mean scores for
the treatment group (12%) from month 2 (4.092.38) to
month 4 (3.612.44) than for the sham group (3%) from
month 2 (4.122.65) to month 4 (4.012.81) (P.05, AN-
COVA).
Numbness and tingling. Numbness and tingling scores
decreased 29% for the treatment group from baseline
Fig 2. Flowchart of the randomized placebo-control trial. Abbreviation: Rx, treatment.
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(5.632.08) to month 4 (4.022.46) and decreased 22% for
the sham group from baseline (5.892.02) to month 4
(4.572.58) (P.000, ANOVA; fig 4). There was a decrease
in mean scores for the treatment group (10%) from month 2
(4.462.23) to month 4 (4.022.46) and a small increase for
the sham group (1%) from month 2 (4.542.58) to month 4
(4.572.58) (P.05, ANCOVA). For patients with severe pain
at baseline, numbness and tingling decreased 32% for the
treatment group from baseline (8.17.85) to month 4
(5.582.43) and decreased 14% for the sham group from
baseline (8.12.95) to month 4 (6.972.38) (P.01,
ANOVA; fig 5). Of the 38 treatment patients with severe pain
at baseline, 27 (71%) had mild or moderate pain at month 4. In
contrast, of the 40 sham patients with severe pain at baseline,
16 (40%) had mild or moderate pain at month 4 (P.01, 2).
Foot pain. Foot pain scores decreased 31% for the treat-
ment group from baseline (5.842.33) to month 4 (4.052.66)
and decreased 25% for the sham group from baseline
(5.762.29) to month 4 (4.312.80) (P.000, ANOVA; fig
6). A larger decrease in mean scores existed for the treatment
group (12%) from month 2 (4.622.53) to month 4
(4.052.66) than for the sham group (4%) from month 2
(4.472.68) to month 4 (4.312.80) (P.05, ANCOVA). For
patients with severe pain at baseline, foot pain decreased 41%
for the treatment group from baseline (8.491.07) to month 4
(4.973.10) and decreased 21% for the sham group from
baseline (8.35.95) to month 4 (6.562.50) (P.01,
ANOVA; fig 7). Of the 40 treatment patients with severe pain
at baseline, 29 (69%) had mild or moderate pain at month 4. In
contrast, of the 35 sham-device patients with severe pain at
baseline, 17 (49%) had mild or moderate pain at month 4. This
trend in category change did not reach statistical significance
(P.07, 2).
Sleep. Sleep scores decreased 30% for the treatment group
from baseline (4.832.66) to month 4 (3.362.76) and de-
creased 30% for the sham group from baseline (5.192.79) to
month 4 (3.653.04) (P.000, ANOVA; fig 8). There was a
nonsignificant trend for a larger decrease in mean scores for the
treatment group (13%) from month 2 (3.832.83) to month
Table 1: Baseline Characteristics of the Subjects
Characteristic
Treatment
Group
(n141)
Sham
Group
(n118)
Age (y)
Mean 62.611.3 63.211.2
Range 36–85 27–85
Weight (lb) 206.747.0 207.141.2
Height (in) 67.74.05 67.94.28
Sex (n)
Female 66 58
Male 75 60
Race (n)
White 107 103
Nonwhite 34 15
Years since onset of diabetes 13.010.8 11.610.2
HB A1c 7.71.8 7.62.1
Nerve conduction velocity (n)
Normal 5 3
Axonal 42 31
Demy 16 14
Mixed 51 49
Insulin (n)
Yes 49 40
No 92 78
NOTE. Values are mean  standard deviation (SD) or as otherwise
indicated.
Abbreviation: Demy, demylinating.
Table 2: Mean Scores for Primary Endpoints From Baseline to Month 4
Outcome Measure n Baseline Month 1 Month 2 Month 3 Month 4
Burning
Treatment 133 5.12.3 4.32.3 4.12.4 3.92.5 3.62.4
Sham 111 5.32.4 4.62.6 4.12.7 4.12.7 4.02.8
Numbness and tingling
Treatment 137 5.62.1 4.72.2 4.52.2 4.32.4 4.02.5
Sham 116 5.92.0 4.92.3 4.52.6 4.62.6 4.62.7
Foot pain
Treatment 121 5.82.3 4.92.4 4.62.5 4.22.6 4.12.7
Sham 106 5.82.3 4.92.4 4.52.7 4.32.8 4.32.8
Sleep
Treatment 112 4.82.7 4.02.8 3.82.8 3.52.7 3.42.8
Sham 98 5.22.8 4.62.6 3.82.8 3.83.0 3.73.0
NOTE. Values are mean  SD.
Fig 3. Burning mean scores for treatment and sham subjects.
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4 (3.362.76) than for the sham group (3%) from month 2
(3.762.83) to month 4 (3.653.04) (P.08, ANCOVA).
Secondary Outcomes
There was no evidence of deterioration of nerve function
clinically or electrophysiologically in those patients reporting
improvement in pain scores. Thus, there was no evidence of
clinical worsening. Of the 259 subjects, 61 (24%) had Neu-
rometer, Case IV, SSR, or biothesiometry studies. No signifi-
cant differences existed between subjects in the treatment
group (n32) and those in the sham group (n29) from
baseline to 4 months on these measures.
Subgroup Analyses
For patients not taking oral antidiabetic agents, a larger
decrease occurred in mean burning scores for the treatment
group (14%) from month 2 (3.812.38) to month 4
(3.302.39) than for the sham group (1%) from month 2
(3.912.87) to month 4 (3.862.85) (P.01, ANCOVA).
There was a nonsignificant trend for a larger decrease in mean
numbness and tingling scores for the treatment group (10%)
from month 2 (4.262.21) to month 4 (3.842.46) than for the
sham group (1%) from month 2 (4.782.68) to month 4
(4.242.59) (P.08, ANCOVA). A similar pattern was re-
ported for patients with severe foot pain scores, with reductions
of 41% and 21% for treatment and sham groups, respectively,
and for numbness and tingling, with reductions of 32% and
23% for the 2 groups, respectively. Results remained signifi-
cant with a Bonferroni correction.57 By using the 30% pain
reduction criterion as suggested by a Farrar stratification anal-
ysis,58 we noted that 50% of patients with magnets had at least
a 30% reduction in severe numbness and tingling, compared
with 25% of patients with sham devices (P.05, 2). Although
the percentages for foot pain (32% vs 19%) and burning (42%
vs 29%) were impressive, they were not statistically significant.
No differences between treatment and sham groups were found
based on family history of diabetes, baseline nerve conduction,
or Hb A1c scores.
Blinding
An interim analysis for bias and breaking the blind was
performed at those active sites 6 months before study termi-
nated (university and private practice). This analysis was to
determine whether the present study was adequately blinded.
Fig 4. Numbness and tingling mean scores for treatment and sham
subjects.
Fig 5. Numbness and tingling mean scores for subjects with base-
line severe pain.
Fig 6. Foot pain mean scores for treatment and sham subjects.
Fig 7. Foot pain mean scores for subjects with baseline severe pain.
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Subjects and examining investigators were asked at the end of
the study to identify the treatment provided. Sixty-three percent
of the subjects responded. Of the 83 treatment group subjects
responding, 40 (48%) believed they had active magnets, 31
(37%) believed they had sham magnets, and 12 (15%) did not
know. Of the 80 sham-device subjects responding, 29 (36%)
believed they had active magnets, 30 (38%) believed they had
sham magnets, and 21 (26%) did not know. Of 46 investigators
of treatment subjects, 23 (50%) believed the subjects had active
magnets, 15 (33%) believed they had sham magnets, and 8
(17%) did not know. Of 50 investigators of sham-device sub-
jects, 22 (40%) believed the subjects had active magnets, 15
(30%) believed they had sham magnets, and 12 (26%) did not
know. There was no significant association between the actual
treatment received and the belief about the treatment received
for subjects or investigators.
Dropouts
The dropouts were evenly represented and did not impact on
the primary analysis for efficacy. We did not use the intention-
to-treat (ITT) model for estimates of missing data, because
75% of the dropouts from the treatment group and 71% from
the sham group dropped out before month 2. As shown in our
figures, the magnetic effects became apparent after month 2;
therefore, using the ITT model with most estimates based on
data before month 2 would severely bias the analysis. Dropouts
secondary to allodynia were equally common in both groups.
Foot sensitivity is a well-known phenomenon in symptomatic
patients with DPN. Thus, it is not surprising that the application
of an insole (magnetized or unmagnetized) would be unpleas-
ant to a small but significant group of patients. There were 90
dropouts (lost to follow-up, allodynia, complications) equally
represented out of a sample size of 349 (25.8%). There were no
mean differences between the 46 treatment and 44 sham-device
patients for age, years since onset of diabetes, and baseline Hb
A1c, burning, numbness and tingling, foot pain, and sleep
scores (P.05, ANOVA). The statistician dropped 26 patients
(equal representation) because of site difficulties obtaining data
and unreliable data.
Safety
Measures of safety included constant reporting of adverse
events and the cause for dropouts. There were no significant
complications.
DISCUSSION
This is the first multicenter, double-blind, placebo-controlled
study to examine the role of static magnetic fields in a homog-
enous cohort of DPN with neuropathic pain. The antinocicep-
tive effect was significantly pronounced during the third and
fourth month, indicating that a tonic and chronic exposure must
be present to inhibit and influence sensitized afferent pain
fibers. The magnitude of the reduction of burning, numbness
and tingling, and exercise-induced foot pain, especially in
severe and extreme cases, was comparable or superior to that
observed in the gabapentin,26 tramadol,28 and lamotrigine24
studies, but without side effects. Additionally, a change of 1.5
in the 0 to 10 pain scale represents a clinically meaningful
difference.59,60 This also reaffirms the data from 2 prior pilot
studies.35,36 Subset analysis identified that subjects with severe
pain55 and those not taking oral hypoglycemic agents re-
sponded more favorably than other symptomatic patients. Al-
though our results show a statistically significant reduction in
predetermined primary outcome measures, it is difficult to
determine the mechanism of action responsible for these ben-
efits. It is of interest that in the pharmacologic trials of tram-
adol28 and gabapentin,26 the subjects with severe and extreme
pain responded better than other subjects. Segal et al61 also
noted in testing bipolar magnetic devices in knee pain second-
ary to rheumatoid arthritis that patients with mild symptoms
did not respond as well. DPN pain appears to arise from an
increase in afferent signals from degenerating nociceptive af-
ferent fibers. It has been shown that early in the course of
painful neuropathies, free nerve endings of nociceptive axons
can disappear from the skin but are still present in the sural
nerve.62 One possibility may be that the magnetic field of these
insoles somehow directly or indirectly interrupts and sup-
presses the afferent signal traffic of the C-fiber firing pattern of
the distal part of the surviving axon thereby producing an
antinociceptive effect. A number of studies have shown that
DPN pain could result from depolarization because of dysregu-
lation of normal sodium,17-19,63 calcium,23,64 and potassium20
channel activities. It is well known that sodium channels ac-
cumulate in areas of axonal damage63 and static magnetic fields
have been shown to block or reduce action potential via effects
on sodium flux.65-68 A number of studies using weak pulsed,
time-varying electromagnetic fields have shown biologic
changes.69-73 Adey and Chopart74,75 considered the cell mem-
brane as the most likely transducer modifying ion transport of
protein and adenosinetriphosphatase activity. Membrane lipids
with organized arrays of polar molecules, diamagnetic, have
been shown to realign anisotropic molecules as well as to
summate and interfere with ionic transport.76,77 Translational
movement or changes in orientation in a magnetic field can
influence amplitude of evoked responses.78,79 Because phos-
pholipids in cell membranes have both diamagnetic and para-
magnetic properties, it is clear that mechanisms exist that can
produce conformational changes in various channels and struc-
tures.80,81 However, it is not known if any of this is pertinent to
putative biologic effects of static magnetic fields. Based on our
data, we speculate that the kinetic activity of channelized
membrane ions and blood flow in a static magnetic field is
sufficiently strong to stimulate living tissues and to induce a
biologic reaction. Signal transduction pathways appeared to be
functionally modulated, and this is a restatement of Faraday’s
law of time variation.70,82,83 It is also known that weak mag-
netic fields can increase the partial pressure of tissue oxygen,
thereby improving oxygen delivery to tissues.84 This property
may be important because of a reported reduction in endoneur-
ial oxygen tension in DPN.85 Thus, it is biologically plausible
Fig 8. Sleep mean scores for treatment and sham subjects.
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that static magnetic fields influence diabetic neurons and cell
membranes of cutaneous nociceptors by amplifying the weak
electromagnetic signals from the imposed and constant static
magnets, thereby inducing changes in the cellular86-88 and
pericellular microenvironment.89,90 Because these devices have
a presumed penetration of up to 20mm—thereby indicating
passage through the epidermal91 and dermal layers, which
contain a rich network of nerves and capillaries—we speculate
that, at this site, there is inhibition and/or interruption of
ectopic firing of the damaged small nociceptive afferent unmy-
elinated C fibers. The specific magnetic flux density at this
target area is not known. Perhaps a gating response with
simultaneous stimulation of the A delta fibers producing an
inhibitory antinociceptive effect on C fibers occurs, compatible
with Melzak–Wall hypothesis.92 Another possibility includes
the recruitment of previously passive C fibers.93,94 Case IV
studies of warm and/or cold thermal thresholds did not reveal
any serial changes from baseline. Thus, at an ionic-membrane
level, we can speculate that either the underlying sodium
channels can be up- or down-regulated95 or, alternatively, rapid
repolarization occurs because of stimulation of the potassium
internal rectifying channels.64 This phenomenon may also pro-
duce a secondary inhibition of the firing from the DRG neu-
rons.23
The major strengths of the present study include random-
ized, placebo design; the cooperative involvement of neurolo-
gists, podiatrists, and diabetologists; and the geographic and
racial diversity of the study population. These factors suggest
that the observed benefits will be applicable to the general
diabetic population. Because pain levels can vary during the
day, patients recorded their score 3 times daily to best derive a
mean daily discomfort level and to reduce recall bias. Simi-
larly, QOL experiences have yet to be standardized and vali-
dated by large cohorts in DPN34; yet, intuitively, quantification
of exercise-induced foot pain and sleep disturbance represents
important functional outcome measures.96,97 Another strength
is the utilization of both academic and private practice centers
that not only showed good interobserver reliability, but also
reduced the likelihood of selection bias.
Despite this provocative data, several limitations exist. We
relied exclusively on patients’ self-report for pain and out-
come.55,98 Despite favorable statistical reduction of neuropathic
pain and QOL scores by wearing these devices, only modest
clinical improvement was achieved. The slopes of our figures
from months 2 to 4 suggest that a more potent clinical benefit
could be anticipated at 8 to 12 months, and, thus, long-term
studies must be performed. Another limitation was that it is a
physical impossibility to blind these foot devices and to prevent
the determination of magnetic activity. Subjects and investiga-
tors were advised of the importance of maintaining the blind,
and the questionnaire at study termination indicates that both
groups remained blinded.99,100 Unfortunately, we were unable
to identify a biologic marker using QST, SSR, and biothesi-
ometry. None of the limitations invalidates the statistical an-
tinociceptive effects. Intraepidermal nerve fiber density mea-
surements were not performed and may have provided a useful
pathologic correlate.101 It has been shown that regeneration of
nerve fibers can occur within 39 days in the dermis after an
injury and after 4 months in the epidermis.102,103 The observa-
tion that both refractory groups improved with lower VAS
scores by 2 months compared with baseline by wearing foot
devices (magnetized, unmagnetized) is provocative and similar
to that seen in pharmaceutical studies and placebo trials; this
suggests either a placebo response or analgesic benefit induced
by foot pressure. It is possible that central regions of the brain
for pain control (ie, rostral anterior cingulate cortex, brainstem)
were somehow activated.29
CONCLUSION
Although many questions remain about a precise mechanism
of action, the present study provides convincing data confirm-
ing that the constant wearing of static, permanent, magnetic
insoles produces statistically significant reduction of neuro-
pathic pain. Considering their safety and minimal cost
($100), our data suggest that the insoles may be used as
adjunctive or monotherapy. Future studies are needed to iden-
tify the optimal time to achieve maximum antinociceptive
effect and to confirm and extend these results. Additional
search for biologic markers (ie, epidermal nerve fiber biopsy,
microneurography) will be necessary in future protocols to
determine if permanent structural changes can be produced.
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